0001103021-21-000106.txt : 20211103 0001103021-21-000106.hdr.sgml : 20211103 20211103161757 ACCESSION NUMBER: 0001103021-21-000106 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 64 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211103 DATE AS OF CHANGE: 20211103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIODELIVERY SCIENCES INTERNATIONAL INC CENTRAL INDEX KEY: 0001103021 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 352089858 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-31361 FILM NUMBER: 211375647 BUSINESS ADDRESS: STREET 1: 4131 PARKLAKE AVENUE STREET 2: SUITE 225 CITY: RALEIGH STATE: NC ZIP: 27612 BUSINESS PHONE: 919 582 9050 MAIL ADDRESS: STREET 1: 4131 PARKLAKE AVENUE STREET 2: SUITE 225 CITY: RALEIGH STATE: NC ZIP: 27612 FORMER COMPANY: FORMER CONFORMED NAME: MAS ACQUISITION XXIII CORP DATE OF NAME CHANGE: 20000111 10-Q 1 bdsi-20210930.htm 10-Q bdsi-20210930
FALSE2021Q30001103021--12-31P1Y00011030212021-01-012021-09-30xbrli:shares00011030212021-11-03iso4217:USD00011030212021-09-3000011030212020-12-31iso4217:USDxbrli:shares0001103021us-gaap:SeriesBPreferredStockMember2020-12-310001103021us-gaap:SeriesBPreferredStockMember2021-09-300001103021us-gaap:ProductMember2021-07-012021-09-300001103021us-gaap:ProductMember2020-07-012020-09-300001103021us-gaap:ProductMember2021-01-012021-09-300001103021us-gaap:ProductMember2020-01-012020-09-300001103021us-gaap:RoyaltyMember2021-07-012021-09-300001103021us-gaap:RoyaltyMember2020-07-012020-09-300001103021us-gaap:RoyaltyMember2021-01-012021-09-300001103021us-gaap:RoyaltyMember2020-01-012020-09-3000011030212021-07-012021-09-3000011030212020-07-012020-09-3000011030212020-01-012020-09-300001103021us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2019-12-310001103021us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2019-12-310001103021us-gaap:CommonStockMember2019-12-310001103021us-gaap:AdditionalPaidInCapitalMember2019-12-310001103021us-gaap:TreasuryStockMember2019-12-310001103021us-gaap:RetainedEarningsMember2019-12-3100011030212019-12-310001103021us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-3100011030212020-01-012020-03-310001103021us-gaap:CommonStockMember2020-01-012020-03-310001103021us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2020-01-012020-03-310001103021us-gaap:SeriesAPreferredStockMemberus-gaap:CommonStockMember2020-01-012020-03-310001103021us-gaap:SeriesAPreferredStockMemberus-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310001103021us-gaap:SeriesAPreferredStockMember2020-01-012020-03-310001103021us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2020-01-012020-03-310001103021us-gaap:SeriesBPreferredStockMemberus-gaap:CommonStockMember2020-01-012020-03-310001103021us-gaap:SeriesBPreferredStockMember2020-01-012020-03-310001103021us-gaap:RetainedEarningsMember2020-01-012020-03-310001103021us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2020-03-310001103021us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2020-03-310001103021us-gaap:CommonStockMember2020-03-310001103021us-gaap:AdditionalPaidInCapitalMember2020-03-310001103021us-gaap:TreasuryStockMember2020-03-310001103021us-gaap:RetainedEarningsMember2020-03-3100011030212020-03-310001103021us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-3000011030212020-04-012020-06-300001103021us-gaap:CommonStockMember2020-04-012020-06-300001103021us-gaap:RetainedEarningsMember2020-04-012020-06-300001103021us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2020-06-300001103021us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2020-06-300001103021us-gaap:CommonStockMember2020-06-300001103021us-gaap:AdditionalPaidInCapitalMember2020-06-300001103021us-gaap:TreasuryStockMember2020-06-300001103021us-gaap:RetainedEarningsMember2020-06-3000011030212020-06-300001103021us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300001103021us-gaap:CommonStockMember2020-07-012020-09-300001103021us-gaap:RetainedEarningsMember2020-07-012020-09-300001103021us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2020-09-300001103021us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2020-09-300001103021us-gaap:CommonStockMember2020-09-300001103021us-gaap:AdditionalPaidInCapitalMember2020-09-300001103021us-gaap:TreasuryStockMember2020-09-300001103021us-gaap:RetainedEarningsMember2020-09-3000011030212020-09-300001103021us-gaap:AdditionalPaidInCapitalMember2020-10-012020-12-3100011030212020-10-012020-12-310001103021us-gaap:CommonStockMember2020-10-012020-12-310001103021us-gaap:TreasuryStockMember2020-10-012020-12-310001103021us-gaap:RetainedEarningsMember2020-10-012020-12-310001103021us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2020-12-310001103021us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2020-12-310001103021us-gaap:CommonStockMember2020-12-310001103021us-gaap:AdditionalPaidInCapitalMember2020-12-310001103021us-gaap:TreasuryStockMember2020-12-310001103021us-gaap:RetainedEarningsMember2020-12-310001103021us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-3100011030212021-01-012021-03-310001103021us-gaap:CommonStockMember2021-01-012021-03-310001103021us-gaap:TreasuryStockMember2021-01-012021-03-310001103021us-gaap:RetainedEarningsMember2021-01-012021-03-310001103021us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2021-03-310001103021us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2021-03-310001103021us-gaap:CommonStockMember2021-03-310001103021us-gaap:AdditionalPaidInCapitalMember2021-03-310001103021us-gaap:TreasuryStockMember2021-03-310001103021us-gaap:RetainedEarningsMember2021-03-3100011030212021-03-310001103021us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-3000011030212021-04-012021-06-300001103021us-gaap:CommonStockMember2021-04-012021-06-300001103021us-gaap:TreasuryStockMember2021-04-012021-06-300001103021us-gaap:RetainedEarningsMember2021-04-012021-06-300001103021us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2021-06-300001103021us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2021-06-300001103021us-gaap:CommonStockMember2021-06-300001103021us-gaap:AdditionalPaidInCapitalMember2021-06-300001103021us-gaap:TreasuryStockMember2021-06-300001103021us-gaap:RetainedEarningsMember2021-06-3000011030212021-06-300001103021us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001103021us-gaap:CommonStockMember2021-07-012021-09-300001103021us-gaap:RetainedEarningsMember2021-07-012021-09-300001103021us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2021-09-300001103021us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2021-09-300001103021us-gaap:CommonStockMember2021-09-300001103021us-gaap:AdditionalPaidInCapitalMember2021-09-300001103021us-gaap:TreasuryStockMember2021-09-300001103021us-gaap:RetainedEarningsMember2021-09-30xbrli:pure00011030212020-01-012020-12-310001103021us-gaap:FairValueInputsLevel1Member2021-09-300001103021us-gaap:FairValueInputsLevel2Member2021-09-300001103021us-gaap:FairValueInputsLevel3Member2021-09-300001103021us-gaap:MachineryAndEquipmentMember2021-09-300001103021us-gaap:MachineryAndEquipmentMember2020-12-310001103021us-gaap:ComputerEquipmentMember2021-09-300001103021us-gaap:ComputerEquipmentMember2020-12-310001103021us-gaap:OfficeEquipmentMember2021-09-300001103021us-gaap:OfficeEquipmentMember2020-12-310001103021us-gaap:LeaseholdImprovementsMember2021-09-300001103021us-gaap:LeaseholdImprovementsMember2020-12-310001103021bdsi:IdleEquipmentMember2021-09-300001103021bdsi:IdleEquipmentMember2020-12-310001103021us-gaap:ConstructionInProgressMember2021-09-300001103021us-gaap:ConstructionInProgressMember2020-12-310001103021bdsi:BunavailMember2020-01-012020-09-300001103021bdsi:LicenseAndDistributionRightsMemberbdsi:BelbucaMember2021-09-300001103021bdsi:LicenseAndDistributionRightsMemberbdsi:BelbucaMember2021-01-012021-09-300001103021bdsi:LicenseAndDistributionRightsMemberbdsi:SymproicMember2021-09-300001103021bdsi:LicenseAndDistributionRightsMemberbdsi:SymproicMember2021-01-012021-09-300001103021bdsi:LicenseAndDistributionRightsMemberbdsi:ELYXYBMember2021-09-300001103021bdsi:LicenseAndDistributionRightsMemberbdsi:ELYXYBMember2021-01-012021-09-300001103021bdsi:ProductRightsMember2020-12-310001103021bdsi:LicenseAndDistributionRightsMemberbdsi:BelbucaMember2020-12-310001103021bdsi:LicenseAndDistributionRightsMemberbdsi:BelbucaMember2020-01-012020-12-310001103021bdsi:LicenseAndDistributionRightsMemberbdsi:SymproicMember2020-12-310001103021bdsi:LicenseAndDistributionRightsMemberbdsi:SymproicMember2020-01-012020-12-310001103021bdsi:ELYXYBMember2021-08-032021-08-0300011030212021-08-032021-08-030001103021bdsi:ELYXYBMembersrt:MinimumMember2021-08-032021-08-030001103021bdsi:ELYXYBMembersrt:MaximumMember2021-08-032021-08-030001103021bdsi:BioPharmaCreditPlcMember2019-05-230001103021us-gaap:LondonInterbankOfferedRateLIBORMemberbdsi:BioPharmaCreditPlcMember2021-01-012021-09-300001103021bdsi:BioPharmaCreditPlcMember2021-01-012021-09-300001103021us-gaap:LondonInterbankOfferedRateLIBORMemberbdsi:BioPharmaCreditPlcMember2021-09-300001103021bdsi:BioPharmaCreditPlcMember2021-09-232021-09-230001103021us-gaap:LineOfCreditMemberbdsi:CRGServicingLLCMember2021-09-300001103021bdsi:BelbucaMember2021-07-012021-09-300001103021bdsi:BelbucaMember2020-07-012020-09-300001103021bdsi:BelbucaMember2021-01-012021-09-300001103021bdsi:BelbucaMember2020-01-012020-09-300001103021bdsi:BelbucaMemberus-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-07-012021-09-300001103021bdsi:BelbucaMemberus-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-07-012020-09-300001103021bdsi:BelbucaMemberus-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-012021-09-300001103021bdsi:BelbucaMemberus-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-01-012020-09-300001103021bdsi:SymproicMember2021-07-012021-09-300001103021bdsi:SymproicMember2020-07-012020-09-300001103021bdsi:SymproicMember2021-01-012021-09-300001103021bdsi:SymproicMember2020-01-012020-09-300001103021bdsi:SymproicMemberus-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-07-012021-09-300001103021bdsi:SymproicMemberus-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-07-012020-09-300001103021bdsi:SymproicMemberus-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-012021-09-300001103021bdsi:SymproicMemberus-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-01-012020-09-300001103021bdsi:BunavailMember2021-07-012021-09-300001103021bdsi:BunavailMember2020-07-012020-09-300001103021bdsi:BunavailMember2021-01-012021-09-300001103021bdsi:BunavailMember2020-01-012020-09-300001103021bdsi:BunavailMemberus-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-07-012021-09-300001103021bdsi:BunavailMemberus-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-07-012020-09-300001103021bdsi:BunavailMemberus-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-012021-09-300001103021bdsi:BunavailMemberus-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-01-012020-09-3000011030212020-11-040001103021bdsi:EmployeesAndDirectorsMember2021-01-012021-09-300001103021srt:MinimumMember2021-01-012021-09-300001103021srt:MaximumMember2021-01-012021-09-300001103021us-gaap:ShareBasedPaymentArrangementNonemployeeMember2021-01-012021-09-300001103021us-gaap:ShareBasedPaymentArrangementEmployeeMember2021-01-012021-09-300001103021bdsi:EmployeesAndDirectorsMember2020-01-012020-09-300001103021us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-09-300001103021srt:MinimumMemberus-gaap:RestrictedStockUnitsRSUMember2021-01-012021-09-300001103021us-gaap:RestrictedStockUnitsRSUMembersrt:MaximumMember2021-01-012021-09-300001103021us-gaap:RestrictedStockUnitsRSUMember2020-12-310001103021us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2021-01-012021-09-300001103021us-gaap:ShareBasedPaymentArrangementEmployeeMemberus-gaap:RestrictedStockUnitsRSUMember2021-01-012021-09-300001103021us-gaap:RestrictedStockUnitsRSUMember2021-09-300001103021srt:MinimumMember2021-09-300001103021srt:MaximumMember2021-09-300001103021bdsi:ChiefAccountingOfficerMemberus-gaap:SubsequentEventMember2021-10-252021-10-250001103021bdsi:ChiefAccountingOfficerMemberus-gaap:StockCompensationPlanMemberus-gaap:SubsequentEventMember2021-10-252021-10-250001103021bdsi:ChiefAccountingOfficerMemberus-gaap:SubsequentEventMemberus-gaap:RestrictedStockUnitsRSUMember2021-10-252021-10-25
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________________________
FORM 10-Q
__________________________________
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2021
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                  to                 
Commission file number 001-31361
__________________________________
BioDelivery Sciences International, Inc.
(Exact name of registrant as specified in its charter)
__________________________________
Delaware35-2089858
(State or other jurisdiction of
incorporation or organization)		(I.R.S. Employer
Identification No.)
4131 ParkLake Ave., Suite 225, Raleigh, NC
27612
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number (including area code): 919-582-9050
__________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)		Name of each exchange
on which registered
Common stock, par value $0.001BDSIThe Nasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer, a smaller reporting company or an emerging growth company. See definition of “large accelerated filer”, “accelerated
filer” and “smaller reporting company”, or “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
Large Accelerated Filer☐
Accelerated Filer
☒
Non-Accelerated Filer☐Smaller Reporting Company☐
Emerging Growth Company☐
If an emerging growth company, indicate by check mark if the registrant has elected not use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒
As of November 3, 2021, there were 102,061,623 shares of company Common Stock issued and 98,795,939 shares of company Common Stock outstanding.


BioDelivery Sciences International, Inc. and Subsidiaries
Quarterly Report on Form 10-Q
TABLE OF CONTENTS
Page
Certifications
We own various trademark registrations and applications, and unregistered trademarks, including BioDelivery Sciences International, Inc., BEMA, BELBUCA, ELYXYB, BUNAVAIL, ONSOLIS and our corporate logo. We have an exclusive license to use and display the Symproic registered trademark in order to commercialize Symproic in the United States. All other trade names, trademarks and service marks of other companies appearing in this prospectus are the property of their respective holders. Solely for convenience, the trademarks and trade names in this prospectus may be referred to without the ® and ™ symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend to use or display other companies’ trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

From time to time, we may use our website, our Facebook page at Facebook.com/BioDeliverySI, our Twitter at @BioDeliverySI and our LinkedIn at linkedin.com/company/biodeliverysciencesinternational to distribute material information. Our financial and other material information is routinely posted to and accessible on the "Investors" section of our website, available at www.bdsi.com. Investors are encouraged to review the Investors section of our website because we may post material information on that site that is not otherwise disseminated by us. Information that is contained in and can be accessed through our website, our Facebook page, our LinkedIn page and our Twitter posts are not incorporated into, and does not form a part of, this Quarterly Report.




PART I - FINANCIAL INFORMATION
Item 1. Financial Statements

BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(U.S. DOLLARS, IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS)
(Unaudited)
September 30,
2021		December 31,
2020
ASSETS
Current assets:
Cash and cash equivalents$100,710 $111,584 
Accounts receivable, net57,572 48,150 
Inventory, net23,075 17,443 
Prepaid expenses and other current assets6,904 5,208 
Total current assets188,261 182,385 
Property and equipment, net1,525 1,418 
Goodwill2,715 2,715 
License and distribution rights, net63,569 53,376 
Total assets$256,070 $239,894 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued liabilities$74,580 $52,995 
Notes payable, current3,077 — 
Total current liabilities77,657 52,995 
Notes payable, less current maturities55,638 78,452 
Other long-term liabilities— 213 
Total liabilities133,295 131,660 
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred Stock, 5,000,000 shares authorized; Series B Non-Voting Convertible Preferred Stock, $0.001 par value, 443 shares outstanding at September 30, 2021 and December 31, 2020, respectively.
— — 
Common Stock, $0.001 par value; 235,000,000 shares authorized at September 30, 2021 and December 31, 2020, respectively; 102,057,290 and 101,417,441 shares issued; 98,791,606 and 101,354,447 shares outstanding at September 30, 2021 and December 31, 2020, respectively.
104 104 
Additional paid-in capital454,738 449,264 
Treasury stock, at cost, 3,265,684 and 62,994 shares, as of September 30, 2021 and December 31, 2020, respectively.
(12,155)(252)
Accumulated deficit(319,912)(340,882)
Total stockholders’ equity122,775 108,234 
Total liabilities and stockholders’ equity$256,070 $239,894 
See notes to condensed consolidated financial statements
1

BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(U.S. DOLLARS, IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS)
(Unaudited)
Three months ended September 30,Nine months ended September 30,
2021202020212020
Revenues:
Product sales, net$41,072 $38,785 $122,398 $112,946 
Product royalty revenues20 658 1,151 1,358 
Total revenues:41,092 39,443 123,549 114,304 
Cost of sales6,365 5,376 16,470 16,371 
Expenses:
Selling, general and administrative25,468 22,461 79,007 77,408 
Total expenses:25,468 22,461 79,007 77,408 
Income from operations9,259 11,606 28,072 20,525 
Interest expense, net(1,984)(2,010)(5,962)(4,997)
Other (expense)/income, net— (2)(1)6 
Income before income taxes$7,275 $9,594 $22,109 $15,534 
Income tax provision(606)(211)(1,139)(19)
Net income attributable to common stockholders$6,669 $9,383 $20,970 $15,515 
Basic
Weighted average common stock shares outstanding98,699,857 101,031,317 99,485,399 99,377,748 
Basic earnings per share $0.07 $0.09 $0.21 $0.16 
Diluted
Weighted average common stock shares outstanding102,430,883 105,783,568 103,473,967 104,836,493 
Diluted earnings per share$0.07 $0.09 $0.20 $0.15 
See notes to condensed consolidated financial statements

2
BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(U.S. DOLLARS, IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS)
(Unaudited)
Preferred Stock
Series A		Preferred Stock
Series B		Common StockAdditional
Paid-In
Capital		Treasury
Stock		Accumulated
Deficit		Total
Stockholders’
Equity
SharesAmountSharesAmountSharesAmount
Balances, January 1, 20202,093,155 $2 618 $— 96,189,074 $96 $436,306 $(47)$(366,593)$69,764 
Stock-based compensation— — — — — — 1,520 — — 1,520 
Stock option exercises— — — — 107,287 — 338 — — 338 
Restricted stock awards— — — — 459,670 — — — — — 
Series A conversion to common stock(2,093,155)(2)— — 2,093,155 2 (1)— — (1)
Series B conversion to common stock— — (175)— 972,222 1 — — — 1 
Net income— — — — — — — — 4,966 4,966 
Balances, March 31, 2020— — 443 $— 99,821,408 99 438,163 (47)(361,627)76,588 
Stock-based compensation— — — — — — 4,786 — — 4,786 
Stock option exercises— — — — 983,437 — 2,231 — — 2,231 
Restricted stock awards— — — — 111,666 — — — — — 
Net income— — — — — — — — 1,165 1,165 
Balances, June 30, 2020— — 443 — 100,916,511 99 445,180 (47)(360,462)84,770 
Stock-based compensation— — — — — — 1,539 — — 1,539 
Stock option exercises— — — — 68,623 1 191 — — 192 
Restricted stock awards— — — — 141,318 — — — — — 
Net income— — — — — — — — 9,384 9,384 
Balances, September 30, 2020— — 443 — 101,126,452 100 446,910 (47)(351,078)95,885 
Stock-based compensation— — — — — — 1,750 — — 1,750 
Stock option exercises— — — — 240,656 1 608 — — 609 
Restricted stock awards— — — — 50,333 3 (4)— — (1)
Share repurchase— — — — — — — (205)— (205)
Net income— — — — — — — — 10,196 10,196 
Balances, December 31, 2020— — 443 — 101,417,441 104 449,264 (252)(340,882)108,234 
Stock-based compensation— — — — — — 1,490 — — 1,490 
Stock option exercises— — — — 16,619 — 40 — — 40 
Restricted stock awards— — — — 268,174 — — — — — 
Share repurchase— — — — — — — (6,147)— (6,147)
Net income— — — — — — — — 5,237 5,237 
Balances, March 31, 2021— — 443 — 101,702,234 104 450,794 (6,399)(335,645)108,854 
Stock-based compensation— — — — — — 1,697 — — 1,697 
Stock option exercises— — — — 25,828 — 59 — — 59 
Restricted stock awards— — — — 66,668 — — — — — 
Share repurchase— — — — — — — (5,756)— (5,756)
Net income— — — — — — — — 9,064 9,064 
Balances, June 30, 2021— — 443 — 101,794,730 104452,550(12,155)(326,581)113,918
Stock-based compensation— — — — — — 1,837 — — 1,837 
Stock option exercises— — — — 113,243 — 351 — — 351 
Restricted stock awards— — — — 149,317 — — — — — 
Net income— — — — — — — — 6,669 6,669 
Balances, September 30, 2021— $— 443 $— 102,057,290 $104 $454,738 $(12,155)$(319,912)$122,775 

See notes to condensed consolidated financial statements
3
BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(U.S. DOLLARS, IN THOUSANDS)
(Unaudited)
Nine months ended September 30,
20212020
Operating activities:
Net income$20,970 $15,515 
Adjustments to reconcile net income to net cash flows from operating activities
Depreciation97 467 
Accretion of debt discount and loan costs264 231 
Amortization of intangible assets5,262 5,248 
Provision for/(release of) inventory obsolescence1,100 (297)
Stock-based compensation expense5,024 7,845 
Net change in operating lease assets and liabilities(30)— 
Changes in assets and liabilities:
Accounts receivable(9,422)(5,040)
Inventories(6,731)(7,278)
Prepaid expenses and other assets(1,856)(1,985)
Accounts payable and accrued liabilities12,005 (701)
Taxes payable606 (40)
Net cash flows provided by operating activities27,289 13,965 
Investing activities:
Product acquisitions(6,456)— 
Acquisitions of property, plant and equipment(415)— 
Net cash flows used in investing activities(6,871)— 
Financing activities:
Payment on notes payable(20,000)— 
Proceeds from notes payable— 20,000 
Proceeds from exercise of stock options611 2,761 
Payment on share repurchase(11,903)— 
Payment on deferred financing fees— (437)
Net cash flows (used in)/provided by financing activities(31,292)22,324 
Net change in cash and cash equivalents(10,874)36,289 
Cash and cash equivalents at beginning of period111,584 63,888 
Cash and cash equivalents at end of period$100,710 $100,177 
Cash paid for interest$5,726 $5,037 
Cash paid for taxes$1,275 $318 
See notes to condensed consolidated financial statements

4
BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(U.S. DOLLARS, IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
(Unaudited)
1. Organization, basis of presentation and summary of significant policies:

Overview
BioDelivery Sciences International, Inc., together with its subsidiaries (collectively, the “Company”) is a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions. The Company has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive ("BEMA") drug-delivery technology to develop and commercialize new applications of proven therapies aimed at addressing important unmet medical needs. The Company commercializes its products in the U.S. using its own sales force while working in partnership with third parties to commercialize its products outside the U.S.
The accompanying unaudited condensed consolidated financial statements include all adjustments (consisting of normal and recurring adjustments) necessary for a fair presentation of these financial statements. The condensed consolidated balance sheet at December 31, 2020 has been derived from the Company’s audited consolidated financial statements included in its annual report on Form 10-K for the year ended December 31, 2020. Certain footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to the Securities and Exchange Commission rules and regulations. It is recommended that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2020.
As used herein, the Company’s common stock, par value $0.001 per share, is referred to as the “Common Stock” and the Company’s preferred stock, par value $0.001 per share, is referred to as the “Preferred Stock”.
Principles of consolidation
The condensed consolidated financial statements include the accounts of the Company, Arius Pharmaceuticals, Inc. and Arius Two, Inc. All significant inter-company balances and transactions have been eliminated.
Use of estimates in financial statements
The preparation of the accompanying condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. The Company reviews all significant estimates affecting the condensed consolidated financial statements on a recurring basis and records the effect of any necessary adjustments prior to their issuance. Significant estimates made by the Company include: revenue recognition associated with sales allowances such as government program rebates, customer voucher redemptions, commercial contracts, rebates and chargebacks; sales returns reserves; sales bonuses; stock-based compensation; and deferred income taxes.
Cash and cash equivalents
Cash and cash equivalents consist of operating and money market accounts. Cash equivalents are carried at cost which approximates fair value due to their short-term nature. The Company considers all highly-liquid investments with an original maturity of 90 days or less to be cash equivalents.
The Company maintains cash equivalent balances with financial institutions that management believes are of high credit quality. The Company’s cash and cash equivalents accounts at times may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk from cash and cash equivalents.
Inventory
Inventories are stated at the lower of cost or net realizable value with costs determined for each batch under the first-in, first-out method. Inventory consists of raw materials, work in process and finished goods. Raw materials include amounts of active pharmaceutical ingredient for a product to be manufactured; work in process includes the bulk inventory of laminate (the
5
BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(U.S. DOLLARS, IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
(Unaudited)
Company’s drug delivery film) prior to being packaged for sale; and finished goods include pharmaceutical products ready for commercial sale.
On a quarterly basis, the Company analyzes its inventory levels and records allowances for inventory that has become obsolete, inventory that has a cost basis in excess of the expected net realizable value and inventory that is in excess of expected demand based upon projected product sales. Inventory obsolescence reserves at September 30, 2021 and December 31, 2020 were $3.4 million and $2.3 million, respectively.
Revenue recognition
Product sales
Product sales amounts relate to sales of BELBUCA and Symproic. Product sales for the nine months ended September 30, 2020 also included sales of BUNAVAIL. Product sales for BUNAVAIL during the three months ended September 30, 2020 were related to the release of gross to net reserves. The Company recognizes revenue on product sales when control of the promised goods is transferred to its customers in an amount that reflects the consideration expected to be received in exchange for transferring those goods. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. When determining whether the customer has obtained control of the goods, the Company considers any future performance obligations. Generally, there is no post-shipment obligation on product sold.
Product royalty revenues
Product royalty revenue amounts are based on sales revenue of the PAINKYL™ product under the Company’s license agreement with TTY Biopharm Co., Ltd., ("TTY") and the BREAKYL™ product under the Company’s license agreement with Meda AB, which was acquired by Mylan N.V. and later acquired by Viatris, Inc. (which we refer to herein as Viatris). Product royalty revenues are recognized when control of the product is transferred to the license partner in an amount that reflects the consideration expected to be received. Supplemental sales-based product royalty revenue may also be earned upon the subsequent sale of the product at agreed upon contractual rates.

Performance obligations
A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The majority of the Company’s product sales contracts have a single performance obligation as the promise to transfer the individual goods is not separately identifiable from other promises in the contracts and, therefore, not distinct. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. The Company has assessed the existence of a significant financing component in the agreements with its customers. The trade payment terms with its customers do not exceed one year and therefore the Company has elected to apply the practical expedient and no amount of consideration has been allocated as a financing component.

Transaction price, including variable consideration
Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration for which reserves are established. Components of variable consideration include trade discounts and allowances, product returns, government chargebacks, discounts and rebates, and other incentives, such as voucher programs, and other fee for service amounts that are detailed within contracts between the Company and its customers relating to the Company’s sale of its products.
The Company establishes allowances for estimated rebates, chargebacks and product returns based on numerous qualitative and quantitative factors, including:
•specific contractual terms of agreements with customers;
•estimated levels of inventory in the distribution channel;
•historical rebates, chargebacks and returns of products;
•direct communication with customers;
•anticipated introduction of competitive products or generics;
6
BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(U.S. DOLLARS, IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
(Unaudited)
•anticipated pricing strategy changes by the Company and/or its competitors;
•analysis of prescription data gathered by third-party prescription data providers;
•the impact of changes in state and federal regulations; and
•the estimated remaining shelf life of products.
In its analyses, the Company uses prescription data purchased from a third-party data provider to develop estimates of historical inventory channel sell-through. The Company utilizes an internal analysis to compare historical net product shipments to estimated historical prescriptions written. Based on that analysis, management develops an estimate of the quantity of product in the channel which may be subject to various rebate and chargeback exposures. To estimate months of ending inventory in the Company’s distribution channel, the Company divides estimated ending inventory in the distribution channel by the Company’s recent prescription data, not considering any future anticipated demand growth beyond the succeeding quarter. Monthly for each product line, the Company prepares an internal estimate of ending inventory units in the distribution channel by adding estimated inventory in the channel at the beginning of the period, plus net product shipments for the period, less estimated prescriptions written for the period, and less units included in the sales returns reserve expected to be returned. This is done for each product line by applying a rate of historical activity for rebates and chargebacks, adjusted for relevant quantitative and qualitative factors discussed above, to the potential exposed product estimated, net of reserved return units, to be in the distribution channel. In addition, the Company receives daily information from the major wholesalers regarding their sales and actual on-hand inventory levels of the Company’s products. This enables the Company to execute accurate provisioning procedures.
Revenue from product sales is recorded after considering the impact of the following variable consideration amounts at the time of revenue recognition:
Product returns-Consistent with industry practice, the Company offers contractual return rights that allow its customers to return the products within an 18-month period that begins six months prior to and ends twelve months after expiration of the products. The Company estimates product returns reserves based upon historical return rates adjusted for qualitative factors and are applied to open product batches that are currently eligible for returns, or will be eligible in the future, within company policy. Other factors considered include expected marketplace changes and the remaining shelf life of product batches. Product returns reserves for newly launched products are based on historical rates of similar products or pre-determined percentage.
Government rebates and chargebacks-Government rebates and chargebacks include mandated discounts under Medicaid, Medicare, U.S. Department of Veterans Affairs and other government agencies ("Government Payors"). The Company estimates the rebates and chargebacks to Government Payors based upon a combination of historical experience, product pricing, estimated payor mix, product growth, and the mix of contract and agreement terms. These reserves are recorded in the same period the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets. In addition, the pricing of covered products under Medicaid is subject to complex calculations and involves interpretation of government rules, regulations and policies as well as adjustments based on current trends in utilization. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company estimates the rebates and chargebacks that it will provide to Government Payors based upon (i) the government-mandated discounts applicable to government-funded programs, (ii) information obtained from its customers and (iii) information obtained from other third parties regarding the payor mix for its products. The Company’s liability for these rebates consists of estimates of claims for the current quarter and estimated future claims that will be made for product shipments that have been recognized as revenue, but remain in the distribution channel inventories at the end of each reporting period.
Commercial Contracts-The Company estimates the rebates to commercial contracts based upon a combination of historical experience, product pricing, estimated payor mix, product growth, and the mix of contract and agreement terms. These reserves are recorded in the same period the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets.
Patient Assistance Voucher program-The Company, from time to time, offers certain promotional product-related incentives to eligible patients. The Company has voucher programs for BELBUCA and Symproic whereby the Company offers a point-of-sale subsidy to retail consumers. The Company estimates its liabilities for these voucher programs based on the current utilization and historical redemption rates as reported to the Company by a third-party claims processing organization. The
7
BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(U.S. DOLLARS, IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
(Unaudited)
Company accounts for the costs of these special promotional programs as price adjustments, which are a reduction of gross revenue.
Trade discounts and distribution fees-Trade discounts relate to prompt settlement discounts provided to customers. In addition, the Company compensates its customers for distribution of its products and the provision of data. The Company has determined that such services received to date are not distinct from its sale of products and may not reasonably represent fair value for these services. Therefore, estimates of these payments are recorded as a reduction of revenue based on contractual terms.
There can be a significant lag between the Company's establishment of an estimate and the timing of the invoicing or claim. The Company believes it has made reasonable estimates for future rebates and claims, however, these estimates involve assumptions pertaining to contractual utilization and performance, and payor mix. If the performance or mix across third-party payors is different from the Company’s estimates, the Company may be required to pay higher or lower total price adjustments and/or chargebacks than it had estimated.
Cost of sales
Cost of sales includes the direct costs attributable to the production of BELBUCA and Symproic. It includes raw materials, production costs at the Company’s contract manufacturing sites, quality testing directly related to the products, inventory reserves, and depreciation on equipment that the Company has purchased to produce BELBUCA, Symproic and formerly BUNAVAIL. It also includes any batches not meeting specifications and raw material yield losses. Yield losses and the costs related to batches not meeting specifications are expensed as incurred. Cost of sales is recognized when sold to the wholesaler from our distribution center.
For BREAKYL and PAINKYL (the Company’s out-licensed breakthrough cancer pain therapies), cost of sales includes all costs related to creating the product at the Company’s contract manufacturing location in Germany. The Company’s contract manufacturer bills the Company for the final product, which includes materials, direct labor costs, quality testing, and certain overhead costs as outlined in applicable supply agreements.
Cost of sales also includes royalty expenses that the Company owes to third parties.
Measurement of credit losses of financial instruments
The Company is exposed to credit losses primarily through its product sales. The Company assesses each counterparty’s ability to pay for the products it sells by conducting a credit review. The credit review considers the Company's expected billing exposure and timing for payment and the counterparty’s established credit rating or the Company's assessment of the counterparty’s creditworthiness based on the Company's analysis of their financial statements when a credit rating is not available. The Company also considers contract terms and conditions, and business strategy in its evaluation. A credit limit is established for each counterparty based on the outcome of this review.
The Company monitors its ongoing credit exposure through active review of counterparty balances against contract terms and due dates. The Company's activities include timely account reconciliations, dispute resolution and payment confirmations. The Company may employ collection agencies and legal counsel to pursue recovery of defaulted receivables.
As of September 30, 2021, the Company reported $57.6 million of trade receivables within accounts receivable. Based on an aging analysis at September 30, 2021, 96% of the Company's accounts receivable were outstanding less than 30 days. There was no change to the allowance for doubtful accounts and credit losses between September 30, 2021 and December 31, 2020. The Company writes off accounts receivable when management determines they are uncollectible and credits payments subsequently received on such receivables to bad debt expense in the period received.
New Accounting Pronouncements, adopted
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740)—Simplifying the Accounting for Income Taxes, which is intended to simplify accounting for income taxes. It removes certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020 and early adoption is permitted. The Company adopted Topic 740 during the nine months ended September 30, 2021 and determined that the new guidance did not have a material impact on its consolidated financial statements.

8
BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(U.S. DOLLARS, IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
(Unaudited)
The Company has reviewed other new accounting pronouncements that were issued as of September 30, 2021 and does not believe that these pronouncements are applicable to the Company, or that they will have a material impact on its financial position or results of operations.

Fair Value of Financial Instruments
The Company measures the fair value of instruments in accordance with GAAP which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.
GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company considers the carrying amount of its cash and cash equivalents to approximate fair value due to short-term nature of this instrument. GAAP describes three levels of inputs that may be used to measure fair value:
Level 1 – quoted prices in active markets for identical assets or liabilities
Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable
Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)
The following table summarizes the financial instruments measured at fair value on a recurring basis as of September 30, 2021:
Level 1Level 2Level 3Balance at September 30, 2021
Cash and cash equivalents$100,710 $— —$100,710 
The cash and cash equivalent balance as of September 30, 2021 includes investments in various money market accounts and cash held in interest bearing accounts.
2. Inventory, net:
The following table represents the components of inventory as of:
September 30,
2021		December 31,
2020
Raw materials $4,143 $3,389 
Work-in-process6,765 9,949 
Finished goods15,520 6,359 
Obsolescence reserve(3,353)(2,254)
Total inventories, net$23,075 $17,443 

9
BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(U.S. DOLLARS, IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
(Unaudited)
3. Accounts payable and accrued liabilities:
The following table represents the components of accounts payable and accrued liabilities as of:
September 30,
2021		December 31,
2020
Accounts payable$7,033 $4,213 
Accrued rebates38,179 34,247 
Accrued compensation and benefits6,832 5,488 
Accrued returns8,009 5,128 
Accrued royalties1,138 704 
Taxes payable583 1,026 
Accrued legal1,819 515 
Accrued regulatory expenses294 397 
Product rights payable9,000 — 
Accrued other1,693 1,277 
Total accounts payable and accrued liabilities$74,580 $52,995 

4. Property and equipment:
Property and equipment, summarized by major category, consist of the following as of:
September 30,
2021		December 31,
2020
Machinery & equipment$4,849 $4,683 
Right of use, building lease260 471 
Computer equipment & software640 272 
Office furniture & equipment174 174 
Leasehold improvements43 43 
Idle equipment679 679 
Construction in progress— 119 
Total6,645 6,441 
Less accumulated depreciation and amortization(5,120)(5,023)
Total property and equipment, net$1,525 $1,418 
Depreciation expense for the three-month periods ended September 30, 2021 and September 30, 2020, was approximately $0.04 million and $0.2 million, respectively. Depreciation expense for the nine-month periods ended September 30, 2021 and September 30, 2020, was approximately $0.1 million and $0.5 million, respectively. Depreciation expense for the nine- month period ended September 30, 2020 includes a $0.3 million one-time charge due to BUNAVAIL equipment write-off.





10
BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(U.S. DOLLARS, IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
(Unaudited)
5. Intangible assets:
Other intangible assets, net, consisting of product rights and licenses are summarized as follows:
September 30, 2021Gross Carrying
Value		Accumulated
Amortization		Intangible Assets,
net		Weighted Average Useful Life
BELBUCA license and distribution rights45,000 (21,375)23,625 5.5
Symproic license and distribution rights30,636 (6,087)24,549 10.5
ELYXYB product rights15,455 (60)15,395 14.8
Total intangible assets$91,091 $(27,522)$63,569 8.8
December 31, 2020Gross Carrying
Value		Accumulated
Amortization		Intangible Assets,
net		Weighted Average Useful Life
Product rights$6,050 $(6,050)$— 
BELBUCA license and distribution rights45,000 (18,000)27,000 6.0
Symproic license and distribution rights30,636 (4,260)26,376 10.8
Total intangible assets$81,686 $(28,310)$53,376 7.9

6. Acquired product rights:
On August 3, 2021, (the “Effective Date”), the Company and Dr. Reddy’s Laboratories Limited, a company incorporated under the laws of India (“DRL”), entered into an asset purchase agreement (the “Asset Purchase Agreement”) for the acquisition by the Company from DRL of certain patents, trademarks, regulatory approvals and other rights related to ELYXYB™ (celecoxib oral solution) (the “Product”) and its commercialization in the United States and Canada (the “Territory”). The closing of the transactions contemplated by the Asset Purchase Agreement occurred on September 9, 2021 (the "Closing").
Pursuant to the terms of the Asset Purchase Agreement, the Company paid DRL a $6 million up-front payment at the Closing. In addition, the Company will pay DRL $9 million on the twelve-month anniversary of the Effective Date and up to an additional $9 million upon achievement of certain regulatory milestones and quarterly earn-out payments on potential sales of the Product in the Territory that range from high single digits to the low double digits (subject to reduction in certain circumstances) of net sales based on volume of sales. DRL will also be entitled to one-time payments upon the achievement of six escalating sales milestones, which range from $4 million to be paid upon the achievement of $50 million in net sales in a calendar year to $100 million to be paid upon the achievement of $1 billion in net sales in a calendar year up to a total of $262 million.
The Company accounted for the ELYXYB purchase as an asset acquisition under ASC 805-10-55-5b, which provides guidance for asset acquisitions. Under the guidance, if substantially all the acquisition is made up of one asset or several similar assets, then the acquisition is an asset acquisition. The Company believes that the asset purchase agreement and other assets acquired from DRL are similar and considers them all to be intangible assets.
The total purchase price was allocated to the acquired asset based on their relative estimated fair values, as follows:
ELYXYB acquired product rights$15,000
Transaction expenses455
Total value$15,455
The $9 million twelve-month anniversary payment has been recorded in accounts payable and accrued liabilities in the accompanying condensed consolidated balance sheet.

11
BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(U.S. DOLLARS, IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
(Unaudited)
7. Notes payable:
On May 23, 2019, the Company entered into a Loan Agreement with BPCR LIMITED PARTNERSHIP (the successor-in-interest to Biopharma Credit PLC), for a senior secured credit facility consisting of a term loan of $60.0 million (the “Term Loan”), with the ability to draw an additional $20.0 million within twelve months of the closing date, which the Company drew down on May 22, 2020.
The loan facility carries a 72-month term with interest only payments on the term loan for the first 36 months. The Term Loan will mature in May 2025 and bears an interest rate of 7.5% plus the LIBOR rate on the first day for the quarter, with a floor of 2% for the LIBOR rate (LIBOR effective rate as of July 1, 2021 was 0.14%.) The Term Loan is subject to mandatory prepayment provisions that require prepayment upon change of control.
On September 23, 2021, the Company elected to repay $20 million plus accrued interest of $1.5 million, representing a portion of the first tranche. The Term loan includes the option for the Company to paydown up to $20 million of tranche A without incurring any prepayment penalties after the 24 month anniversary of the loan. As a result, no prepayment penalty was incurred in connection with this prepayment.
The debt balance has been categorized within Level 2 of the fair value hierarchy. The notes payable debt balance as of September 30, 2021 approximates its fair value based on prevailing interest rates as of the balance sheet date.
The following table represents future maturities of the notes payable obligation as of September 30, 2021:
2021— 
20224,615 
202318,462 
202424,615 
202512,308 
Total maturities$60,000 
Unamortized discount and loan costs(1,285)
Total notes payable obligation$58,715 

8. Net sales by product:
The Company’s business is classified as a single reportable segment.
However, the following table presents net sales by product:
Three months ended September 30,
Nine months ended September 30,
2021202020212020
BELBUCA$36,930 $34,758 $109,836 $100,572 
     % of net product sales90 %90 %90 %89 %
Symproic4,142 3,453 12,562 11,046 
     % of net product sales10 %9 %10 %10 %
BUNAVAIL— 574 — 1,328 
     % of net product sales— %1 %— %1 %
Net product sales$41,072 $38,785 $122,398 $112,946 


12
BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(U.S. DOLLARS, IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
(Unaudited)
9. Stockholders’ equity:
Common Stock
On November 4, 2020, the Board of Directors authorized the repurchase of up to $25 million of the Company's shares of Common Stock. The timing and amount of any shares purchased on the open market will be determined based on the Company's evaluation of market conditions, share price and other factors. The Company plans to utilize existing cash on hand to fund the share repurchase program.

During the nine months ended September 30, 2021, a cumulative total of 3,202,690 shares, with a weighted average price of $3.72, for a value of $11.9 million,were repurchased and recorded as Treasury Stock in the condensed consolidated balance sheet.
Stock-based compensation
During the nine months ended September 30, 2021, a total of 3,192,505 options to purchase Common Stock, with an aggregate fair market value of approximately $12.9 million, were granted to employees, executive officers and Board of Directors of the Company. Options have a term of 10 years from the grant date. Options granted to employees and officers will vest ratably over a three-year period. Options granted to Board of Directors vest one half immediately and the remaining half on the anniversary of grant.
The fair value of each option award is estimated on the grant date using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, expected rate of forfeiture and the risk-free interest rate. Expected volatilities are based on implied volatilities from historical volatility of the Common Stock, and other factors estimated over the expected term of the options.
Expected term of options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus contract term. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term.
The key assumptions used in determining the fair value of options granted during the nine months ended September 30, 2021 follows:
Expected price volatility
53.70%-59.87%
Risk-free interest rate
0.50%-1.17%
Weighted average expected life in years6 years
Dividend yield— 
Option activity during the nine months ended September 30, 2021 was as follows:
Number of
shares		Weighted average
exercise price per
share		Aggregate
intrinsic
value
Outstanding at January 1, 20217,060,966 $4.55 $2,831 
Granted in 2021:
Officers and Directors1,345,292 3.83 
Employees1,847,213 4.20 
Exercised(155,690)2.90 
Forfeitures(539,802)4.72 
Outstanding at September 30, 20219,557,979 $4.40 $8,589 
During the nine months ended September 30, 2021 and 2020, Company employees and directors exercised approximately 155,690 and 1,159,347 stock options, respectively, with net proceeds to the Company of approximately $0.5 million and
13
BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(U.S. DOLLARS, IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
(Unaudited)
$2.8 million, respectively. The intrinsic value of options exercised during the nine months ended September 30, 2021 and 2020 was approximately $0.1 million and $3.1 million, respectively.
As of September 30, 2021, options exercisable totaled 4,153,242. There are approximately $9.3 million of unrecognized compensation costs related to non-vested share-based compensation awards, including options and restricted stock units (“RSUs”) granted. These costs will be expensed through 2024.
Restricted stock units
During the nine months ended September 30, 2021, a cumulative total of 278,369 RSUs were granted to the Company’s executive officers, members of senior management and the Board of Directors, with a fair market value of approximately $1.1 million. The fair value of restricted units is determined using quoted market prices of the Common Stock and the number of shares expected to vest. RSU grants are time-based, all of which generally vest from a one to three-year period.
Restricted stock activity during the nine months ended September 30, 2021 was as follows:
Number of
restricted
shares		Weighted
average fair
market value
per RSU
Outstanding at January 1, 2021940,759 $3.71 
Granted:
Officers and Directors242,562 3.83 
Employees35,807 3.84 
Vested(484,159)3.84 
Forfeitures— — 
Outstanding at September 30, 2021734,969 $4.08 
Warrants

The Company has granted warrants to purchase shares of Common Stock. Warrants may be granted to affiliates in connection with certain agreements.

As of September 30, 2021, a cumulative total of 2,051,033 warrants, with exercise prices ranging from $2.38 to $3.42, remain exercisable and outstanding. The warrants were valued using the Black-Scholes Model, which a cumulative fair value of approximately $4.5 million. There were no warrants granted or exercised during the nine months ended September 30, 2021.

Preferred Stock
As of September 30, 2021, 443 shares of Series B Preferred Stock (“Series B”) are outstanding. There were no conversions of Series B during the nine months ended September 30, 2021.
14
BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(U.S. DOLLARS, IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
(Unaudited)
Earnings Per Share
Three months ended September 30,Nine months ended September 30,
2021202020212020
Basic:
Net income attributable to common stockholders, basic$6,669 $9,383 $20,970 $15,515 
Weighted average common shares outstanding98,699,857 101,031,317 99,485,399 99,377,748 
Basic earnings per common share$0.07 $0.09 $0.21 $0.16 
Diluted:
Effect of dilutive securities:
Net income attributable to common stockholders, diluted$6,669 $9,383 $20,970 $15,515 
Weighted average common shares outstanding98,699,857 101,031,317 99,485,399 99,377,748 
Effect of dilutive options and warrants3,731,026 4,752,251 3,988,568 5,458,745 
Dilutive weighted average common shares outstanding102,430,883 105,783,568 103,473,967 104,836,493 
Diluted earnings per common share$0.07$0.09$0.20$0.15
10. Commitments and contingencies:
The Company is involved from time to time in routine legal matters incidental to our business. Based upon available information, the Company believes that the resolution of such matters will not have a material adverse effect on its condensed consolidated financial position or results of operations. Except as discussed below, the Company is not the subject of any pending legal proceedings and, to the knowledge of management, no proceedings are presently contemplated against the Company by any federal, state or local governmental agency.
Indivior (formerly RB Pharmaceuticals Ltd.) and Aquestive Therapeutics (formerly MonoSol Rx)
The following disclosure regarding the Company’s ongoing litigations with Aquestive Therapeutics, Inc. (formerly MonoSol Rx, “Aquestive”) and Indivior PLC (formerly RB Pharmaceuticals Limited, “Indivior”) is intended to provide some background and an update on the matter as per disclosure requirements of the SEC. Additional details regarding the past procedural history of the matter can be found in the Company’s previously filed periodic filings with the SEC.

Litigation related to BUNAVAIL
On October 29, 2013, Reckitt Benckiser, Inc., Indivior, and Aquestive (collectively, the “RB Plaintiffs”) filed an action against the Company relating to its BUNAVAIL product in the United States District Court for the Eastern District of North Carolina (“EDNC”) for alleged patent infringement. BUNAVAIL is a drug approved for the maintenance treatment of opioid dependence. The RB Plaintiffs claim that the formulation for BUNAVAIL, which has never been disclosed publicly, infringes its US Patent No. 8,475,832 (the “‘832 Patent”). On May 21, 2014, the Court granted the Company’s motion to dismiss.
On January 22, 2014, Aquestive initiated an inter partes review (“IPR”) on U.S. Patent No. 7,579,019, the (“‘019 Patent”). The PTAB upheld all claims of the Company’s ‘019 Patent in 2015 and this decision was not appealed by Aquestive.
On September 20, 2014, the Company proactively filed a declaratory judgment action in the United States District Court for the EDNC requesting the Court to make a determination that the Company’s BUNAVAIL product does not infringe the ‘832 Patent, US Patent No. 7,897,080 (the “‘080 Patent”) and US Patent No. 8,652,378 (the “‘378 Patent”). The Company invalidated the “‘080 Patent” in its entirety in an inter partes reexamination proceeding. The Company invalidated all relevant claims of the ‘832 Patent in an IPR proceeding. And, in an IPR proceeding for the ‘378 Patent, in its decision not to institute the IPR proceeding, the PTAB construed the claims of the ‘378 Patent narrowly. Shortly thereafter, by joint motion of the parties, the ‘378 Patent was subsequently removed from the action.
On June 6, 2016, in an unrelated case in which Indivior and Aquestive asserted the ‘832 Patent against other parties, the Delaware District Court entered an order invalidating other claims in the ‘832 Patent. Indivior and Aquestive did not appeal the
15
BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(U.S. DOLLARS, IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
(Unaudited)
Delaware Court’s holding that other claims of the ‘832 Patent are invalid. On February 10, 2021, the parties in our EDNC declaratory judgment action filed a covenant by Indivior and Aquestive not to sue us for infringement of the ‘832 Patent. In view of that covenant and the prior invalidation of the ‘080 patent, we filed a notice of voluntary dismissal of the Company’s EDNC declaratory judgement action.
On September 22, 2014, the RB Plaintiffs filed an action against the Company (and the Company’s commercial partner) relating to the Company’s BUNAVAIL product in the United States District Court for the District of New Jersey for alleged patent infringement. The RB Plaintiffs claim that BUNAVAIL, whose formulation and manufacturing processes have never been disclosed publicly, infringes its patent U.S. Patent No. 8,765,167 (the “‘167 Patent”). The Company believes this is an anticompetitive attempt by the RB Plaintiffs to distract the Company’s efforts from commercializing BUNAVAIL.
On December 12, 2014, the Company filed a motion to transfer the case from New Jersey to North Carolina and a motion to dismiss the case against its commercial partner. On October 28, 2014, the Company filed multiple IPR petitions on certain claims of the ‘167 Patent. The USPTO instituted three of the four IPR petitions. The PTAB upheld the claims and denied collateral estoppel applied to the PTAB decisions in March 2016. The Company appealed to Court of Appeals for the Federal Circuit. The USPTO intervened with respect to whether collateral estoppel applied to the PTAB.
On June 19, 2018, the Company filed a motion to remand the case for further consideration by the PTAB in view of intervening authority. On July 31, 2018, the Federal Circuit vacated the decisions, and remanded the ‘167 Patent IPRs for further consideration on the merits.
On February 7, 2019, the PTAB issued three decisions on remand purporting to deny institution of the three previously instituted IPRs of the ‘167 patent. On March 11, 2019, the Company timely appealed the PTAB decisions on remand to U.S. Court of Appeal for the Federal Circuit. On March 20, 2019, Aquestive and Indivior moved to dismiss the appeal, and the Company opposed that motion.
On August 29, 2019, a three-judge panel of the Court of Appeals for the Federal Circuit granted the motion and dismissed the Company’s appeal. On September 30, 2019, the Company filed a petition for an en banc rehearing of the order dismissing the Company’s appeal by the full Federal Circuit Court of Appeals.
On January 13, 2020, by the Court of Appeals for the Federal Circuit denied BDSI’s petition for en banc rehearing of the dismissal of BDSI’s appeal relating to inter partes review proceedings on the ’167 patent. On June 11, 2020, BDSI filed a petition for certiorari seeking U.S. Supreme Court review of the Federal Circuit’s decision. On October 5, 2020, the U.S. Supreme Court denied the Company’s petition for certiorari.
The Company strongly refutes as without merit the Plaintiffs’ assertion of patent infringement and will vigorously defend the lawsuit.

Litigation related to BELBUCA
On January 13, 2017, Aquestive filed a complaint in the United States District Court for the District of New Jersey alleging BELBUCA infringes the ‘167 Patent. In lieu of answering the complaint, the Company filed motions to dismiss the complaint and, in the alternative, to transfer the case to the EDNC. On July 25, 2017, the New Jersey Court administratively terminated the case pending the parties submission of a joint stipulation of transfer because the District of New Jersey was an inappropriate venue. This case was later transferred to the Delaware District Court. On October 31, 2017, the Company filed motions to dismiss the complaint and, in the alternative, to transfer the case to the EDNC. On October 16, 2018, denying the motion to dismiss as moot, the Delaware District Court granted the Company’s motion to transfer the case to the EDNC. On November 20, 2018, the Company moved the EDNC to dismiss the complaint for patent infringement for failure to state a claim for relief.
On August 6, 2019, the EDNC granted the Company’s motion to dismiss, and dismissed the complaint without prejudice. On or about November 11, 2019, Aquestive refiled a complaint in the EDNC against the Company alleging that BELBUCA infringes the ‘167 Patent. On January 13, 2020, in lieu of answering the complaint, we filed a motion to dismiss the complaint. After the two motions were denied, on April 16, 2020, we answered the complaint. Aquestive moved to dismiss our counter-claim of unenforceability, but the court denied that motion. The Company strongly refutes as without merit Aquestive’s assertion of patent infringement and will vigorously defend the lawsuit.



16
BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(U.S. DOLLARS, IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
(Unaudited)
Teva Pharmaceuticals USA (formerly Actavis)
On February 8, 2016, the Company received a notice relating to a Paragraph IV certification from Teva Pharmaceuticals USA, or (formerly Actavis, “Teva”) seeking to find invalid three Orange Book listed patents relating specifically to BUNAVAIL. The Paragraph IV certification related to an ANDA filed by Teva with the FDA for a generic formulation of BUNAVAIL. The patents subject to Teva’s certification were the ‘019 Patent, U.S. Patent No. 8,147,866 (the “‘866 Patent”) and 8,703,177 (the “‘177 Patent”).
On March 18, 2016, the Company asserted three different patents against Teva, the ‘019 Patent, the ‘866 Patent, and the ‘177 Patent. Teva did not raise non-infringement positions about the ‘019 and the ‘866 Patents in its Paragraph IV certification. Teva did raise a non-infringement position on the ‘177 Patent but the Company asserted in its complaint that Teva infringed the ‘177 Patent either literally or under the doctrine of equivalents.
On December 20, 2016 the USPTO issued U.S. Patent No. 9,522,188 (the “‘188 Patent””), and this patent was properly listed in the Orange Book as covering the BUNAVAIL product. On February 23, 2017 Teva sent a Paragraph IV certification adding the 9,522,188 to its ANDA. An amended Complaint was filed, adding the ‘188 Patent to the litigation.
On January 31, 2017, the Company received a notice relating to a Paragraph IV certification from Teva relating to Teva’s ANDA on additional strengths of BUNAVAIL and on March 16, 2017, the Company brought suit against Teva and its parent company on these additional strengths. On June 20, 2017, the Court entered orders staying both BUNAVAIL suits at the request of the parties.
On May 23, 2017, the USPTO issued U.S. Patent 9,655,843 (the “‘843 Patent”) relating to the BEMA technology, and this patent was properly listed in the Orange Book as covering the BUNAVAIL product.
Finally, on October 12, 2017, the Company announced that it had entered into a settlement agreement with Teva that resolved the Company’s BUNAVAIL patent litigation against Teva pending in the U.S. District Court for the District of Delaware. As part of the Settlement Agreement, which is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice, the Company has entered into a non-exclusive license agreement with Teva that permits Teva to first begin selling its generic version of BUNAVAIL in the U.S. on July 23, 2028 or earlier under certain circumstances. Other terms of the agreement are confidential.
The Company received notices regarding Paragraph IV certifications from Teva on November 8, 2016, November 10, 2016, and December 22, 2016, seeking to find invalid two Orange Book listed patents relating specifically to BELBUCA. The Paragraph IV certifications relate to three ANDAs filed by Teva with the FDA for a generic formulation of BELBUCA. The patents subject to Teva’s certification were the ‘019 Patent and the ‘866 Patent. The Company filed complaints in Delaware against Teva on December 22, 2016 and February 3, 2017 in which it asserted against Teva the ‘019 Patent and the ‘866 Patent. Teva did not contest infringement of the claims of the ‘019 Patent and did not contest infringement of the claims of the ‘866 Patent. The ‘019 Patent had already been the subject of an unrelated IPR before the USPTO under which the Company prevailed, and all claims of the ‘019 Patent survived. Aquestive’s request for rehearing of the final IPR decision regarding the ‘019 Patent was denied by the USPTO on December 19, 2016. Aquestive did not file a timely appeal at the Federal Circuit.
On May 23, 2017, the USPTO issued U.S. Patent 9,655,843 (the “‘843 Patent”) relating to the BEMA technology, and this patent was properly listed in the Orange Book as covering the BELBUCA product.
On August 28, 2017, the Court entered orders staying both BELBUCA suits at the request of the parties.
In February 2018, the Company announced that it had entered into a settlement agreement with Teva that resolved the Company’s BELBUCA patent litigation against Teva pending in the U.S. District Court for the District of Delaware. As part of the settlement agreement, which is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice, the Company has granted Teva a non-exclusive license (for which the Company will receive no current or future payments) that permits Teva to first begin selling the generic version of the Company’s BELBUCA product in the U.S. on January 23, 2027 or earlier under certain circumstances (including, for example, upon (i) the delisting of the patents-in-suit from the U.S. FDA Orange Book, (ii) the granting of a license by us to a third party to launch another generic form of BELBUCA at a date prior to January 23, 2027, or (iii) the occurrence of certain conditions regarding BELBUCA market share). Other terms of the Agreement are confidential.




17
BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(U.S. DOLLARS, IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
(Unaudited)
Alvogen
On September 7, 2018, the Company filed a complaint for patent infringement in Delaware against Alvogen Pb Research & Development LLC, Alvogen Malta Operations Ltd., Alvogen Pine Brook LLC, Alvogen, Incorporated, and Alvogen Group, Incorporated (collectively, “Alvogen”), asserting that Alvogen infringes the Company’s Orange Book listed patents for BELBUCA, including U.S. Patent Nos. 8,147,866 and 9,655,843, both expiring in July of 2027, and U.S. Patent No. 9,901,539, expiring in December of 2032. This complaint follows receipt by the Company on July 30, 2018 of a Paragraph IV Patent Certification from Alvogen stating that Alvogen had filed an ANDA with the FDA for a generic version of BELBUCA Buccal Film (75 mcg, 150 mcg, 300 mcg, 450 mcg, 600 mcg, 750 mcg and 900 mcg). Because the Company initiated a patent infringement suit to defend the patents identified in the Paragraph IV notice within 45 days after receipt of the Paragraph IV Certification, the FDA is prevented from approving the ANDA until the earlier of 30 months or a decision in the case that each of the patents is not infringed or invalid. Alvogen’s notice letter also does not provide any information on the timing or approval status of its ANDA.
In its Paragraph IV Certification, Alvogen does not contest infringement of at least several independent claims of each of the ’866, ’843, and ’539 patents. Rather, Alvogen advances only invalidly arguments for these independent claims. The Company believes that it will be able to prevail on its claims of infringement of these patents, particularly as Alvogen does not contest infringement of certain claims of each patent. Additionally, as the Company has done in the past, it intends to vigorously defend its intellectual property against assertions of invalidity. Each of the three patents carry a presumption of validity, which can only be overcome by clear and convincing evidence.
The Court scheduled a bench trial to commence on November 9, 2020 to adjudicate issues concerning the validity of the Orange Book patents listed for BELBUCA. On October 6, 2020, the Court rescheduled the bench trial with Alvogen to commence on March 1, 2021. A three day bench trial against Alvogen was conducted commencing on March 1, 2021. At the conclusion of trial, the Court ordered the parties to submit post-trial briefs. Post-trial briefing was completed on May 26, 2021. The Company subsequently moved the Court to strike (i.e., remove from the Court’s consideration) three patent invalidity defenses raised for the first time in Alvogen’s post-trial briefs and two documents improperly cited in Alvogen’s post-trial briefs. On June 28, 2021, the Court granted the Company’s motion to strike in its entirety. In addition, on June 28, 2021, the Court enjoined Alvogen from launching its generic product until the Court issues its final decision on the merits.
On September 21, 2021, the Company filed under seal a Motion for Order to Show Cause why Defendants Should not be Held in Contempt for Violating the Court Order of June 28, 2021 (the “Motion”). On June 28, 2021, citing the statute authorizing the Court to extend the 30-month stay under the Hatch-Waxman Act, the Court ordered Alvogen (as defined below) not to “launch” its generic product until it could reach a final decision on the merits in the case. In the Motion, the Company contends that Alvogen violated the order of the United States District Court for the District of Delaware commencing in or about August 2021 by, among other things, offering the generic product for sale through five compendia / price reporting services, including First Databank, Medi-Span (Wolters Kluwer), Red Book, Gold Standard and ScriptPro. As alleged in the Motion, after Alvogen’s product launch, certain payers began declining insurance coverage for the Company’s brand BELBUCA and directing use of Alvogen’s generic substitute and/or made it more difficult for patients to obtain insurance coverage for BELBUCA, and thereby damaged the Company. In addition to filing the Motion, the Company demanded that Alvogen withdraw its compendia listings. Alvogen claims to have withdrawn its compendia product listings on or about September 9, 2021.

The Company remains confident in the validity of its Orange Book patents listed for BELBUCA and will continue to vigorously defend its patent rights.

2018 Arkansas Opioid Litigation
On March 15, 2018, the State of Arkansas, and certain counties and cities in that State, filed an action in the Circuit Court of Arkansas, Crittenden County against multiple manufacturers, distributors, retailers, and prescribers of opioid analgesics, including the Company. The Company was served with the complaint on April 27, 2018. The complaint specifically alleged that it licensed its branded fentanyl buccal soluble film ONSOLIS to Collegium, and Collegium is also named as a defendant in the lawsuit. ONSOLIS is not presently sold in the United States and the license agreement with Collegium was terminated prior to Collegium launching ONSOLIS in the United States. Therefore, on June 28, 2018, the Company moved to dismiss the case against it and most recently, on July 6, 2018, the plaintiffs filed a notice to voluntarily dismiss us from the Arkansas case, without prejudice.
18
BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(U.S. DOLLARS, IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
(Unaudited)

Chemo Research, S.L
On March 1, 2019, the Company filed a complaint for patent infringement in Delaware against Chemo Research, S.L., Insud Pharma S.L., IntelGenx Corp., and IntelGenx Technologies Corp. (collectively, the “Chemo Defendants”), asserting that the Chemo Defendants infringe its Orange Book listed patents for BELBUCA, including U.S. Patent Nos. 8,147,866 and 9,655,843, both expiring in July of 2027, and U.S. Patent No. 9,901,539 expiring December of 2032. This complaint follows a receipt by the Company on January 31, 2019, of a Notice Letter from Chemo Research S.L. stating that it has filed with the FDA an ANDA containing a Paragraph IV Patent Certification, for a generic version of BELBUCA Buccal Film in strengths 75 mcg, 150 mcg, 300 mcg, 450 mcg, and 900 mcg. Because the Company initiated a patent infringement suit to defend the patents identified in the Notice Letter within 45 days after receipt, the FDA is prevented from approving the ANDA until the earlier of 30 months or a decision in the case that each of the patents is not infringed or invalid. Chemo Research S.L.’s Notice Letter also does not provide any information on the timing or approval status of its ANDA. On March 15, 2019, the Company filed a complaint against the Defendants in New Jersey asserting the same claims for patent infringement made in the Delaware lawsuit. On April 19, 2019, Defendants filed an answer to the Delaware complaint wherein they denied infringement of the ‘866, ‘843 and ‘539 patents and asserted counterclaims seeking declaratory relief concerning the alleged invalidity and non-infringement of such patents.
On April 25, 2019, the Company voluntarily dismissed the New Jersey lawsuit given Defendants’ consent to jurisdiction in Delaware.

The Court scheduled a bench trial to commence on November 9, 2020 (jointly with Alvogen) to adjudicate issues concerning the validity of the Orange Book patents listed for BELBUCA. On October 6, 2020, the Court rescheduled the bench trial with Chemo and Alvogen to adjudicate issues concerning the validity of the Orange Book patents listed for BELBUCA to commence on March 1, 2021. Chemo did not participate in the bench trial that commenced on March 1, 2021. Instead, on February 26, 2021, Chemo agreed to be bound by the decision of the Court with respect to the validity of the BEMA patents from the March 1, 2021 trial with Alvogen. The Court had scheduled a bench trial to commence on May 3, 2021 to adjudicate issues concerning the Chemo Defendants’ infringement of the Orange Book patents. On December 1, 2020, the Court rescheduled the bench trial to adjudicate issues concerning the Chemo Defendants’ infringement of the Orange Book patents to commence on November 15, 2021. On July 15, 2021, the Court rescheduled the bench trial to adjudicate issues concerning the Chemo Defendants’ infringement of the Orange Book patents to commence on April 25, 2022.
The Company believes that it will be able to prevail in this lawsuit. As it has done in the past, the Company intends to vigorously defend its intellectual property against assertions of invalidity.

Derivative Litigation
On July 2, 2018, the Company filed a Schedule 14A Proxy Statement (the “Proxy”) with the U.S. Securities and Exchange Commission (the “SEC”) in connection with its 2018 Annual Meeting. Proposals 1 and 2 of the Proxy sought stockholder approval to amend the Company’s Certificate of Incorporation by deleting Article TWELFTH of the Company’s Certificate of Incorporation in its entirety and replacing it with a new Article TWELFTH that, among other things (i) provided for the declassification of the Company’s Board in phases, with the full declassification to be achieved in 2020 (the “Declassification Amendment”) and (ii) changed the voting standard for the uncontested election of directors to the Board from a plurality standard to the majority of votes cast standard as set forth in the bylaws of the Company (the “Election Amendment” and together with the “Declassification Amendment”, the “Amendments”).
On August 2, 2018, the Company held the 2018 Annual Meeting, at which time the stockholders voted on the Amendments. Following the 2018 Annual Meeting, based on consultation with the Company’s advisors, the Company determined that the Amendments had been adopted by the requisite vote of stockholders and effected the Amendments by filing a Certificate of Amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware on August 6, 2018.
On September 11, 2019, two purported stockholders of the Company filed a putative class action against the Company and our directors in the Court of Chancery of the State of Delaware, captioned Drachman v. BioDelivery Sciences International, Inc., et al., C.A. No. 2019-0728-AGB (Del. Ch.) (the “Complaint”). The Complaint alleged that the Amendments did not receive the requisite vote of stockholders at the 2018 Annual Meeting and asserted claims for violation of the Delaware General Corporation Law, breach of fiduciary duties, and declaratory judgment. The Complaint sought, inter alia, a declaration that the Amendments were not validly approved and invalidation of the Amendments, including altering the one-year terms of all directors duly elected at the 2018 and 2019 Annual Meetings to three-year terms. The Complaint also sought costs and
19
BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(U.S. DOLLARS, IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
(Unaudited)
disbursements, including attorneys’ fees. On July 1, 2020, the Company filed their response to the Complaint and denied the claims asserted therein.
On November 5, 2019, the Board determined that ratifying the declassification of the Board and the change in the voting standard as set forth in the Amendments, as well as ratifying the filing and effectiveness of the Amendments, is in the best interests of the Company and its stockholders. The Board thus approved resolutions ratifying such acts and the filing and effectiveness of the Amendments under Section 204 of the Delaware General Corporation Law. On July 23, 2020, the stockholders of the Company approved the ratification of the declassification of the Board and the change in the voting standard as set forth in the Amendments as well as the filing and effectiveness of the Amendments. On July 23, 2020, the Company filed a Certificate of Validation with the Delaware Secretary of State.
On October 8, 2020, the Court entered an agreed-to order dismissing the plaintiffs’ claims for violation of the Delaware General Corporation Law. On October 13, 2020, plaintiffs filed an amended complaint, asserting individual, class and derivative claims for breach of fiduciary duties against our directors. On October 26, 2020, the defendants filed a motion to dismiss the amended complaint. On February 19, 2021, plaintiffs filed their opposition to the motion to dismiss. On March 8, 2021, the defendants filed a reply in further support of the motion to dismiss. The oral argument on defendants’ motion to dismiss took place on June 10, 2021 and, pursuant to a request from the Court, the parties are in the process of filing supplemental briefing. The defendants intend to continue to defend against the litigation vigorously.
20
BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(U.S. DOLLARS, IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
(Unaudited)

11. Subsequent Events:

Appointment of Chief Accounting Officer
On October 21, 2021, the Board of Directors of the Company announced that the Company had appointed John Golubieski as the Company’s Chief Accounting Officer, effective as of October 25, 2021. Mr. Golubieski will serve as Chief Accounting Officer until November 4, 2021, at which time he will resign from the position of Chief Accounting Officer and become Chief Financial Officer. Mr. Golubieski will also serve as the Company’s principal financial officer and principal accounting officer, effective as of November 4, 2021.
In connection with Mr. Golubieski’s appointment, the Company entered into an employment agreement with Mr. Golubieski, effective as of October 25, 2021 (the “Employment Agreement”). Pursuant to the Employment Agreement, Mr. Golubieski will be paid an annual base salary of $0.4 million and will be eligible for an annual performance-based incentive cash bonus in an amount up to 45% of Mr. Golubieski’s then-current base salary. Mr. Golubieski’s bonus for 2021 will be pro-rated to reflect his start date with the Company. In connection with his appointment, Mr. Golubieski will receive (i) an inaugural, one-time grant of options to purchase common stock with a value of $0.7 million (the “Option Award”) and (ii) an inaugural, one-time grant of restricted stock units with a value of $0.2 million (the “RSU Award”). The strike price for the Option Award will be the closing price of the Company’s common stock on the Nasdaq Global Select Market on the date of the grant. Both the Option Award and the RSU Award will vest in three equal portions on the first, second and third anniversary date of the grant date, subject to Mr. Golubieski’s continued service with the Company through the applicable vesting dates.

Departure of Chief Financial Officer
On October 15, 2021, Mary Theresa Coelho resigned as Executive Vice President, Chief Financial Officer and Treasurer of the Company to pursue other professional opportunities. Ms. Coelho’s resignation is effective as of November 3, 2021 and is not the result of any disagreement regarding the Company’s financial reporting or accounting policies, procedures, estimates or judgments.
21
Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion and analysis should be read in conjunction with the Condensed Consolidated Financial Statements and Notes thereto included elsewhere in this Quarterly Report. This discussion contains certain forward-looking statements that involve risks and uncertainties. Our actual results and the timing of certain events could differ materially from those discussed in these forward-looking statements as a result of certain factors, including, but not limited to, those set forth herein and elsewhere in this Quarterly Report and in our other filings with the SEC. See “Cautionary Note Regarding Forward-Looking Statements” below.
Overview
Strategy
Our strategy is evolving with the establishment of our commercial footprint. We seek to continue to build a well-balanced, diversified, high-growth specialty pharmaceutical company focused on delivering innovative therapies for individuals living with serious and debilitating chronic conditions. Through our industry-leading commercialization infrastructure, we are executing the commercialization of our existing products. As part of our corporate growth strategy, we have licensed, and will continue to explore opportunities to acquire or license, additional products that meet the needs of patients living with debilitating chronic conditions. As we gain access to these drugs and technologies, we will employ our commercialization experience to bring them to the marketplace. With a strong commitment to patient access and a focused business-development approach for transformative acquisitions or licensing opportunities, we will leverage our experience and apply it to developing new partnerships that enable us to commercialize novel products that can change the lives of people suffering from debilitating chronic conditions.
Our commercial strategy for BELBUCA (buprenorphine buccal film) is to further drive continued adoption in the large long-acting opioid market based on its unique profile coupled with growing physician interest, policy tailwinds, and expanding payor access. We aim to leverage the specialized commercial infrastructure we established for BELBUCA as a vehicle to enable commercial growth in Symproic, a peripherally acting mu-opioid receptor antagonist, which we view as a complementary asset.

Recent Developments
In September 2021, we completed our acquisition of the U.S. and Canadian rights to ELYXYB™ (celecoxib oral solution), the only FDA-approved ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. We believe the acquisition will allow us to expand into the migraine market and deepen our presence in neurology. We intend to launch ELYXYB in the first quarter of 2022.

Appointment of Chief Accounting Officer
On October 21, 2021, our Board of Directors announced that we had appointed John Golubieski as our Chief Accounting Officer, effective as of October 25, 2021. Mr. Golubieski will serve as Chief Accounting Officer until November 4, 2021, at which time he will resign from the position of Chief Accounting Officer and become Chief Financial Officer. Mr. Golubieski will also serve as the Company’s principal financial officer and principal accounting officer, effective as of November 4, 2021.
Results of Operations
Comparison of the three months ended September 30, 2021 and 2020
Product Sales. We recognized $41.1 million and $38.8 million in product sales during the three months ended September 30, 2021 and 2020, respectively. The increase in 2021 is principally due to BELBUCA and Symproic product sales which have been driven by increased paid prescriptions across all channels of business.
Product Royalty Revenues. During the three months ended September 30, 2021 and 2020, we recognized $0.02 million and $0.7 million in PAINKYL and BREAKYL product royalty revenue under our license agreements with TTY and Mylan, respectively.
Cost of Sales. We incurred $6.4 million and $5.4 million in cost of sales during the three months ended September 30, 2021 and 2020, respectively. Cost of sales includes product cost, royalties paid, obsolescence reserves, depreciation, yield adjustments and quarterly minimum royalty payments to CDC IV, LLC (“CDC”).
22
Selling, General and Administrative Expenses. During the three months ended September 30, 2021 and 2020, selling, general and administrative expenses totaled $25.5 million and $22.5 million, respectively. Selling, general and administrative costs include all costs not related to the manufacturing of product. The increase in selling, general and administrative expenses during the three months ended September 30, 2021 as compared to the same period in the prior year is primarily due to increased sales and marketing expenses associated with BELBUCA and Symproic.
Interest expense, net . During the three months ended September 30, 2021 and 2020, we had net interest expense of $2.0 million, which consisted of $1.9 million of scheduled interest payments, and $0.1 million of amortization of discount and loan costs, respectively.
Comparison of the nine months ended September 30, 2021 and 2020
Product Sales. We recognized $122.4 million and $112.9 million in product sales during the nine months ended September 30, 2021 and 2020, respectively. The increase in 2021 is principally due to increased BELBUCA and Symproic product sales from higher patient utilization and the impact of price increases.

Product Royalty Revenues. During the nine months ended September 30, 2021 and 2020, we recognized $1.2 million and $1.4 million in PAINKYL and BREAKYL product royalty revenue under our license agreements with TTY and Mylan, respectively. Product royalty revenue related to PAINKYL and BREAKYL is primarily via government demand in the Ex-U.S. countries where the products are sold by TTY and Mylan, respectively.
Cost of Sales. We incurred $16.5 million and $16.4 million in cost of sales during the nine months ended September 30, 2021 and 2020, respectively. Cost of sales includes product cost, royalties paid, obsolescence reserves, depreciation, yield adjustments and quarterly minimum royalty payments to CDC. Cost of sales for the nine months ended September 30, 2021 includes $1.4 million for the recovery of certain costs associated with previously reserved inventory, which was offset by $0.7 million of obsolescence reserves. Cost of sales for the nine months ended September 30, 2020 includes a $0.3 million one-time depreciation charge due to BUNAVAIL equipment write-off.
Selling, General and Administrative Expenses. During the nine months ended September 30, 2021 and 2020, selling, general and administrative expenses totaled $79.0 million and $77.4 million, respectively. Selling, general and administrative costs include commercialization costs for BELBUCA and Symproic, legal, accounting, salaries and wages, consulting and professional fees, travel costs, stock based compensation and amortization. The increase in selling, general and administrative expenses during the nine months ended September 30, 2021 as compared to the same period in the prior year is primarily due to an increase in legal spend and sales and marketing expenses in 2021, partially offset by the accelerated stock compensation and severance expense related to the departure of the Company's Chief Executive Officer in 2020.
Interest expense, net. During the nine months ended September 30, 2021, we had net interest expense of $6.0 million, which includes interest expense of $5.7 million and $0.3 million of amortization of discount and loan costs.

During the nine months ended September 30, 2020, we had net interest expense of $5.0 million, which includes interest expense of $5.0 million and $0.2 million of amortization of discount and loan costs. During the nine months ended September 30, 2020, we also had interest income of $0.2 million.
Non-GAAP Financial Information:
We report our condensed consolidated financial results in accordance with GAAP; however, we believe that earnings before interest, taxes, depreciation and amortization (“EBITDA”) and other non-GAAP results should not be considered in isolation of or as an alternative for, earnings measures prepared in accordance with GAAP. Management uses these non-GAAP measures internally to measure the ongoing operating performance of our Company along with other metrics, and for planning and forecasting purposes. In addition, when evaluating non-GAAP results, we exclude certain items that are considered to be non-cash and if applicable, non-recurring, in nature.
EBITDA and Non-GAAP Income:
We have presented EBITDA because it is a key measure used by our management and board of directors to understand and evaluate our operating performance and to develop operational goals for managing our business. We believe this financial measure helps identify underlying trends in our business that could otherwise be masked by the effect of the expenses that we exclude. In particular, we believe that the exclusion of the expenses eliminated in calculating EBITDA can provide a useful measure for period-to-period comparisons of our core operating performance. Accordingly, we believe that EBITDA provides
23
useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and future prospects, and allowing for greater transparency with respect to key financial metrics used by our management in its financial and operational decision-making.
EBITDA is not prepared in accordance with GAAP, and should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. There are a number of limitations related to the use of EBITDA rather than net income, which is the nearest GAAP equivalent. Some of these limitations are:
•EBITDA excludes depreciation and amortization and, although these are non-cash expenses, the assets being depreciated or amortized may have to be replaced in the future, the cash requirements for which are not reflected in EBITDA;
•EBITDA does not reflect provision for income taxes or the cash requirements to pay taxes; and
•EBITDA excludes the impact of currency translation and net interest, including both interest expense and interest income.
Non-GAAP net income is an alternative view of our performance that we are providing because management believes this information enhances investors’ understanding of our results as it permits investors to better understand the ongoing operations of the business, the impact of any non-recurring one-time events, the cash results of the organization and is an additional measure used by management to assess performance.
Non-GAAP net income is not prepared in accordance with GAAP, and should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. There are a number of limitations related to the use of non-GAAP net income rather than net income, which is the nearest GAAP equivalent. Some of these limitations are:
•The expenses and other items that we exclude in our calculation of non-GAAP net income may differ from the expenses and other items, if any, that other companies may exclude from non-GAAP net income when they report their operating results since non-GAAP income is not a measure determined in accordance with GAAP, and it has no standardized meaning prescribed by GAAP;
•We exclude stock-based compensation expense from non-GAAP net income although (a) it has been, and will likely continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our compensation strategy and (b) if we did not pay out a portion of our compensation in the form of stock-based compensation, the cash salary expense included in operating expenses would likely be higher, which would affect our cash position; and
•We exclude amortization of intangible assets from non-GAAP net income due to the non-cash nature of this expense and although it has been and will continue to be for the foreseeable future a recurring expense for our business, these expenses do not affect our cash position.









24
Reconciliations of non-GAAP metrics to most directly comparable U.S. GAAP financial measures:
The following tables reconcile net income earnings and computations (in thousands) under GAAP to a Non-GAAP basis.
Three Months Ended
September 30,		Nine Months Ended
September 30,
Reconciliation of GAAP net income to EBITDA (non-GAAP) 2021202020212020
GAAP net income$6,669 $9,383 $20,970 $15,515 
Add back/(subtract):
Income tax provision606 211 1,139 19 
Net interest expense1,984 2,012 5,962 4,991 
Depreciation and amortization1,837 1,754 5,359 5,715 
EBITDA$11,096 $13,360 $33,430 $26,240 
Reconciliation of GAAP net income to Non-GAAP net income
GAAP net income$6,669 $9,383 $20,970 $15,515 
Non-GAAP adjustments:
Stock-based compensation expense1,837 1,473 5,024 4,424 
Amortization of intangible assets1,795 1,734 5,262 5,248 
Non-recurring financial impact of CEO transition— 67 — 5,078 
Non-recurring financial impact of BUNAVAIL discontinuation— — — 295 
Non-GAAP net income$10,301 $12,657 $31,256 $30,560 

Liquidity and Capital Resources

Since inception, we have financed our operations principally from the sale of equity securities, proceeds from borrowings, convertible notes, and notes payable, funded research arrangements, revenue generated as a result of our worldwide license and development agreements and the commercialization of our BELBUCA, Symproic and BUNAVAIL products. We intend to finance our commercialization and working capital needs from existing cash, earnings from the commercialization of BELBUCA and Symproic, royalty revenue, existing and new licensing and commercial partnership agreements and, potentially, through the exercise of outstanding common stock options and warrants to purchase common stock. We expect to incur additional costs in preparation for the expected commercialization of ELYXYB projected for Q1 2022.
As of September 30, 2021, we had cash and cash equivalents of approximately $100.7 million. We generated $27.3 million of cash in operations during the nine months ended September 30, 2021 . We believe that we have sufficient cash, along with expected proceeds from sales of BELBUCA and Symproic, to manage the business as currently planned.
Additional capital may be required to support the continued commercialization of our BELBUCA and Symproic products, our commercial launch of ELYXYB, or other products which may be acquired or licensed by us, and for general working capital requirements. Based on agreements with our partners, the ability to scale up or reduce personnel and associated costs are factors considered throughout the product life cycle. Available resources may be consumed more rapidly than currently anticipated, potentially resulting in the need for additional funding.
Accordingly, it is possible that we may be required to raise additional capital, which may be available to us through a variety of sources, including:
•public equity markets;
•private equity financings;
•commercialization agreements and collaborative arrangements;
•grants and new license revenues;
•bank loans;
25
•equipment financing;
•public or private debt; and
•exercise of existing warrants and options.
Readers are cautioned that additional funding, capital or loans (including, without limitation, milestone or other payments from commercialization agreements) may be unavailable on favorable terms, if at all. If adequate funds are not available, we may be required to significantly reduce or refocus our operations or to obtain funds through arrangements that may require us to relinquish rights to certain technologies and drug formulations or potential markets, either of which could have a material adverse effect on us, our financial condition and our results of operations in 2021 and beyond. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of such securities would result in ownership dilution to existing stockholders.
Off-Balance Sheet Arrangements
As of September 30, 2021, we had no off-balance sheet arrangements.
Effects of Inflation
We do not believe that inflation has had a material effect on our financial position or results of operations. However, there can be no assurance that our business will not be affected by inflation in the future.
Critical Accounting Policies
For information regarding our critical accounting policies and estimates, please refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies and Estimates” contained in our annual report on Form 10-K for the year ended December 31, 2020.
Item 3.    Quantitative and Qualitative Disclosures About Market Risk
Interest rate risk
Our cash includes all fully liquid investments with an original maturity of three months or less. Because of the short-term maturities of our cash, we do not believe that an increase in market rates would have a significant impact on the realized value of our investments. We place our cash on deposit with financial institutions in the U.S. The Federal Deposit Insurance Corporation covers $0.25 million for substantially all depository accounts.
Foreign currency exchange risk
We currently have, and may in the future have increased, commercial, manufacturing and clinical agreements which are denominated in Euros or other foreign currencies. As a result, our financial results could be affected by factors such as a change in the foreign currency exchange rate between the U.S. dollar or Euro or other applicable currencies, or by weak economic conditions in Europe or elsewhere in the world. Such amounts are currently immaterial to our financial position or results of operations. We are not currently engaged in any foreign currency hedging activities.
Market Risk
We do not engage in speculative transactions nor do we hold or issue financial instruments for trading purposes. In connection with the recapitalization of our business, we have entered into a secured credit facility consisting of a term loan. Our term loan note bears interest which includes fluctuating interest rates based on LIBOR.
Additionally, LIBOR is to be phased out by June 23, 2023 and replaced. However, we will not be required to renegotiate our loan documents with our current lender.
Item 4.    Controls and Procedures
Evaluation of Disclosure Controls and Procedures
As of the end of the period covered by this Quarterly Report, our management, with the participation of our Chief Executive Officer (our principal executive officer) and Executive Vice President, Treasurer and Chief Financial Officer (our principal financial officer) (the “Certifying Officers”), conducted evaluations of our disclosure controls and procedures. As defined under Sections 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the term “disclosure controls and procedures” means controls and other procedures of an issuer that are designed to ensure that
26
information required to be disclosed by the issuer in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC. Disclosure controls and procedures include without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including the Certifying Officers, to allow timely decisions regarding required disclosures.
Readers are cautioned that our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will necessarily prevent all fraud and material error. An internal control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our control have been detected. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any control design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate.
Based on this evaluation, the Certifying Officers have concluded that our disclosure controls and procedures were effective as of September 30, 2021.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting during our third quarter of 2021 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS

Certain information set forth in this Quarterly Report on Form 10-Q, including in Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” (and the “Liquidity and Capital Resources” section thereof) and elsewhere may address or relate to future events and expectations and as such constitutes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to our plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “will,” “potential,” “intends,” “plans” or similar expressions. These statements are based upon the current beliefs and expectations of our management and are subject to significant risks and uncertainties, including those detailed in our filings with the U.S. Securities and Exchange Commission. Actual results, including, without limitation: (i) actual sales results (including the results of our continuing commercial efforts with BELBUCA and Symproic), (ii) the success of our planned launch of ELYXYB in the first quarter or 2022, (iii) the application and availability of corporate funds and our need for future funds, (iv) the FDA’s review of our products and any regulatory filings related thereto, or (v) the results of our ongoing intellectual property litigations and patent office proceedings, may differ materially from those set forth or implied in the forward-looking statements. Such forward-looking statements also involve other factors which may cause our actual results, performance or achievements to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Such factors include, among others, the impact of the COVID-19 pandemic on our business and results of operations, those listed under Item 1A of our most recent Annual Report on Form 10-K filed with the SEC on March 11, 2021 and under Item 1A of this Quarterly Report on Form 10-Q and other factors detailed from time to time in our other filings with the U.S. Securities and Exchange Commission. Although management believes that the assumptions made and expectations reflected in the forward-looking statements are reasonable, there is no assurance that the underlying assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this Quarterly Report. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
PART II. OTHER INFORMATION
Item 1.    Legal Proceedings.
See Note 10, Commitments and Contingencies, to our condensed consolidated financial statements included in Part I, Item I of this Quarterly Report on Form 10-Q, which is incorporated into this item by reference.
Item 1A.    Risk Factors.
27
To our knowledge and except to the extent additional factual information disclosed in this Quarterly Report on Form 10-Q relates to such risk factors, there have been no material changes in the risk factors described in Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the SEC on March 11, 2021.
Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds.
Issuer Purchases of Equity Securities
Period (In millions, except share and per share data)Total number of shares purchasedAverage price paid per share
Total number of shares purchased as part of the publicly announced plan (a)
Maximum approximate dollar value of shares that may yet be purchased under the plan (b)
July 1-31, 2021— $— — $12,989 
August 1-31, 2021— $— — $12,989 
September 1-30, 2021— $— — $12,989 
Total— — 
(a) The repurchase plan was authorized on November 4, 2020
(b) The repurchase plan approved repurchase of up to $25 million of our Company's shares of Common Stock
On November 4, 2020, our Board of Directors authorized the repurchase of up to $25 million of our Company's shares of Common Stock. The timing and amount of any shares purchased on the open market is determined based on our evaluation of market conditions, share price and other factors. We have utilized and plan to utilize existing cash on hand to fund the share repurchase program.

During the nine months ended September 30, 2021, a cumulative total of 3,202,690 shares, with a weighted average price of $3.72 for a value of $11.9 million were repurchased by the Company under its repurchase program and recorded as Treasury Stock in the 2021 condensed consolidated balance sheet. During the three months ended September 30, 2021, no shares were repurchased by the Company under its repurchase program.
Item 3.    Defaults upon Senior Securities.
None.
Item 4.    Mine Safety Disclosures.
Not applicable.
Item 5.    Other Information.
None.
28
Item 6.    Exhibits.
NumberDescription
10.1
10.2
31.1
31.2
32.1
32.2
101.insXBRL Instance Document
101.schXBRL Taxonomy Extension Schema Document
101.calXBRL Taxonomy Calculation Linkbase Document
101.defXBRL Taxonomy Definition Linkbase Document
101.labXBRL Taxonomy Label Linkbase Document
101.preXBRL Taxonomy Presentation Linkbase Document
104Cover Page Interactive Data File (embedded within the Inline XBRL document contained in Exhibit 101)*

*Filed herewith
**Filed herewith, a signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
#This certification will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing.
† Certain portions of this exhibit have been omitted because they are not material and the registrant customarily and actually treats that information as private or confidential.
(1) Indicates a management contract or any compensatory plan, contract or arrangement.
29
SIGNATURES
Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
BIODELIVERY SCIENCES INTERNATIONAL, INC.
Date: November 3, 2021By:/s/ Jeffrey Bailey
Jeffrey Bailey
Director and Chief Executive Officer
(Principal Executive Officer)
Date: November 3, 2021By:/s/ Mary Theresa Coelho
Mary Theresa Coelho
Executive Vice President, Treasurer and Chief Financial Officer
(Principal Financial and Accounting Officer)

S-1
 EX-10.2 2 bdsi-cfoemploymentagreemen.htm EX-10.2 Document

image_0.jpg

October 18, 2021

John Golubieski CPA, MBA

Re:    Employment Agreement

Dear John:
BioDelivery Sciences International, Inc. (the “Company”) is pleased to extend you an offer of employment as the Company’s Chief Accounting Officer (“CAO”), effective October 25, 2021 (the “Effective Date”). The initial terms and conditions of your employment, should you accept this offer, are set forth in the below agreement (the “Agreement”).
WHEREAS, the Company desires to employ you and you desire to be employed by the Company beginning on the Effective Date on the terms contained herein.
NOW, THEREFORE, for good and valuable and valuable consideration, the receipt of which is hereby acknowledged, you and the Company hereby agree as follows:

1.Term. The Company shall employ you as CAO pursuant to this Agreement commencing on the Effective Date until November 3, 2021 and Chief Financial Officer (“CFO”) beginning November 3, 2021 and continuing until such employment is terminated in accordance with the provisions hereof (the “Term”). Your employment with the Company will be “at will,” meaning that your employment may be terminated by the Company or you at any time and for any reason subject to the terms of this Agreement.
2.Position. As the CAO and CFO, respectively, you shall have such powers and duties as may from time to time be prescribed by the Company’s Chief Executive Officer (the “CEO”). You shall devote your full working time and efforts to the business and affairs of the Company. Notwithstanding the foregoing, you may serve on other boards of directors, with the approval of the Company’s Board of Directors (the “Board”), and engage in religious, charitable or other community activities as long as such services and activities do not interfere with the performance of your duties to the Company.
3.Salary. The Company will pay you an initial base salary at the rate of $440,000 per year, payable in accordance with the Company’s standard payroll schedule and subject to applicable deductions and withholdings. Your base salary shall be subject to periodic review by the Company. The base salary in effect at any given time is referred to herein as “Base Salary.” The Base Salary shall be payable in a manner that is consistent with the Company’s usual payroll practices for its executive officers.
4.Bonus. Upon commencement of your employment, you will be entitled to a one-time signing bonus of $8,461.54 payable in your initial payroll. You will be eligible to receive cash incentive compensation as determined by the Company from time to time. Your initial target annual incentive compensation shall be 45 percent of your Base Salary. The target annual incentive compensation in
1

image_0.jpg
effect at any given time is referred to herein as “Target Bonus.” The actual amount of your annual incentive compensation, if any, shall be determined in the sole discretion of the Company, subject to the terms of any applicable incentive compensation plan that may be in effect from time to time. Except as otherwise provided herein, you must be employed on the date a bonus is paid to earn any part of a bonus. For calendar year 2021, you will be eligible for a prorated bonus, prorated based on the Effective Date. Any annual bonus you earn and become entitled to receive shall be paid on the same date such bonus is paid to other executives who have earned a bonus.
5.Equity.
(a)Subject to approval by the Board, you will receive an option to purchase shares of the Company’s common stock (the “Option”) with a value of $720,000, the vesting of which will in one-third (1/3) increments over three (3) years, beginning on the first anniversary of the Effective Date, subject to your continued employment or service to the Company through each applicable vesting date. The Option shall be governed by the terms of the Company’s 2019 Equity Incentive Plan and any amendments thereto (the “Plan”) and a separate option agreement to be entered into under the Plan as soon as practicable after the Option is granted; provided, that the exercise price per share of the Option will be equal to the closing price of Company’s publicly-traded common stock on the date of the grant.
(b)In addition, subject to approval by the Board, you will be granted restricted stock units under the Plan (the “RSUs”) with a value of $240,000, the vesting of which will be in one-third (1/3) increments over three (3) years, beginning on the first anniversary of the Effective Date, subject to your continued employment or service to the Company through each applicable vesting date. The terms for the grant of the RSUs shall be governed by the Plan and a separate award agreement to be entered into between you and the Company.
(c)You shall be eligible to earn and receive future annual stock grants in the Board’s discretion; provided that the Board will first consider such grants in the first quarter of calendar year 2023, subject to your continued employment at such time.
6.Benefits. You will be eligible, subject to the terms of the applicable plans and programs, to participate in the employee benefits and insurance programs generally made available to the Company’s executive officers. The Company reserves the right to modify, amend or cancel any of its benefits plans or programs at any time.
7.Paid Time Off. You shall be entitled to accrue up to four (4) weeks of vacation each calendar year in accordance with the Company’s applicable vacation policy, as may be in effect from time to time. You will also be eligible for Company-paid holidays and any other paid time off provided for under the Company’s applicable time off policies.
8.Business Expenses. You shall be entitled to receive prompt reimbursement for all reasonable expenses that you incur during the Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its executive officers.
2

image_0.jpg
9.Location. You will be permitted to work remotely from your home office in New Jersey, provided that, you are expected to travel regularly to the Company’s Raleigh, NC office and you may be required to travel elsewhere for business from time to time, consistent with the Company’s business needs.
10.At-will Employment. At all times your employment is “at will,” meaning you or the Company may terminate it at any time for any or no reason. Although your job duties, title, reporting structure, compensation and benefits, as well as the Company’s benefit plans and personnel policies and procedures, may change from time to time, the “at will” nature of your employment may only be changed in an express written agreement signed by you and a duly authorized executive officer of the Company (excluding yourself). Your last day of employment is referred to herein as the “Date of Termination.” To the extent applicable, you shall be deemed to have resigned from all officer and board member positions that you hold with the Company or any of its respective subsidiaries and affiliates upon the termination of your employment for any reason.
In the event of the ending of your employment for any reason, the Company shall pay you (i) your Base Salary through the Date of Termination, (ii) any accrued but unused vacation through the Date of Termination, (iii) the amount of any documented expenses properly incurred by you on behalf of the Company prior to any such termination and not yet reimbursed and (iv) any vested benefits you may have under, or any rights that you may have been specifically granted pursuant to, any of the Company’s or its successor’s equity incentive plans, retirement plans, supplementary retirement plans, profit sharing and savings plans, healthcare, 401(k) and any other employee benefit plans sponsored by the Company or its successor through the Date of Termination, which vested benefits shall be paid and/or provided in accordance with the terms of such incentive plans or employee benefit plans (the “Accrued Obligations”).
11.Severance Payment Outside of a CIC Severance Triggering Event. If the Company terminates your employment other than for “Cause” (as defined below) or if your employment is terminated as a result of your death or permanent disability or by you for “Good Reason” (as defined below), and you comply with the terms stated below, then provided that you (and/or your beneficiaries) enter into a release agreement in a form provided by the Company at the time of such termination (a “Release”) and the Release becomes effective within 60 days after the Date of Termination (or such shorter period as set forth in the Release), the Company will pay you a one-time cash severance payment equal to (i) 100% of your annual Base Salary, plus (ii) the pro-rata share of your Target Bonus for the year in which the Date of Termination occurs (the “Severance Payment”), and, if the Date of Termination occurs after the completion of a calendar year but prior to the payment of annual bonuses for such year, the Company will pay you the bonus amount that you otherwise would have earned if you remained employed on the date of payment, as determined in the sole discretion of the Company in accordance with Section 4 of this Agreement (the “Prior Year Bonus”). The Severance Payment will be paid within 60 days of the Date of Termination, provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, such payment to the extent it qualifies as “non-qualified deferred compensation” within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), shall be paid in the second calendar year by the last day of such 60-day period. If applicable, the Prior Year Bonus shall be paid to you at the time that the Company’s other
3

image_0.jpg
executives receive their annual bonuses, which shall be no later than March 15 of the calendar year in which the Date of Termination occurs.
12.Change in Control Benefits following a CIC Severance Triggering Event. If your employment with the Company is terminated by the Company or its successor without Cause or by you for Good Reason, in either case within twelve (12) months following the occurrence of a “Change in Control” (as defined below) (a “CIC Severance Triggering Event”), then, in lieu of the Severance Payment: (i) you will be entitled to (A) a one-time cash severance payment equal to 100% of your then current annual Base Salary, plus (B) a one-time cash payment of 100% of your Target Bonus (the “CIC Severance Payment”); (ii) if the Date of Termination occurs after the completion of a calendar year but prior to the payment of annual bonuses for such year, you will be entitled to the Prior Year Bonus; and (iii) all unvested time-based options, restricted stock units or other equity securities to acquire shares of the Company’s common stock granted to you under the Company’s 2019 Equity Incentive Plans or any similar plan shall immediately become fully vested, such restricted stock units and other equity securities shall be paid no later than the date the CIC Severance Payment is made and such vested options shall be exercisable for the period provided for in the respective plan (collectively the “Change in Control Benefits”). Following the Company’s or its successor’s compliance with clauses (i), (ii) and (iii) above, along with the Company’s or its successor’s payment or provision of the Accrued Obligations, the Company or its successor shall have no further obligations to you following termination. In addition, as a condition to the Change in Control Benefits, you must enter into a Release and the Release must become effective within 60 days after the Date of Termination (or such shorter period as set forth in the Release). The CIC Severance Payment will be paid within 60 days of the Date of Termination, provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, such payment to the extent it qualifies as “non-qualified deferred compensation” within the meaning of Section 409A of the Code, shall be paid in the second calendar year by the last day of such 60-day period. If applicable, the Prior Year Bonus shall be paid to you at the time that the Company’s or its successor’s other executives receive their annual bonuses, which shall be no later than March 15 of the calendar year in which the Date of Termination occurs. All such payments shall comply with Section 409A of the Code and all regulations promulgated thereunder.
13.Definitions. For purposes of this Agreement, the following terms shall have the following meanings:
(a)“Cause” shall mean (i) a material breach or material default (including, without limitation, any material dereliction of duty) by you of any agreement between you and the Company or your continuing failure to follow any valid and legal direction of the CEO or the Board; (ii) your gross negligence, willful misfeasance or breach of fiduciary duty; (iii) your commission of an act of fraud, embezzlement or any felony or crime of dishonesty in connection with your duties with the Company; (iv) your continued non-performance of your duties hereunder (other than by reason of your physical or mental illness, incapacity or disability) which has continued for more than 15 days following written notice of such non-performance from the CEO; or (v) your conviction of a felony or any other crime that would materially and adversely affect: (a) the Company’s business reputation, or (b) the performance of your duties for the Company. For the avoidance of doubt, in the event of a termination of your employment for Cause, the Company will pay you the Accrued Obligations, and thereafter the Company shall have no further responsibility for termination or other payments to you.
4

image_0.jpg
(b)“Good Reason” shall mean the occurrence of any of the following in each case during the Term without your consent: (i) a reduction in your Base Salary; (ii) a reduction in your Target Bonus opportunity; (iii) any material breach by the Company of any material provision of this Agreement or of any other agreement between the Company and you, including any representation, warranties or covenants set forth herein; (iv) the Company’s failure to obtain an agreement from any successor to the Company following a Change in Control to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no succession had taken place, except where such assumption occurs by operation of law; or (v) a material, adverse change in your authority, duties, or responsibilities (other than temporarily while you are physically or mentally incapacitated or as required by applicable law). You shall not terminate your employment for Good Reason unless you have first provided written notice to the Company of the existence of the circumstances providing grounds for termination for Good Reason within sixty (60) days of the date you learn of the initial existence of such grounds and the Company has had at least thirty (30) days from the date on which such notice is provided to cure such circumstances and has failed to cure such circumstances. If you do not terminate your employment for Good Reason within ninety (90) days after the date you learn of the first occurrence of the applicable grounds, then you will be deemed to have waived your right to terminate for Good Reason with respect to such grounds.
(c)“Change in Control” means the occurrence of any one or more of the following events (it being agreed that, with respect to paragraphs (i) and (iii) of this definition below, a “Change in Control” shall not be deemed to have occurred if the applicable third party acquiring party is an “affiliate” of the Company within the meaning of Rule 405 promulgated under the Securities Act of 1933, as amended): (i) an acquisition (whether directly from the Company or otherwise) of any voting securities of the Company (the “Voting Securities”) by any “Person” (as the term person is used for purposes of Section 13(d) or 14(d) of the Securities and Exchange Act of 1934, as amended (the “1934 Act”)), immediately after which such Person has “Beneficial Ownership” (within the meaning of Rule 13d-3 promulgated under the 1934 Act) of fifty percent (50%) or more of the combined voting power of the Company’s then outstanding Voting Securities; (ii) the individuals who, as of the date hereof, are members of the Company’s Board cease, by reason of a financing, merger, combination, acquisition, takeover or other non-ordinary course transaction affecting the Company, to constitute at least fifty-one percent (51%) of the members of the Company’s Board; or (iii) the consummation of: (A) a merger, consolidation or reorganization involving the Company, where either or both of the events described in clauses (i) or (ii) above would be the result; (B) a liquidation or dissolution of or appointment of a receiver, rehabilitator, conservator or similar person for, or the filing by a third party of an involuntary bankruptcy against, the Company; or (C) an agreement for the sale or other disposition of all or substantially all of the assets of the Company to any Person (other than a transfer to a subsidiary of the Company).
14.Confidential Information and Restricted Activities. You also will be required to sign, as a condition of your employment, the Employee Confidentiality, Assignment, Nonsolicitation and Noncompetition Agreement that is enclosed with this Agreement (the “Restrictive Covenants Agreement”). This Agreement is conditioned on your representation that you are not subject to any confidentiality, noncompetition, nonsolicitation, invention assignment or other agreement that restricts your employment activities or that may affect your ability to devote full time and attention to your work
5

image_0.jpg
at the Company. You further represent that you have not used and will not use or disclose any trade secret or other proprietary right of any previous employer or any other party.
15.Taxes; Section 409A. All forms of compensation referred to in this Agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law. You hereby acknowledge that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or the Board related to tax liabilities arising from your compensation. Anything in this Agreement to the contrary notwithstanding, if at the time of your separation from service within the meaning of Section 409A of the Code, the Company determines that you are a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that you become entitled to under this Agreement on account of your separation from service would be considered deferred compensation subject to the 20% additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after your separation from service, or (B) your death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule. All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by you during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided, or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year. Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit. To the extent that any payment or benefit described in this Agreement constitutes “non-qualified deferred compensation” under Section 409A of the Code, and to the extent that such payment or benefit is payable upon your termination of employment, then such payments or benefits shall be payable only upon your “separation from service.” The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-1(h). The Company and you intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A2(b)(2). The Company makes no representation or warranty and shall have no liability to you or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.
16.Section 280G. Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any compensation, payment or distribution by the Company to you or for your benefit, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement
6

image_0.jpg
or otherwise, calculated in a manner consistent with Section 280G of the Code, and the applicable regulations thereunder (the “Aggregate Payments”), would be subject to the excise tax imposed by Section 4999 of the Code, then the Aggregate Payments shall be reduced (but not below zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at which you become subject to the excise tax imposed by Section 4999 of the Code; provided that such reduction shall only occur if it would result in you receiving a higher After Tax Amount (as defined below) than you would receive if the Aggregate Payments were not subject to such reduction. In such event, the Aggregate Payments shall be reduced in the following order, in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section 280G of the Code: (1) cash payments not subject to Section 409A of the Code; (2) cash payments subject to Section 409A of the Code; (3) equity-based payments and acceleration; and (4) non-cash forms of benefits; provided that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. §1.280G-1, Q&A-24(b) or (c) shall be reduced before any amounts that are subject to calculation under Treas. Reg. §1.280G-1, Q&A-24(b) or (c). For purposes of this paragraph, the “After Tax Amount” means the amount of the Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on you as a result of your receipt of the Aggregate Payments. For purposes of determining the After Tax Amount, you shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes. The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to this paragraph shall be made by a nationally recognized accounting firm selected by the Company (the “Accounting Firm”), which shall provide detailed supporting calculations both to the Company and you within 15 business days of the date of termination, if applicable, or at such earlier time as is reasonably requested by the Company or you. Any determination by the Accounting Firm shall be binding upon the Company and you.
17.Waiver. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.
18.Amendment. This Agreement may be amended or modified only by a written instrument signed by you and by a duly authorized representative of the Company.
19.Interpretation and Enforcement. This Agreement, together with the Restrictive Covenants Agreement, constitutes the complete agreement between you and the Company, contains all of the terms of your employment with the Company and supersedes any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. The terms of this Agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this Agreement or arising out of, related to, or in any way connected with this Agreement, your employment with the Company or any other relationship between you and the Company (the “Disputes”) will be governed by North Carolina law, excluding laws relating to conflicts or choice of
7

image_0.jpg
law. You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in the State of North Carolina in connection with any Dispute or any claim related to any Dispute.
20.Assignment. Neither you nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement without your consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its properties or assets; provided further that if you remain employed or become employed by the Company, the purchaser or any of their affiliates in connection with any such transaction, then you shall not be entitled to any payments, benefits or vesting pursuant to Section 11 or Section 12 of this Agreement solely as a result of such transaction. This Agreement shall inure to the benefit of and be binding upon you and the Company, and each of your and its respective successors, executors, administrators, heirs and permitted assigns.
21.Conditions. Notwithstanding anything to the contrary herein, the effectiveness of this Agreement shall be conditioned on (i) your satisfactory completion of reference and background checks, if so requested by the Company, and (ii) your submission of satisfactory proof of your legal authorization to work in the United States.
22.Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document.
[Signature page follows.]
8

image_0.jpg
We look forward to working with you. You may indicate your agreement with these terms by signing and dating this Agreement, together with the signed Restrictive Covenants Agreement, and returning them both to me. If you have any questions, please do not hesitate to contact me.
Very truly yours,
BIODELIVERY SCIENCES INTERNATIONAL, INC.
/s/ Jeffrey A. Bailey        
By: Jeffrey A. Bailey
Title: Chief Executive Officer
Enclosure: Restrictive Covenants Agreement
I have read and accept this Agreement:
/s/ John Golubieski            
By: John Golubieski CPA, MBA

Dated: October 18, 2021

9
 EX-31.1 3 bdsi-20210930x10qex311.htm EX-31.1 Document

Exhibit 31.1
Certification of Principal Executive Officer
Pursuant to Rule 13a-14(a)
I, Jeffrey Bailey, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of BioDelivery Sciences International, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 3, 2021
/s/ Jeffrey Bailey
Jeffrey Bailey
Chief Executive Officer and Director
(Principal Executive Officer)


 EX-31.2 4 bdsi-20210930x10qex312.htm EX-31.2 Document

Exhibit 31.2
Certification of Chief Financial Officer
Pursuant to Rule 13a-14(a)
I, Mary Theresa Coelho, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of BioDelivery Sciences International, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 3, 2021
/s/ Mary Theresa Coelho
Mary Theresa Coelho
Executive Vice President, Treasurer and Chief Financial Officer
(Principal Financial and Accounting Officer)


 EX-32.1 5 bdsi-20210930x10qex321.htm EX-32.1 Document

Exhibit 32.1
BIODELIVERY SCIENCES INTERNATIONAL, INC.
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of BioDelivery Sciences International, Inc. (the “Company”) on Form 10-Q for the period ending September 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jeffrey Bailey, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. ss.1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
/s/ Jeffrey Bailey
Jeffrey Bailey
Chief Executive Officer and Director
(Principal Executive Officer)
November 3, 2021


 EX-32.2 6 bdsi-20210930x10qex322.htm EX-32.2 Document

Exhibit 32.2
BIODELIVERY SCIENCES INTERNATIONAL, INC.
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of BioDelivery Sciences International, Inc. (the “Company”) on Form 10-Q for the period ending September 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Mary Theresa Coelho, Executive Vice President, Treasurer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. ss.1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
/s/ Mary Theresa Coelho
Mary Theresa Coelho
Executive Vice President, Treasurer and Chief Financial Officer
(Principal Financial and Accounting Officer)
November 3, 2021


 EX-101.SCH 7 bdsi-20210930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Organization, basis of presentation and summary of significant policies link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Organization, basis of presentation and summary of significant policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Organization, basis of presentation and summary of significant policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2404401 - Disclosure - Organization, basis of presentation and summary of significant policies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Organization, basis of presentation and summary of significant policies - Cash and Cash Equivalents a Recurring Basis (Detail) link:presentationLink link:calculationLink link:definitionLink 2106102 - Disclosure - Inventory, net link:presentationLink link:calculationLink link:definitionLink 2307302 - Disclosure - Inventory, net (Tables) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Inventory, net (Detail) link:presentationLink link:calculationLink link:definitionLink 2109103 - Disclosure - Accounts Payable and Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 2310303 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - Accounts Payable and Accrued Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 2112104 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 2313304 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 2414405 - Disclosure - Property and Equipment - Summarized Category of Fixed Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 2415406 - Disclosure - Property and Equipment - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2116105 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 2317305 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2418407 - Disclosure - Intangible Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 2119106 - Disclosure - Acquired product rights link:presentationLink link:calculationLink link:definitionLink 2320306 - Disclosure - Acquired product rights (Tables) link:presentationLink link:calculationLink link:definitionLink 2421408 - Disclosure - Acquired product rights - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2422409 - Disclosure - Acquired product rights - Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 2123107 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 2324307 - Disclosure - Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 2425410 - Disclosure - Notes Payable - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2426411 - Disclosure - Notes Payable - Future Maturities of the CRG Obligation (Detail) link:presentationLink link:calculationLink link:definitionLink 2127108 - Disclosure - Net Sales by Product link:presentationLink link:calculationLink link:definitionLink 2328308 - Disclosure - Net Sales by Product (Tables) link:presentationLink link:calculationLink link:definitionLink 2429412 - Disclosure - Net Sales by Product (Detail) link:presentationLink link:calculationLink link:definitionLink 2130109 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 2331309 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2432413 - Disclosure - Stockholders' Equity - Additional information (Detail) link:presentationLink link:calculationLink link:definitionLink 2433414 - Disclosure - Stockholders' Equity - Key Assumptions Used in Determining Fair Value of Options Granted (Detail) link:presentationLink link:calculationLink link:definitionLink 2434415 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Detail) link:presentationLink link:calculationLink link:definitionLink 2435416 - Disclosure - Stockholders' Equity - Summary of Restricted Stock Activity (Detail) link:presentationLink link:calculationLink link:definitionLink 2436417 - Disclosure - Stockholder's Equity - Schedule of Earnings per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2137110 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2138111 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2439418 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 bdsi-20210930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 bdsi-20210930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 bdsi-20210930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Total notes payable obligation Long-term Debt Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period License and Distribution Rights License And Distribution Rights [Member] License and distribution rights. Document Type Document Type Aggregate intrinsic value, Outstanding, balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Other (expense)/income, net Other Nonoperating Income (Expense) Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Preferred Stock Series A Series A Preferred Stock [Member] Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Treasury Stock Treasury Stock [Member] Price of acquisition Asset Acquisition, Price Of Acquisition Expected Asset Acquisition, Price Of Acquisition Expected Payables and Accruals [Abstract] Payables and Accruals [Abstract] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Cost of sales Cost of Goods and Services Sold BELBUCA Belbuca [Member] BELBUCA (buprenorphine) buccal film for Chronic Pain. BELBUCA is a partial mu-opioid agonist and a treatment indicated for the management of pain severe enough to require daily, around the clock, long-term opioid treatment for which alternative treatment options are inadequate. Equity Components [Axis] Equity Components [Axis] Weighted average fair market value per RSU, Vested (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Minimum Minimum [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Provision for/(release of) inventory obsolescence Inventory Write-down Consolidated Entities [Domain] Consolidated Entities [Domain] Property and equipment, net Total property and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Payment on notes payable Repayment on notes payable Repayments of Notes Payable BUNAVAIL Bunavail [Member] BUNAVAIL [Member] Range [Domain] Statistical Measurement [Domain] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Line of Credit Line of Credit [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Weighted average fair market value per RSU, Forfeitures (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Key Assumptions Used in Determining Fair Value of Options Granted Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Entity Interactive Data Current Entity Interactive Data Current Milestone payment requirement, net sales Asset Acquisition, Milestone Payment Requirement, Net Sales Asset Acquisition, Milestone Payment Requirement, Net Sales Preferred Stock Preferred Stock [Member] Weighted average exercise price per share, Exercised (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Revenues: Revenues [Abstract] Security Exchange Name Security Exchange Name Operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Summary of Stock Option Activity Share-based Payment Arrangement, Option, Activity [Table Text Block] Right of use, building lease Finance Lease, Right-of-Use Asset, before Accumulated Amortization Income from operations Operating Income (Loss) Interest only, payment term Debt Instrument, Interest Only Payment Term Debt Instrument, Interest Only Payment Term Total current liabilities Liabilities, Current Accrued returns Accrued Returns, Current Accrued returns. Entity Registrant Name Entity Registrant Name Subsequent Event Type [Domain] Subsequent Event Type [Domain] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Accrued compensation and benefits Accrued Employee Benefits, Current Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Weighted average fair market value per RSU, Outstanding at beginning of period (in usd per share) Weighted average fair market value per RSU, Outstanding at end of period (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Variable Rate [Domain] Variable Rate [Domain] Variable Rate [Axis] Variable Rate [Axis] Commitments and contingencies (Note 10) Commitments and Contingencies Restricted stock awards Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Payment on share repurchase Payments for Repurchase of Common Stock ASSETS Assets [Abstract] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Vesting period of shares Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Accounting Policies [Abstract] Accounting Policies [Abstract] Weighted average exercise price per share Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Stock-based compensation Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Entity Address, State or Province Entity Address, State or Province Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Accounts payable Accounts Payable, Current 2024 Long-Term Debt, Maturity, Year Three Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Product rights payable Product Rights Payable, Current Product Rights Payable, Current Accrued legal Accrued Legal, Current Accrued legal current. Accumulated deficit Retained Earnings (Accumulated Deficit) Preferred stock conversion to common stock Stock Issued During Period, Value, Conversion of Convertible Securities Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Finished goods Inventory, Finished Goods, Gross Asset Aquisition [Axis] Asset Aquisition [Axis] Asset Aquisition Cost of sales Cost of Goods and Service [Policy Text Block] Product Concentration Risk Product Concentration Risk [Member] Treasury stock, shares acquired (in shares) Treasury Stock, Shares, Acquired Cash paid for taxes Income Taxes Paid Outstanding at beginning of period (in shares) Outstanding at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Unrecognized compensation cost related to non-vested share-based compensation awards granted Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Entity Address, Postal Zip Code Entity Address, Postal Zip Code Threshold limit for liquid investments Threshold Limit For Liquid Investments Threshold Limit For Investments Of A Liquid Nature Transaction expenses Asset Acquisition, Consideration Transferred, Transaction Cost Asset Acquisition, Consideration Transferred, Transaction Cost Preferred Stock, 5,000,000 shares authorized; Series B Non-Voting Convertible Preferred Stock, $0.001 par value, 443 shares outstanding at September 30, 2021 and December 31, 2020, respectively. Preferred Stock, Value, Issued Goodwill Goodwill Asset Aquisition [Domain] Asset Aquisition [Domain] Asset Aquisition [Domain] Symproic Symproic [Member] SymproicMember Total expenses: Operating Expenses Document Transition Report Document Transition Report Stock option exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Common Stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Title of Individual [Axis] Title of Individual [Axis] Payment on deferred financing fees Payments of Financing Costs Other long-term liabilities Other Liabilities, Noncurrent Warrants outstanding (in shares) Class of Warrant or Right, Outstanding Taxes payable Increase (Decrease) in Income Taxes Payable Summary of Net Sales by Product Schedule of Product Information [Table Text Block] Level 2 Fair Value, Inputs, Level 2 [Member] Overview Entity Overview [Policy Text Block] Entity Overview Policy [Text Block] Document Quarterly Report Document Quarterly Report Inventory, net Total inventories, net Inventory, Net Total revenues: Net product sales Revenue from Contract with Customer, Excluding Assessed Tax Forfeitures (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Lender Name [Axis] Lender Name [Axis] Milestone payment, net sales Asset Acquisition, Milestone Payment, Net Sales Asset Acquisition, Milestone Payment, Net Sales Percent of net product sales Concentration Risk, Percentage Subsequent Event [Line Items] Subsequent Event [Line Items] Weighted average exercise price per share, Granted (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Bio Pharma Credit Plc Bio Pharma Credit Plc [Member] XXX_Bio Pharma Credit Plc [Member] Statement [Line Items] Statement [Line Items] Credit Facility [Domain] Credit Facility [Domain] Weighted average common stock shares outstanding, diluted (in shares) Weighted average common stock shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Basic earnings per share (in usd per share) Earnings Per Share, Basic Class of Stock [Domain] Class of Stock [Domain] Basic and diluted: Earnings Per Share, Basic and Diluted [Abstract] CRG CRG Servicing LLC [Member] CRG servicing LLC. Computer equipment & software Computer Equipment [Member] Debt instrument, term Debt Instrument, Term Weighted average expected life in years Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Entity File Number Entity File Number Summary of Components of Accounts Payable and Accrued Liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Forfeitures (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Debt Disclosure [Abstract] Debt Disclosure [Abstract] Statement [Table] Statement [Table] Range [Axis] Statistical Measurement [Axis] Credit Facility [Axis] Credit Facility [Axis] Net cash flows (used in)/provided by financing activities Net Cash Provided by (Used in) Financing Activities Inventory obsolescence reserved Obsolescence reserve Inventory Valuation Reserves Warrant exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Common Stock, $0.001 par value; 235,000,000 shares authorized at September 30, 2021 and December 31, 2020, respectively; 102,057,290 and 101,417,441 shares issued; 98,791,606 and 101,354,447 shares outstanding at September 30, 2021 and December 31, 2020, respectively. Common Stock, Value, Issued Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Document Fiscal Year Focus Document Fiscal Year Focus Entity Small Business Entity Small Business Principles of consolidation Consolidation, Policy [Policy Text Block] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Entity Current Reporting Status Entity Current Reporting Status Notes Payable Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Amendment Flag Amendment Flag Subsequent Event [Table] Subsequent Event [Table] Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Fair market value of RSUs granted Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Fair Value Share based compensation arrangement by share based payment award equity instruments other than options grants in period fair value. Weighted average fair market value per RSU, Granted (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Accretion of debt discount and loan costs Accretion Expense Officers and Directors Share-based Payment Arrangement, Nonemployee [Member] Fair Value, Assets Measured on Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Common Stock, shares issued (in shares) Common Stock, Shares, Issued Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Accrued other Other Accrued Liabilities, Current Proceeds from notes payable Proceeds from Secured Notes Payable Additional payment Asset Acquisition, Price Of Acquisition Expected, Additional Payment Asset Acquisition, Price Of Acquisition Expected, Additional Payment Net cash flows provided by operating activities Net Cash Provided by (Used in) Operating Activities Entity Central Index Key Entity Central Index Key Segment Reporting [Abstract] Segment Reporting [Abstract] Accounts receivable, after allowance for credit loss Accounts Receivable, after Allowance for Credit Loss Asset Acquisition Asset Acquisition [Table Text Block] Asset Acquisition Accounts receivable Increase (Decrease) in Accounts Receivable Debt Instrument [Line Items] Debt Instrument [Line Items] Preferred Stock Series B Series B Preferred Stock [Member] Measurement of credit losses of financial instruments Credit Loss, Financial Instrument [Policy Text Block] Total stockholders’ equity Beginning Balance Ending Balance Stockholders' Equity Attributable to Parent Acquired product rights License Agreements And Acquired Product Rights [Text Block] License Agreements And Acquired Product Rights Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Summary of Other Intangible Assets Net Consisting of Product Rights and Licenses Schedule Of Finite Lived Intangible Assets By Major Class [Table Text Block] Schedule Of Finite Lived Intangible Assets By Major Class [Table Text Block] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Total liabilities and stockholders’ equity Liabilities and Equity Entity Address, City or Town Entity Address, City or Town Subsequent Events Subsequent Events [Text Block] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Accounts payable and accrued liabilities Total accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities, Current Selling, general and administrative General and Administrative Expense Net change in operating lease assets and liabilities Increase (Decrease) In Operating Lease Assets And Liabilities Increase (Decrease) In Operating Lease Assets And Liabilities Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Product sales, net Product [Member] Chief Accounting Officer Chief Accounting Officer [Member] Chief Accounting Officer 2025 Long-Term Debt, Maturity, Year Four Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Variable rate floor Variable Rate, Floor Variable Rate, Floor Weighted Average Useful Life Finite-Lived Intangible Asset, Useful Life Equity Component [Domain] Equity Component [Domain] Grantee Status [Domain] Grantee Status [Domain] Entity common stock, shares outstanding (in shares) Entity Common Stock, Shares Outstanding Fair market value of shares granted Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Fair Value Share based compensation arrangement by share based payment award options granted in period fair value. Treasury stock, weighted average price (in dollars per share) Treasury Stock Acquired, Average Cost Per Share Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Construction in progress Construction in Progress [Member] Accrued rebates Accrued Marketing Costs, Current Entity Tax Identification Number Entity Tax Identification Number Stockholders' Equity Note [Abstract] Annual performance-based incentive cash bonus, percent of base salary Annual Performance-Based Incentive Cash Bonus, Percent Of Base Salary, Officer Annual Performance-Based Incentive Cash Bonus, Percent Of Base Salary, Officer Amortization of intangible assets Amortization of Intangible Assets Percent of accounts receivable outstanding for 30 days Accounts Receivable, Allowance for Credit Loss, Percentage Of Accounts Receivable Outstanding Less Than Thirty Days Accounts Receivable, Allowance for Credit Loss, Percentage Of Accounts Receivable Outstanding Less Than Thirty Days Net income Net Income (Loss) Attributable to Parent Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] London Interbank Offered Rate (LIBOR) London Interbank Offered Rate (LIBOR) [Member] Inventory, net Inventory Disclosure [Text Block] Work-in-process Inventory, Work in Process, Gross Effect of dilutive options and warrants (in shares) Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants Net Sales by Product Segment Reporting Disclosure [Text Block] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Restricted stock awards (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Product Rights Product Rights [Member] ProductRightsMember Total assets Assets Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Total current assets Assets, Current Current Fiscal Year End Date Current Fiscal Year End Date Expenses: Operating Expenses [Abstract] Organization, basis of presentation and summary of significant policies Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Outstanding at beginning of period (in shares) Outstanding at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Title of 12(b) Security Title of 12(b) Security Total Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization Intangible Assets, net Finite-Lived Intangible Assets, Net Milestone payments, total Asset Acquisition, Milestone Payments Asset Acquisition, Milestone Payments Taxes payable Accrued Income Taxes, Current Subsequent Event Type [Axis] Subsequent Event Type [Axis] Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Number of shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Document Fiscal Period Focus Document Fiscal Period Focus Interest expense, net Interest Expense Depreciation Depreciation, Depletion and Amortization Less accumulated depreciation and amortization Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization Product and Service Product and Service [Axis] Total liabilities Liabilities License and distribution rights, net License And Distribution Rights license and distribution rights. Net income (loss) attributable to common stockholders, diluted Net Income (Loss) Available to Common Stockholders, Diluted Expected price volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Entity Filer Category Entity Filer Category Common Stock Common Stock [Member] 2023 Long-Term Debt, Maturity, Year Two Asset Acquisition [Abstract] Asset Acquisition Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Product and Service [Domain] Product and Service [Domain] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Net income attributable to common stockholders Net income (loss) attributable to common stockholders, basic Net Income (Loss) Available to Common Stockholders, Basic ELYXYB ELYXYB [Member] ELYXYB Level 1 Fair Value, Inputs, Level 1 [Member] Inventories Increase (Decrease) in Inventories Summarized Category of Fixed Assets Property, Plant and Equipment [Table Text Block] Accrued regulatory expenses Accrued Regulatory Costs, Current Accrued Regulatory Costs, Current Number of restricted shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Asset Acquisition [Table] Asset Acquisition [Table] Asset Acquisition Leasehold improvements Leasehold Improvements [Member] Gross Carrying Value Finite-Lived Intangible Assets, Gross Revenue Benchmark Revenue Benchmark [Member] Additional Paid-In Capital Additional Paid-in Capital [Member] Preferred stock conversion to common stock (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Option Share-based Payment Arrangement [Member] Treasury stock, amount repurchased Treasury Stock, Value, Acquired, Cost Method Adjustments to reconcile net income to net cash flows from operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Beginning Balance (in shares) Ending Balance (in shares) Shares, Issued Stock option exercises (in shares) Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Future Maturities of the Notes Payable Obligation Schedule Of Future Maturities Of Debt Obligation [Table Text Block] Schedule of future maturities of debt obligation table. Machinery & equipment Machinery and Equipment [Member] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Common Stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Idle equipment Idle Equipment [Member] Idle equipment. Change in allowance for doubtful accounts and credit losses Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) Employees Share-based Payment Arrangement, Employee [Member] Weighted average common stock shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Subsequent Events [Abstract] Weighted average exercise price per share, Forfeitures (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Grantee Status [Axis] Grantee Status [Axis] Treasury stock, shares (in shares) Treasury Stock, Shares Subsequent Event Subsequent Event [Member] Weighted average exercise price per share, Outstanding at beginning of period (in usd per share) Weighted average exercise price per share, Outstanding at end of period (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Product royalty revenues Royalty [Member] Common Stock, shares authorized (in shares) Common Stock, Shares Authorized Summary of Restricted Stock Activity Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Property, plant, and equipment, gross Property, Plant and Equipment, Gross Proceeds from exercise of stock options Proceeds from Stock Options Exercised Additional facility funds that can be obtained Debt Instrument Additional Facility That Can Be Obtained Additional Amount Of Debt Facility that Can be availed Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Annual base salary Annual Base Salary, Officer Annual Base Salary, Officer Revenue recognition Revenue [Policy Text Block] Notes payable, less current maturities Notes Payable, Noncurrent Additional paid-in capital Additional Paid in Capital Cash and cash equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Class of Stock [Axis] Class of Stock [Axis] Inventory Inventory, Policy [Policy Text Block] Income tax provision Income Tax Expense (Benefit) Term of options granted period Share Based Compensation Arrangements By Share Based Payment Award Term Of Options Granted Share based compensation arrangements by share based payment award term of options granted. Income Statement [Abstract] Income Statement [Abstract] Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Relationship to Entity [Domain] Title of Individual [Domain] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Diluted earnings per share (in usd per share) Earnings Per Share, Diluted Local Phone Number Local Phone Number Up-front payment Asset Acquisition, Up-front Payment Asset Acquisition, Up-front Payment Accrued royalties Accrued Royalties, Current Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Total value Asset Acquisition, Consideration Transferred Asset Acquisition, Consideration Transferred Intrinsic value of options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Use of estimates in financial statements Use of Estimates, Policy [Policy Text Block] Current assets: Assets, Current [Abstract] Product acquisitions Payments To Acquire Products Payments To Acquire Products Total maturities Long-term Debt, Gross Depreciation Depreciation Entity Address, Address Line One Entity Address, Address Line One Sales Information [Line Items] Sales Information [Line Items] Sales Information [Line Items] Entity Emerging Growth Company Entity Emerging Growth Company Stock option exercises Stock Issued During Period, Value, Stock Options Exercised Consolidated Entities [Axis] Consolidated Entities [Axis] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Preferred Stock, par value (in usd per share) Preferred Stock, Par or Stated Value Per Share 2022 Long-Term Debt, Maturity, Year One Secured credit term loan Line of Credit Facility, Maximum Borrowing Capacity Award Type [Axis] Award Type [Axis] Weighted average fair market value per RSU Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Acquisitions of property, plant and equipment Payments to Acquire Property, Plant, and Equipment City Area Code City Area Code Maximum Maximum [Member] Preferred Stock, shares authorized (in shares) Preferred Stock, Shares Authorized Document Period End Date Document Period End Date Raw materials  Inventory, Raw Materials and Supplies, Gross Share repurchase Treasury Stock, Value, Acquired, Par Value Method Accumulated Deficit Retained Earnings [Member] Preferred Stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Asset Acquisition [Line Items] Asset Acquisition [Line Items] Asset Acquisition Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Unamortized discount and loan costs Unamortized Loan Commitment and Origination Fees and Unamortized Discounts or Premiums Net cash flows used in investing activities Net Cash Provided by (Used in) Investing Activities Aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Authorized stock repurchase amount Stock Repurchase Program, Authorized Amount Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Warrants fair value Warrants and Rights Outstanding Equity Award [Domain] Award Type [Domain] Grant value of options to purchase common stock Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture Repayment of loan, accrued interest portion Repayments Of Lines Of Credit, Accrued Interest Portion Repayments Of Lines Of Credit, Accrued Interest Portion Trading Symbol Trading Symbol Summary of Inventories Schedule of Inventory, Current [Table Text Block] Notes payable, current Notes Payable, Current Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Stock-based compensation expense Share-based Payment Arrangement, Noncash Expense ELYXYB acquired product rights Payments to Acquire Productive Assets 2021 Long-Term Debt, Maturity, Remainder of Fiscal Year Treasury stock, at cost, 3,265,684 and 62,994 shares, as of September 30, 2021 and December 31, 2020, respectively. Treasury Stock, Value Office furniture & equipment Office Equipment [Member] Cover [Abstract] Current liabilities: Liabilities, Current [Abstract] Entity Shell Company Entity Shell Company Employees And Directors Employees And Directors [Member] Employees and directors. Intangible Assets Intangible Assets Disclosure [Text Block] New Accounting Pronouncements, adopted New Accounting Pronouncements, Policy [Policy Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] EX-101.PRE 11 bdsi-20210930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 12 image_0.jpg begin 644 image_0.jpg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bdsi-20210930_htm.xml IDEA: XBRL DOCUMENT 0001103021 2021-01-01 2021-09-30 0001103021 2021-11-03 0001103021 2021-09-30 0001103021 2020-12-31 0001103021 us-gaap:SeriesBPreferredStockMember 2020-12-31 0001103021 us-gaap:SeriesBPreferredStockMember 2021-09-30 0001103021 us-gaap:ProductMember 2021-07-01 2021-09-30 0001103021 us-gaap:ProductMember 2020-07-01 2020-09-30 0001103021 us-gaap:ProductMember 2021-01-01 2021-09-30 0001103021 us-gaap:ProductMember 2020-01-01 2020-09-30 0001103021 us-gaap:RoyaltyMember 2021-07-01 2021-09-30 0001103021 us-gaap:RoyaltyMember 2020-07-01 2020-09-30 0001103021 us-gaap:RoyaltyMember 2021-01-01 2021-09-30 0001103021 us-gaap:RoyaltyMember 2020-01-01 2020-09-30 0001103021 2021-07-01 2021-09-30 0001103021 2020-07-01 2020-09-30 0001103021 2020-01-01 2020-09-30 0001103021 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001103021 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001103021 us-gaap:CommonStockMember 2019-12-31 0001103021 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001103021 us-gaap:TreasuryStockMember 2019-12-31 0001103021 us-gaap:RetainedEarningsMember 2019-12-31 0001103021 2019-12-31 0001103021 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001103021 2020-01-01 2020-03-31 0001103021 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001103021 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-03-31 0001103021 us-gaap:SeriesAPreferredStockMember us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001103021 us-gaap:SeriesAPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001103021 us-gaap:SeriesAPreferredStockMember 2020-01-01 2020-03-31 0001103021 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-03-31 0001103021 us-gaap:SeriesBPreferredStockMember us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001103021 us-gaap:SeriesBPreferredStockMember 2020-01-01 2020-03-31 0001103021 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001103021 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-03-31 0001103021 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2020-03-31 0001103021 us-gaap:CommonStockMember 2020-03-31 0001103021 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001103021 us-gaap:TreasuryStockMember 2020-03-31 0001103021 us-gaap:RetainedEarningsMember 2020-03-31 0001103021 2020-03-31 0001103021 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001103021 2020-04-01 2020-06-30 0001103021 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001103021 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001103021 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-06-30 0001103021 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2020-06-30 0001103021 us-gaap:CommonStockMember 2020-06-30 0001103021 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001103021 us-gaap:TreasuryStockMember 2020-06-30 0001103021 us-gaap:RetainedEarningsMember 2020-06-30 0001103021 2020-06-30 0001103021 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001103021 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001103021 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001103021 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-09-30 0001103021 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2020-09-30 0001103021 us-gaap:CommonStockMember 2020-09-30 0001103021 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001103021 us-gaap:TreasuryStockMember 2020-09-30 0001103021 us-gaap:RetainedEarningsMember 2020-09-30 0001103021 2020-09-30 0001103021 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2020-12-31 0001103021 2020-10-01 2020-12-31 0001103021 us-gaap:CommonStockMember 2020-10-01 2020-12-31 0001103021 us-gaap:TreasuryStockMember 2020-10-01 2020-12-31 0001103021 us-gaap:RetainedEarningsMember 2020-10-01 2020-12-31 0001103021 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001103021 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001103021 us-gaap:CommonStockMember 2020-12-31 0001103021 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001103021 us-gaap:TreasuryStockMember 2020-12-31 0001103021 us-gaap:RetainedEarningsMember 2020-12-31 0001103021 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001103021 2021-01-01 2021-03-31 0001103021 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001103021 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0001103021 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001103021 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-03-31 0001103021 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-03-31 0001103021 us-gaap:CommonStockMember 2021-03-31 0001103021 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001103021 us-gaap:TreasuryStockMember 2021-03-31 0001103021 us-gaap:RetainedEarningsMember 2021-03-31 0001103021 2021-03-31 0001103021 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001103021 2021-04-01 2021-06-30 0001103021 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001103021 us-gaap:TreasuryStockMember 2021-04-01 2021-06-30 0001103021 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001103021 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-06-30 0001103021 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-06-30 0001103021 us-gaap:CommonStockMember 2021-06-30 0001103021 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001103021 us-gaap:TreasuryStockMember 2021-06-30 0001103021 us-gaap:RetainedEarningsMember 2021-06-30 0001103021 2021-06-30 0001103021 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001103021 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001103021 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001103021 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-09-30 0001103021 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-09-30 0001103021 us-gaap:CommonStockMember 2021-09-30 0001103021 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001103021 us-gaap:TreasuryStockMember 2021-09-30 0001103021 us-gaap:RetainedEarningsMember 2021-09-30 0001103021 2020-01-01 2020-12-31 0001103021 us-gaap:FairValueInputsLevel1Member 2021-09-30 0001103021 us-gaap:FairValueInputsLevel2Member 2021-09-30 0001103021 us-gaap:FairValueInputsLevel3Member 2021-09-30 0001103021 us-gaap:MachineryAndEquipmentMember 2021-09-30 0001103021 us-gaap:MachineryAndEquipmentMember 2020-12-31 0001103021 us-gaap:ComputerEquipmentMember 2021-09-30 0001103021 us-gaap:ComputerEquipmentMember 2020-12-31 0001103021 us-gaap:OfficeEquipmentMember 2021-09-30 0001103021 us-gaap:OfficeEquipmentMember 2020-12-31 0001103021 us-gaap:LeaseholdImprovementsMember 2021-09-30 0001103021 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001103021 bdsi:IdleEquipmentMember 2021-09-30 0001103021 bdsi:IdleEquipmentMember 2020-12-31 0001103021 us-gaap:ConstructionInProgressMember 2021-09-30 0001103021 us-gaap:ConstructionInProgressMember 2020-12-31 0001103021 bdsi:BunavailMember 2020-01-01 2020-09-30 0001103021 bdsi:BelbucaMember bdsi:LicenseAndDistributionRightsMember 2021-09-30 0001103021 bdsi:BelbucaMember bdsi:LicenseAndDistributionRightsMember 2021-01-01 2021-09-30 0001103021 bdsi:SymproicMember bdsi:LicenseAndDistributionRightsMember 2021-09-30 0001103021 bdsi:SymproicMember bdsi:LicenseAndDistributionRightsMember 2021-01-01 2021-09-30 0001103021 bdsi:ELYXYBMember bdsi:LicenseAndDistributionRightsMember 2021-09-30 0001103021 bdsi:ELYXYBMember bdsi:LicenseAndDistributionRightsMember 2021-01-01 2021-09-30 0001103021 bdsi:ProductRightsMember 2020-12-31 0001103021 bdsi:BelbucaMember bdsi:LicenseAndDistributionRightsMember 2020-12-31 0001103021 bdsi:BelbucaMember bdsi:LicenseAndDistributionRightsMember 2020-01-01 2020-12-31 0001103021 bdsi:SymproicMember bdsi:LicenseAndDistributionRightsMember 2020-12-31 0001103021 bdsi:SymproicMember bdsi:LicenseAndDistributionRightsMember 2020-01-01 2020-12-31 0001103021 bdsi:ELYXYBMember 2021-08-03 2021-08-03 0001103021 2021-08-03 2021-08-03 0001103021 srt:MinimumMember bdsi:ELYXYBMember 2021-08-03 2021-08-03 0001103021 srt:MaximumMember bdsi:ELYXYBMember 2021-08-03 2021-08-03 0001103021 bdsi:BioPharmaCreditPlcMember 2019-05-23 0001103021 bdsi:BioPharmaCreditPlcMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-01-01 2021-09-30 0001103021 bdsi:BioPharmaCreditPlcMember 2021-01-01 2021-09-30 0001103021 bdsi:BioPharmaCreditPlcMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-09-30 0001103021 bdsi:BioPharmaCreditPlcMember 2021-09-23 2021-09-23 0001103021 us-gaap:LineOfCreditMember bdsi:CRGServicingLLCMember 2021-09-30 0001103021 bdsi:BelbucaMember 2021-07-01 2021-09-30 0001103021 bdsi:BelbucaMember 2020-07-01 2020-09-30 0001103021 bdsi:BelbucaMember 2021-01-01 2021-09-30 0001103021 bdsi:BelbucaMember 2020-01-01 2020-09-30 0001103021 bdsi:BelbucaMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-07-01 2021-09-30 0001103021 bdsi:BelbucaMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-07-01 2020-09-30 0001103021 bdsi:BelbucaMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-09-30 0001103021 bdsi:BelbucaMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-01-01 2020-09-30 0001103021 bdsi:SymproicMember 2021-07-01 2021-09-30 0001103021 bdsi:SymproicMember 2020-07-01 2020-09-30 0001103021 bdsi:SymproicMember 2021-01-01 2021-09-30 0001103021 bdsi:SymproicMember 2020-01-01 2020-09-30 0001103021 bdsi:SymproicMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-07-01 2021-09-30 0001103021 bdsi:SymproicMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-07-01 2020-09-30 0001103021 bdsi:SymproicMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-09-30 0001103021 bdsi:SymproicMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-01-01 2020-09-30 0001103021 bdsi:BunavailMember 2021-07-01 2021-09-30 0001103021 bdsi:BunavailMember 2020-07-01 2020-09-30 0001103021 bdsi:BunavailMember 2021-01-01 2021-09-30 0001103021 bdsi:BunavailMember 2020-01-01 2020-09-30 0001103021 bdsi:BunavailMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-07-01 2021-09-30 0001103021 bdsi:BunavailMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-07-01 2020-09-30 0001103021 bdsi:BunavailMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-09-30 0001103021 bdsi:BunavailMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2020-01-01 2020-09-30 0001103021 2020-11-04 0001103021 bdsi:EmployeesAndDirectorsMember 2021-01-01 2021-09-30 0001103021 srt:MinimumMember 2021-01-01 2021-09-30 0001103021 srt:MaximumMember 2021-01-01 2021-09-30 0001103021 us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2021-01-01 2021-09-30 0001103021 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2021-01-01 2021-09-30 0001103021 bdsi:EmployeesAndDirectorsMember 2020-01-01 2020-09-30 0001103021 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0001103021 srt:MinimumMember us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0001103021 srt:MaximumMember us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0001103021 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001103021 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2021-01-01 2021-09-30 0001103021 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2021-01-01 2021-09-30 0001103021 us-gaap:RestrictedStockUnitsRSUMember 2021-09-30 0001103021 srt:MinimumMember 2021-09-30 0001103021 srt:MaximumMember 2021-09-30 0001103021 bdsi:ChiefAccountingOfficerMember us-gaap:SubsequentEventMember 2021-10-25 2021-10-25 0001103021 bdsi:ChiefAccountingOfficerMember us-gaap:StockCompensationPlanMember us-gaap:SubsequentEventMember 2021-10-25 2021-10-25 0001103021 bdsi:ChiefAccountingOfficerMember us-gaap:RestrictedStockUnitsRSUMember us-gaap:SubsequentEventMember 2021-10-25 2021-10-25 shares iso4217:USD iso4217:USD shares pure false 2021 Q3 0001103021 --12-31 P1Y 10-Q true 2021-09-30 false 001-31361 BioDelivery Sciences International, Inc. DE 35-2089858 4131 ParkLake Ave., Suite 225 Raleigh NC 27612 919 582-9050 Common stock, par value $0.001 BDSI NASDAQ Yes Yes Accelerated Filer false false false 98795939 100710000 111584000 57572000 48150000 23075000 17443000 6904000 5208000 188261000 182385000 1525000 1418000 2715000 2715000 63569000 53376000 256070000 239894000 74580000 52995000 3077000 0 77657000 52995000 55638000 78452000 0 213000 133295000 131660000 5000000 5000000 0.001 0.001 443 443 0 0 0.001 0.001 235000000 235000000 102057290 101417441 98791606 101354447 104000 104000 454738000 449264000 3265684 62994 12155000 252000 -319912000 -340882000 122775000 108234000 256070000 239894000 41072000 38785000 122398000 112946000 20000 658000 1151000 1358000 41092000 39443000 123549000 114304000 6365000 5376000 16470000 16371000 25468000 22461000 79007000 77408000 25468000 22461000 79007000 77408000 9259000 11606000 28072000 20525000 1984000 2010000 5962000 4997000 0 -2000 -1000 6000 7275000 9594000 22109000 15534000 606000 211000 1139000 19000 6669000 9383000 20970000 15515000 98699857 101031317 99485399 99377748 0.07 0.09 0.21 0.16 102430883 105783568 103473967 104836493 0.07 0.09 0.20 0.15 2093155 2000 618 0 96189074 96000 436306000 -47000 -366593000 69764000 1520000 1520000 107287 338000 338000 459670 -2093155 -2000 2093155 2000 -1000 -1000 -175 972222 1000 1000 4966000 4966000 0 0 443 0 99821408 99000 438163000 -47000 -361627000 76588000 4786000 4786000 983437 2231000 2231000 111666 1165000 1165000 0 0 443 0 100916511 99000 445180000 -47000 -360462000 84770000 1539000 1539000 68623 1000 191000 192000 141318 9384000 9384000 0 0 443 0 101126452 100000 446910000 -47000 -351078000 95885000 1750000 1750000 240656 1000 608000 609000 50333 3000 -4000 -1000 205000 205000 10196000 10196000 0 0 443 0 101417441 104000 449264000 -252000 -340882000 108234000 1490000 1490000 16619 40000 40000 268174 6147000 6147000 5237000 5237000 0 0 443 0 101702234 104000 450794000 -6399000 -335645000 108854000 1697000 1697000 25828 59000 59000 66668 5756000 5756000 9064000 9064000 0 0 443 0 101794730 104000 452550000 -12155000 -326581000 113918000 1837000 1837000 113243 351000 351000 149317 6669000 6669000 0 0 443 0 102057290 104000 454738000 -12155000 -319912000 122775000 20970000 15515000 97000 467000 264000 231000 5262000 5248000 1100000 -297000 5024000 7845000 30000 0 9422000 5040000 6731000 7278000 1856000 1985000 12005000 -701000 606000 -40000 27289000 13965000 6456000 0 415000 0 -6871000 0 20000000 0 0 20000000 611000 611000 2761000 2761000 11903000 0 0 437000 -31292000 22324000 -10874000 36289000 111584000 63888000 100710000 100177000 5726000 5037000 1275000 318000 Organization, basis of presentation and summary of significant policies:<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioDelivery Sciences International, Inc., together with its subsidiaries (collectively, the “Company”) is a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions. The Company has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive ("BEMA") drug-delivery technology to develop and commercialize new applications of proven therapies aimed at addressing important unmet medical needs. The Company commercializes its products in the U.S. using its own sales force while working in partnership with third parties to commercialize its products outside the U.S.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements include all adjustments (consisting of normal and recurring adjustments) necessary for a fair presentation of these financial statements. The condensed consolidated balance sheet at December 31, 2020 has been derived from the Company’s audited consolidated financial statements included in its annual report on Form 10-K for the year ended December 31, 2020. Certain footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to the Securities and Exchange Commission rules and regulations. It is recommended that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used herein, the Company’s common stock, par value $0.001 per share, is referred to as the “Common Stock” and the Company’s preferred stock, par value $0.001 per share, is referred to as the “Preferred Stock”.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of consolidation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company, Arius Pharmaceuticals, Inc. and Arius Two, Inc. All significant inter-company balances and transactions have been eliminated.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates in financial statements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. The Company reviews all significant estimates affecting the condensed consolidated financial statements on a recurring basis and records the effect of any necessary adjustments prior to their issuance. Significant estimates made by the Company include: revenue recognition associated with sales allowances such as government program rebates, customer voucher redemptions, commercial contracts, rebates and chargebacks; sales returns reserves; sales bonuses; stock-based compensation; and deferred income taxes.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and cash equivalents</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of operating and money market accounts. Cash equivalents are carried at cost which approximates fair value due to their short-term nature. The Company considers all highly-liquid investments with an original maturity of 90 days or less to be cash equivalents.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains cash equivalent balances with financial institutions that management believes are of high credit quality. The Company’s cash and cash equivalents accounts at times may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk from cash and cash equivalents.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value with costs determined for each batch under the first-in, first-out method. Inventory consists of raw materials, work in process and finished goods. Raw materials include amounts of active pharmaceutical ingredient for a product to be manufactured; work in process includes the bulk inventory of laminate (the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company’s drug delivery film) prior to being packaged for sale; and finished goods include pharmaceutical products ready for commercial sale.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a quarterly basis, the Company analyzes its inventory levels and records allowances for inventory that has become obsolete, inventory that has a cost basis in excess of the expected net realizable value and inventory that is in excess of expected demand based upon projected product sales. Inventory obsolescence reserves at September 30, 2021 and December 31, 2020 were $3.4 million and $2.3 million, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product sales</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales amounts relate to sales of BELBUCA and Symproic. Product sales for the nine months ended September 30, 2020 also included sales of BUNAVAIL. Product sales for BUNAVAIL during the three months ended September 30, 2020 were related to the release of gross to net reserves. The Company recognizes revenue on product sales when control of the promised goods is transferred to its customers in an amount that reflects the consideration expected to be received in exchange for transferring those goods. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. When determining whether the customer has obtained control of the goods, the Company considers any future performance obligations. Generally, there is no post-shipment obligation on product sold. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product royalty revenues</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product royalty revenue amounts are based on sales revenue of the PAINKYL™ product under the Company’s license agreement with TTY Biopharm Co., Ltd., ("TTY") and the BREAKYL™ product under the Company’s license agreement with Meda AB, which was acquired by Mylan N.V. and later acquired by Viatris, Inc. (which we refer to herein as Viatris). Product royalty revenues are recognized when control of the product is transferred to the license partner in an amount that reflects the consideration expected to be received. Supplemental sales-based product royalty revenue may also be earned upon the subsequent sale of the product at agreed upon contractual rates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The majority of the Company’s product sales contracts have a single performance obligation as the promise to transfer the individual goods is not separately identifiable from other promises in the contracts and, therefore, not distinct. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. The Company has assessed the existence of a significant financing component in the agreements with its customers. The trade payment terms with its customers do not exceed one year and therefore the Company has elected to apply the practical expedient and no amount of consideration has been allocated as a financing component.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transaction price, including variable consideration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration for which reserves are established. Components of variable consideration include trade discounts and allowances, product returns, government chargebacks, discounts and rebates, and other incentives, such as voucher programs, and other fee for service amounts that are detailed within contracts between the Company and its customers relating to the Company’s sale of its products. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company establishes allowances for estimated rebates, chargebacks and product returns based on numerous qualitative and quantitative factors, including:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">specific contractual terms of agreements with customers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">estimated levels of inventory in the distribution channel;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">historical rebates, chargebacks and returns of products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">direct communication with customers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">anticipated introduction of competitive products or generics;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">anticipated pricing strategy changes by the Company and/or its competitors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">analysis of prescription data gathered by third-party prescription data providers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the impact of changes in state and federal regulations; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the estimated remaining shelf life of products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In its analyses, the Company uses prescription data purchased from a third-party data provider to develop estimates of historical inventory channel sell-through. The Company utilizes an internal analysis to compare historical net product shipments to estimated historical prescriptions written. Based on that analysis, management develops an estimate of the quantity of product in the channel which may be subject to various rebate and chargeback exposures. To estimate months of ending inventory in the Company’s distribution channel, the Company divides estimated ending inventory in the distribution channel by the Company’s recent prescription data, not considering any future anticipated demand growth beyond the succeeding quarter. Monthly for each product line, the Company prepares an internal estimate of ending inventory units in the distribution channel by adding estimated inventory in the channel at the beginning of the period, plus net product shipments for the period, less estimated prescriptions written for the period, and less units included in the sales returns reserve expected to be returned. This is done for each product line by applying a rate of historical activity for rebates and chargebacks, adjusted for relevant quantitative and qualitative factors discussed above, to the potential exposed product estimated, net of reserved return units, to be in the distribution channel. In addition, the Company receives daily information from the major wholesalers regarding their sales and actual on-hand inventory levels of the Company’s products. This enables the Company to execute accurate provisioning procedures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded after considering the impact of the following variable consideration amounts at the time of revenue recognition:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product returns</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-Consistent with industry practice, the Company offers contractual return rights that allow its customers to return the products within an 18-month period that begins six months prior to and ends twelve months after expiration of the products. The Company estimates product returns reserves based upon historical return rates adjusted for qualitative factors and are applied to open product batches that are currently eligible for returns, or will be eligible in the future, within company policy. Other factors considered include expected marketplace changes and the remaining shelf life of product batches. Product returns reserves for newly launched products are based on historical rates of similar products or pre-determined percentage. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government rebates and chargebacks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-Government rebates and chargebacks include mandated discounts under Medicaid, Medicare, U.S. Department of Veterans Affairs and other government agencies ("Government Payors"). The Company estimates the rebates and chargebacks to Government Payors based upon a combination of historical experience, product pricing, estimated payor mix, product growth, and the mix of contract and agreement terms. These reserves are recorded in the same period the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets. In addition, the pricing of covered products under Medicaid is subject to complex calculations and involves interpretation of government rules, regulations and policies as well as adjustments based on current trends in utilization. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company estimates the rebates and chargebacks that it will provide to Government Payors based upon (i) the government-mandated discounts applicable to government-funded programs, (ii) information obtained from its customers and (iii) information obtained from other third parties regarding the payor mix for its products. The Company’s liability for these rebates consists of estimates of claims for the current quarter and estimated future claims that will be made for product shipments that have been recognized as revenue, but remain in the distribution channel inventories at the end of each reporting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-The Company estimates the rebates to commercial contracts based upon a combination of historical experience, product pricing, estimated payor mix, product growth, and the mix of contract and agreement terms. These reserves are recorded in the same period the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient Assistance Voucher program-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company, from time to time, offers certain promotional product-related incentives to eligible patients. The Company has voucher programs for BELBUCA and Symproic whereby the Company offers a point-of-sale subsidy to retail consumers. The Company estimates its liabilities for these voucher programs based on the current utilization and historical redemption rates as reported to the Company by a third-party claims processing organization. The </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company accounts for the costs of these special promotional programs as price adjustments, which are a reduction of gross revenue.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade discounts and distribution fees-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade discounts relate to prompt settlement discounts provided to customers. In addition, the Company compensates its customers for distribution of its products and the provision of data. The Company has determined that such services received to date are not distinct from its sale of products and may not reasonably represent fair value for these services. Therefore, estimates of these payments are recorded as a reduction of revenue based on contractual terms.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be a significant lag between the Company's establishment of an estimate and the timing of the invoicing or claim. The Company believes it has made reasonable estimates for future rebates and claims, however, these estimates involve assumptions pertaining to contractual utilization and performance, and payor mix. If the performance or mix across third-party payors is different from the Company’s estimates, the Company may be required to pay higher or lower total price adjustments and/or chargebacks than it had estimated.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of sales</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales includes the direct costs attributable to the production of BELBUCA and Symproic. It includes raw materials, production costs at the Company’s contract manufacturing sites, quality testing directly related to the products, inventory reserves, and depreciation on equipment that the Company has purchased to produce BELBUCA, Symproic and formerly BUNAVAIL. It also includes any batches not meeting specifications and raw material yield losses. Yield losses and the costs related to batches not meeting specifications are expensed as incurred. Cost of sales is recognized when sold to the wholesaler from our distribution center.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For BREAKYL and PAINKYL (the Company’s out-licensed breakthrough cancer pain therapies), cost of sales includes all costs related to creating the product at the Company’s contract manufacturing location in Germany. The Company’s contract manufacturer bills the Company for the final product, which includes materials, direct labor costs, quality testing, and certain overhead costs as outlined in applicable supply agreements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales also includes royalty expenses that the Company owes to third parties.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Measurement of credit losses of financial instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to credit losses primarily through its product sales. The Company assesses each counterparty’s ability to pay for the products it sells by conducting a credit review. The credit review considers the Company's expected billing exposure and timing for payment and the counterparty’s established credit rating or the Company's assessment of the counterparty’s creditworthiness based on the Company's analysis of their financial statements when a credit rating is not available. The Company also considers contract terms and conditions, and business strategy in its evaluation. A credit limit is established for each counterparty based on the outcome of this review.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company monitors its ongoing credit exposure through active review of counterparty balances against contract terms and due dates. The Company's activities include timely account reconciliations, dispute resolution and payment confirmations. The Company may employ collection agencies and legal counsel to pursue recovery of defaulted receivables.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, the Company reported $57.6 million of trade receivables within accounts receivable. Based on an aging analysis at September 30, 2021, 96% of the Company's accounts receivable were outstanding less than 30 days. There was no change to the allowance for doubtful accounts and credit losses between September 30, 2021 and December 31, 2020. The Company writes off accounts receivable when management determines they are uncollectible and credits payments subsequently received on such receivables to bad debt expense in the period received.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements, adopted</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740)—Simplifying the Accounting for Income Taxes, which is intended to simplify accounting for income taxes. It removes certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020 and early adoption is permitted. The Company adopted Topic 740 during the nine months ended September 30, 2021 and determined that the new guidance did not have a material impact on its consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The Company has reviewed other new accounting pronouncements that were issued as of September 30, 2021 and does not believe that these pronouncements are applicable to the Company, or that they will have a material impact on its financial position or results of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the fair value of instruments in accordance with GAAP which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company considers the carrying amount of its cash and cash equivalents to approximate fair value due to short-term nature of this instrument. GAAP describes three levels of inputs that may be used to measure fair value:</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 – quoted prices in active markets for identical assets or liabilities</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the financial instruments measured at fair value on a recurring basis as of September 30, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,710 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,710 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The cash and cash equivalent balance as of September 30, 2021 includes investments in various money market accounts and cash held in interest bearing accounts <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BioDelivery Sciences International, Inc., together with its subsidiaries (collectively, the “Company”) is a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions. The Company has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive ("BEMA") drug-delivery technology to develop and commercialize new applications of proven therapies aimed at addressing important unmet medical needs. The Company commercializes its products in the U.S. using its own sales force while working in partnership with third parties to commercialize its products outside the U.S.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements include all adjustments (consisting of normal and recurring adjustments) necessary for a fair presentation of these financial statements. The condensed consolidated balance sheet at December 31, 2020 has been derived from the Company’s audited consolidated financial statements included in its annual report on Form 10-K for the year ended December 31, 2020. Certain footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to the Securities and Exchange Commission rules and regulations. It is recommended that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2020.</span></div> 0.001 0.001 <div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of consolidation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company, Arius Pharmaceuticals, Inc. and Arius Two, Inc. All significant inter-company balances and transactions have been eliminated.</span></div> <div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates in financial statements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. The Company reviews all significant estimates affecting the condensed consolidated financial statements on a recurring basis and records the effect of any necessary adjustments prior to their issuance. Significant estimates made by the Company include: revenue recognition associated with sales allowances such as government program rebates, customer voucher redemptions, commercial contracts, rebates and chargebacks; sales returns reserves; sales bonuses; stock-based compensation; and deferred income taxes.</span></div> <div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and cash equivalents</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of operating and money market accounts. Cash equivalents are carried at cost which approximates fair value due to their short-term nature. The Company considers all highly-liquid investments with an original maturity of 90 days or less to be cash equivalents.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains cash equivalent balances with financial institutions that management believes are of high credit quality. The Company’s cash and cash equivalents accounts at times may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk from cash and cash equivalents.</span></div> P90D <div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value with costs determined for each batch under the first-in, first-out method. Inventory consists of raw materials, work in process and finished goods. Raw materials include amounts of active pharmaceutical ingredient for a product to be manufactured; work in process includes the bulk inventory of laminate (the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company’s drug delivery film) prior to being packaged for sale; and finished goods include pharmaceutical products ready for commercial sale.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a quarterly basis, the Company analyzes its inventory levels and records allowances for inventory that has become obsolete, inventory that has a cost basis in excess of the expected net realizable value and inventory that is in excess of expected demand based upon projected product sales. Inventory obsolescence reserves at September 30, 2021 and December 31, 2020 were $3.4 million and $2.3 million, respectively.</span></div> 3400000 2300000 <div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product sales</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales amounts relate to sales of BELBUCA and Symproic. Product sales for the nine months ended September 30, 2020 also included sales of BUNAVAIL. Product sales for BUNAVAIL during the three months ended September 30, 2020 were related to the release of gross to net reserves. The Company recognizes revenue on product sales when control of the promised goods is transferred to its customers in an amount that reflects the consideration expected to be received in exchange for transferring those goods. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. When determining whether the customer has obtained control of the goods, the Company considers any future performance obligations. Generally, there is no post-shipment obligation on product sold. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product royalty revenues</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product royalty revenue amounts are based on sales revenue of the PAINKYL™ product under the Company’s license agreement with TTY Biopharm Co., Ltd., ("TTY") and the BREAKYL™ product under the Company’s license agreement with Meda AB, which was acquired by Mylan N.V. and later acquired by Viatris, Inc. (which we refer to herein as Viatris). Product royalty revenues are recognized when control of the product is transferred to the license partner in an amount that reflects the consideration expected to be received. Supplemental sales-based product royalty revenue may also be earned upon the subsequent sale of the product at agreed upon contractual rates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The majority of the Company’s product sales contracts have a single performance obligation as the promise to transfer the individual goods is not separately identifiable from other promises in the contracts and, therefore, not distinct. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. The Company has assessed the existence of a significant financing component in the agreements with its customers. The trade payment terms with its customers do not exceed one year and therefore the Company has elected to apply the practical expedient and no amount of consideration has been allocated as a financing component.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transaction price, including variable consideration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration for which reserves are established. Components of variable consideration include trade discounts and allowances, product returns, government chargebacks, discounts and rebates, and other incentives, such as voucher programs, and other fee for service amounts that are detailed within contracts between the Company and its customers relating to the Company’s sale of its products. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company establishes allowances for estimated rebates, chargebacks and product returns based on numerous qualitative and quantitative factors, including:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">specific contractual terms of agreements with customers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">estimated levels of inventory in the distribution channel;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">historical rebates, chargebacks and returns of products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">direct communication with customers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">anticipated introduction of competitive products or generics;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">anticipated pricing strategy changes by the Company and/or its competitors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">analysis of prescription data gathered by third-party prescription data providers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the impact of changes in state and federal regulations; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">the estimated remaining shelf life of products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In its analyses, the Company uses prescription data purchased from a third-party data provider to develop estimates of historical inventory channel sell-through. The Company utilizes an internal analysis to compare historical net product shipments to estimated historical prescriptions written. Based on that analysis, management develops an estimate of the quantity of product in the channel which may be subject to various rebate and chargeback exposures. To estimate months of ending inventory in the Company’s distribution channel, the Company divides estimated ending inventory in the distribution channel by the Company’s recent prescription data, not considering any future anticipated demand growth beyond the succeeding quarter. Monthly for each product line, the Company prepares an internal estimate of ending inventory units in the distribution channel by adding estimated inventory in the channel at the beginning of the period, plus net product shipments for the period, less estimated prescriptions written for the period, and less units included in the sales returns reserve expected to be returned. This is done for each product line by applying a rate of historical activity for rebates and chargebacks, adjusted for relevant quantitative and qualitative factors discussed above, to the potential exposed product estimated, net of reserved return units, to be in the distribution channel. In addition, the Company receives daily information from the major wholesalers regarding their sales and actual on-hand inventory levels of the Company’s products. This enables the Company to execute accurate provisioning procedures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded after considering the impact of the following variable consideration amounts at the time of revenue recognition:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product returns</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-Consistent with industry practice, the Company offers contractual return rights that allow its customers to return the products within an 18-month period that begins six months prior to and ends twelve months after expiration of the products. The Company estimates product returns reserves based upon historical return rates adjusted for qualitative factors and are applied to open product batches that are currently eligible for returns, or will be eligible in the future, within company policy. Other factors considered include expected marketplace changes and the remaining shelf life of product batches. Product returns reserves for newly launched products are based on historical rates of similar products or pre-determined percentage. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government rebates and chargebacks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-Government rebates and chargebacks include mandated discounts under Medicaid, Medicare, U.S. Department of Veterans Affairs and other government agencies ("Government Payors"). The Company estimates the rebates and chargebacks to Government Payors based upon a combination of historical experience, product pricing, estimated payor mix, product growth, and the mix of contract and agreement terms. These reserves are recorded in the same period the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets. In addition, the pricing of covered products under Medicaid is subject to complex calculations and involves interpretation of government rules, regulations and policies as well as adjustments based on current trends in utilization. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company estimates the rebates and chargebacks that it will provide to Government Payors based upon (i) the government-mandated discounts applicable to government-funded programs, (ii) information obtained from its customers and (iii) information obtained from other third parties regarding the payor mix for its products. The Company’s liability for these rebates consists of estimates of claims for the current quarter and estimated future claims that will be made for product shipments that have been recognized as revenue, but remain in the distribution channel inventories at the end of each reporting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-The Company estimates the rebates to commercial contracts based upon a combination of historical experience, product pricing, estimated payor mix, product growth, and the mix of contract and agreement terms. These reserves are recorded in the same period the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient Assistance Voucher program-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company, from time to time, offers certain promotional product-related incentives to eligible patients. The Company has voucher programs for BELBUCA and Symproic whereby the Company offers a point-of-sale subsidy to retail consumers. The Company estimates its liabilities for these voucher programs based on the current utilization and historical redemption rates as reported to the Company by a third-party claims processing organization. The </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company accounts for the costs of these special promotional programs as price adjustments, which are a reduction of gross revenue.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade discounts and distribution fees-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade discounts relate to prompt settlement discounts provided to customers. In addition, the Company compensates its customers for distribution of its products and the provision of data. The Company has determined that such services received to date are not distinct from its sale of products and may not reasonably represent fair value for these services. Therefore, estimates of these payments are recorded as a reduction of revenue based on contractual terms.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be a significant lag between the Company's establishment of an estimate and the timing of the invoicing or claim. The Company believes it has made reasonable estimates for future rebates and claims, however, these estimates involve assumptions pertaining to contractual utilization and performance, and payor mix. If the performance or mix across third-party payors is different from the Company’s estimates, the Company may be required to pay higher or lower total price adjustments and/or chargebacks than it had estimated.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of sales</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales includes the direct costs attributable to the production of BELBUCA and Symproic. It includes raw materials, production costs at the Company’s contract manufacturing sites, quality testing directly related to the products, inventory reserves, and depreciation on equipment that the Company has purchased to produce BELBUCA, Symproic and formerly BUNAVAIL. It also includes any batches not meeting specifications and raw material yield losses. Yield losses and the costs related to batches not meeting specifications are expensed as incurred. Cost of sales is recognized when sold to the wholesaler from our distribution center.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For BREAKYL and PAINKYL (the Company’s out-licensed breakthrough cancer pain therapies), cost of sales includes all costs related to creating the product at the Company’s contract manufacturing location in Germany. The Company’s contract manufacturer bills the Company for the final product, which includes materials, direct labor costs, quality testing, and certain overhead costs as outlined in applicable supply agreements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales also includes royalty expenses that the Company owes to third parties.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Measurement of credit losses of financial instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to credit losses primarily through its product sales. The Company assesses each counterparty’s ability to pay for the products it sells by conducting a credit review. The credit review considers the Company's expected billing exposure and timing for payment and the counterparty’s established credit rating or the Company's assessment of the counterparty’s creditworthiness based on the Company's analysis of their financial statements when a credit rating is not available. The Company also considers contract terms and conditions, and business strategy in its evaluation. A credit limit is established for each counterparty based on the outcome of this review.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company monitors its ongoing credit exposure through active review of counterparty balances against contract terms and due dates. The Company's activities include timely account reconciliations, dispute resolution and payment confirmations. The Company may employ collection agencies and legal counsel to pursue recovery of defaulted receivables.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, the Company reported $57.6 million of trade receivables within accounts receivable. Based on an aging analysis at September 30, 2021, 96% of the Company's accounts receivable were outstanding less than 30 days. There was no change to the allowance for doubtful accounts and credit losses between September 30, 2021 and December 31, 2020. The Company writes off accounts receivable when management determines they are uncollectible and credits payments subsequently received on such receivables to bad debt expense in the period received.</span></div> 57600000 0.96 0 0 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements, adopted</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740)—Simplifying the Accounting for Income Taxes, which is intended to simplify accounting for income taxes. It removes certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020 and early adoption is permitted. The Company adopted Topic 740 during the nine months ended September 30, 2021 and determined that the new guidance did not have a material impact on its consolidated financial statements.</span></div>The Company has reviewed other new accounting pronouncements that were issued as of September 30, 2021 and does not believe that these pronouncements are applicable to the Company, or that they will have a material impact on its financial position or results of operations. <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the fair value of instruments in accordance with GAAP which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company considers the carrying amount of its cash and cash equivalents to approximate fair value due to short-term nature of this instrument. GAAP describes three levels of inputs that may be used to measure fair value:</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 – quoted prices in active markets for identical assets or liabilities</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the financial instruments measured at fair value on a recurring basis as of September 30, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,710 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,710 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The cash and cash equivalent balance as of September 30, 2021 includes investments in various money market accounts and cash held in interest bearing accounts <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the financial instruments measured at fair value on a recurring basis as of September 30, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,710 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,710 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 100710000 0 0 100710000 Inventory, net:<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the components of inventory as of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.625%"><tr><td style="width:1.0%"/><td style="width:67.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.111%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,143 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,389 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,765 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,949 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,520 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,359 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obsolescence reserve</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,353)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,254)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,075 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,443 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the components of inventory as of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.625%"><tr><td style="width:1.0%"/><td style="width:67.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.111%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,143 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,389 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,765 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,949 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,520 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,359 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obsolescence reserve</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,353)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,254)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,075 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,443 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 4143000 3389000 6765000 9949000 15520000 6359000 3353000 2254000 23075000 17443000 Accounts payable and accrued liabilities:<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the components of accounts payable and accrued liabilities as of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.625%"><tr><td style="width:1.0%"/><td style="width:67.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.111%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,033 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,213 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,179 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,247 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,832 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,488 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued returns</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,009 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,128 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,819 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued regulatory expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rights payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,580 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,995 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the components of accounts payable and accrued liabilities as of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.625%"><tr><td style="width:1.0%"/><td style="width:67.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.111%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,033 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,213 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,179 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,247 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,832 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,488 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued returns</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,009 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,128 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,819 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued regulatory expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rights payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,580 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,995 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 7033000 4213000 38179000 34247000 6832000 5488000 8009000 5128000 1138000 704000 583000 1026000 1819000 515000 294000 397000 9000000 0 1693000 1277000 74580000 52995000 Property and equipment:<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, summarized by major category, consist of the following as of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.625%"><tr><td style="width:1.0%"/><td style="width:67.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.111%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery &amp; equipment</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,849 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,683 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use, building lease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment &amp; software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture &amp; equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Idle equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,645 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,441 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,120)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,023)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,525 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,418 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the three-month periods ended September 30, 2021 and September 30, 2020, was approximately $0.04 million and $0.2 million, respectively. Depreciation expense for the nine-month periods ended September 30, 2021 and September 30, 2020, was approximately $0.1 million and $0.5 million, respectively. Depreciation expense for the nine- month period ended September 30, 2020 includes a $0.3 million one-time charge due to BUNAVAIL equipment write-off.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, summarized by major category, consist of the following as of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.625%"><tr><td style="width:1.0%"/><td style="width:67.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.111%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery &amp; equipment</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,849 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,683 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use, building lease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment &amp; software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture &amp; equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Idle equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,645 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,441 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,120)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,023)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,525 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,418 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 4849000 4683000 260000 471000 640000 272000 174000 174000 43000 43000 679000 679000 0 119000 6645000 6441000 5120000 5023000 1525000 1418000 40000.00 200000 100000 500000 300000 Intangible assets:<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangible assets, net, consisting of product rights and licenses are summarized as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:0.1%"/><td style="width:2.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.213%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.216%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intangible Assets,<br/>net</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Useful Life</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BELBUCA license and distribution rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,375)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,625 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Symproic license and distribution rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,636 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,087)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,549 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ELYXYB product rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,455 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,091 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,522)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,569 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"/><td style="width:40.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.673%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intangible Assets,<br/>net</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,050 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,050)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BELBUCA license and distribution rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Symproic license and distribution rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,636 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,376 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,686 </span></td><td style="background-color:#cceeff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,310)</span></td><td style="background-color:#cceeff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,376 </span></td><td style="background-color:#cceeff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9</span></td></tr></table></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangible assets, net, consisting of product rights and licenses are summarized as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:0.1%"/><td style="width:2.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.213%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.216%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intangible Assets,<br/>net</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Useful Life</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BELBUCA license and distribution rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,375)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,625 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Symproic license and distribution rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,636 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,087)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,549 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ELYXYB product rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,455 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,091 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,522)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,569 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"/><td style="width:40.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.673%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intangible Assets,<br/>net</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,050 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,050)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BELBUCA license and distribution rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Symproic license and distribution rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,636 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,260)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,376 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,686 </span></td><td style="background-color:#cceeff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,310)</span></td><td style="background-color:#cceeff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,376 </span></td><td style="background-color:#cceeff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9</span></td></tr></table></div> 45000000 21375000 23625000 P5Y6M 30636000 6087000 24549000 P10Y6M 15455000 60000 15395000 P14Y9M18D 91091000 27522000 63569000 P8Y9M18D 6050000 6050000 0 45000000 18000000 27000000 P6Y 30636000 4260000 26376000 P10Y9M18D 81686000 28310000 53376000 P7Y10M24D Acquired product rights:<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 3, 2021, (the “Effective Date”), the Company and Dr. Reddy’s Laboratories Limited, a company incorporated under the laws of India (“DRL”), entered into an asset purchase agreement (the “Asset Purchase Agreement”) for the acquisition by the Company from DRL of certain patents, trademarks, regulatory approvals and other rights related to ELYXYB™ (celecoxib oral solution) (the “Product”) and its commercialization in the United States and Canada (the “Territory”). The closing of the transactions contemplated by the Asset Purchase Agreement occurred on September 9, 2021 (the "Closing").</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Asset Purchase Agreement, the Company paid DRL a $6 million up-front payment at the Closing. In addition, the Company will pay DRL $9 million on the twelve-month anniversary of the Effective Date and up to an additional $9 million upon achievement of certain regulatory milestones and quarterly earn-out payments on potential sales of the Product in the Territory that range from high single digits to the low double digits (subject to reduction in certain circumstances) of net sales based on volume of sales. DRL will also be entitled to one-time payments upon the achievement of six escalating sales milestones, which range from $4 million to be paid upon the achievement of $50 million in net sales in a calendar year to $100 million to be paid upon the achievement of $1 billion in net sales in a calendar year up to a total of $262 million. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for the ELYXYB purchase as an asset acquisition under ASC 805-10-55-5b, which provides guidance for asset acquisitions. Under the guidance, if substantially all the acquisition is made up of one asset or several similar assets, then the acquisition is an asset acquisition. The Company believes that the asset purchase agreement and other assets acquired from DRL are similar and considers them all to be intangible assets. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total purchase price was allocated to the acquired asset based on their relative estimated fair values, as follows: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.625%"><tr><td style="width:1.0%"/><td style="width:5.368%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:68.655%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.677%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ELYXYB acquired product rights</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15,000</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total value</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15,455</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $9 million twelve-month anniversary payment has been recorded in accounts payable and accrued liabilities in the accompanying condensed consolidated balance sheet.</span></div> 6000000 9000000 9000000 4000000 50000000 100000000 1000000000 262000000 <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total purchase price was allocated to the acquired asset based on their relative estimated fair values, as follows: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.625%"><tr><td style="width:1.0%"/><td style="width:5.368%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:68.655%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.677%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ELYXYB acquired product rights</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15,000</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total value</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15,455</span></td></tr></table></div> 15000000 455000 15455000 9000000 Notes payable:<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 23, 2019, the Company entered into a Loan Agreement with BPCR LIMITED PARTNERSHIP (the successor-in-interest to Biopharma Credit PLC), for a senior secured credit facility consisting of a term loan of $60.0 million (the “Term Loan”), with the ability to draw an additional $20.0 million within twelve months of the closing date, which the Company drew down on May 22, 2020. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loan facility carries a 72-month term with interest only payments on the term loan for the first 36 months. The Term Loan will mature in May 2025 and bears an interest rate of 7.5% plus the LIBOR rate on the first day for the quarter, with a floor of 2% for the LIBOR rate (LIBOR effective rate as of July 1, 2021 was 0.14%.) The Term Loan is subject to mandatory prepayment provisions that require prepayment upon change of control.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 23, 2021, the Company elected to repay $20 million plus accrued interest of $1.5 million, representing a portion of the first tranche. The Term loan includes the option for the Company to paydown up to $20 million of tranche A without incurring any prepayment penalties after the 24 month anniversary of the loan. As a result, no prepayment penalty was incurred in connection with this prepayment. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The debt balance has been categorized within Level 2 of the fair value hierarchy. The notes payable debt balance as of September 30, 2021 approximates its fair value based on prevailing interest rates as of the balance sheet date. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents future maturities of the notes payable obligation as of September 30, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.631%"><tr><td style="width:1.0%"/><td style="width:5.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:75.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,615 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,615 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized discount and loan costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,285)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total notes payable obligation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,715 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 60000000 20000000 P72M P36M 0.075 0.02 20000000 1500000 20000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents future maturities of the notes payable obligation as of September 30, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.631%"><tr><td style="width:1.0%"/><td style="width:5.867%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:75.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,615 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,615 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,308 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized discount and loan costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,285)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total notes payable obligation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,715 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 0 4615000 18462000 24615000 12308000 60000000 1285000 58715000 Net sales by product:<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s business is classified as a single reportable segment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, the following table presents net sales by product:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.216%"><tr><td style="width:1.0%"/><td style="width:31.236%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.734%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.734%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.166%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BELBUCA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,930 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,758 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,836 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,572 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     % of net product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Symproic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,453 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,562 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,046 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     % of net product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BUNAVAIL</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,328 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     % of net product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,072 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,785 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,398 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,946 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, the following table presents net sales by product:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.216%"><tr><td style="width:1.0%"/><td style="width:31.236%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.734%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.734%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.166%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BELBUCA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,930 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,758 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,836 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,572 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     % of net product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Symproic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,453 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,562 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,046 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     % of net product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BUNAVAIL</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,328 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     % of net product sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,072 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,785 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,398 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,946 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 36930000 34758000 109836000 100572000 0.90 0.90 0.90 0.89 4142000 3453000 12562000 11046000 0.10 0.09 0.10 0.10 0 574000 0 1328000 0 0.01 0 0.01 41072000 38785000 122398000 112946000 Stockholders’ equity:<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 4, 2020, the Board of Directors authorized the repurchase of up to $25 million of the Company's shares of Common Stock. The timing and amount of any shares purchased on the open market will be determined based on the Company's evaluation of market conditions, share price and other factors. The Company plans to utilize existing cash on hand to fund the share repurchase program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021, a cumulative total of 3,202,690 shares, with a weighted average price of $3.72, for a value of $11.9 million,were repurchased and recorded as Treasury Stock in the condensed consolidated balance sheet.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021, a total of 3,192,505 options to purchase Common Stock, with an aggregate fair market value of approximately $12.9 million, were granted to employees, executive officers and Board of Directors of the Company. Options have a term of 10 years from the grant date. Options granted to employees and officers will vest ratably over a three-year period. Options granted to Board of Directors vest one half immediately and the remaining half on the anniversary of grant. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award is estimated on the grant date using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, expected rate of forfeiture and the risk-free interest rate. Expected volatilities are based on implied volatilities from historical volatility of the Common Stock, and other factors estimated over the expected term of the options.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term of options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus contract term. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key assumptions used in determining the fair value of options granted during the nine months ended September 30, 2021 follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tr><td style="width:1.0%"/><td style="width:79.176%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.70%-59.87%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50%-1.17%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option activity during the nine months ended September 30, 2021 was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.304%"><tr><td style="width:1.0%"/><td style="width:54.032%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.308%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average<br/>exercise price per<br/>share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>intrinsic<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,060,966 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.55 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,831 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted in 2021:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and Directors</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345,292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,847,213 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155,690)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(539,802)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,557,979 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,589 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021 and 2020, Company employees and directors exercised approximately 155,690 and 1,159,347 stock options, respectively, with net proceeds to the Company of approximately $0.5 million and </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.8 million, respectively.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intrinsic value of options exercised during the nine months ended September 30, 2021 and 2020 was approximately $0.1 million and $3.1 million, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, options exercisable totaled 4,153,242. There are approximately $9.3 million of unrecognized compensation costs related to non-vested share-based compensation awards, including options and restricted stock units (“RSUs”) granted. These costs will be expensed through 2024.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted stock units</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021, a cumulative total of 278,369 RSUs were granted to the Company’s executive officers, members of senior management and the Board of Directors, with a fair market value of approximately $1.1 million. The fair value of restricted units is determined using quoted market prices of the Common Stock and the number of shares expected to vest. RSU grants are time-based, all of which generally vest from a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU4OWI1OGMwNWRjNjQ3ZTk4NjhhOTExNTNlMDcxMGNhL3NlYzo1ODliNThjMDVkYzY0N2U5ODY4YTkxMTUzZTA3MTBjYV81Mi9mcmFnOmViYjA4ZDEyNzAyZTRmNzFhOWRiOTIwMmMyYzYwYmZlL3RleHRyZWdpb246ZWJiMDhkMTI3MDJlNGY3MWE5ZGI5MjAyYzJjNjBiZmVfMjkwMg_212f699e-baf0-4250-ae94-b4409524fa47">one</span> to three-year period. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock activity during the nine months ended September 30, 2021 was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.625%"><tr><td style="width:1.0%"/><td style="width:67.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.111%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>restricted<br/>shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>average fair<br/>market value<br/>per RSU</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940,759 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.71 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and Directors</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,562 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,807 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(484,159)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">734,969 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.08 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has granted warrants to purchase shares of Common Stock. Warrants may be granted to affiliates in connection with certain agreements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, a cumulative total of 2,051,033 warrants, with exercise prices ranging from $2.38 to $3.42, remain exercisable and outstanding. The warrants were valued using the Black-Scholes Model, which a cumulative fair value of approximately $4.5 million.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no warrants granted or exercised during the nine months ended September 30, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, 443 shares of Series B Preferred Stock (“Series B”) are outstanding. There were no conversions of Series B during the nine months ended September 30, 2021.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings Per Share</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:40.715%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to common stockholders, basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,669 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,383 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,970 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,515 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,699,857 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,031,317 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,485,399 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,377,748 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic earnings per common share</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.07</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.09</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to common stockholders, diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,669 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,383 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,970 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,515 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,699,857 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,031,317 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,485,399 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,377,748 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive options and warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,731,026 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,752,251 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,988,568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,458,745 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,430,883 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,783,568 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,473,967 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,836,493 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted earnings per common share</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$0.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$0.09</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$0.20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$0.15</span></td></tr></table> 25000000 3202690 3.72 11900000 3192505 12900000 P10Y P3Y <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key assumptions used in determining the fair value of options granted during the nine months ended September 30, 2021 follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tr><td style="width:1.0%"/><td style="width:79.176%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.70%-59.87%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50%-1.17%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0.5370 0.5987 0.0050 0.0117 P6Y 0 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option activity during the nine months ended September 30, 2021 was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.304%"><tr><td style="width:1.0%"/><td style="width:54.032%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.308%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average<br/>exercise price per<br/>share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>intrinsic<br/>value</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,060,966 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.55 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,831 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted in 2021:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and Directors</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345,292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,847,213 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155,690)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(539,802)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,557,979 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.40 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,589 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 7060966 4.55 2831000 1345292 3.83 1847213 4.20 155690 2.90 539802 4.72 9557979 4.40 8589000 155690 1159347 500000 2800000 100000 3100000 4153242 9300000 278369 1100000 P3Y <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock activity during the nine months ended September 30, 2021 was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.625%"><tr><td style="width:1.0%"/><td style="width:67.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.111%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>restricted<br/>shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>average fair<br/>market value<br/>per RSU</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940,759 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.71 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and Directors</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,562 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,807 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(484,159)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.84 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeitures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">734,969 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.08 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 940759 3.71 242562 3.83 35807 3.84 484159 3.84 0 0 734969 4.08 2051033 2.38 3.42 4500000 443 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:40.715%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to common stockholders, basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,669 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,383 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,970 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,515 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,699,857 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,031,317 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,485,399 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,377,748 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic earnings per common share</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.07</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.09</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to common stockholders, diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,669 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,383 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,970 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,515 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,699,857 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,031,317 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,485,399 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,377,748 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive options and warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,731,026 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,752,251 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,988,568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,458,745 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,430,883 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,783,568 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,473,967 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,836,493 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted earnings per common share</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$0.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$0.09</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$0.20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$0.15</span></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:40.715%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended September 30,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to common stockholders, basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,669 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,383 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,970 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,515 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,699,857 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,031,317 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,485,399 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,377,748 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic earnings per common share</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.07</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.09</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to common stockholders, diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,669 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,383 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,970 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,515 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,699,857 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,031,317 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,485,399 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,377,748 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive options and warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,731,026 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,752,251 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,988,568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,458,745 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,430,883 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,783,568 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,473,967 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,836,493 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted earnings per common share</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$0.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$0.09</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$0.20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$0.15</span></td></tr></table> 6669000 9383000 20970000 15515000 98699857 101031317 99485399 99377748 0.07 0.09 0.21 0.16 6669000 9383000 20970000 15515000 98699857 101031317 99485399 99377748 3731026 4752251 3988568 5458745 102430883 105783568 103473967 104836493 0.07 0.09 0.20 0.15 Commitments and contingencies:<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved from time to time in routine legal matters incidental to our business. Based upon available information, the Company believes that the resolution of such matters will not have a material adverse effect on its condensed consolidated financial position or results of operations. Except as discussed below, the Company is not the subject of any pending legal proceedings and, to the knowledge of management, no proceedings are presently contemplated against the Company by any federal, state or local governmental agency.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Indivior (formerly RB Pharmaceuticals Ltd.) and Aquestive Therapeutics (formerly MonoSol Rx)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following disclosure regarding the Company’s ongoing litigations with Aquestive Therapeutics, Inc. (formerly MonoSol Rx, “Aquestive”) and Indivior PLC (formerly RB Pharmaceuticals Limited, “Indivior”) is intended to provide some background and an update on the matter as per disclosure requirements of the SEC. Additional details regarding the past procedural history of the matter can be found in the Company’s previously filed periodic filings with the SEC.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Litigation related to BUNAVAIL</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 29, 2013, Reckitt Benckiser, Inc., Indivior, and Aquestive (collectively, the “RB Plaintiffs”) filed an action against the Company relating to its BUNAVAIL product in the United States District Court for the Eastern District of North Carolina (“EDNC”) for alleged patent infringement. BUNAVAIL is a drug approved for the maintenance treatment of opioid dependence. The RB Plaintiffs claim that the formulation for BUNAVAIL, which has never been disclosed publicly, infringes its US Patent No. 8,475,832 (the “‘832 Patent”). On May 21, 2014, the Court granted the Company’s motion to dismiss.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 22, 2014, Aquestive initiated an inter partes review (“IPR”) on U.S. Patent No. 7,579,019, the (“‘019 Patent”). The PTAB upheld all claims of the Company’s ‘019 Patent in 2015 and this decision was not appealed by Aquestive.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2014, the Company proactively filed a declaratory judgment action in the United States District Court for the EDNC requesting the Court to make a determination that the Company’s BUNAVAIL product does not infringe the ‘832 Patent, US Patent No. 7,897,080 (the “‘080 Patent”) and US Patent No. 8,652,378 (the “‘378 Patent”). The Company invalidated the “‘080 Patent” in its entirety in an inter partes reexamination proceeding. The Company invalidated all relevant claims of the ‘832 Patent in an IPR proceeding. And, in an IPR proceeding for the ‘378 Patent, in its decision not to institute the IPR proceeding, the PTAB construed the claims of the ‘378 Patent narrowly. Shortly thereafter, by joint motion of the parties, the ‘378 Patent was subsequently removed from the action.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2016, in an unrelated case in which Indivior and Aquestive asserted the ‘832 Patent against other parties, the Delaware District Court entered an order invalidating other claims in the ‘832 Patent. Indivior and Aquestive did not appeal the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware Court’s holding that other claims of the ‘832 Patent are invalid. On February 10, 2021, the parties in our EDNC declaratory judgment action filed a covenant by Indivior and Aquestive not to sue us for infringement of the ‘832 Patent. In view of that covenant and the prior invalidation of the ‘080 patent, we filed a notice of voluntary dismissal of the Company’s EDNC declaratory judgement action. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 22, 2014, the RB Plaintiffs filed an action against the Company (and the Company’s commercial partner) relating to the Company’s BUNAVAIL product in the United States District Court for the District of New Jersey for alleged patent infringement. The RB Plaintiffs claim that BUNAVAIL, whose formulation and manufacturing processes have never been disclosed publicly, infringes its patent U.S. Patent No. 8,765,167 (the “‘167 Patent”). The Company believes this is an anticompetitive attempt by the RB Plaintiffs to distract the Company’s efforts from commercializing BUNAVAIL. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 12, 2014, the Company filed a motion to transfer the case from New Jersey to North Carolina and a motion to dismiss the case against its commercial partner. On October 28, 2014, the Company filed multiple IPR petitions on certain claims of the ‘167 Patent. The USPTO instituted three of the four IPR petitions. The PTAB upheld the claims and denied collateral estoppel applied to the PTAB decisions in March 2016. The Company appealed to Court of Appeals for the Federal Circuit. The USPTO intervened with respect to whether collateral estoppel applied to the PTAB. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2018, the Company filed a motion to remand the case for further consideration by the PTAB in view of intervening authority. On July 31, 2018, the Federal Circuit vacated the decisions, and remanded the ‘167 Patent IPRs for further consideration on the merits. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 7, 2019, the PTAB issued three decisions on remand purporting to deny institution of the three previously instituted IPRs of the ‘167 patent. On March 11, 2019, the Company timely appealed the PTAB decisions on remand to U.S. Court of Appeal for the Federal Circuit. On March 20, 2019, Aquestive and Indivior moved to dismiss the appeal, and the Company opposed that motion. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 29, 2019, a three-judge panel of the Court of Appeals for the Federal Circuit granted the motion and dismissed the Company’s appeal. On September 30, 2019, the Company filed a petition for an en banc rehearing of the order dismissing the Company’s appeal by the full Federal Circuit Court of Appeals.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 13, 2020, by the Court of Appeals for the Federal Circuit denied BDSI’s petition for en banc rehearing of the dismissal of BDSI’s appeal relating to inter partes review proceedings on the ’167 patent. On June 11, 2020, BDSI filed a petition for certiorari seeking U.S. Supreme Court review of the Federal Circuit’s decision. On October 5, 2020, the U.S. Supreme Court denied the Company’s petition for certiorari.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company strongly refutes as without merit the Plaintiffs’ assertion of patent infringement and will vigorously defend the lawsuit.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Litigation related to BELBUCA</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 13, 2017, Aquestive filed a complaint in the United States District Court for the District of New Jersey alleging BELBUCA infringes the ‘167 Patent. In lieu of answering the complaint, the Company filed motions to dismiss the complaint and, in the alternative, to transfer the case to the EDNC. On July 25, 2017, the New Jersey Court administratively terminated the case pending the parties submission of a joint stipulation of transfer because the District of New Jersey was an inappropriate venue. This case was later transferred to the Delaware District Court. On October 31, 2017, the Company filed motions to dismiss the complaint and, in the alternative, to transfer the case to the EDNC. On October 16, 2018, denying the motion to dismiss as moot, the Delaware District Court granted the Company’s motion to transfer the case to the EDNC. On November 20, 2018, the Company moved the EDNC to dismiss the complaint for patent infringement for failure to state a claim for relief. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2019, the EDNC granted the Company’s motion to dismiss, and dismissed the complaint without prejudice. On or about November 11, 2019, Aquestive refiled a complaint in the EDNC against the Company alleging that BELBUCA infringes the ‘167 Patent. On January 13, 2020, in lieu of answering the complaint, we filed a motion to dismiss the complaint. After the two motions were denied, on April 16, 2020, we answered the complaint. Aquestive moved to dismiss our counter-claim of unenforceability, but the court denied that motion. The Company strongly refutes as without merit Aquestive’s assertion of patent infringement and will vigorously defend the lawsuit.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Teva Pharmaceuticals USA (formerly Actavis)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2016, the Company received a notice relating to a Paragraph IV certification from Teva Pharmaceuticals USA, or (formerly Actavis, “Teva”) seeking to find invalid three Orange Book listed patents relating specifically to BUNAVAIL. The Paragraph IV certification related to an ANDA filed by Teva with the FDA for a generic formulation of BUNAVAIL. The patents subject to Teva’s certification were the ‘019 Patent, U.S. Patent No. 8,147,866 (the “‘866 Patent”) and 8,703,177 (the “‘177 Patent”).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 18, 2016, the Company asserted three different patents against Teva, the ‘019 Patent, the ‘866 Patent, and the ‘177 Patent. Teva did not raise non-infringement positions about the ‘019 and the ‘866 Patents in its Paragraph IV certification. Teva did raise a non-infringement position on the ‘177 Patent but the Company asserted in its complaint that Teva infringed the ‘177 Patent either literally or under the doctrine of equivalents.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 20, 2016 the USPTO issued U.S. Patent No. 9,522,188 (the “‘188 Patent””), and this patent was properly listed in the Orange Book as covering the BUNAVAIL product. On February 23, 2017 Teva sent a Paragraph IV certification adding the 9,522,188 to its ANDA. An amended Complaint was filed, adding the ‘188 Patent to the litigation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2017, the Company received a notice relating to a Paragraph IV certification from Teva relating to Teva’s ANDA on additional strengths of BUNAVAIL and on March 16, 2017, the Company brought suit against Teva and its parent company on these additional strengths. On June 20, 2017, the Court entered orders staying both BUNAVAIL suits at the request of the parties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 23, 2017, the USPTO issued U.S. Patent 9,655,843 (the “‘843 Patent”) relating to the BEMA technology, and this patent was properly listed in the Orange Book as covering the BUNAVAIL product.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, on October 12, 2017, the Company announced that it had entered into a settlement agreement with Teva that resolved the Company’s BUNAVAIL patent litigation against Teva pending in the U.S. District Court for the District of Delaware. As part of the Settlement Agreement, which is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice, the Company has entered into a non-exclusive license agreement with Teva that permits Teva to first begin selling its generic version of BUNAVAIL in the U.S. on July 23, 2028 or earlier under certain circumstances. Other terms of the agreement are confidential.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received notices regarding Paragraph IV certifications from Teva on November 8, 2016, November 10, 2016, and December 22, 2016, seeking to find invalid two Orange Book listed patents relating specifically to BELBUCA. The Paragraph IV certifications relate to three ANDAs filed by Teva with the FDA for a generic formulation of BELBUCA. The patents subject to Teva’s certification were the ‘019 Patent and the ‘866 Patent. The Company filed complaints in Delaware against Teva on December 22, 2016 and February 3, 2017 in which it asserted against Teva the ‘019 Patent and the ‘866 Patent. Teva did not contest infringement of the claims of the ‘019 Patent and did not contest infringement of the claims of the ‘866 Patent. The ‘019 Patent had already been the subject of an unrelated IPR before the USPTO under which the Company prevailed, and all claims of the ‘019 Patent survived. Aquestive’s request for rehearing of the final IPR decision regarding the ‘019 Patent was denied by the USPTO on December 19, 2016. Aquestive did not file a timely appeal at the Federal Circuit.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 23, 2017, the USPTO issued U.S. Patent 9,655,843 (the “‘843 Patent”) relating to the BEMA technology, and this patent was properly listed in the Orange Book as covering the BELBUCA product.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 28, 2017, the Court entered orders staying both BELBUCA suits at the request of the parties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, the Company announced that it had entered into a settlement agreement with Teva that resolved the Company’s BELBUCA patent litigation against Teva pending in the U.S. District Court for the District of Delaware. As part of the settlement agreement, which is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice, the Company has granted Teva a non-exclusive license (for which the Company will receive no current or future payments) that permits Teva to first begin selling the generic version of the Company’s BELBUCA product in the U.S. on January 23, 2027 or earlier under certain circumstances (including, for example, upon (i) the delisting of the patents-in-suit from the U.S. FDA Orange Book, (ii) the granting of a license by us to a third party to launch another generic form of BELBUCA at a date prior to January 23, 2027, or (iii) the occurrence of certain conditions regarding BELBUCA market share). Other terms of the Agreement are confidential.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Alvogen</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 7, 2018, the Company filed a complaint for patent infringement in Delaware against Alvogen Pb Research &amp; Development LLC, Alvogen Malta Operations Ltd., Alvogen Pine Brook LLC, Alvogen, Incorporated, and Alvogen Group, Incorporated (collectively, “Alvogen”), asserting that Alvogen infringes the Company’s Orange Book listed patents for BELBUCA, including U.S. Patent Nos. 8,147,866 and 9,655,843, both expiring in July of 2027, and U.S. Patent No. 9,901,539, expiring in December of 2032. This complaint follows receipt by the Company on July 30, 2018 of a Paragraph IV Patent Certification from Alvogen stating that Alvogen had filed an ANDA with the FDA for a generic version of BELBUCA Buccal Film (75 mcg, 150 mcg, 300 mcg, 450 mcg, 600 mcg, 750 mcg and 900 mcg). Because the Company initiated a patent infringement suit to defend the patents identified in the Paragraph IV notice within 45 days after receipt of the Paragraph IV Certification, the FDA is prevented from approving the ANDA until the earlier of 30 months or a decision in the case that each of the patents is not infringed or invalid. Alvogen’s notice letter also does not provide any information on the timing or approval status of its ANDA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In its Paragraph IV Certification, Alvogen does not contest infringement of at least several independent claims of each of the ’866, ’843, and ’539 patents. Rather, Alvogen advances only invalidly arguments for these independent claims. The Company believes that it will be able to prevail on its claims of infringement of these patents, particularly as Alvogen does not contest infringement of certain claims of each patent. Additionally, as the Company has done in the past, it intends to vigorously defend its intellectual property against assertions of invalidity. Each of the three patents carry a presumption of validity, which can only be overcome by clear and convincing evidence.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Court scheduled a bench trial to commence on November 9, 2020 to adjudicate issues concerning the validity of the Orange Book patents listed for BELBUCA. On October 6, 2020, the Court rescheduled the bench trial with Alvogen to commence on March 1, 2021. A three day bench trial against Alvogen was conducted commencing on March 1, 2021. At the conclusion of trial, the Court ordered the parties to submit post-trial briefs. Post-trial briefing was completed on May 26, 2021. The Company subsequently moved the Court to strike (i.e., remove from the Court’s consideration) three patent invalidity defenses raised for the first time in Alvogen’s post-trial briefs and two documents improperly cited in Alvogen’s post-trial briefs. On June 28, 2021, the Court granted the Company’s motion to strike in its entirety. In addition, on June 28, 2021, the Court enjoined Alvogen from launching its generic product until the Court issues its final decision on the merits. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 21, 2021, the Company filed under seal a Motion for Order to Show Cause why Defendants Should not be Held in Contempt for Violating the Court Order of June 28, 2021 (the “Motion”). On June 28, 2021, citing the statute authorizing the Court to extend the 30-month stay under the Hatch-Waxman Act, the Court ordered Alvogen (as defined below) not to “launch” its generic product until it could reach a final decision on the merits in the case. In the Motion, the Company contends that Alvogen violated the order of the United States District Court for the District of Delaware commencing in or about August 2021 by, among other things, offering the generic product for sale through five compendia / price reporting services, including First Databank, Medi-Span (Wolters Kluwer), Red Book, Gold Standard and ScriptPro. As alleged in the Motion, after Alvogen’s product launch, certain payers began declining insurance coverage for the Company’s brand BELBUCA and directing use of Alvogen’s generic substitute and/or made it more difficult for patients to obtain insurance coverage for BELBUCA, and thereby damaged the Company. In addition to filing the Motion, the Company demanded that Alvogen withdraw its compendia listings. Alvogen claims to have withdrawn its compendia product listings on or about September 9, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company remains confident in the validity of its Orange Book patents listed for BELBUCA and will continue to vigorously defend its patent rights.</span></div><div style="margin-top:6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">2018 Arkansas Opioid Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 15, 2018, the State of Arkansas, and certain counties and cities in that State, filed an action in the Circuit Court of Arkansas, Crittenden County against multiple manufacturers, distributors, retailers, and prescribers of opioid analgesics, including the Company. The Company was served with the complaint on April 27, 2018. The complaint specifically alleged that it licensed its branded fentanyl buccal soluble film ONSOLIS to Collegium, and Collegium is also named as a defendant in the lawsuit. ONSOLIS is not presently sold in the United States and the license agreement with Collegium was terminated prior to Collegium launching ONSOLIS in the United States. Therefore, on June 28, 2018, the Company moved to dismiss the case against it and most recently, on July 6, 2018, the plaintiffs filed a notice to voluntarily dismiss us from the Arkansas case, without prejudice.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Chemo Research, S.L</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 1, 2019, the Company filed a complaint for patent infringement in Delaware against Chemo Research, S.L., Insud Pharma S.L., IntelGenx Corp., and IntelGenx Technologies Corp. (collectively, the “Chemo Defendants”), asserting that the Chemo Defendants infringe its Orange Book listed patents for BELBUCA, including U.S. Patent Nos. 8,147,866 and 9,655,843, both expiring in July of 2027, and U.S. Patent No. 9,901,539 expiring December of 2032. This complaint follows a receipt by the Company on January 31, 2019, of a Notice Letter from Chemo Research S.L. stating that it has filed with the FDA an ANDA containing a Paragraph IV Patent Certification, for a generic version of BELBUCA Buccal Film in strengths 75 mcg, 150 mcg, 300 mcg, 450 mcg, and 900 mcg. Because the Company initiated a patent infringement suit to defend the patents identified in the Notice Letter within 45 days after receipt, the FDA is prevented from approving the ANDA until the earlier of 30 months or a decision in the case that each of the patents is not infringed or invalid. Chemo Research S.L.’s Notice Letter also does not provide any information on the timing or approval status of its ANDA. On March 15, 2019, the Company filed a complaint against the Defendants in New Jersey asserting the same claims for patent infringement made in the Delaware lawsuit. On April 19, 2019, Defendants filed an answer to the Delaware complaint wherein they denied infringement of the ‘866, ‘843 and ‘539 patents and asserted counterclaims seeking declaratory relief concerning the alleged invalidity and non-infringement of such patents. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2019, the Company voluntarily dismissed the New Jersey lawsuit given Defendants’ consent to jurisdiction in Delaware.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Court scheduled a bench trial to commence on November 9, 2020 (jointly with Alvogen) to adjudicate issues concerning the validity of the Orange Book patents listed for BELBUCA. On October 6, 2020, the Court rescheduled the bench trial with Chemo and Alvogen to adjudicate issues concerning the validity of the Orange Book patents listed for BELBUCA to commence on March 1, 2021. Chemo did not participate in the bench trial that commenced on March 1, 2021. Instead, on February 26, 2021, Chemo agreed to be bound by the decision of the Court with respect to the validity of the BEMA patents from the March 1, 2021 trial with Alvogen. The Court had scheduled a bench trial to commence on May 3, 2021 to adjudicate issues concerning the Chemo Defendants’ infringement of the Orange Book patents. On December 1, 2020, the Court rescheduled the bench trial to adjudicate issues concerning the Chemo Defendants’ infringement of the Orange Book patents to commence on November 15, 2021. On July 15, 2021, the Court rescheduled the bench trial to adjudicate issues concerning the Chemo Defendants’ infringement of the Orange Book patents to commence on April 25, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that it will be able to prevail in this lawsuit. As it has done in the past, the Company intends to vigorously defend its intellectual property against assertions of invalidity.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Derivative Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 2, 2018, the Company filed a Schedule 14A Proxy Statement (the “Proxy”) with the U.S. Securities and Exchange Commission (the “SEC”) in connection with its 2018 Annual Meeting. Proposals 1 and 2 of the Proxy sought stockholder approval to amend the Company’s Certificate of Incorporation by deleting Article TWELFTH of the Company’s Certificate of Incorporation in its entirety and replacing it with a new Article TWELFTH that, among other things (i) provided for the declassification of the Company’s Board in phases, with the full declassification to be achieved in 2020 (the “Declassification Amendment”) and (ii) changed the voting standard for the uncontested election of directors to the Board from a plurality standard to the majority of votes cast standard as set forth in the bylaws of the Company (the “Election Amendment” and together with the “Declassification Amendment”, the “Amendments”). </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2018, the Company held the 2018 Annual Meeting, at which time the stockholders voted on the Amendments. Following the 2018 Annual Meeting, based on consultation with the Company’s advisors, the Company determined that the Amendments had been adopted by the requisite vote of stockholders and effected the Amendments by filing a Certificate of Amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware on August 6, 2018.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 11, 2019, two purported stockholders of the Company filed a putative class action against the Company and our directors in the Court of Chancery of the State of Delaware, captioned Drachman v. BioDelivery Sciences International, Inc., et al., C.A. No. 2019-0728-AGB (Del. Ch.) (the “Complaint”). The Complaint alleged that the Amendments did not receive the requisite vote of stockholders at the 2018 Annual Meeting and asserted claims for violation of the Delaware General Corporation Law, breach of fiduciary duties, and declaratory judgment. The Complaint sought, inter alia, a declaration that the Amendments were not validly approved and invalidation of the Amendments, including altering the one-year terms of all directors duly elected at the 2018 and 2019 Annual Meetings to three-year terms. The Complaint also sought costs and </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disbursements, including attorneys’ fees. On July 1, 2020, the Company filed their response to the Complaint and denied the claims asserted therein.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 5, 2019, the Board determined that ratifying the declassification of the Board and the change in the voting standard as set forth in the Amendments, as well as ratifying the filing and effectiveness of the Amendments, is in the best interests of the Company and its stockholders. The Board thus approved resolutions ratifying such acts and the filing and effectiveness of the Amendments under Section 204 of the Delaware General Corporation Law. On July 23, 2020, the stockholders of the Company approved the ratification of the declassification of the Board and the change in the voting standard as set forth in the Amendments as well as the filing and effectiveness of the Amendments. On July 23, 2020, the Company filed a Certificate of Validation with the Delaware Secretary of State.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8, 2020, the Court entered an agreed-to order dismissing the plaintiffs’ claims for violation of the Delaware General Corporation Law. On October 13, 2020, plaintiffs filed an amended complaint, asserting individual, class and derivative claims for breach of fiduciary duties against our directors. On October 26, 2020, the defendants filed a motion to dismiss the amended complaint. On February 19, 2021, plaintiffs filed their opposition to the motion to dismiss. On March 8, 2021, the defendants filed a reply in further support of the motion to dismiss. The oral argument on defendants’ motion to dismiss took place on June 10, 2021 and, pursuant to a request from the Court, the parties are in the process of filing supplemental briefing. The defendants intend to continue to defend against the litigation vigorously.</span></div> Subsequent Events:<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline">Appointment of Chief Accounting Officer</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 21, 2021, the Board of Directors of the Company announced that the Company had appointed John Golubieski as the Company’s Chief Accounting Officer, effective as of October 25, 2021. Mr. Golubieski will serve as Chief Accounting Officer until November 4, 2021, at which time he will resign from the position of Chief Accounting Officer and become Chief Financial Officer. Mr. Golubieski will also serve as the Company’s principal financial officer and principal accounting officer, effective as of November 4, 2021. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with Mr. Golubieski’s appointment, the Company entered into an employment agreement with Mr. Golubieski, effective as of October 25, 2021 (the “Employment Agreement”). Pursuant to the Employment Agreement, Mr. Golubieski will be paid an annual base salary of $0.4 million and will be eligible for an annual performance-based incentive cash bonus in an amount up to 45% of Mr. Golubieski’s then-current base salary. Mr. Golubieski’s bonus for 2021 will be pro-rated to reflect his start date with the Company. In connection with his appointment, Mr. Golubieski will receive (i) an inaugural, one-time grant of options to purchase common stock with a value of $0.7 million (the “Option Award”) and (ii) an inaugural, one-time grant of restricted stock units with a value of $0.2 million (the “RSU Award”). The strike price for the Option Award will be the closing price of the Company’s common stock on the Nasdaq Global Select Market on the date of the grant. Both the Option Award and the RSU Award will vest in three equal portions on the first, second and third anniversary date of the grant date, subject to Mr. Golubieski’s continued service with the Company through the applicable vesting dates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;text-decoration:underline">Departure of Chief Financial Officer</span></div>On October 15, 2021, Mary Theresa Coelho resigned as Executive Vice President, Chief Financial Officer and Treasurer of the Company to pursue other professional opportunities. Ms. Coelho’s resignation is effective as of November 3, 2021 and is not the result of any disagreement regarding the Company’s financial reporting or accounting policies, procedures, estimates or judgments. 400000 0.45 700000 200000 XML 14 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover Page - shares
 9 Months Ended
Sep. 30, 2021
Nov. 03, 2021
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2021  
Document Transition Report false  
Entity File Number 001-31361  
Entity Registrant Name BioDelivery Sciences International, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 35-2089858  
Entity Address, Address Line One 4131 ParkLake Ave., Suite 225  
Entity Address, City or Town Raleigh  
Entity Address, State or Province NC  
Entity Address, Postal Zip Code 27612  
City Area Code 919  
Local Phone Number 582-9050  
Title of 12(b) Security Common stock, par value $0.001  
Trading Symbol BDSI  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity common stock, shares outstanding (in shares)   98,795,939
Amendment Flag false  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q3  
Entity Central Index Key 0001103021  
Current Fiscal Year End Date --12-31  
XML 15 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 100,710 $ 111,584
Accounts receivable, net 57,572 48,150
Inventory, net 23,075 17,443
Prepaid expenses and other current assets 6,904 5,208
Total current assets 188,261 182,385
Property and equipment, net 1,525 1,418
Goodwill 2,715 2,715
License and distribution rights, net 63,569 53,376
Total assets 256,070 239,894
Current liabilities:    
Accounts payable and accrued liabilities 74,580 52,995
Notes payable, current 3,077 0
Total current liabilities 77,657 52,995
Notes payable, less current maturities 55,638 78,452
Other long-term liabilities 0 213
Total liabilities 133,295 131,660
Commitments and contingencies (Note 10)
Stockholders’ equity:    
Preferred Stock, 5,000,000 shares authorized; Series B Non-Voting Convertible Preferred Stock, $0.001 par value, 443 shares outstanding at September 30, 2021 and December 31, 2020, respectively. 0 0
Common Stock, $0.001 par value; 235,000,000 shares authorized at September 30, 2021 and December 31, 2020, respectively; 102,057,290 and 101,417,441 shares issued; 98,791,606 and 101,354,447 shares outstanding at September 30, 2021 and December 31, 2020, respectively. 104 104
Additional paid-in capital 454,738 449,264
Treasury stock, at cost, 3,265,684 and 62,994 shares, as of September 30, 2021 and December 31, 2020, respectively. (12,155) (252)
Accumulated deficit (319,912) (340,882)
Total stockholders’ equity 122,775 108,234
Total liabilities and stockholders’ equity $ 256,070 $ 239,894
XML 16 R3.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2021
Dec. 31, 2020
Preferred Stock, shares authorized (in shares) 5,000,000 5,000,000
Preferred Stock, par value (in usd per share) $ 0.001  
Common Stock, par value (in usd per share) $ 0.001 $ 0.001
Common Stock, shares authorized (in shares) 235,000,000 235,000,000
Common Stock, shares issued (in shares) 102,057,290 101,417,441
Common Stock, shares outstanding (in shares) 98,791,606 101,354,447
Treasury stock, shares (in shares) 3,265,684 62,994
Preferred Stock Series B    
Preferred Stock, par value (in usd per share) $ 0.001 $ 0.001
Preferred Stock, shares outstanding (in shares) 443 443
XML 17 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Revenues:        
Total revenues: $ 41,092 $ 39,443 $ 123,549 $ 114,304
Cost of sales 6,365 5,376 16,470 16,371
Expenses:        
Selling, general and administrative 25,468 22,461 79,007 77,408
Total expenses: 25,468 22,461 79,007 77,408
Income from operations 9,259 11,606 28,072 20,525
Interest expense, net (1,984) (2,010) (5,962) (4,997)
Other (expense)/income, net 0 (2) (1) 6
Income before income taxes 7,275 9,594 22,109 15,534
Income tax provision (606) (211) (1,139) (19)
Net income attributable to common stockholders $ 6,669 $ 9,383 $ 20,970 $ 15,515
Basic and diluted:        
Weighted average common stock shares outstanding, basic (in shares) 98,699,857 101,031,317 99,485,399 99,377,748
Basic earnings per share (in usd per share) $ 0.07 $ 0.09 $ 0.21 $ 0.16
Weighted average common stock shares outstanding, diluted (in shares) 102,430,883 105,783,568 103,473,967 104,836,493
Diluted earnings per share (in usd per share) $ 0.07 $ 0.09 $ 0.20 $ 0.15
Product sales, net        
Revenues:        
Total revenues: $ 41,072 $ 38,785 $ 122,398 $ 112,946
Product royalty revenues        
Revenues:        
Total revenues: $ 20 $ 658 $ 1,151 $ 1,358
XML 18 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Treasury Stock
Accumulated Deficit
Preferred Stock Series A
Preferred Stock Series A
Preferred Stock
Preferred Stock Series A
Common Stock
Preferred Stock Series A
Additional Paid-In Capital
Preferred Stock Series B
Preferred Stock Series B
Preferred Stock
Preferred Stock Series B
Common Stock
Beginning Balance (in shares) at Dec. 31, 2019   96,189,074         2,093,155       618  
Beginning Balance at Dec. 31, 2019 $ 69,764 $ 96 $ 436,306 $ (47) $ (366,593)   $ 2       $ 0  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Stock-based compensation 1,520   1,520                  
Stock option exercises (in shares)   107,287                    
Stock option exercises 338   338                  
Restricted stock awards (in shares)   459,670                    
Preferred stock conversion to common stock (in shares)             (2,093,155) 2,093,155     (175) 972,222
Preferred stock conversion to common stock           $ (1) $ (2) $ 2 $ (1) $ 1   $ 1
Net income 4,966       4,966              
Ending Balance (in shares) at Mar. 31, 2020   99,821,408         0       443  
Ending Balance at Mar. 31, 2020 76,588 $ 99 438,163 (47) (361,627)   $ 0       $ 0  
Beginning Balance (in shares) at Dec. 31, 2019   96,189,074         2,093,155       618  
Beginning Balance at Dec. 31, 2019 69,764 $ 96 436,306 (47) (366,593)   $ 2       $ 0  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Net income 15,515                      
Ending Balance (in shares) at Sep. 30, 2020   101,126,452         0       443  
Ending Balance at Sep. 30, 2020 95,885 $ 100 446,910 (47) (351,078)   $ 0       $ 0  
Beginning Balance (in shares) at Mar. 31, 2020   99,821,408         0       443  
Beginning Balance at Mar. 31, 2020 76,588 $ 99 438,163 (47) (361,627)   $ 0       $ 0  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Stock-based compensation 4,786   4,786                  
Stock option exercises (in shares)   983,437                    
Stock option exercises 2,231   2,231                  
Restricted stock awards (in shares)   111,666                    
Net income 1,165       1,165              
Ending Balance (in shares) at Jun. 30, 2020   100,916,511         0       443  
Ending Balance at Jun. 30, 2020 84,770 $ 99 445,180 (47) (360,462)   $ 0       $ 0  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Stock-based compensation 1,539   1,539                  
Stock option exercises (in shares)   68,623                    
Stock option exercises 192 $ 1 191                  
Restricted stock awards (in shares)   141,318                    
Net income 9,384       9,384              
Ending Balance (in shares) at Sep. 30, 2020   101,126,452         0       443  
Ending Balance at Sep. 30, 2020 95,885 $ 100 446,910 (47) (351,078)   $ 0       $ 0  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Stock-based compensation 1,750   1,750                  
Stock option exercises (in shares)   240,656                    
Stock option exercises 609 $ 1 608                  
Restricted stock awards (in shares)   50,333                    
Restricted stock awards (1) $ 3 (4)                  
Share repurchase (205)     (205)                
Net income 10,196       10,196              
Ending Balance (in shares) at Dec. 31, 2020   101,417,441         0       443  
Ending Balance at Dec. 31, 2020 108,234 $ 104 449,264 (252) (340,882)   $ 0       $ 0  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Stock-based compensation 1,490   1,490                  
Stock option exercises (in shares)   16,619                    
Stock option exercises 40   40                  
Restricted stock awards (in shares)   268,174                    
Share repurchase (6,147)     (6,147)                
Net income 5,237       5,237              
Ending Balance (in shares) at Mar. 31, 2021   101,702,234         0       443  
Ending Balance at Mar. 31, 2021 108,854 $ 104 450,794 (6,399) (335,645)   $ 0       $ 0  
Beginning Balance (in shares) at Dec. 31, 2020   101,417,441         0       443  
Beginning Balance at Dec. 31, 2020 $ 108,234 $ 104 449,264 (252) (340,882)   $ 0       $ 0  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Stock option exercises (in shares) 155,690                      
Net income $ 20,970                      
Ending Balance (in shares) at Sep. 30, 2021   102,057,290         0       443  
Ending Balance at Sep. 30, 2021 122,775 $ 104 454,738 (12,155) (319,912)   $ 0       $ 0  
Beginning Balance (in shares) at Mar. 31, 2021   101,702,234         0       443  
Beginning Balance at Mar. 31, 2021 108,854 $ 104 450,794 (6,399) (335,645)   $ 0       $ 0  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Stock-based compensation 1,697   1,697                  
Stock option exercises (in shares)   25,828                    
Stock option exercises 59   59                  
Restricted stock awards (in shares)   66,668                    
Share repurchase (5,756)     (5,756)                
Net income 9,064       9,064              
Ending Balance (in shares) at Jun. 30, 2021   101,794,730         0       443  
Ending Balance at Jun. 30, 2021 113,918 $ 104 452,550 (12,155) (326,581)   $ 0       $ 0  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Stock-based compensation 1,837   1,837                  
Stock option exercises (in shares)   113,243                    
Stock option exercises 351   351                  
Restricted stock awards (in shares)   149,317                    
Net income 6,669       6,669              
Ending Balance (in shares) at Sep. 30, 2021   102,057,290         0       443  
Ending Balance at Sep. 30, 2021 $ 122,775 $ 104 $ 454,738 $ (12,155) $ (319,912)   $ 0       $ 0  
XML 19 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Operating activities:    
Net income $ 20,970 $ 15,515
Adjustments to reconcile net income to net cash flows from operating activities    
Depreciation 97 467
Accretion of debt discount and loan costs 264 231
Amortization of intangible assets 5,262 5,248
Provision for/(release of) inventory obsolescence 1,100 (297)
Stock-based compensation expense 5,024 7,845
Net change in operating lease assets and liabilities (30) 0
Changes in assets and liabilities:    
Accounts receivable (9,422) (5,040)
Inventories (6,731) (7,278)
Prepaid expenses and other assets (1,856) (1,985)
Accounts payable and accrued liabilities 12,005 (701)
Taxes payable 606 (40)
Net cash flows provided by operating activities 27,289 13,965
Investing activities:    
Product acquisitions (6,456) 0
Acquisitions of property, plant and equipment (415) 0
Net cash flows used in investing activities (6,871) 0
Financing activities:    
Payment on notes payable (20,000) 0
Proceeds from notes payable 0 20,000
Proceeds from exercise of stock options 611 2,761
Payment on share repurchase (11,903) 0
Payment on deferred financing fees 0 (437)
Net cash flows (used in)/provided by financing activities (31,292) 22,324
Net change in cash and cash equivalents (10,874) 36,289
Cash and cash equivalents at beginning of period 111,584 63,888
Cash and cash equivalents at end of period 100,710 100,177
Cash paid for interest 5,726 5,037
Cash paid for taxes $ 1,275 $ 318
XML 20 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Organization, basis of presentation and summary of significant policies
 9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Organization, basis of presentation and summary of significant policies Organization, basis of presentation and summary of significant policies:
Overview
BioDelivery Sciences International, Inc., together with its subsidiaries (collectively, the “Company”) is a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions. The Company has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive ("BEMA") drug-delivery technology to develop and commercialize new applications of proven therapies aimed at addressing important unmet medical needs. The Company commercializes its products in the U.S. using its own sales force while working in partnership with third parties to commercialize its products outside the U.S.
The accompanying unaudited condensed consolidated financial statements include all adjustments (consisting of normal and recurring adjustments) necessary for a fair presentation of these financial statements. The condensed consolidated balance sheet at December 31, 2020 has been derived from the Company’s audited consolidated financial statements included in its annual report on Form 10-K for the year ended December 31, 2020. Certain footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to the Securities and Exchange Commission rules and regulations. It is recommended that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2020.
As used herein, the Company’s common stock, par value $0.001 per share, is referred to as the “Common Stock” and the Company’s preferred stock, par value $0.001 per share, is referred to as the “Preferred Stock”.
Principles of consolidation
The condensed consolidated financial statements include the accounts of the Company, Arius Pharmaceuticals, Inc. and Arius Two, Inc. All significant inter-company balances and transactions have been eliminated.
Use of estimates in financial statements
The preparation of the accompanying condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. The Company reviews all significant estimates affecting the condensed consolidated financial statements on a recurring basis and records the effect of any necessary adjustments prior to their issuance. Significant estimates made by the Company include: revenue recognition associated with sales allowances such as government program rebates, customer voucher redemptions, commercial contracts, rebates and chargebacks; sales returns reserves; sales bonuses; stock-based compensation; and deferred income taxes.
Cash and cash equivalents
Cash and cash equivalents consist of operating and money market accounts. Cash equivalents are carried at cost which approximates fair value due to their short-term nature. The Company considers all highly-liquid investments with an original maturity of 90 days or less to be cash equivalents.
The Company maintains cash equivalent balances with financial institutions that management believes are of high credit quality. The Company’s cash and cash equivalents accounts at times may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk from cash and cash equivalents.
Inventory
Inventories are stated at the lower of cost or net realizable value with costs determined for each batch under the first-in, first-out method. Inventory consists of raw materials, work in process and finished goods. Raw materials include amounts of active pharmaceutical ingredient for a product to be manufactured; work in process includes the bulk inventory of laminate (the
Company’s drug delivery film) prior to being packaged for sale; and finished goods include pharmaceutical products ready for commercial sale.
On a quarterly basis, the Company analyzes its inventory levels and records allowances for inventory that has become obsolete, inventory that has a cost basis in excess of the expected net realizable value and inventory that is in excess of expected demand based upon projected product sales. Inventory obsolescence reserves at September 30, 2021 and December 31, 2020 were $3.4 million and $2.3 million, respectively.
Revenue recognition
Product sales
Product sales amounts relate to sales of BELBUCA and Symproic. Product sales for the nine months ended September 30, 2020 also included sales of BUNAVAIL. Product sales for BUNAVAIL during the three months ended September 30, 2020 were related to the release of gross to net reserves. The Company recognizes revenue on product sales when control of the promised goods is transferred to its customers in an amount that reflects the consideration expected to be received in exchange for transferring those goods. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. When determining whether the customer has obtained control of the goods, the Company considers any future performance obligations. Generally, there is no post-shipment obligation on product sold.
Product royalty revenues
Product royalty revenue amounts are based on sales revenue of the PAINKYL™ product under the Company’s license agreement with TTY Biopharm Co., Ltd., ("TTY") and the BREAKYL™ product under the Company’s license agreement with Meda AB, which was acquired by Mylan N.V. and later acquired by Viatris, Inc. (which we refer to herein as Viatris). Product royalty revenues are recognized when control of the product is transferred to the license partner in an amount that reflects the consideration expected to be received. Supplemental sales-based product royalty revenue may also be earned upon the subsequent sale of the product at agreed upon contractual rates.

Performance obligations
A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The majority of the Company’s product sales contracts have a single performance obligation as the promise to transfer the individual goods is not separately identifiable from other promises in the contracts and, therefore, not distinct. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. The Company has assessed the existence of a significant financing component in the agreements with its customers. The trade payment terms with its customers do not exceed one year and therefore the Company has elected to apply the practical expedient and no amount of consideration has been allocated as a financing component.

Transaction price, including variable consideration
Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration for which reserves are established. Components of variable consideration include trade discounts and allowances, product returns, government chargebacks, discounts and rebates, and other incentives, such as voucher programs, and other fee for service amounts that are detailed within contracts between the Company and its customers relating to the Company’s sale of its products.
The Company establishes allowances for estimated rebates, chargebacks and product returns based on numerous qualitative and quantitative factors, including:
•specific contractual terms of agreements with customers;
•estimated levels of inventory in the distribution channel;
•historical rebates, chargebacks and returns of products;
•direct communication with customers;
•anticipated introduction of competitive products or generics;
•anticipated pricing strategy changes by the Company and/or its competitors;
•analysis of prescription data gathered by third-party prescription data providers;
•the impact of changes in state and federal regulations; and
•the estimated remaining shelf life of products.
In its analyses, the Company uses prescription data purchased from a third-party data provider to develop estimates of historical inventory channel sell-through. The Company utilizes an internal analysis to compare historical net product shipments to estimated historical prescriptions written. Based on that analysis, management develops an estimate of the quantity of product in the channel which may be subject to various rebate and chargeback exposures. To estimate months of ending inventory in the Company’s distribution channel, the Company divides estimated ending inventory in the distribution channel by the Company’s recent prescription data, not considering any future anticipated demand growth beyond the succeeding quarter. Monthly for each product line, the Company prepares an internal estimate of ending inventory units in the distribution channel by adding estimated inventory in the channel at the beginning of the period, plus net product shipments for the period, less estimated prescriptions written for the period, and less units included in the sales returns reserve expected to be returned. This is done for each product line by applying a rate of historical activity for rebates and chargebacks, adjusted for relevant quantitative and qualitative factors discussed above, to the potential exposed product estimated, net of reserved return units, to be in the distribution channel. In addition, the Company receives daily information from the major wholesalers regarding their sales and actual on-hand inventory levels of the Company’s products. This enables the Company to execute accurate provisioning procedures.
Revenue from product sales is recorded after considering the impact of the following variable consideration amounts at the time of revenue recognition:
Product returns-Consistent with industry practice, the Company offers contractual return rights that allow its customers to return the products within an 18-month period that begins six months prior to and ends twelve months after expiration of the products. The Company estimates product returns reserves based upon historical return rates adjusted for qualitative factors and are applied to open product batches that are currently eligible for returns, or will be eligible in the future, within company policy. Other factors considered include expected marketplace changes and the remaining shelf life of product batches. Product returns reserves for newly launched products are based on historical rates of similar products or pre-determined percentage.
Government rebates and chargebacks-Government rebates and chargebacks include mandated discounts under Medicaid, Medicare, U.S. Department of Veterans Affairs and other government agencies ("Government Payors"). The Company estimates the rebates and chargebacks to Government Payors based upon a combination of historical experience, product pricing, estimated payor mix, product growth, and the mix of contract and agreement terms. These reserves are recorded in the same period the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets. In addition, the pricing of covered products under Medicaid is subject to complex calculations and involves interpretation of government rules, regulations and policies as well as adjustments based on current trends in utilization. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company estimates the rebates and chargebacks that it will provide to Government Payors based upon (i) the government-mandated discounts applicable to government-funded programs, (ii) information obtained from its customers and (iii) information obtained from other third parties regarding the payor mix for its products. The Company’s liability for these rebates consists of estimates of claims for the current quarter and estimated future claims that will be made for product shipments that have been recognized as revenue, but remain in the distribution channel inventories at the end of each reporting period.
Commercial Contracts-The Company estimates the rebates to commercial contracts based upon a combination of historical experience, product pricing, estimated payor mix, product growth, and the mix of contract and agreement terms. These reserves are recorded in the same period the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets.
Patient Assistance Voucher program-The Company, from time to time, offers certain promotional product-related incentives to eligible patients. The Company has voucher programs for BELBUCA and Symproic whereby the Company offers a point-of-sale subsidy to retail consumers. The Company estimates its liabilities for these voucher programs based on the current utilization and historical redemption rates as reported to the Company by a third-party claims processing organization. The
Company accounts for the costs of these special promotional programs as price adjustments, which are a reduction of gross revenue.
Trade discounts and distribution fees-Trade discounts relate to prompt settlement discounts provided to customers. In addition, the Company compensates its customers for distribution of its products and the provision of data. The Company has determined that such services received to date are not distinct from its sale of products and may not reasonably represent fair value for these services. Therefore, estimates of these payments are recorded as a reduction of revenue based on contractual terms.
There can be a significant lag between the Company's establishment of an estimate and the timing of the invoicing or claim. The Company believes it has made reasonable estimates for future rebates and claims, however, these estimates involve assumptions pertaining to contractual utilization and performance, and payor mix. If the performance or mix across third-party payors is different from the Company’s estimates, the Company may be required to pay higher or lower total price adjustments and/or chargebacks than it had estimated.
Cost of sales
Cost of sales includes the direct costs attributable to the production of BELBUCA and Symproic. It includes raw materials, production costs at the Company’s contract manufacturing sites, quality testing directly related to the products, inventory reserves, and depreciation on equipment that the Company has purchased to produce BELBUCA, Symproic and formerly BUNAVAIL. It also includes any batches not meeting specifications and raw material yield losses. Yield losses and the costs related to batches not meeting specifications are expensed as incurred. Cost of sales is recognized when sold to the wholesaler from our distribution center.
For BREAKYL and PAINKYL (the Company’s out-licensed breakthrough cancer pain therapies), cost of sales includes all costs related to creating the product at the Company’s contract manufacturing location in Germany. The Company’s contract manufacturer bills the Company for the final product, which includes materials, direct labor costs, quality testing, and certain overhead costs as outlined in applicable supply agreements.
Cost of sales also includes royalty expenses that the Company owes to third parties.
Measurement of credit losses of financial instruments
The Company is exposed to credit losses primarily through its product sales. The Company assesses each counterparty’s ability to pay for the products it sells by conducting a credit review. The credit review considers the Company's expected billing exposure and timing for payment and the counterparty’s established credit rating or the Company's assessment of the counterparty’s creditworthiness based on the Company's analysis of their financial statements when a credit rating is not available. The Company also considers contract terms and conditions, and business strategy in its evaluation. A credit limit is established for each counterparty based on the outcome of this review.
The Company monitors its ongoing credit exposure through active review of counterparty balances against contract terms and due dates. The Company's activities include timely account reconciliations, dispute resolution and payment confirmations. The Company may employ collection agencies and legal counsel to pursue recovery of defaulted receivables.
As of September 30, 2021, the Company reported $57.6 million of trade receivables within accounts receivable. Based on an aging analysis at September 30, 2021, 96% of the Company's accounts receivable were outstanding less than 30 days. There was no change to the allowance for doubtful accounts and credit losses between September 30, 2021 and December 31, 2020. The Company writes off accounts receivable when management determines they are uncollectible and credits payments subsequently received on such receivables to bad debt expense in the period received.
New Accounting Pronouncements, adopted
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740)—Simplifying the Accounting for Income Taxes, which is intended to simplify accounting for income taxes. It removes certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020 and early adoption is permitted. The Company adopted Topic 740 during the nine months ended September 30, 2021 and determined that the new guidance did not have a material impact on its consolidated financial statements.
The Company has reviewed other new accounting pronouncements that were issued as of September 30, 2021 and does not believe that these pronouncements are applicable to the Company, or that they will have a material impact on its financial position or results of operations.

Fair Value of Financial Instruments
The Company measures the fair value of instruments in accordance with GAAP which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.
GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company considers the carrying amount of its cash and cash equivalents to approximate fair value due to short-term nature of this instrument. GAAP describes three levels of inputs that may be used to measure fair value:
Level 1 – quoted prices in active markets for identical assets or liabilities
Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable
Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)
The following table summarizes the financial instruments measured at fair value on a recurring basis as of September 30, 2021:
Level 1Level 2Level 3Balance at September 30, 2021
Cash and cash equivalents$100,710 $— —$100,710 
The cash and cash equivalent balance as of September 30, 2021 includes investments in various money market accounts and cash held in interest bearing accounts
XML 21 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Inventory, net
 9 Months Ended
Sep. 30, 2021
Inventory Disclosure [Abstract]  
Inventory, net Inventory, net:The following table represents the components of inventory as of:
September 30,
2021		December 31,
2020
Raw materials $4,143 $3,389 
Work-in-process6,765 9,949 
Finished goods15,520 6,359 
Obsolescence reserve(3,353)(2,254)
Total inventories, net$23,075 $17,443 
XML 22 R9.htm IDEA: XBRL DOCUMENT v3.21.2
Accounts Payable and Accrued Liabilities
 9 Months Ended
Sep. 30, 2021
Payables and Accruals [Abstract]  
Accounts Payable and Accrued Liabilities Accounts payable and accrued liabilities:The following table represents the components of accounts payable and accrued liabilities as of:
September 30,
2021		December 31,
2020
Accounts payable$7,033 $4,213 
Accrued rebates38,179 34,247 
Accrued compensation and benefits6,832 5,488 
Accrued returns8,009 5,128 
Accrued royalties1,138 704 
Taxes payable583 1,026 
Accrued legal1,819 515 
Accrued regulatory expenses294 397 
Product rights payable9,000 — 
Accrued other1,693 1,277 
Total accounts payable and accrued liabilities$74,580 $52,995 
XML 23 R10.htm IDEA: XBRL DOCUMENT v3.21.2
Property and Equipment
 9 Months Ended
Sep. 30, 2021
Property, Plant and Equipment [Abstract]  
Property and Equipment Property and equipment:
Property and equipment, summarized by major category, consist of the following as of:
September 30,
2021		December 31,
2020
Machinery & equipment$4,849 $4,683 
Right of use, building lease260 471 
Computer equipment & software640 272 
Office furniture & equipment174 174 
Leasehold improvements43 43 
Idle equipment679 679 
Construction in progress— 119 
Total6,645 6,441 
Less accumulated depreciation and amortization(5,120)(5,023)
Total property and equipment, net$1,525 $1,418 
Depreciation expense for the three-month periods ended September 30, 2021 and September 30, 2020, was approximately $0.04 million and $0.2 million, respectively. Depreciation expense for the nine-month periods ended September 30, 2021 and September 30, 2020, was approximately $0.1 million and $0.5 million, respectively. Depreciation expense for the nine- month period ended September 30, 2020 includes a $0.3 million one-time charge due to BUNAVAIL equipment write-off.
XML 24 R11.htm IDEA: XBRL DOCUMENT v3.21.2
Intangible Assets
 9 Months Ended
Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets Intangible assets:
Other intangible assets, net, consisting of product rights and licenses are summarized as follows:
September 30, 2021Gross Carrying
Value		Accumulated
Amortization		Intangible Assets,
net		Weighted Average Useful Life
BELBUCA license and distribution rights45,000 (21,375)23,625 5.5
Symproic license and distribution rights30,636 (6,087)24,549 10.5
ELYXYB product rights15,455 (60)15,395 14.8
Total intangible assets$91,091 $(27,522)$63,569 8.8
December 31, 2020Gross Carrying
Value		Accumulated
Amortization		Intangible Assets,
net		Weighted Average Useful Life
Product rights$6,050 $(6,050)$— 
BELBUCA license and distribution rights45,000 (18,000)27,000 6.0
Symproic license and distribution rights30,636 (4,260)26,376 10.8
Total intangible assets$81,686 $(28,310)$53,376 7.9
XML 25 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Acquired product rights
 9 Months Ended
Sep. 30, 2021
Asset Acquisition [Abstract]  
Acquired product rights Acquired product rights:
On August 3, 2021, (the “Effective Date”), the Company and Dr. Reddy’s Laboratories Limited, a company incorporated under the laws of India (“DRL”), entered into an asset purchase agreement (the “Asset Purchase Agreement”) for the acquisition by the Company from DRL of certain patents, trademarks, regulatory approvals and other rights related to ELYXYB™ (celecoxib oral solution) (the “Product”) and its commercialization in the United States and Canada (the “Territory”). The closing of the transactions contemplated by the Asset Purchase Agreement occurred on September 9, 2021 (the "Closing").
Pursuant to the terms of the Asset Purchase Agreement, the Company paid DRL a $6 million up-front payment at the Closing. In addition, the Company will pay DRL $9 million on the twelve-month anniversary of the Effective Date and up to an additional $9 million upon achievement of certain regulatory milestones and quarterly earn-out payments on potential sales of the Product in the Territory that range from high single digits to the low double digits (subject to reduction in certain circumstances) of net sales based on volume of sales. DRL will also be entitled to one-time payments upon the achievement of six escalating sales milestones, which range from $4 million to be paid upon the achievement of $50 million in net sales in a calendar year to $100 million to be paid upon the achievement of $1 billion in net sales in a calendar year up to a total of $262 million.
The Company accounted for the ELYXYB purchase as an asset acquisition under ASC 805-10-55-5b, which provides guidance for asset acquisitions. Under the guidance, if substantially all the acquisition is made up of one asset or several similar assets, then the acquisition is an asset acquisition. The Company believes that the asset purchase agreement and other assets acquired from DRL are similar and considers them all to be intangible assets.
The total purchase price was allocated to the acquired asset based on their relative estimated fair values, as follows:
ELYXYB acquired product rights$15,000
Transaction expenses455
Total value$15,455
The $9 million twelve-month anniversary payment has been recorded in accounts payable and accrued liabilities in the accompanying condensed consolidated balance sheet.
XML 26 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Notes Payable
 9 Months Ended
Sep. 30, 2021
Debt Disclosure [Abstract]  
Notes Payable Notes payable:
On May 23, 2019, the Company entered into a Loan Agreement with BPCR LIMITED PARTNERSHIP (the successor-in-interest to Biopharma Credit PLC), for a senior secured credit facility consisting of a term loan of $60.0 million (the “Term Loan”), with the ability to draw an additional $20.0 million within twelve months of the closing date, which the Company drew down on May 22, 2020.
The loan facility carries a 72-month term with interest only payments on the term loan for the first 36 months. The Term Loan will mature in May 2025 and bears an interest rate of 7.5% plus the LIBOR rate on the first day for the quarter, with a floor of 2% for the LIBOR rate (LIBOR effective rate as of July 1, 2021 was 0.14%.) The Term Loan is subject to mandatory prepayment provisions that require prepayment upon change of control.
On September 23, 2021, the Company elected to repay $20 million plus accrued interest of $1.5 million, representing a portion of the first tranche. The Term loan includes the option for the Company to paydown up to $20 million of tranche A without incurring any prepayment penalties after the 24 month anniversary of the loan. As a result, no prepayment penalty was incurred in connection with this prepayment.
The debt balance has been categorized within Level 2 of the fair value hierarchy. The notes payable debt balance as of September 30, 2021 approximates its fair value based on prevailing interest rates as of the balance sheet date.
The following table represents future maturities of the notes payable obligation as of September 30, 2021:
2021— 
20224,615 
202318,462 
202424,615 
202512,308 
Total maturities$60,000 
Unamortized discount and loan costs(1,285)
Total notes payable obligation$58,715 
XML 27 R14.htm IDEA: XBRL DOCUMENT v3.21.2
Net Sales by Product
 9 Months Ended
Sep. 30, 2021
Segment Reporting [Abstract]  
Net Sales by Product Net sales by product:
The Company’s business is classified as a single reportable segment.
However, the following table presents net sales by product:
Three months ended September 30,
Nine months ended September 30,
2021202020212020
BELBUCA$36,930 $34,758 $109,836 $100,572 
     % of net product sales90 %90 %90 %89 %
Symproic4,142 3,453 12,562 11,046 
     % of net product sales10 %9 %10 %10 %
BUNAVAIL— 574 — 1,328 
     % of net product sales— %1 %— %1 %
Net product sales$41,072 $38,785 $122,398 $112,946 
XML 28 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Stockholders' Equity
 9 Months Ended
Sep. 30, 2021
Stockholders' Equity Note [Abstract]  
Stockholders' Equity Stockholders’ equity:
Common Stock
On November 4, 2020, the Board of Directors authorized the repurchase of up to $25 million of the Company's shares of Common Stock. The timing and amount of any shares purchased on the open market will be determined based on the Company's evaluation of market conditions, share price and other factors. The Company plans to utilize existing cash on hand to fund the share repurchase program.

During the nine months ended September 30, 2021, a cumulative total of 3,202,690 shares, with a weighted average price of $3.72, for a value of $11.9 million,were repurchased and recorded as Treasury Stock in the condensed consolidated balance sheet.
Stock-based compensation
During the nine months ended September 30, 2021, a total of 3,192,505 options to purchase Common Stock, with an aggregate fair market value of approximately $12.9 million, were granted to employees, executive officers and Board of Directors of the Company. Options have a term of 10 years from the grant date. Options granted to employees and officers will vest ratably over a three-year period. Options granted to Board of Directors vest one half immediately and the remaining half on the anniversary of grant.
The fair value of each option award is estimated on the grant date using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, expected rate of forfeiture and the risk-free interest rate. Expected volatilities are based on implied volatilities from historical volatility of the Common Stock, and other factors estimated over the expected term of the options.
Expected term of options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus contract term. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term.
The key assumptions used in determining the fair value of options granted during the nine months ended September 30, 2021 follows:
Expected price volatility
53.70%-59.87%
Risk-free interest rate
0.50%-1.17%
Weighted average expected life in years6 years
Dividend yield— 
Option activity during the nine months ended September 30, 2021 was as follows:
Number of
shares		Weighted average
exercise price per
share		Aggregate
intrinsic
value
Outstanding at January 1, 20217,060,966 $4.55 $2,831 
Granted in 2021:
Officers and Directors1,345,292 3.83 
Employees1,847,213 4.20 
Exercised(155,690)2.90 
Forfeitures(539,802)4.72 
Outstanding at September 30, 20219,557,979 $4.40 $8,589 
During the nine months ended September 30, 2021 and 2020, Company employees and directors exercised approximately 155,690 and 1,159,347 stock options, respectively, with net proceeds to the Company of approximately $0.5 million and
$2.8 million, respectively. The intrinsic value of options exercised during the nine months ended September 30, 2021 and 2020 was approximately $0.1 million and $3.1 million, respectively.
As of September 30, 2021, options exercisable totaled 4,153,242. There are approximately $9.3 million of unrecognized compensation costs related to non-vested share-based compensation awards, including options and restricted stock units (“RSUs”) granted. These costs will be expensed through 2024.
Restricted stock units
During the nine months ended September 30, 2021, a cumulative total of 278,369 RSUs were granted to the Company’s executive officers, members of senior management and the Board of Directors, with a fair market value of approximately $1.1 million. The fair value of restricted units is determined using quoted market prices of the Common Stock and the number of shares expected to vest. RSU grants are time-based, all of which generally vest from a one to three-year period.
Restricted stock activity during the nine months ended September 30, 2021 was as follows:
Number of
restricted
shares		Weighted
average fair
market value
per RSU
Outstanding at January 1, 2021940,759 $3.71 
Granted:
Officers and Directors242,562 3.83 
Employees35,807 3.84 
Vested(484,159)3.84 
Forfeitures— — 
Outstanding at September 30, 2021734,969 $4.08 
Warrants

The Company has granted warrants to purchase shares of Common Stock. Warrants may be granted to affiliates in connection with certain agreements.

As of September 30, 2021, a cumulative total of 2,051,033 warrants, with exercise prices ranging from $2.38 to $3.42, remain exercisable and outstanding. The warrants were valued using the Black-Scholes Model, which a cumulative fair value of approximately $4.5 million. There were no warrants granted or exercised during the nine months ended September 30, 2021.

Preferred Stock
As of September 30, 2021, 443 shares of Series B Preferred Stock (“Series B”) are outstanding. There were no conversions of Series B during the nine months ended September 30, 2021.
Earnings Per Share
Three months ended September 30,Nine months ended September 30,
2021202020212020
Basic:
Net income attributable to common stockholders, basic$6,669 $9,383 $20,970 $15,515 
Weighted average common shares outstanding98,699,857 101,031,317 99,485,399 99,377,748 
Basic earnings per common share$0.07 $0.09 $0.21 $0.16 
Diluted:
Effect of dilutive securities:
Net income attributable to common stockholders, diluted$6,669 $9,383 $20,970 $15,515 
Weighted average common shares outstanding98,699,857 101,031,317 99,485,399 99,377,748 
Effect of dilutive options and warrants3,731,026 4,752,251 3,988,568 5,458,745 
Dilutive weighted average common shares outstanding102,430,883 105,783,568 103,473,967 104,836,493 
Diluted earnings per common share$0.07$0.09$0.20$0.15
XML 29 R16.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and contingencies:
The Company is involved from time to time in routine legal matters incidental to our business. Based upon available information, the Company believes that the resolution of such matters will not have a material adverse effect on its condensed consolidated financial position or results of operations. Except as discussed below, the Company is not the subject of any pending legal proceedings and, to the knowledge of management, no proceedings are presently contemplated against the Company by any federal, state or local governmental agency.
Indivior (formerly RB Pharmaceuticals Ltd.) and Aquestive Therapeutics (formerly MonoSol Rx)
The following disclosure regarding the Company’s ongoing litigations with Aquestive Therapeutics, Inc. (formerly MonoSol Rx, “Aquestive”) and Indivior PLC (formerly RB Pharmaceuticals Limited, “Indivior”) is intended to provide some background and an update on the matter as per disclosure requirements of the SEC. Additional details regarding the past procedural history of the matter can be found in the Company’s previously filed periodic filings with the SEC.

Litigation related to BUNAVAIL
On October 29, 2013, Reckitt Benckiser, Inc., Indivior, and Aquestive (collectively, the “RB Plaintiffs”) filed an action against the Company relating to its BUNAVAIL product in the United States District Court for the Eastern District of North Carolina (“EDNC”) for alleged patent infringement. BUNAVAIL is a drug approved for the maintenance treatment of opioid dependence. The RB Plaintiffs claim that the formulation for BUNAVAIL, which has never been disclosed publicly, infringes its US Patent No. 8,475,832 (the “‘832 Patent”). On May 21, 2014, the Court granted the Company’s motion to dismiss.
On January 22, 2014, Aquestive initiated an inter partes review (“IPR”) on U.S. Patent No. 7,579,019, the (“‘019 Patent”). The PTAB upheld all claims of the Company’s ‘019 Patent in 2015 and this decision was not appealed by Aquestive.
On September 20, 2014, the Company proactively filed a declaratory judgment action in the United States District Court for the EDNC requesting the Court to make a determination that the Company’s BUNAVAIL product does not infringe the ‘832 Patent, US Patent No. 7,897,080 (the “‘080 Patent”) and US Patent No. 8,652,378 (the “‘378 Patent”). The Company invalidated the “‘080 Patent” in its entirety in an inter partes reexamination proceeding. The Company invalidated all relevant claims of the ‘832 Patent in an IPR proceeding. And, in an IPR proceeding for the ‘378 Patent, in its decision not to institute the IPR proceeding, the PTAB construed the claims of the ‘378 Patent narrowly. Shortly thereafter, by joint motion of the parties, the ‘378 Patent was subsequently removed from the action.
On June 6, 2016, in an unrelated case in which Indivior and Aquestive asserted the ‘832 Patent against other parties, the Delaware District Court entered an order invalidating other claims in the ‘832 Patent. Indivior and Aquestive did not appeal the
Delaware Court’s holding that other claims of the ‘832 Patent are invalid. On February 10, 2021, the parties in our EDNC declaratory judgment action filed a covenant by Indivior and Aquestive not to sue us for infringement of the ‘832 Patent. In view of that covenant and the prior invalidation of the ‘080 patent, we filed a notice of voluntary dismissal of the Company’s EDNC declaratory judgement action.
On September 22, 2014, the RB Plaintiffs filed an action against the Company (and the Company’s commercial partner) relating to the Company’s BUNAVAIL product in the United States District Court for the District of New Jersey for alleged patent infringement. The RB Plaintiffs claim that BUNAVAIL, whose formulation and manufacturing processes have never been disclosed publicly, infringes its patent U.S. Patent No. 8,765,167 (the “‘167 Patent”). The Company believes this is an anticompetitive attempt by the RB Plaintiffs to distract the Company’s efforts from commercializing BUNAVAIL.
On December 12, 2014, the Company filed a motion to transfer the case from New Jersey to North Carolina and a motion to dismiss the case against its commercial partner. On October 28, 2014, the Company filed multiple IPR petitions on certain claims of the ‘167 Patent. The USPTO instituted three of the four IPR petitions. The PTAB upheld the claims and denied collateral estoppel applied to the PTAB decisions in March 2016. The Company appealed to Court of Appeals for the Federal Circuit. The USPTO intervened with respect to whether collateral estoppel applied to the PTAB.
On June 19, 2018, the Company filed a motion to remand the case for further consideration by the PTAB in view of intervening authority. On July 31, 2018, the Federal Circuit vacated the decisions, and remanded the ‘167 Patent IPRs for further consideration on the merits.
On February 7, 2019, the PTAB issued three decisions on remand purporting to deny institution of the three previously instituted IPRs of the ‘167 patent. On March 11, 2019, the Company timely appealed the PTAB decisions on remand to U.S. Court of Appeal for the Federal Circuit. On March 20, 2019, Aquestive and Indivior moved to dismiss the appeal, and the Company opposed that motion.
On August 29, 2019, a three-judge panel of the Court of Appeals for the Federal Circuit granted the motion and dismissed the Company’s appeal. On September 30, 2019, the Company filed a petition for an en banc rehearing of the order dismissing the Company’s appeal by the full Federal Circuit Court of Appeals.
On January 13, 2020, by the Court of Appeals for the Federal Circuit denied BDSI’s petition for en banc rehearing of the dismissal of BDSI’s appeal relating to inter partes review proceedings on the ’167 patent. On June 11, 2020, BDSI filed a petition for certiorari seeking U.S. Supreme Court review of the Federal Circuit’s decision. On October 5, 2020, the U.S. Supreme Court denied the Company’s petition for certiorari.
The Company strongly refutes as without merit the Plaintiffs’ assertion of patent infringement and will vigorously defend the lawsuit.

Litigation related to BELBUCA
On January 13, 2017, Aquestive filed a complaint in the United States District Court for the District of New Jersey alleging BELBUCA infringes the ‘167 Patent. In lieu of answering the complaint, the Company filed motions to dismiss the complaint and, in the alternative, to transfer the case to the EDNC. On July 25, 2017, the New Jersey Court administratively terminated the case pending the parties submission of a joint stipulation of transfer because the District of New Jersey was an inappropriate venue. This case was later transferred to the Delaware District Court. On October 31, 2017, the Company filed motions to dismiss the complaint and, in the alternative, to transfer the case to the EDNC. On October 16, 2018, denying the motion to dismiss as moot, the Delaware District Court granted the Company’s motion to transfer the case to the EDNC. On November 20, 2018, the Company moved the EDNC to dismiss the complaint for patent infringement for failure to state a claim for relief.
On August 6, 2019, the EDNC granted the Company’s motion to dismiss, and dismissed the complaint without prejudice. On or about November 11, 2019, Aquestive refiled a complaint in the EDNC against the Company alleging that BELBUCA infringes the ‘167 Patent. On January 13, 2020, in lieu of answering the complaint, we filed a motion to dismiss the complaint. After the two motions were denied, on April 16, 2020, we answered the complaint. Aquestive moved to dismiss our counter-claim of unenforceability, but the court denied that motion. The Company strongly refutes as without merit Aquestive’s assertion of patent infringement and will vigorously defend the lawsuit.
Teva Pharmaceuticals USA (formerly Actavis)
On February 8, 2016, the Company received a notice relating to a Paragraph IV certification from Teva Pharmaceuticals USA, or (formerly Actavis, “Teva”) seeking to find invalid three Orange Book listed patents relating specifically to BUNAVAIL. The Paragraph IV certification related to an ANDA filed by Teva with the FDA for a generic formulation of BUNAVAIL. The patents subject to Teva’s certification were the ‘019 Patent, U.S. Patent No. 8,147,866 (the “‘866 Patent”) and 8,703,177 (the “‘177 Patent”).
On March 18, 2016, the Company asserted three different patents against Teva, the ‘019 Patent, the ‘866 Patent, and the ‘177 Patent. Teva did not raise non-infringement positions about the ‘019 and the ‘866 Patents in its Paragraph IV certification. Teva did raise a non-infringement position on the ‘177 Patent but the Company asserted in its complaint that Teva infringed the ‘177 Patent either literally or under the doctrine of equivalents.
On December 20, 2016 the USPTO issued U.S. Patent No. 9,522,188 (the “‘188 Patent””), and this patent was properly listed in the Orange Book as covering the BUNAVAIL product. On February 23, 2017 Teva sent a Paragraph IV certification adding the 9,522,188 to its ANDA. An amended Complaint was filed, adding the ‘188 Patent to the litigation.
On January 31, 2017, the Company received a notice relating to a Paragraph IV certification from Teva relating to Teva’s ANDA on additional strengths of BUNAVAIL and on March 16, 2017, the Company brought suit against Teva and its parent company on these additional strengths. On June 20, 2017, the Court entered orders staying both BUNAVAIL suits at the request of the parties.
On May 23, 2017, the USPTO issued U.S. Patent 9,655,843 (the “‘843 Patent”) relating to the BEMA technology, and this patent was properly listed in the Orange Book as covering the BUNAVAIL product.
Finally, on October 12, 2017, the Company announced that it had entered into a settlement agreement with Teva that resolved the Company’s BUNAVAIL patent litigation against Teva pending in the U.S. District Court for the District of Delaware. As part of the Settlement Agreement, which is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice, the Company has entered into a non-exclusive license agreement with Teva that permits Teva to first begin selling its generic version of BUNAVAIL in the U.S. on July 23, 2028 or earlier under certain circumstances. Other terms of the agreement are confidential.
The Company received notices regarding Paragraph IV certifications from Teva on November 8, 2016, November 10, 2016, and December 22, 2016, seeking to find invalid two Orange Book listed patents relating specifically to BELBUCA. The Paragraph IV certifications relate to three ANDAs filed by Teva with the FDA for a generic formulation of BELBUCA. The patents subject to Teva’s certification were the ‘019 Patent and the ‘866 Patent. The Company filed complaints in Delaware against Teva on December 22, 2016 and February 3, 2017 in which it asserted against Teva the ‘019 Patent and the ‘866 Patent. Teva did not contest infringement of the claims of the ‘019 Patent and did not contest infringement of the claims of the ‘866 Patent. The ‘019 Patent had already been the subject of an unrelated IPR before the USPTO under which the Company prevailed, and all claims of the ‘019 Patent survived. Aquestive’s request for rehearing of the final IPR decision regarding the ‘019 Patent was denied by the USPTO on December 19, 2016. Aquestive did not file a timely appeal at the Federal Circuit.
On May 23, 2017, the USPTO issued U.S. Patent 9,655,843 (the “‘843 Patent”) relating to the BEMA technology, and this patent was properly listed in the Orange Book as covering the BELBUCA product.
On August 28, 2017, the Court entered orders staying both BELBUCA suits at the request of the parties.
In February 2018, the Company announced that it had entered into a settlement agreement with Teva that resolved the Company’s BELBUCA patent litigation against Teva pending in the U.S. District Court for the District of Delaware. As part of the settlement agreement, which is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice, the Company has granted Teva a non-exclusive license (for which the Company will receive no current or future payments) that permits Teva to first begin selling the generic version of the Company’s BELBUCA product in the U.S. on January 23, 2027 or earlier under certain circumstances (including, for example, upon (i) the delisting of the patents-in-suit from the U.S. FDA Orange Book, (ii) the granting of a license by us to a third party to launch another generic form of BELBUCA at a date prior to January 23, 2027, or (iii) the occurrence of certain conditions regarding BELBUCA market share). Other terms of the Agreement are confidential.
Alvogen
On September 7, 2018, the Company filed a complaint for patent infringement in Delaware against Alvogen Pb Research & Development LLC, Alvogen Malta Operations Ltd., Alvogen Pine Brook LLC, Alvogen, Incorporated, and Alvogen Group, Incorporated (collectively, “Alvogen”), asserting that Alvogen infringes the Company’s Orange Book listed patents for BELBUCA, including U.S. Patent Nos. 8,147,866 and 9,655,843, both expiring in July of 2027, and U.S. Patent No. 9,901,539, expiring in December of 2032. This complaint follows receipt by the Company on July 30, 2018 of a Paragraph IV Patent Certification from Alvogen stating that Alvogen had filed an ANDA with the FDA for a generic version of BELBUCA Buccal Film (75 mcg, 150 mcg, 300 mcg, 450 mcg, 600 mcg, 750 mcg and 900 mcg). Because the Company initiated a patent infringement suit to defend the patents identified in the Paragraph IV notice within 45 days after receipt of the Paragraph IV Certification, the FDA is prevented from approving the ANDA until the earlier of 30 months or a decision in the case that each of the patents is not infringed or invalid. Alvogen’s notice letter also does not provide any information on the timing or approval status of its ANDA.
In its Paragraph IV Certification, Alvogen does not contest infringement of at least several independent claims of each of the ’866, ’843, and ’539 patents. Rather, Alvogen advances only invalidly arguments for these independent claims. The Company believes that it will be able to prevail on its claims of infringement of these patents, particularly as Alvogen does not contest infringement of certain claims of each patent. Additionally, as the Company has done in the past, it intends to vigorously defend its intellectual property against assertions of invalidity. Each of the three patents carry a presumption of validity, which can only be overcome by clear and convincing evidence.
The Court scheduled a bench trial to commence on November 9, 2020 to adjudicate issues concerning the validity of the Orange Book patents listed for BELBUCA. On October 6, 2020, the Court rescheduled the bench trial with Alvogen to commence on March 1, 2021. A three day bench trial against Alvogen was conducted commencing on March 1, 2021. At the conclusion of trial, the Court ordered the parties to submit post-trial briefs. Post-trial briefing was completed on May 26, 2021. The Company subsequently moved the Court to strike (i.e., remove from the Court’s consideration) three patent invalidity defenses raised for the first time in Alvogen’s post-trial briefs and two documents improperly cited in Alvogen’s post-trial briefs. On June 28, 2021, the Court granted the Company’s motion to strike in its entirety. In addition, on June 28, 2021, the Court enjoined Alvogen from launching its generic product until the Court issues its final decision on the merits.
On September 21, 2021, the Company filed under seal a Motion for Order to Show Cause why Defendants Should not be Held in Contempt for Violating the Court Order of June 28, 2021 (the “Motion”). On June 28, 2021, citing the statute authorizing the Court to extend the 30-month stay under the Hatch-Waxman Act, the Court ordered Alvogen (as defined below) not to “launch” its generic product until it could reach a final decision on the merits in the case. In the Motion, the Company contends that Alvogen violated the order of the United States District Court for the District of Delaware commencing in or about August 2021 by, among other things, offering the generic product for sale through five compendia / price reporting services, including First Databank, Medi-Span (Wolters Kluwer), Red Book, Gold Standard and ScriptPro. As alleged in the Motion, after Alvogen’s product launch, certain payers began declining insurance coverage for the Company’s brand BELBUCA and directing use of Alvogen’s generic substitute and/or made it more difficult for patients to obtain insurance coverage for BELBUCA, and thereby damaged the Company. In addition to filing the Motion, the Company demanded that Alvogen withdraw its compendia listings. Alvogen claims to have withdrawn its compendia product listings on or about September 9, 2021.

The Company remains confident in the validity of its Orange Book patents listed for BELBUCA and will continue to vigorously defend its patent rights.

2018 Arkansas Opioid Litigation
On March 15, 2018, the State of Arkansas, and certain counties and cities in that State, filed an action in the Circuit Court of Arkansas, Crittenden County against multiple manufacturers, distributors, retailers, and prescribers of opioid analgesics, including the Company. The Company was served with the complaint on April 27, 2018. The complaint specifically alleged that it licensed its branded fentanyl buccal soluble film ONSOLIS to Collegium, and Collegium is also named as a defendant in the lawsuit. ONSOLIS is not presently sold in the United States and the license agreement with Collegium was terminated prior to Collegium launching ONSOLIS in the United States. Therefore, on June 28, 2018, the Company moved to dismiss the case against it and most recently, on July 6, 2018, the plaintiffs filed a notice to voluntarily dismiss us from the Arkansas case, without prejudice.
Chemo Research, S.L
On March 1, 2019, the Company filed a complaint for patent infringement in Delaware against Chemo Research, S.L., Insud Pharma S.L., IntelGenx Corp., and IntelGenx Technologies Corp. (collectively, the “Chemo Defendants”), asserting that the Chemo Defendants infringe its Orange Book listed patents for BELBUCA, including U.S. Patent Nos. 8,147,866 and 9,655,843, both expiring in July of 2027, and U.S. Patent No. 9,901,539 expiring December of 2032. This complaint follows a receipt by the Company on January 31, 2019, of a Notice Letter from Chemo Research S.L. stating that it has filed with the FDA an ANDA containing a Paragraph IV Patent Certification, for a generic version of BELBUCA Buccal Film in strengths 75 mcg, 150 mcg, 300 mcg, 450 mcg, and 900 mcg. Because the Company initiated a patent infringement suit to defend the patents identified in the Notice Letter within 45 days after receipt, the FDA is prevented from approving the ANDA until the earlier of 30 months or a decision in the case that each of the patents is not infringed or invalid. Chemo Research S.L.’s Notice Letter also does not provide any information on the timing or approval status of its ANDA. On March 15, 2019, the Company filed a complaint against the Defendants in New Jersey asserting the same claims for patent infringement made in the Delaware lawsuit. On April 19, 2019, Defendants filed an answer to the Delaware complaint wherein they denied infringement of the ‘866, ‘843 and ‘539 patents and asserted counterclaims seeking declaratory relief concerning the alleged invalidity and non-infringement of such patents.
On April 25, 2019, the Company voluntarily dismissed the New Jersey lawsuit given Defendants’ consent to jurisdiction in Delaware.

The Court scheduled a bench trial to commence on November 9, 2020 (jointly with Alvogen) to adjudicate issues concerning the validity of the Orange Book patents listed for BELBUCA. On October 6, 2020, the Court rescheduled the bench trial with Chemo and Alvogen to adjudicate issues concerning the validity of the Orange Book patents listed for BELBUCA to commence on March 1, 2021. Chemo did not participate in the bench trial that commenced on March 1, 2021. Instead, on February 26, 2021, Chemo agreed to be bound by the decision of the Court with respect to the validity of the BEMA patents from the March 1, 2021 trial with Alvogen. The Court had scheduled a bench trial to commence on May 3, 2021 to adjudicate issues concerning the Chemo Defendants’ infringement of the Orange Book patents. On December 1, 2020, the Court rescheduled the bench trial to adjudicate issues concerning the Chemo Defendants’ infringement of the Orange Book patents to commence on November 15, 2021. On July 15, 2021, the Court rescheduled the bench trial to adjudicate issues concerning the Chemo Defendants’ infringement of the Orange Book patents to commence on April 25, 2022.
The Company believes that it will be able to prevail in this lawsuit. As it has done in the past, the Company intends to vigorously defend its intellectual property against assertions of invalidity.

Derivative Litigation
On July 2, 2018, the Company filed a Schedule 14A Proxy Statement (the “Proxy”) with the U.S. Securities and Exchange Commission (the “SEC”) in connection with its 2018 Annual Meeting. Proposals 1 and 2 of the Proxy sought stockholder approval to amend the Company’s Certificate of Incorporation by deleting Article TWELFTH of the Company’s Certificate of Incorporation in its entirety and replacing it with a new Article TWELFTH that, among other things (i) provided for the declassification of the Company’s Board in phases, with the full declassification to be achieved in 2020 (the “Declassification Amendment”) and (ii) changed the voting standard for the uncontested election of directors to the Board from a plurality standard to the majority of votes cast standard as set forth in the bylaws of the Company (the “Election Amendment” and together with the “Declassification Amendment”, the “Amendments”).
On August 2, 2018, the Company held the 2018 Annual Meeting, at which time the stockholders voted on the Amendments. Following the 2018 Annual Meeting, based on consultation with the Company’s advisors, the Company determined that the Amendments had been adopted by the requisite vote of stockholders and effected the Amendments by filing a Certificate of Amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware on August 6, 2018.
On September 11, 2019, two purported stockholders of the Company filed a putative class action against the Company and our directors in the Court of Chancery of the State of Delaware, captioned Drachman v. BioDelivery Sciences International, Inc., et al., C.A. No. 2019-0728-AGB (Del. Ch.) (the “Complaint”). The Complaint alleged that the Amendments did not receive the requisite vote of stockholders at the 2018 Annual Meeting and asserted claims for violation of the Delaware General Corporation Law, breach of fiduciary duties, and declaratory judgment. The Complaint sought, inter alia, a declaration that the Amendments were not validly approved and invalidation of the Amendments, including altering the one-year terms of all directors duly elected at the 2018 and 2019 Annual Meetings to three-year terms. The Complaint also sought costs and
disbursements, including attorneys’ fees. On July 1, 2020, the Company filed their response to the Complaint and denied the claims asserted therein.
On November 5, 2019, the Board determined that ratifying the declassification of the Board and the change in the voting standard as set forth in the Amendments, as well as ratifying the filing and effectiveness of the Amendments, is in the best interests of the Company and its stockholders. The Board thus approved resolutions ratifying such acts and the filing and effectiveness of the Amendments under Section 204 of the Delaware General Corporation Law. On July 23, 2020, the stockholders of the Company approved the ratification of the declassification of the Board and the change in the voting standard as set forth in the Amendments as well as the filing and effectiveness of the Amendments. On July 23, 2020, the Company filed a Certificate of Validation with the Delaware Secretary of State.
On October 8, 2020, the Court entered an agreed-to order dismissing the plaintiffs’ claims for violation of the Delaware General Corporation Law. On October 13, 2020, plaintiffs filed an amended complaint, asserting individual, class and derivative claims for breach of fiduciary duties against our directors. On October 26, 2020, the defendants filed a motion to dismiss the amended complaint. On February 19, 2021, plaintiffs filed their opposition to the motion to dismiss. On March 8, 2021, the defendants filed a reply in further support of the motion to dismiss. The oral argument on defendants’ motion to dismiss took place on June 10, 2021 and, pursuant to a request from the Court, the parties are in the process of filing supplemental briefing. The defendants intend to continue to defend against the litigation vigorously.
XML 30 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Subsequent Events
 9 Months Ended
Sep. 30, 2021
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events:
Appointment of Chief Accounting Officer
On October 21, 2021, the Board of Directors of the Company announced that the Company had appointed John Golubieski as the Company’s Chief Accounting Officer, effective as of October 25, 2021. Mr. Golubieski will serve as Chief Accounting Officer until November 4, 2021, at which time he will resign from the position of Chief Accounting Officer and become Chief Financial Officer. Mr. Golubieski will also serve as the Company’s principal financial officer and principal accounting officer, effective as of November 4, 2021.
In connection with Mr. Golubieski’s appointment, the Company entered into an employment agreement with Mr. Golubieski, effective as of October 25, 2021 (the “Employment Agreement”). Pursuant to the Employment Agreement, Mr. Golubieski will be paid an annual base salary of $0.4 million and will be eligible for an annual performance-based incentive cash bonus in an amount up to 45% of Mr. Golubieski’s then-current base salary. Mr. Golubieski’s bonus for 2021 will be pro-rated to reflect his start date with the Company. In connection with his appointment, Mr. Golubieski will receive (i) an inaugural, one-time grant of options to purchase common stock with a value of $0.7 million (the “Option Award”) and (ii) an inaugural, one-time grant of restricted stock units with a value of $0.2 million (the “RSU Award”). The strike price for the Option Award will be the closing price of the Company’s common stock on the Nasdaq Global Select Market on the date of the grant. Both the Option Award and the RSU Award will vest in three equal portions on the first, second and third anniversary date of the grant date, subject to Mr. Golubieski’s continued service with the Company through the applicable vesting dates.

Departure of Chief Financial Officer
On October 15, 2021, Mary Theresa Coelho resigned as Executive Vice President, Chief Financial Officer and Treasurer of the Company to pursue other professional opportunities. Ms. Coelho’s resignation is effective as of November 3, 2021 and is not the result of any disagreement regarding the Company’s financial reporting or accounting policies, procedures, estimates or judgments.
XML 31 R18.htm IDEA: XBRL DOCUMENT v3.21.2
Organization, basis of presentation and summary of significant policies (Policies)
 9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Overview
Overview
BioDelivery Sciences International, Inc., together with its subsidiaries (collectively, the “Company”) is a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions. The Company has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive ("BEMA") drug-delivery technology to develop and commercialize new applications of proven therapies aimed at addressing important unmet medical needs. The Company commercializes its products in the U.S. using its own sales force while working in partnership with third parties to commercialize its products outside the U.S.
The accompanying unaudited condensed consolidated financial statements include all adjustments (consisting of normal and recurring adjustments) necessary for a fair presentation of these financial statements. The condensed consolidated balance sheet at December 31, 2020 has been derived from the Company’s audited consolidated financial statements included in its annual report on Form 10-K for the year ended December 31, 2020. Certain footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to the Securities and Exchange Commission rules and regulations. It is recommended that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2020.
Principles of consolidation
Principles of consolidation
The condensed consolidated financial statements include the accounts of the Company, Arius Pharmaceuticals, Inc. and Arius Two, Inc. All significant inter-company balances and transactions have been eliminated.
Use of estimates in financial statements
Use of estimates in financial statements
The preparation of the accompanying condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. The Company reviews all significant estimates affecting the condensed consolidated financial statements on a recurring basis and records the effect of any necessary adjustments prior to their issuance. Significant estimates made by the Company include: revenue recognition associated with sales allowances such as government program rebates, customer voucher redemptions, commercial contracts, rebates and chargebacks; sales returns reserves; sales bonuses; stock-based compensation; and deferred income taxes.
Cash and cash equivalents
Cash and cash equivalents
Cash and cash equivalents consist of operating and money market accounts. Cash equivalents are carried at cost which approximates fair value due to their short-term nature. The Company considers all highly-liquid investments with an original maturity of 90 days or less to be cash equivalents.
The Company maintains cash equivalent balances with financial institutions that management believes are of high credit quality. The Company’s cash and cash equivalents accounts at times may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk from cash and cash equivalents.
Inventory
Inventory
Inventories are stated at the lower of cost or net realizable value with costs determined for each batch under the first-in, first-out method. Inventory consists of raw materials, work in process and finished goods. Raw materials include amounts of active pharmaceutical ingredient for a product to be manufactured; work in process includes the bulk inventory of laminate (the
Company’s drug delivery film) prior to being packaged for sale; and finished goods include pharmaceutical products ready for commercial sale.
On a quarterly basis, the Company analyzes its inventory levels and records allowances for inventory that has become obsolete, inventory that has a cost basis in excess of the expected net realizable value and inventory that is in excess of expected demand based upon projected product sales. Inventory obsolescence reserves at September 30, 2021 and December 31, 2020 were $3.4 million and $2.3 million, respectively.
Revenue recognition
Revenue recognition
Product sales
Product sales amounts relate to sales of BELBUCA and Symproic. Product sales for the nine months ended September 30, 2020 also included sales of BUNAVAIL. Product sales for BUNAVAIL during the three months ended September 30, 2020 were related to the release of gross to net reserves. The Company recognizes revenue on product sales when control of the promised goods is transferred to its customers in an amount that reflects the consideration expected to be received in exchange for transferring those goods. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. When determining whether the customer has obtained control of the goods, the Company considers any future performance obligations. Generally, there is no post-shipment obligation on product sold.
Product royalty revenues
Product royalty revenue amounts are based on sales revenue of the PAINKYL™ product under the Company’s license agreement with TTY Biopharm Co., Ltd., ("TTY") and the BREAKYL™ product under the Company’s license agreement with Meda AB, which was acquired by Mylan N.V. and later acquired by Viatris, Inc. (which we refer to herein as Viatris). Product royalty revenues are recognized when control of the product is transferred to the license partner in an amount that reflects the consideration expected to be received. Supplemental sales-based product royalty revenue may also be earned upon the subsequent sale of the product at agreed upon contractual rates.

Performance obligations
A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The majority of the Company’s product sales contracts have a single performance obligation as the promise to transfer the individual goods is not separately identifiable from other promises in the contracts and, therefore, not distinct. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. The Company has assessed the existence of a significant financing component in the agreements with its customers. The trade payment terms with its customers do not exceed one year and therefore the Company has elected to apply the practical expedient and no amount of consideration has been allocated as a financing component.

Transaction price, including variable consideration
Revenue from product sales is recorded at the net sales price, which includes estimates of variable consideration for which reserves are established. Components of variable consideration include trade discounts and allowances, product returns, government chargebacks, discounts and rebates, and other incentives, such as voucher programs, and other fee for service amounts that are detailed within contracts between the Company and its customers relating to the Company’s sale of its products.
The Company establishes allowances for estimated rebates, chargebacks and product returns based on numerous qualitative and quantitative factors, including:
•specific contractual terms of agreements with customers;
•estimated levels of inventory in the distribution channel;
•historical rebates, chargebacks and returns of products;
•direct communication with customers;
•anticipated introduction of competitive products or generics;
•anticipated pricing strategy changes by the Company and/or its competitors;
•analysis of prescription data gathered by third-party prescription data providers;
•the impact of changes in state and federal regulations; and
•the estimated remaining shelf life of products.
In its analyses, the Company uses prescription data purchased from a third-party data provider to develop estimates of historical inventory channel sell-through. The Company utilizes an internal analysis to compare historical net product shipments to estimated historical prescriptions written. Based on that analysis, management develops an estimate of the quantity of product in the channel which may be subject to various rebate and chargeback exposures. To estimate months of ending inventory in the Company’s distribution channel, the Company divides estimated ending inventory in the distribution channel by the Company’s recent prescription data, not considering any future anticipated demand growth beyond the succeeding quarter. Monthly for each product line, the Company prepares an internal estimate of ending inventory units in the distribution channel by adding estimated inventory in the channel at the beginning of the period, plus net product shipments for the period, less estimated prescriptions written for the period, and less units included in the sales returns reserve expected to be returned. This is done for each product line by applying a rate of historical activity for rebates and chargebacks, adjusted for relevant quantitative and qualitative factors discussed above, to the potential exposed product estimated, net of reserved return units, to be in the distribution channel. In addition, the Company receives daily information from the major wholesalers regarding their sales and actual on-hand inventory levels of the Company’s products. This enables the Company to execute accurate provisioning procedures.
Revenue from product sales is recorded after considering the impact of the following variable consideration amounts at the time of revenue recognition:
Product returns-Consistent with industry practice, the Company offers contractual return rights that allow its customers to return the products within an 18-month period that begins six months prior to and ends twelve months after expiration of the products. The Company estimates product returns reserves based upon historical return rates adjusted for qualitative factors and are applied to open product batches that are currently eligible for returns, or will be eligible in the future, within company policy. Other factors considered include expected marketplace changes and the remaining shelf life of product batches. Product returns reserves for newly launched products are based on historical rates of similar products or pre-determined percentage.
Government rebates and chargebacks-Government rebates and chargebacks include mandated discounts under Medicaid, Medicare, U.S. Department of Veterans Affairs and other government agencies ("Government Payors"). The Company estimates the rebates and chargebacks to Government Payors based upon a combination of historical experience, product pricing, estimated payor mix, product growth, and the mix of contract and agreement terms. These reserves are recorded in the same period the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets. In addition, the pricing of covered products under Medicaid is subject to complex calculations and involves interpretation of government rules, regulations and policies as well as adjustments based on current trends in utilization. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company estimates the rebates and chargebacks that it will provide to Government Payors based upon (i) the government-mandated discounts applicable to government-funded programs, (ii) information obtained from its customers and (iii) information obtained from other third parties regarding the payor mix for its products. The Company’s liability for these rebates consists of estimates of claims for the current quarter and estimated future claims that will be made for product shipments that have been recognized as revenue, but remain in the distribution channel inventories at the end of each reporting period.
Commercial Contracts-The Company estimates the rebates to commercial contracts based upon a combination of historical experience, product pricing, estimated payor mix, product growth, and the mix of contract and agreement terms. These reserves are recorded in the same period the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets.
Patient Assistance Voucher program-The Company, from time to time, offers certain promotional product-related incentives to eligible patients. The Company has voucher programs for BELBUCA and Symproic whereby the Company offers a point-of-sale subsidy to retail consumers. The Company estimates its liabilities for these voucher programs based on the current utilization and historical redemption rates as reported to the Company by a third-party claims processing organization. The
Company accounts for the costs of these special promotional programs as price adjustments, which are a reduction of gross revenue.
Trade discounts and distribution fees-Trade discounts relate to prompt settlement discounts provided to customers. In addition, the Company compensates its customers for distribution of its products and the provision of data. The Company has determined that such services received to date are not distinct from its sale of products and may not reasonably represent fair value for these services. Therefore, estimates of these payments are recorded as a reduction of revenue based on contractual terms.
There can be a significant lag between the Company's establishment of an estimate and the timing of the invoicing or claim. The Company believes it has made reasonable estimates for future rebates and claims, however, these estimates involve assumptions pertaining to contractual utilization and performance, and payor mix. If the performance or mix across third-party payors is different from the Company’s estimates, the Company may be required to pay higher or lower total price adjustments and/or chargebacks than it had estimated.
Cost of sales
Cost of sales
Cost of sales includes the direct costs attributable to the production of BELBUCA and Symproic. It includes raw materials, production costs at the Company’s contract manufacturing sites, quality testing directly related to the products, inventory reserves, and depreciation on equipment that the Company has purchased to produce BELBUCA, Symproic and formerly BUNAVAIL. It also includes any batches not meeting specifications and raw material yield losses. Yield losses and the costs related to batches not meeting specifications are expensed as incurred. Cost of sales is recognized when sold to the wholesaler from our distribution center.
For BREAKYL and PAINKYL (the Company’s out-licensed breakthrough cancer pain therapies), cost of sales includes all costs related to creating the product at the Company’s contract manufacturing location in Germany. The Company’s contract manufacturer bills the Company for the final product, which includes materials, direct labor costs, quality testing, and certain overhead costs as outlined in applicable supply agreements.
Cost of sales also includes royalty expenses that the Company owes to third parties.
Measurement of credit losses of financial instruments
Measurement of credit losses of financial instruments
The Company is exposed to credit losses primarily through its product sales. The Company assesses each counterparty’s ability to pay for the products it sells by conducting a credit review. The credit review considers the Company's expected billing exposure and timing for payment and the counterparty’s established credit rating or the Company's assessment of the counterparty’s creditworthiness based on the Company's analysis of their financial statements when a credit rating is not available. The Company also considers contract terms and conditions, and business strategy in its evaluation. A credit limit is established for each counterparty based on the outcome of this review.
The Company monitors its ongoing credit exposure through active review of counterparty balances against contract terms and due dates. The Company's activities include timely account reconciliations, dispute resolution and payment confirmations. The Company may employ collection agencies and legal counsel to pursue recovery of defaulted receivables.
As of September 30, 2021, the Company reported $57.6 million of trade receivables within accounts receivable. Based on an aging analysis at September 30, 2021, 96% of the Company's accounts receivable were outstanding less than 30 days. There was no change to the allowance for doubtful accounts and credit losses between September 30, 2021 and December 31, 2020. The Company writes off accounts receivable when management determines they are uncollectible and credits payments subsequently received on such receivables to bad debt expense in the period received.
New Accounting Pronouncements, adopted
New Accounting Pronouncements, adopted
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740)—Simplifying the Accounting for Income Taxes, which is intended to simplify accounting for income taxes. It removes certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020 and early adoption is permitted. The Company adopted Topic 740 during the nine months ended September 30, 2021 and determined that the new guidance did not have a material impact on its consolidated financial statements.
The Company has reviewed other new accounting pronouncements that were issued as of September 30, 2021 and does not believe that these pronouncements are applicable to the Company, or that they will have a material impact on its financial position or results of operations.
Fair Value of Financial Instruments
Fair Value of Financial Instruments
The Company measures the fair value of instruments in accordance with GAAP which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.
GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company considers the carrying amount of its cash and cash equivalents to approximate fair value due to short-term nature of this instrument. GAAP describes three levels of inputs that may be used to measure fair value:
Level 1 – quoted prices in active markets for identical assets or liabilities
Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable
Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)
The following table summarizes the financial instruments measured at fair value on a recurring basis as of September 30, 2021:
Level 1Level 2Level 3Balance at September 30, 2021
Cash and cash equivalents$100,710 $— —$100,710 
The cash and cash equivalent balance as of September 30, 2021 includes investments in various money market accounts and cash held in interest bearing accounts
XML 32 R19.htm IDEA: XBRL DOCUMENT v3.21.2
Organization, basis of presentation and summary of significant policies (Tables)
 9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Fair Value, Assets Measured on Recurring Basis The following table summarizes the financial instruments measured at fair value on a recurring basis as of September 30, 2021:
Level 1Level 2Level 3Balance at September 30, 2021
Cash and cash equivalents$100,710 $— —$100,710 
XML 33 R20.htm IDEA: XBRL DOCUMENT v3.21.2
Inventory, net (Tables)
 9 Months Ended
Sep. 30, 2021
Inventory Disclosure [Abstract]  
Summary of Inventories The following table represents the components of inventory as of:
September 30,
2021		December 31,
2020
Raw materials $4,143 $3,389 
Work-in-process6,765 9,949 
Finished goods15,520 6,359 
Obsolescence reserve(3,353)(2,254)
Total inventories, net$23,075 $17,443 
XML 34 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Accounts Payable and Accrued Liabilities (Tables)
 9 Months Ended
Sep. 30, 2021
Payables and Accruals [Abstract]  
Summary of Components of Accounts Payable and Accrued Liabilities The following table represents the components of accounts payable and accrued liabilities as of:
September 30,
2021		December 31,
2020
Accounts payable$7,033 $4,213 
Accrued rebates38,179 34,247 
Accrued compensation and benefits6,832 5,488 
Accrued returns8,009 5,128 
Accrued royalties1,138 704 
Taxes payable583 1,026 
Accrued legal1,819 515 
Accrued regulatory expenses294 397 
Product rights payable9,000 — 
Accrued other1,693 1,277 
Total accounts payable and accrued liabilities$74,580 $52,995 
XML 35 R22.htm IDEA: XBRL DOCUMENT v3.21.2
Property and Equipment (Tables)
 9 Months Ended
Sep. 30, 2021
Property, Plant and Equipment [Abstract]  
Summarized Category of Fixed Assets Property and equipment, summarized by major category, consist of the following as of:
September 30,
2021		December 31,
2020
Machinery & equipment$4,849 $4,683 
Right of use, building lease260 471 
Computer equipment & software640 272 
Office furniture & equipment174 174 
Leasehold improvements43 43 
Idle equipment679 679 
Construction in progress— 119 
Total6,645 6,441 
Less accumulated depreciation and amortization(5,120)(5,023)
Total property and equipment, net$1,525 $1,418 
XML 36 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Intangible Assets (Tables)
 9 Months Ended
Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Summary of Other Intangible Assets Net Consisting of Product Rights and Licenses
Other intangible assets, net, consisting of product rights and licenses are summarized as follows:
September 30, 2021Gross Carrying
Value		Accumulated
Amortization		Intangible Assets,
net		Weighted Average Useful Life
BELBUCA license and distribution rights45,000 (21,375)23,625 5.5
Symproic license and distribution rights30,636 (6,087)24,549 10.5
ELYXYB product rights15,455 (60)15,395 14.8
Total intangible assets$91,091 $(27,522)$63,569 8.8
December 31, 2020Gross Carrying
Value		Accumulated
Amortization		Intangible Assets,
net		Weighted Average Useful Life
Product rights$6,050 $(6,050)$— 
BELBUCA license and distribution rights45,000 (18,000)27,000 6.0
Symproic license and distribution rights30,636 (4,260)26,376 10.8
Total intangible assets$81,686 $(28,310)$53,376 7.9
XML 37 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Acquired product rights (Tables)
 9 Months Ended
Sep. 30, 2021
Asset Acquisition [Abstract]  
Asset Acquisition
The total purchase price was allocated to the acquired asset based on their relative estimated fair values, as follows:
ELYXYB acquired product rights$15,000
Transaction expenses455
Total value$15,455
XML 38 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Notes Payable (Tables)
 9 Months Ended
Sep. 30, 2021
Debt Disclosure [Abstract]  
Future Maturities of the Notes Payable Obligation The following table represents future maturities of the notes payable obligation as of September 30, 2021:
2021— 
20224,615 
202318,462 
202424,615 
202512,308 
Total maturities$60,000 
Unamortized discount and loan costs(1,285)
Total notes payable obligation$58,715 
XML 39 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Net Sales by Product (Tables)
 9 Months Ended
Sep. 30, 2021
Segment Reporting [Abstract]  
Summary of Net Sales by Product However, the following table presents net sales by product:
Three months ended September 30,
Nine months ended September 30,
2021202020212020
BELBUCA$36,930 $34,758 $109,836 $100,572 
     % of net product sales90 %90 %90 %89 %
Symproic4,142 3,453 12,562 11,046 
     % of net product sales10 %9 %10 %10 %
BUNAVAIL— 574 — 1,328 
     % of net product sales— %1 %— %1 %
Net product sales$41,072 $38,785 $122,398 $112,946 
XML 40 R27.htm IDEA: XBRL DOCUMENT v3.21.2
Stockholders' Equity (Tables)
 9 Months Ended
Sep. 30, 2021
Stockholders' Equity Note [Abstract]  
Key Assumptions Used in Determining Fair Value of Options Granted
The key assumptions used in determining the fair value of options granted during the nine months ended September 30, 2021 follows:
Expected price volatility
53.70%-59.87%
Risk-free interest rate
0.50%-1.17%
Weighted average expected life in years6 years
Dividend yield— 
Summary of Stock Option Activity Option activity during the nine months ended September 30, 2021 was as follows:
Number of
shares		Weighted average
exercise price per
share		Aggregate
intrinsic
value
Outstanding at January 1, 20217,060,966 $4.55 $2,831 
Granted in 2021:
Officers and Directors1,345,292 3.83 
Employees1,847,213 4.20 
Exercised(155,690)2.90 
Forfeitures(539,802)4.72 
Outstanding at September 30, 20219,557,979 $4.40 $8,589 
Summary of Restricted Stock Activity Restricted stock activity during the nine months ended September 30, 2021 was as follows:
Number of
restricted
shares		Weighted
average fair
market value
per RSU
Outstanding at January 1, 2021940,759 $3.71 
Granted:
Officers and Directors242,562 3.83 
Employees35,807 3.84 
Vested(484,159)3.84 
Forfeitures— — 
Outstanding at September 30, 2021734,969 $4.08 
Schedule of Earnings Per Share, Basic and Diluted
Three months ended September 30,Nine months ended September 30,
2021202020212020
Basic:
Net income attributable to common stockholders, basic$6,669 $9,383 $20,970 $15,515 
Weighted average common shares outstanding98,699,857 101,031,317 99,485,399 99,377,748 
Basic earnings per common share$0.07 $0.09 $0.21 $0.16 
Diluted:
Effect of dilutive securities:
Net income attributable to common stockholders, diluted$6,669 $9,383 $20,970 $15,515 
Weighted average common shares outstanding98,699,857 101,031,317 99,485,399 99,377,748 
Effect of dilutive options and warrants3,731,026 4,752,251 3,988,568 5,458,745 
Dilutive weighted average common shares outstanding102,430,883 105,783,568 103,473,967 104,836,493 
Diluted earnings per common share$0.07$0.09$0.20$0.15
XML 41 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Organization, basis of presentation and summary of significant policies - Additional Information (Detail) - USD ($)
 9 Months Ended 12 Months Ended
Sep. 30, 2021
Dec. 31, 2020
Accounting Policies [Abstract]    
Common Stock, par value (in usd per share) $ 0.001 $ 0.001
Preferred Stock, par value (in usd per share) $ 0.001  
Threshold limit for liquid investments 90 days  
Inventory obsolescence reserved $ 3,353,000 $ 2,254,000
Accounts receivable, after allowance for credit loss $ 57,600,000  
Percent of accounts receivable outstanding for 30 days 96.00%  
Change in allowance for doubtful accounts and credit losses $ 0 $ 0
XML 42 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Organization, basis of presentation and summary of significant policies - Cash and Cash Equivalents a Recurring Basis (Detail)
$ in Thousands
Sep. 30, 2021
USD ($)
Cash and cash equivalents $ 100,710
Level 1  
Cash and cash equivalents 100,710
Level 2  
Cash and cash equivalents 0
Level 3  
Cash and cash equivalents $ 0
XML 43 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Inventory, net (Detail) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Inventory Disclosure [Abstract]    
Raw materials  $ 4,143 $ 3,389
Work-in-process 6,765 9,949
Finished goods 15,520 6,359
Obsolescence reserve (3,353) (2,254)
Total inventories, net $ 23,075 $ 17,443
XML 44 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Accounts Payable and Accrued Liabilities (Detail) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Payables and Accruals [Abstract]    
Accounts payable $ 7,033 $ 4,213
Accrued rebates 38,179 34,247
Accrued compensation and benefits 6,832 5,488
Accrued returns 8,009 5,128
Accrued royalties 1,138 704
Taxes payable 583 1,026
Accrued legal 1,819 515
Accrued regulatory expenses 294 397
Product rights payable 9,000 0
Accrued other 1,693 1,277
Total accounts payable and accrued liabilities $ 74,580 $ 52,995
XML 45 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Property and Equipment - Summarized Category of Fixed Assets (Detail) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Property, Plant and Equipment [Line Items]    
Right of use, building lease $ 260 $ 471
Total 6,645 6,441
Less accumulated depreciation and amortization (5,120) (5,023)
Total property and equipment, net 1,525 1,418
Machinery & equipment    
Property, Plant and Equipment [Line Items]    
Property, plant, and equipment, gross 4,849 4,683
Computer equipment & software    
Property, Plant and Equipment [Line Items]    
Property, plant, and equipment, gross 640 272
Office furniture & equipment    
Property, Plant and Equipment [Line Items]    
Property, plant, and equipment, gross 174 174
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property, plant, and equipment, gross 43 43
Idle equipment    
Property, Plant and Equipment [Line Items]    
Property, plant, and equipment, gross 679 679
Construction in progress    
Property, Plant and Equipment [Line Items]    
Property, plant, and equipment, gross $ 0 $ 119
XML 46 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Property and Equipment - Additional Information (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Property, Plant and Equipment [Line Items]        
Depreciation $ 40 $ 200 $ 100 $ 500
BUNAVAIL        
Property, Plant and Equipment [Line Items]        
Depreciation       $ 300
XML 47 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Intangible Assets (Detail) - USD ($)
$ in Thousands
 9 Months Ended 12 Months Ended
Sep. 30, 2021
Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value $ 91,091 $ 81,686
Accumulated Amortization (27,522) (28,310)
Intangible Assets, net $ 63,569 $ 53,376
Weighted Average Useful Life 8 years 9 months 18 days 7 years 10 months 24 days
License and Distribution Rights | BELBUCA    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value $ 45,000 $ 45,000
Accumulated Amortization (21,375) (18,000)
Intangible Assets, net $ 23,625 $ 27,000
Weighted Average Useful Life 5 years 6 months 6 years
License and Distribution Rights | Symproic    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value $ 30,636 $ 30,636
Accumulated Amortization (6,087) (4,260)
Intangible Assets, net $ 24,549 $ 26,376
Weighted Average Useful Life 10 years 6 months 10 years 9 months 18 days
License and Distribution Rights | ELYXYB    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value $ 15,455  
Accumulated Amortization (60)  
Intangible Assets, net $ 15,395  
Weighted Average Useful Life 14 years 9 months 18 days  
Product Rights    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value   $ 6,050
Accumulated Amortization   (6,050)
Intangible Assets, net   $ 0
XML 48 R35.htm IDEA: XBRL DOCUMENT v3.21.2
Acquired product rights - Additional Information (Details)
$ in Millions
Aug. 03, 2021
USD ($)
Asset Acquisition [Line Items]  
Price of acquisition $ 9
ELYXYB  
Asset Acquisition [Line Items]  
Up-front payment 6
Additional payment 9
Milestone payments, total 262
ELYXYB | Minimum  
Asset Acquisition [Line Items]  
Milestone payment, net sales 4
Milestone payment requirement, net sales 50
ELYXYB | Maximum  
Asset Acquisition [Line Items]  
Milestone payment, net sales 100
Milestone payment requirement, net sales $ 1,000
XML 49 R36.htm IDEA: XBRL DOCUMENT v3.21.2
Acquired product rights - Consideration (Details) - ELYXYB
$ in Thousands
Aug. 03, 2021
USD ($)
Asset Acquisition [Line Items]  
ELYXYB acquired product rights $ 15,000
Transaction expenses 455
Total value $ 15,455
XML 50 R37.htm IDEA: XBRL DOCUMENT v3.21.2
Notes Payable - Additional Information (Detail) - USD ($)
 9 Months Ended
Sep. 23, 2021
Sep. 30, 2021
Sep. 30, 2020
May 23, 2019
Debt Instrument [Line Items]        
Repayment on notes payable   $ 20,000,000 $ 0  
Bio Pharma Credit Plc        
Debt Instrument [Line Items]        
Secured credit term loan       $ 60,000,000
Additional facility funds that can be obtained       $ 20,000,000
Interest only, payment term   36 months    
Repayment on notes payable   $ 20,000,000    
Repayment of loan, accrued interest portion $ 1,500,000      
Bio Pharma Credit Plc | London Interbank Offered Rate (LIBOR)        
Debt Instrument [Line Items]        
Debt instrument, term   72 months    
Basis spread on variable rate   7.50%    
Variable rate floor   2.00%    
XML 51 R38.htm IDEA: XBRL DOCUMENT v3.21.2
Notes Payable - Future Maturities of the CRG Obligation (Detail) - CRG - Line of Credit
$ in Thousands
Sep. 30, 2021
USD ($)
Debt Instrument [Line Items]  
2021 $ 0
2022 4,615
2023 18,462
2024 24,615
2025 12,308
Total maturities 60,000
Unamortized discount and loan costs (1,285)
Total notes payable obligation $ 58,715
XML 52 R39.htm IDEA: XBRL DOCUMENT v3.21.2
Net Sales by Product (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Sales Information [Line Items]        
Net product sales $ 41,092 $ 39,443 $ 123,549 $ 114,304
BELBUCA        
Sales Information [Line Items]        
Net product sales $ 36,930 $ 34,758 $ 109,836 $ 100,572
BELBUCA | Revenue Benchmark | Product Concentration Risk        
Sales Information [Line Items]        
Percent of net product sales 90.00% 90.00% 90.00% 89.00%
Symproic        
Sales Information [Line Items]        
Net product sales $ 4,142 $ 3,453 $ 12,562 $ 11,046
Symproic | Revenue Benchmark | Product Concentration Risk        
Sales Information [Line Items]        
Percent of net product sales 10.00% 9.00% 10.00% 10.00%
BUNAVAIL        
Sales Information [Line Items]        
Net product sales $ 0 $ 574 $ 0 $ 1,328
BUNAVAIL | Revenue Benchmark | Product Concentration Risk        
Sales Information [Line Items]        
Percent of net product sales 0.00% 1.00% 0.00% 1.00%
Product sales, net        
Sales Information [Line Items]        
Net product sales $ 41,072 $ 38,785 $ 122,398 $ 112,946
XML 53 R40.htm IDEA: XBRL DOCUMENT v3.21.2
Stockholders' Equity - Additional information (Detail) - USD ($)
 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Nov. 04, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Authorized stock repurchase amount       $ 25,000,000
Treasury stock, shares acquired (in shares) 3,202,690      
Treasury stock, weighted average price (in dollars per share) $ 3.72      
Treasury stock, amount repurchased $ 11,900,000      
Stock option exercises (in shares) 155,690      
Proceeds from exercise of stock options $ 611,000 $ 2,761,000    
Stock option exercisable (in shares) 4,153,242      
Unrecognized compensation cost related to non-vested share-based compensation awards granted $ 9,300,000      
Warrants outstanding (in shares) 2,051,033      
Warrants fair value $ 4,500,000      
Employees And Directors        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Granted (in shares) 3,192,505      
Fair market value of shares granted $ 12,900,000      
Term of options granted period 10 years      
Vesting period of shares 3 years      
Stock option exercises (in shares) 155,690 1,159,347    
Proceeds from exercise of stock options $ 500,000 $ 2,800,000    
Intrinsic value of options exercised $ 100,000 $ 3,100,000    
Minimum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Warrant exercise price (in dollars per share) $ 2.38      
Maximum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Warrant exercise price (in dollars per share) $ 3.42      
Restricted Stock Units (RSUs)        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Granted (in shares) 278,369      
Fair market value of RSUs granted $ 1,100,000      
Restricted Stock Units (RSUs) | Minimum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Vesting period of shares 1 year      
Restricted Stock Units (RSUs) | Maximum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Vesting period of shares 3 years      
Preferred Stock Series B        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Preferred Stock, shares outstanding (in shares) 443   443  
XML 54 R41.htm IDEA: XBRL DOCUMENT v3.21.2
Stockholders' Equity - Key Assumptions Used in Determining Fair Value of Options Granted (Detail)
 9 Months Ended
Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Weighted average expected life in years 6 years
Dividend yield 0.00%
Minimum  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Expected price volatility 53.70%
Risk-free interest rate 0.50%
Maximum  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Expected price volatility 59.87%
Risk-free interest rate 1.17%
XML 55 R42.htm IDEA: XBRL DOCUMENT v3.21.2
Stockholders' Equity - Summary of Stock Option Activity (Detail)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Dec. 31, 2020
USD ($)
$ / shares
shares
Sep. 30, 2021
USD ($)
$ / shares
shares
Number of shares    
Outstanding at beginning of period (in shares) | shares   7,060,966
Exercised (in shares) | shares   (155,690)
Forfeitures (in shares) | shares   (539,802)
Outstanding at end of period (in shares) | shares 7,060,966 9,557,979
Weighted average exercise price per share    
Weighted average exercise price per share, Outstanding at beginning of period (in usd per share) | $ / shares   $ 4.55
Weighted average exercise price per share, Exercised (in usd per share) | $ / shares   2.90
Weighted average exercise price per share, Forfeitures (in usd per share) | $ / shares   4.72
Weighted average exercise price per share, Outstanding at end of period (in usd per share) | $ / shares $ 4.55 $ 4.40
Aggregate intrinsic value    
Aggregate intrinsic value, Outstanding, balance | $ $ 2,831 $ 8,589
Officers and Directors    
Number of shares    
Granted (in shares) | shares   1,345,292
Weighted average exercise price per share    
Weighted average exercise price per share, Granted (in usd per share) | $ / shares   $ 3.83
Employees    
Number of shares    
Granted (in shares) | shares   1,847,213
Weighted average exercise price per share    
Weighted average exercise price per share, Granted (in usd per share) | $ / shares   $ 4.20
XML 56 R43.htm IDEA: XBRL DOCUMENT v3.21.2
Stockholders' Equity - Summary of Restricted Stock Activity (Detail) - Restricted Stock Units (RSUs)
 9 Months Ended
Sep. 30, 2021
$ / shares
shares
Number of restricted shares  
Outstanding at beginning of period (in shares) 940,759
Granted (in shares) 278,369
Vested (in shares) (484,159)
Forfeitures (in shares) 0
Outstanding at end of period (in shares) 734,969
Weighted average fair market value per RSU  
Weighted average fair market value per RSU, Outstanding at beginning of period (in usd per share) | $ / shares $ 3.71
Weighted average fair market value per RSU, Vested (in usd per share) | $ / shares 3.84
Weighted average fair market value per RSU, Forfeitures (in usd per share) | $ / shares 0
Weighted average fair market value per RSU, Outstanding at end of period (in usd per share) | $ / shares $ 4.08
Officers and Directors  
Number of restricted shares  
Granted (in shares) 242,562
Weighted average fair market value per RSU  
Weighted average fair market value per RSU, Granted (in usd per share) | $ / shares $ 3.83
Employees  
Number of restricted shares  
Granted (in shares) 35,807
Weighted average fair market value per RSU  
Weighted average fair market value per RSU, Granted (in usd per share) | $ / shares $ 3.84
XML 57 R44.htm IDEA: XBRL DOCUMENT v3.21.2
Stockholder's Equity - Schedule of Earnings per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Stockholders' Equity Note [Abstract]        
Net income (loss) attributable to common stockholders, basic $ 6,669 $ 9,383 $ 20,970 $ 15,515
Weighted average common stock shares outstanding, basic (in shares) 98,699,857 101,031,317 99,485,399 99,377,748
Basic earnings per share (in usd per share) $ 0.07 $ 0.09 $ 0.21 $ 0.16
Net income (loss) attributable to common stockholders, diluted $ 6,669 $ 9,383 $ 20,970 $ 15,515
Effect of dilutive options and warrants (in shares) 3,731,026 4,752,251 3,988,568 5,458,745
Weighted average common stock shares outstanding, diluted (in shares) 102,430,883 105,783,568 103,473,967 104,836,493
Diluted earnings per share (in usd per share) $ 0.07 $ 0.09 $ 0.20 $ 0.15
XML 58 R45.htm IDEA: XBRL DOCUMENT v3.21.2
Subsequent Events (Details) - Subsequent Event - Chief Accounting Officer
$ in Millions
Oct. 25, 2021
USD ($)
Subsequent Event [Line Items]  
Annual base salary $ 0.4
Annual performance-based incentive cash bonus, percent of base salary 45.00%
Option  
Subsequent Event [Line Items]  
Grant value of options to purchase common stock $ 0.7
Restricted Stock Units (RSUs)  
Subsequent Event [Line Items]  
Grant value of options to purchase common stock $ 0.2
EXCEL 59 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( #J"8U,'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " Z@F-30B9,^>X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)OIVE!,71S43PI""XHWL)D=C?8M"$9:??M;>-N%]$'\)B9/]]\ M ]-B4#A$>HY#H,B.TM7DNSXI#!MQ8 X*(.&!O$GEG.CGYFZ(WO#\C'L(!C_, MGJ"NJFOPQ,8:-K B[ 2A6XM*HQD>(@GO,45'SYCEV$6@3KRU',"64H0>ID8 MCE/7P@6PP)BB3]\%LBLQ5__$Y@Z(4W)*;DV-XUB.3<[-.TAX>WI\R>L6KD]L M>J3Y5W**CX$VXCSYM;F[WSX(75>U+*0LJF9;5TK>J.;V?7']X7<1]H-U._>/ MC<^"NH5?=Z&_ %!+ P04 " Z@F-3F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M #J"8U,R+7::0P4 'T5 8 >&PO=V]R:W-H965T&UL ME9A=<^(V%(:OM[]"P_1B=R9@6X8$=@@S!))MIMF4A+2=;:<7PA98$]MR91G" MO^^1#3;)F&/W!OQU7C\ZDM\C:;R3ZC4-.-?D+0KC]+H3:)U\M:S4"WC$TIY, M> QWUE)%3,.IVEAIHCCS\Z HM*AM7UH1$W%G,LZO+=1D+#,=BI@O%$FS*&)J M?\-#N;ON.)WCA6>Q";2Y8$W&"=OP)=>_)PL%9U:IXHN(QZF0,5%\?=V9.E]G M+C4!^1-_"+Y+3XZ):)EJ9;1(1@((A$7_^SMD(B3@+YS)H > NB' *=_)L ]!+AY0PNRO%ES MIMEDK.2.*/,TJ)F#/#=Y-+1&Q*8;EUK!70%Q>C*36Z[( GJ,=$D:,,73L:5! MV-RVO(/(32%"SXB,R'<9ZR EM['/_??Q%@"55/1(=4-1P25/>L2U+PBUJ5/# M,\/#'^6V1VRW+OP=CELFR>2*5KB/"I;3*.$)T61)=MB-: M<"6D;T84@8%=FR)0@.K_9DZ0D>>SPE]S&,T9B9Q+/P DZ]'H+LV)4'VFV@04\JZ,[\ M!1=DJ6'<$:G(3&:Q!HZ9]&M;TJ ^O\4@3XS::0/YPM[(O0^C4*R%EY,B_=X@ MZ0ZZU!Z.AH,A1D@K0MJ&<.K[4$72B^,!>8#GR&]Q?>YPR;[C.E"=U.L#>^5D MNN4]Z)=,0+]0.L"@*VMWW/\%/3-GT.DO F *NN+>$.6^V@EPUK&AAHR7]YCD]&J/E#SSR(^ M7/Y2N[ MWC+(WV+V8+:3T?!J-!BY4).V=825^5/P=O'S];=AHOZ!ZK $/(&5#:79LMR%?E=&[N"T?:\]I)V+K]0:Y M;M>AL ZM0[-.-KB,&>7[?BE\;+ P*_:ZRJOEWN(TWU&SJL>+C&PO=V]R:W-H965T&ULO5AM;]LV$/XKA%L4+>#$)/6>%P-MBFT%MBYHVNXS(]$Q44ET22II M]NMWE!W)%BDYQ89]2"S9=\>'=\=[[GCQ(-4WO>;O+V=J8S=EBH?,U MKY@^E1M>PR\KJ2IFX%7=+?1&<5:T2E6YH!C'BXJ)>K:\:+^[5LL+V9A2U/Q: M(=U4%5./[W@I'RYG9/;TQ2=QMS;VB\7R8L/N^ TW7S;7"MX6G95"5+S60M9( M\=7E["TYNZ*)56@EO@K^H/>>D=W*K93?[,N'XG*&+2)>\MQ8$PP^[OD5+TMK M"7!\WQF==6M:Q?WG)^N_M)N'S=PRS:]D^9L*KV/WK8R>(9RAMM9+53!@25J+>?[,?.$7L*)!Q1H#L%^ER%8*<0M!O= M(FNW]9X9MKQ0\@$I*PW6[$/KFU8;=B-J&\8;H^!7 7IF>27K H+""P1/6I:B M8 9>WK&2U3E'-]:P1B?HR\U[]/KE&_02B1I]7LM&L[K0%PL#&*RE1;Y;[]UV M/3JRW@W?G*( SQ'%E'C4KZ;5W_,W"?5(^CX")G61K@)!J FC57<'CW4\N'.W80Q1D.![!=H8CBU(\ZZ5 GDZ@_ M2\/*9P!,7)>E*8W) *)/C 9IY >9=B#3(ZX%KE+FL76I/4<;8 \SF@2I"R*B MPQSP"(5DQ)E9AS.;Q/FKE,6#*$L?J,S-S(0,01T1.@!%<%_7\22LWT5N,[+U M7B&T4>*V:8E366+3HW[_Y46+Q 78J 4IT, M<;I2(R1">A8ATS1R6/..^=,EBR2)(P>G*S;ESYY4R#2K#/Q9O2 Q/G\:C]J@P\2S_]-N])E#TZXW MO)V!R\=37PI0EP&'AVM2Y-"M>P,5/9JTT&6,>.$"(T&&X M^JZ#'NDZBD+8MA#*H1UD3F"ZS]E&0'GT G4;B# *$X=??')A1N,QN'VG0:<[ MC<^*,]VH1Z2W^041R:6&J2"8TSB:QVG81B*F\RP+=R$$*0CCZEFA0S\3-;=+ M.2&41$-^\,G1,:ZE?4-#IQL:Z!>;JBG;ZYJ"KT0NO!T7=7N4DX!D&1D.[U[! M$,/ -X*T;V?H=#NS95L]6L^]L-T.A5":.%.]3P[#]#F6:7TK0Y\S(^^U"&V> M_.0F$N?BQCNL^.1\P\IB[Y[/7K+^P=2=J#4TB"M0Q*<)N$%M[RVW+T9NVJN_ M6VF,K-K'-6< W@K [RL)/<3NQ=XF=K?'RW\ 4$L#!!0 ( #J"8U/;UKH' M^ ( %@* 8 >&PO=V]R:W-H965T&ULM59K;]HP%/TK M5C9-G=21=P(=( VJ:?LP"94]/KO)A5A-XLQVH-VOW[639KPIE<8'XL<]Q^=< M/X=K+AYD!J#(8Y&7[R"$GL67!14854L;5D)H*D!%;GM M.4YD%Y25UGAHVF9B/.2URED),T%D7114/$T@Y^N1Y5K/#7=LF2G=8(^'%5W" M'-2/:B:P9G9+>"[-/UDWL5%LD:26BAAC@UGO(RQ4F! ME&!)\IRE5&%E0G-:)D#FFEB2JQD54*H,%$MH_IY\(&^)362&K7)H*]2AV>RD M'7/2C.D=&7,.58_XSC7Q',\] )^>AM]"@G#7P)UMN(WNNQ1X70H\PQ<3ANO5%:*TR+M@?[+AB9=OZ_I#=AC\T_'K?K,:A8WY#>[7IZWS< ME@&_,^!?9J"B@JQH7H,17LN45" : P?U-_3QABZGYSCN855!IRHXJ6K*BP+W MZ2LE!67RG(5X3]B@'P_U$8]8,=V?MQD3<8 M!(=(>_>8*8^FN23.0@&LFF9G#AI7>??;>/\WZ.JY3]W,)P-V]:_ M<5NZK[HK+EB>[0B;\Q<$_J[^TT&->GOCVM=OKF]4+%DI20X+1#F]&.&B><8T M%<4K\Q*XYPK?%::8X=,/A [ _@7GZKFB'Q?=8W+\%U!+ P04 " Z@F-3 M>A/4O:$% "'%P & 'AL+W=OU#MYFFW3YC"]N:2L(KL)/^^Z*/2#9=9H>XF>ZT/M].IVNQ%SM6-/(C"?-G*,N?: MO):[J3J4@B>U49Y-B>>%TYRGQ60^J]L>ROE,'G66%N*A1.J8Y[S\<2\R^70W MP9.7AL_I;J^KANE\=N [\2CTU\-#:=ZFG9XD9FJ_Z.G!AO1 M"=HS:M"[]#7QR5Z_>H->H72 GW9RZ/B1:)F M4VU&4_F<;MJ>[YN>R4#/%'V4A=XKM#(C2 #[Y;@]&[&?FBATH2 OH;@GHPX? MQ>$&4>\M(A[!P'@6UYM[$)T_ZWWUV[U?!(-VZX+6_NB O\_B)(JC4+=YC[V&)E-3^<3X*(H\WUZB5JZ*$QH MX+-+V J 89]Z?@>[X!IT7(-1K@NI=+5E%,\$N"D:\^"LVY"&@474!04T"BV> M+@B'?N19-"$4C3#,,NQ8AJ.K8_5\J)+&Z.J(.E_1:,0>39%(B]U;M!.%23,9 M,ND$\<3DNE3I*NVO8><5$D]B(KKZP E!>0 .:+O;ZT>K]@K$4I3#YHI_MUR?C-- MZWD?YHZ=87@V;Q?RCMBD 0RV&;N8<( MZ=F2:U;U6AC-+E##%6G^#"?_UMG% MSB*1G?T!% N8;S-V4828HFF3=F$X".A F<.]/L#T&N*&*CJ4\I16)P>0,G4G MQMFG"PA%L)V](!3&U*$,P=@ X5[$X'$5\X\YM;7SR[4NT_51\W5F(B"1:(]Z[235VIDS0[FA/#F!+ O:S X6B,O]7G.G/^X"=3(';B(K)([;E)I\@<=Y4V M7=>B85T/Y+4YBC1?WX"!#]T-%8>,Q4%D!]]%8I-A*:8XLF< <,K\.*#,68\0 MDD:FI@Z45-QK)SPNGIIY$+PL3#04,F6UB4,=D:-*^A8X,(WW^#SYWGB1=_&' M[1B!1LP.#X0B3DJ&4'@H*_>B"H^KJO^_CMIE_,N5Y$HC[!%S;(CM';H H4$4 MT\#6;DL02OV(LM"69B#4CVGH,SH0M5Z@X7&%MFQC\/O+B?W.<@*-G.4$H1Q) M X&&DAWI=1P9UW$/I4R.&]V$P8?[ )B>] B'C"N1E6DKY@V?Z1\=]+)Q] MM2?^GT].7R[)^*W -9,3 7=GAD7$P9V,@% & =VXH50-+#KT?3L8C$7Y:Z^ MT54FFQX+W=PE=:W=K?'[^J[4:K_'MPL,M"_Q[:JY$^[=-U?4'WFY2PN%,K$U M77DWD1EPV=SZ-B]:'NIKS;746N;UXUYPH[TJ@/F^E5*_O%0=='?O\Y]02P,$ M% @ .H)C4UPBTSB8LY+H M)>DX^?<%95H0@0.0DO+(AUBR#RXN+H![S@4AG3R4U1_U;9XWT>?E8E6_.+IM MFKM?)I-Z=ILOL_IY>9>O]%]NRFJ9-?IM]7%2WU5Y-E\W6BXF-([E9)D5JZ/3 MD_7OWE6G)^5]LRA6^;LJJN^7RZSZ,LT7Y<.+(W+T](OWQ;/MN&VZ^?K%^N!Z\' M\R&K\[-R\9]BWMR^.$J.HGE^D]TOFO?EPZN\&Y!H[+(O5X\_L(K0:$>1K0K@$=VX!U#9C5@"I/ ]XUX'8/PM- = V$ MW8-OT+)K(.T&OAY4UT!9#;BOAZ1KD%@-F&_0:=<@M1H(XINX^&GFXK&C()O) MMF?;.P[R--W$GF_O2,C3A)/UC$\>U^)Z(9]G379Z4I4/4=7BM;WVQ7HWK-OK M]5NLVHU[W53ZKX5NUYR>E:NYWH;Y/-*OZG)1S+-&O[EN] ^]/YLZ*F_TNW+V MQVVYF.=5_;?HXL_[HOD2'4>_7Y]'/__T+/HI*E;1;[?E?9VMYO7)I-%^M=8G ML\Z'Z:,/U./#;V63+4"SLW"SLW*Y+%=__0N1\3_6'@(3YV$3+^?SHLT?V2)Z MEQ7SXZM5=);=%=B=BX%1Z+Q9WU=?(I\OEP.^S&;WR_O%.OSG^4TQ*QI@Y)]A M(^]TVLNK*I]OA26ZSJLBKQ]_\Q+8?'6HS0W"._:K0[L8,]FO#^UDI^7PZX&] M38'--X?:')Z)MX=V,3 3$YV -EF(;K(07??*/;U.\X_%:E6L/D;3;)&M9GGT MLTXI]6U6Y?6S*&OTAI@]CQCY>T1CDJ)4\6A?K.VW8N73:2I)DL:*GTP^;:]U M%TCCE!$A^K@W+D[;VV!ZHV2;4;(=1SEB9--'FW+;D51):UAG+BJ5?8)\M9JUB5BO(!W9 M]:MG+3U!"OOO^W*QB+0 ?,BJ^?\"ZUAL.A?!&5[WK85S_CFO9D6=U]L[#FTPZ7H2*YHH[(O: M^*+V\ 6%2SG],Y98T0IC>@XF&P>3H(/O\[JIBEE+RO7:UZQ=*X/12AQ/N$BE M\LQ;$2N1(8R5RJX QH*\'M'5KP!C0=X& M(?T8;M4!)!C#?^6-SI,Z5CD4\,1=T*FTJ.-R"-5WS8@#$E8'%ZMY0!J\S:HG M FTS(Z@B@#9($TIXG-BS["*MA/P&0#AGGA$:84#"RL :X8A133N+VXXH*1)K M2&<$"(/42IO %&<)D1:;7P"<*PT0B$DBJ;*#':+^+MBCU0$Q\H#P;RPUNPY& M:$V Q-D3 +UJDQ@Q0L)J9#^]25S-@01G!PLJ3F *2DZ PL+@*#H!)[9JA- M? O+J"HBO[_P)$9(D;"2&LC?KC32JY (SZ"-.B)A>11.S=?YG5YK<2 UNSJ) MQ(10R06U9]6%.ND"J"YO;C::BX1%EYN;AX8U)4#HZ-0L["V4NC0>VQ4 L,6Y M3$EL[R&@P-P]!$!,:"'O,*'KFA/M$*1_"F"$' T+N<'D/$CV70HA4>'V_"DL%BJ1"G&K'B%VL ZB3:7:0"M1(!;JK5!@:UI2Z MC)QPI6([K;MDZZ9UI!0$26RE ' @K2.E(&,N;5T&/'."/5HI,*,46/S]TSHS M',["'+Y+6F@ R@@U'977F MLAQ)K;5WQMSS 3OO0SN>M,\,6;(P6>Z9]IG+EH03YGVN9-B2A=DRG/:9RWTI M2ZR"_G((U7?-,"0+,^2!%2)#SQUPA0B@=B8"$&_:9X9T69AT]Z@0F@_RYW'M/82I@70ZB^@X9?^2'\RL%3^IC8I^&7 M@["^CQF60X;E1'%N%U8 :N=\ /$R+#<,RW=EV*%A33FH8N.$ M,OLY!D<4R^U5CR@VI?9#D0N .Z:V4+E$*,;C)+$5#?#-B?=HCN6&8_D/X%AN M.)9_/8[E@#UY:G/L$*I_U\=PK/@6'"MQ$K2.& M-16(3G5E9_-.APOS#C#&1:Q2FW< [E@R^X3P$L$8$[J6M@/N.N<$/ 3IA]O0 MO C3_"YW,["8$8CUL9@!4&>,B/9]B\K0JP@?A ]=R\!ZIC/:7R] ST"P6@]B(#$.^^ED9- MR%TO\0T-:RK!Z32ERKXX>R;!0;>SJ8$Q+KBR;TE? -PQH-CI%A';/GYTA*E'&8)5 M88(-7V>!O*, HQ*6$ON:8H<+\PXPQ@45]B.T"X"#@@;A&)4BL4M#X)T3\1"D M'V]#]4I\?^)1AO?4B,\%CB0>!4XY$OO@Z7P(U7=TZS.#^WQH<#"-HFMMC'JW MB>%!M0\/PJBYW,>$_>!R -1WTM"C"M/COMP#3\X9\#$)\^*!I6H"+G)Y2E4 M?,,@'@S>V)X-=FI&A]3JG86>QD;E:H( MYV1V (*E*L#!S(YPL%0%0"?B(OS&H,B_WY1E\_2F_5:7S?&PO=V]R:W-H965T&ULE5EM<]LV#/XK/*^W:^_J6J3>["S)7>*NMWYHEVO:[3,MT397271) MVDGVZP=*BB2+%--]B5X,0 ] _(7#X(^5WM&=/HL2PJ=37;:WVX6"Q4MF_$@57PRU;(DFIXE+N%.DA&\UJI+!8D"))%27DUN[ZLW]W)ZTMQU 6OV)U$ MZEB65#[=LD(\7,WP[/G%%[[;:_-B<7UYH#MVS_2WPYV$IT5G)>S6[P1?K,#(*M<1?G#VHP3TRKFR$^&X>/N97L\ @8@7+M#%!X7)B:U84QA+@ M^-$:G77?-(K#^V?K'VKGP9D-56PMBK]YKO=7L^4,Y6Q+CX7^(A[^8*U#L;&7 MB4+5?]%#*QO,4'946I2M,B H>=5*\E_,I!3U^O197#HK O7[U!KU"O$)?]^*H:)6KRX4&-,;F M(FN_?-M\F4Q\>84^B4KO%?H=$.3G^@OPHG.%/+MR2[P&[]GA'0J#MX@$!#OP MK']>/?# ";O(AK6]<,+>GP;5[M=?U<:C">.? MHW^3_0-(V MF:,%%'HFJHP7#%4=8O/>/&4FJ[9U5FVE*)%X#ACJ8^4)5=(A2KRA>L^@OV6< MFJ[A"E:C'0_"L$I'D;)%HB1UQRGM4*5>5#=9)EG=R*"^KB?S 0=^8 R_^>RVR[W-#43ED0@F\K9K( MLT=S[X3;FCP+9$#&J>&02I?11.'C 9/@%WM2MH>,8(89^FINXMYD2)/24\K:FV>@<'+.!EC=HFMEE/UT?,0]A-1M^X' M^D3KI@F8*?# D;U<$S8%89C4XS%T6VR>!A-M'_=/\A+_"$RQO)VY_$R5)L2+)2VR+DS MYTA[UB!^UCA'RAZ9S'@]QB)E!D1H=TVGC>+(?=M'27N=,.Q>0DQ68W'3(<< M(>%@:W%^1M)35.BGJ/--0^V6:?GUC>G[)UJ8LP07]-#!6CA8IN/MCD,N3(;T M?@Z]IZ[03UWK*;"(:K1A.UY5)OZ&U)CD(G?Z8/,2QCA>6C[8]';W 2[XQ2/"\$MA].)4@@'1VS^K50-O]X(P![?G$91Q2(1XGPF)P(EPR MN:L/RA6J-R#-B6KWMCN,OZF/H$?O;_'%NCE2[\TT)_R?J(045["]WX+)X%T* M49/-H7GSH,6A/G?>"*U%6=_N&2_2N%7N^.!+"I[I9\2;:!;OD882Q;<-L:#!;[(5F5)-,J5M*5 M5=VB?_W&BX@\BD=;WADLL,!^L-4DLS(S(N-X<61]<>_[=V%M[5"]W[1=^/)L M/0S;YT^>A'IM-R;,_=9V],O2]QLST,=^]21L>VL:?FC3/KFZN/CDR<:X[NRK M+_B[-_U77_AQ:%UGW_15&#<;T^]N;.OOOSR[/(M?_.16ZP%?//GJBZU9V5L[ M_+)]T].G)VF6QFUL%YSOJMXNOSR[OGQ^\PSC>O\.'5\V7 M9Q?8D&UM/6 &0__V;3$1;>,WG?,L+8D'R[_C[-\R[43+P@3[TK=_=\VP M_O+LL[.JL4LSML-/_OZO5NGY&//5O@W\_^I>QGYZ=5;58QC\1A^F'6Q<)_^: M]\J'XH'/+DX\<*4/7/&^92'>Y==F,%]]T?O[JL=HF@U_,*G\-&W.=3B4VZ&G M7QT]-WSU8[\RG?O=@$4ST.="Y9<5'7"PW6"$>\GQ/3\QW7==^[ ;7K:HW2F7UG]>+,/0D2?_U MP +/T@+/>(%G__NL?W!AZ/GSL#6U_?*,%^OO[-F_:C?/JQ_O:$*HXXWS7]N6 M=(Y&W])O74T.3\& M9@">:NW[JE[WOG,U?>X:!WK"O/J9MJ9[JM8F5(O1M0-M:>O[84D<\L)2WXPU MK3"LS5"YKF['AJBD3;7N=RP)!G2>B.7U:/B6V#" Z<32;^AIMVAM]7JL_76S MMH'84CTZN_GF]?79XZKIQ]5Y$]D^V'K=^=:O=B"ML32GWT8J-K8'7]SOMNKH MN,QVVX(-H$2W>6<[/R8J!B4R<<+Q.]T=%9]4-G M^[!V6SFG8>WZAK_&AHGD*9F3-!-,1N6&[T0"O3TODUOY()E^\?X5$7V* 0>SOX%#GAWM9C MW^/[8OQCXB$I3,"Q$_DD1$OC^JD^TC2T^V"/;D0(.K'SA6GI 5N)XZL@6]$/FU) $-"?\=J.W]AKE5:-WEIR](,#*7/HPW#0X/AV&Z;J01 MO8445401/&UU>7'^-Z89B^VLZ2L+'W&XQWGUTI+TT61+[X?.#[9J7*A;'T9B MD[*8+$&Y[-%]$5=):&0 1*!OF#LL4]]=7[\A9I"2,3._-F;B4,,XH^9#?+[S_=>O[LF:U;Z>P<_?AX]J)H3D1D" M2%TPM3B2K#CDDPB_8MOSZA<29MJ1)6M(P-J&DXH)VD4Y2XLW-=-_AC>]_6UT ML T;TU',@2]Q2!OSSA:[ 14F$-+9"A&L@F:Y) S"RXN PQEN$G=IO%6E:9U9 MD"]/ZI]MDAXN? !6/O6,K (R(L%_AL8HQ<=VV1,$Z$;=EWV_Q9RA:D;V/GAH M"Z1#)W1=#Z+*@<(;*-W8@A#B01\=@0\%SZ:^GI9!^,0^L)2:@L7,S;CJGR$/ M.+1PF8)4U8V2X19ULW)8.!?:3O:DI4,F5 6CQ!:;/"O9Y1%"/*]NC^YX8TBG M%KM2C:*J/8]\Y3W0PX*60_"T>1 B()*A#+'$WXNRA+%>PSZL"&CU'1I-_Y+ML"J7LP+>L%@A,J%O]6'!>:3A*_I^P[\,_=/W"]^1\<5'F*9SQ+J"=NED6/O$0#;1@A'QM+-J,.]Q_"]-6,N* M^ -J1@:2^7SZ%T5$."9/@F=8'C"2++/=$QUPW]EXX\K$E!SLF0;2HR3*2?^XBU T+L18[7%-^W MN_/6T?H@GCBG@L2G:\@X]6Y%$MO2Q@>X?PZ2/K\@1=X%H 5B,H/2A3U@Q71A M)%, :\+^N&QH>.#$IMH;8DHKT"+U@]6#<"2D?B(X(7;(5ZC@X;5E:R ME$$\@NA'.OWRX4228[RD\_B@/I=&E&9':>U=>"?&ZR1A!,#H8+O!DZV(?SGE M'-N@)EIGTF+21K;GD.">C,P Q$6!AD%X)N+&QX019&0M!(U"\8;!D#5$'.DI M_7\DXR?H:.GZ,)P#^'"$]T;I'60H) 9@EVBH,*V:;5S_"ZY"RD$/MVYUXG0D^I?5,NXN1;::N M1= ]=5"%"\!:>2PKKL1=;%K]@GPAB]M" M]$B6Y'LB_N:;[V]^>7G-2][N-D2FJ^=[C\>(IB.5AL-"+E,"FP,:+^C(0Q$^ MY75^^>'Z[?6K[X_-'7\KT=FP[NT?+\:L$ZJ:&)'21VL$=:]Z+WY(1$/.9A^_ M,0M_9[0@7)5S+_9XOY9H>.A]&Z6.1E!\F_4M2#"0HR'H1H0T+'#D-N4<1 HI M/$*F+Z00%?Y7H'\22+$WM$7+:0F16HFO^4SBBL(TH%0U?"6%R8&)+8OH2:AR MJF' $'>:I(%%<.SPQ84L/%EVS32)(>A1 $@*&)-0\!Q$!&'^):$4A(X[B3K( M&1S^JF3+7K"'TA"-"W)!4"C9#^=$)6K8Q:@QL\MQJFL!I9]7?U]S'D<<$&=_($7+[H6> MF<^J[X>&_O_HC'XY>YPBLYN?OKG^5ZSWVC:FNKZ9*>:]A\S6'. VB%1>[P@L M5C_,WTI(#WO03P:\I>BD=S'L?Z2S6,E?0,\D#X,818<^?N <3&^SX6A.V0=^ M]M P,*12*C6M^R\Q#Q3-C=MMRTQ39QXTM-F>D!L@6;;7-(TU?1?='M:$#A)< MQ E@JGVZD"; $>D349,YDI8H^V-^]3&8.IZ<*[U2"H,E\V0J5!/:D\MI=B[RM^0H MOG==X^Y<@_-+'@VQ1I",E$6(H]:;T15[!L^65:=,M8V\,6*2VD#:$6$[3!@9 M2^)*MG ;XV#R:DW+'X!R7'(H4?23N"_'EG!QRZ:A'(M$%HW'$@?/F$3&">X< MQFM(6 4.LAABTJ89X"%FF 1<&IARRX"]YQ0?#>8P:LZL9*(>FB@EH/D:[4V1()JQD7*N9.]<5VKNPP[VUD_J'A%,3V63TS0#4'S5:T7F4%5-SS! U!H'I@=#UV6O4^N6$PIG9;WK(#GL%D6HW@_"CQC1,F MJ;3<5RO 75>?F 5*RJT) \SO:E=)_!+V\\M$QQ-D"#A7*@OYZK> M<6H8M0-3D15?6X5Z7!D_![+:'1F).(>A?)Z:W1_M0K+H<7_(RB$-)MD5R?.5 M!4Q)NY1SE,**O":3O;;MDN#>TI:G@_R!5H5!E=T+-Y";/K;UL:?-A5B?-A-* M)\25+1 3>UA(4Y9#E3DR$6U[3G&W'U?KJ89*PP9[62F'=1PJZHE(\P&JRN7\ ML-/)F&O4PV,SFXK1);6D3SV*S>25;Z(RB[G2%6=ERE?IY+W%J2. 4DW?%;Q/ M($6)%C< (+Q@S/NK%;@)@P_C(4JW5V"0#"PJ[\2G3%%,5R"GU#72N;&G[ <) MOR/*/Q4&AF6%7VM.SGULKCTU2^LB:. BS)Z0S28 2L!9BGA+O=9<&3J/R)0L M[,YKQ$=."2@%CVH2<2[];^TN9X/C8:!?:TJN]B=,1:T\UP/JR:KEOII3/# - M/Y69>,"].%AAQL*N7-=I!TLN%Y(K;TDJC@MWS)/%H5P%R4L>E?&#ASA^Q8.1 MKFDCPM'"UF%(B)\EK'",HAJ QJ/L9^X '_)A<_"V9RD49J'EI MY.#N (\GOE:=;[OG>QGTC RVS8)PT2Q"B:T?@'4$K/HRD$U,G?%1<+F7.1&= MH7!OIOQX0#C8%$,ZI!NP%$4-K&E_!) @)](8S R-@AQR$9&!"E@.AG&0RO3 M-YK&='W,P (0"H#PW?EZFI7.X."!J"_H8=H..#1,=@JK^M[6X\#] J,$.O % MZ+_AH@&*$XT8K ^%VTOD4$I+,/637,3Q@&L/0/N4F!*E0OVLJ,V7^>OG.=NB MLGW^4HH_*0=$(2I)6+^+0Y?"HV(=I)D)D0=.5XD.PXST(2^S3D46&(T1 M3(;H\K-S-NVJI#(36PC"M^Y]M/NI4L,M!QT*]/>VO4M^05A*LNRF/1XG8;$Z M[GV(FX*6HE(QP8E"M>AIJ9;'E"\&SMP4*18$??!I42[4UM($^4(#..:4X0!50_,@LAQIJ\]%1NYM7/TK$HALKHO@89B4S)_7R M;6MJFP!;;@9Y$'Q%@N8' I?8NN0:YSU1V)JQJ]?9\.RE6$NF1X@5W,:UII] M9++\YT51E*0(WI<0S+SZ+@>")TQK=?X!8R*'X)3%/Z= 4G*MK[E=U9'!E+]P M#-P+^C7\K63[:?=OL4N#+-T2K02AB"2+D)5VWG&7^*.S8F]OS([.[>SQ*3&6 MPSF^?Y*Z@YE*\48N<+-P7=*;@O6YK)X#;0T[9J7[Q:35QKW/HP2]S)+HT(^Q M;XG3CJP;*1'-D1\3%\I*G^:"^XF3WMAL*VRR=VI?)6[/P7.UJ=LWA^VU88C7C0& M?LS/.U;CI!)3D>1,:$;>J>OX,+V>1NTUD9J4F: M(%YL,&38+1J6PZ1%*NET9,70LP4GODGTHWG";WU?:- D@D4B?2KMW*T)EDWT$^26S85T+IS*7A6%JW@,BNA#YFG9QC*) MQ^O6N$T.'*+L:> D."(9,(W"]!D^E^AHN6-OZ?LC08EV4<3>U*,UBUE%H%@= MYX.1E"L;A03361B1I<05TH?)@%.;*U_FHN[+E%@\_V,IG%QH*'.2_^\2_L^X MA#=B\ZKK .'GG]Y.,]7GI2;--*I"C( D/Z=)5"OEQ]0:O)J]Y0=Y['](V?& M.1Z*T#-:WL,2SW[:7'I1CO3#H*1'@CE-6.K.<..)_-&Y7YYSIENN<^TTIJ# MD7DTYI+/H=R[(4RXG.W'P0X7.1^6K47AGZ245H8"L84VA@,A-TM/$_:C-M_P"%*J.UG-(A1X'ET&2J!]+5HUK M):>#VLO$>"VM#><'PW(O%/:T1:5S&%K-*:91ZO"8647M[F3.(#41Z[EFKP3& M3+:U5Q-)ZIP"=XQ 3NY0:>QV#MQ=#)."YU[%I*KB9,3CA8N@[+] M HRN1""QTP)O49-MS>I8\>HOX8BI+)+&\0 &W-Y(>3^@3D6RO:C$Z?Y$ MI$5R1B7S>+ODJ^)RZUZ;T\PTE(1UJ\?3>Q-+GF)(:29K>1";/L(+E&1B+$ M'<.YU?/5,&D'E?:YF%""B=D04D@7EY?I3BX7-0L^5CMGVT;[Y>?5/XI/26N% MNP4_/F2=WD;HPV:(]@F?>B _$Y F[5[HU(M<#\.Y]HG1MB*+,H[KIRQ6'S]/V">^TTS1VQ Y+5^"[@P:/0KE4>5NS MX$;V,!RJBDA]Q(\(,=>X*ZJZR%QNV9$"#>=X-(S<,I-K_/LB,97KV%B7WU#1IB^F]U[Z,=\53!>S0GD?9#H!6="-Z1WW M_HCH%(@CMK)/8)QT/04)YQ@#V9[-?[[YJE&NFNY4ODH7W CHK3\V+V9O;]J-9^XHHI!& MY\FQ01@S^W+;I'1>=TWQZ@91B 7>/8"]IKX,O:=N@>T4X%\G<<*E)I:T@GFI MFE@R94H[*9?<[@#!;$3SV2=(X#MN]9#W('0KSQUELFXZZ"B^>E]'!8;C\LG: M\6[N"E?*AF.,P*VXYN :)TXG]Q*FKBX*0=L4V[ +H--JQ7E*L]86-3?RL+X= M,^)2,:312Z?IIX-K;V0K-MO6[V)W.S\]*RMN'FOR<-53V!^K@SRW7+Z\?#^R7YY4^/ CS[^=/Y)NGN"L^H%PZ8I4RFL3L%3 M_*WHT4!:5Z!]Y>,1BI^LN]0D"^IW+9 M,,8!]WS%3FM!T2^G9C()OORX&)9C6]SHZYH]@QFCA@^]NS,]593TV6POCU,# MQ9YTKF@4QP9OQVAD[*(\X(F\P9!CI]R8W>YRK.?U$F%Y:@R" /D60_1,*?\L MF:C<._X#Z5/Y'J#>=_1W;348-XW?0E8H\$U,N+JX_%Q$ZMOKVQN^54PCKF]_ MX5_.+Z^XVQ[Z_S,NSE:/?O9;PHJ?/KMXS+;SZL6M(QUPRUW$(<4&<&+ETY,$ MUJ#OB_"HMO$,D>'QT>F-W5>GX$+/QM^CTQ,]K(CRB^:T>I]>@#&5"Z&WXEX+EU Q@:- MO6JCN.Y6D1IS.J/+C^.U+*22#> Y'V6\-P,!'(;8@)[\ MB9YV)KZXF?4!M\ N-=289BGX81*SQ(/&\6LW8O]Z0ONQR:#3=L _N"=_F!\1 M_V!C*I/?^9/E8SN1;4VDRST=EF!SPGP*45Y#"HW[J^*E)7L3IZIZ7<:3*=O) M<$.>U=K.PWS(I)-3E#M_7':7UQ;DB^7L;+Y%FN8MIVGHEV_3HZ].H,B-X%"! M7D6.AQM6\R.G7AHCNDGNB*U9?GXV;>ZE\(@TB&_,0N1E45;9X@E]7X.!HI7O MN"&0/T[R3YN,G7'K"OLXW$&\]Y NSDE600Z=7_50WK#C*W*=O*V""_>Y1HW*]%"*E9]7W^/!ZI([B"\O7U#'3L[\$4<,[PW* M^W)(2_1B;3PNO'/%BQ].$421[WS,XI#;S08-TO&"/FY,CFF#PUA9><_W1TK# M=O3=*BBUO$$S#Y?WD+XV/;>PM79)CU[,/_WX3'KE MXH?!;_E]F@L_#'[#?R)[8GL,H-_Q+K+X 0ND%ZQ^]=]02P,$% @ .H)C M4T#T@J>/ @ 8@4 !@ !X;"]W;W)K M8E_[GG//=7P\W2C];!I$"Z^MD&86--9VDR@R98,M,Z>J0TD[M=(MLQ3J560Z MC:SRH%9$:1R?12WC,IA/_=J=GD_5V@HN\4Z#6;(M2L.5!(WU++A()HOP$H<#2.@9&PPM>HA".B&3\V'(&0TD'W)_OV*]][]3+DAF\5.*)5[:9 M!>0;@&IU]T7\BJOF&7SJ58;T"Z;V-S$M^K1)(Y+]U,>K*9=3C@[OY$O**W2 M;R%(M-/($J?;B0 MQ2&D<9H /T@D\-@BU$N0A+E=@V5(@><+G2VO TG:IVDY)'ZH: M^- W<_$$Z& MMDO4_G2OL-P&20CW;$-WRJ+F3!CX 'F8Y!F-69B=C^&);'7" MY4FG58G&P%DX.BM@'([S,5QSR>GR5;!2JC*0%&&1QI21%6/XO#1*H"E1EDZK M;PR.B+/(CN$H#=,B/X9'99D8Q'(TOE^JG69A/"IHDHS"G-3\[4=%>_>^1;WR M[C9T$&MI>PL,J\,#.[@.K.N^BI;+D M23]MZ!%$[1)HOU;*[@)78'A6YS\!4$L#!!0 ( #J"8U.N(3^WZ ( *4& M 8 >&PO=V]R:W-H965T&ULM55-CYLP$/TK(UKUA!8P M9 -I$FFW'VJEKA1UM^VAZL' )+%J,+5-L_OO.S:$I&IWU4LOX/EZ[XV-A^5! MZ>]FCVCAOI&M605[:[M%%)EJCPTW%ZK#EB);I1MNR=2[R'0:>>V+&AFQ.+Z, M&B[:8+WTOHU>+U5OI6AQH\'T3 MY6MN^7JIU0&TRR8TM_"M^FH2)UIW*+=64U10G5U?597J6VM@PQ]X*1%X6P,Y M=8\U?!"\%%)8@68966)S-5$U(E\/R.P1Y )N5&OW!MZT-=:_UT>D1W5U=F(Y7N KH,AK4/S$XT75G='RDDR>Z!=SM$;9*TI44[0ZL3];H MD5R]I7"EFDZUWE1;A_)/T,!=^@+HL"PV)6I_8J^Q&HTDA#]4/H=Y&*FT01I+;@DRS<-D7D!*T6P^19T^&@Y\N-RDIL06MX)P+\,\93 +LSP_P[*] M;@WD81P7%$O864P]<.G%)V&2YC"/,[CC]WA2.,M3BL7L&PO=V]R M:W-H965TF/ID*T M<%<+:99!96US&44FK[!F9J0:E+12*ETS2U.]CTRCD15>J191&L?3J&9(W2<"5!8[D,ULGE)G/[_88/' _F[!N<)SNE/KK)=;$,8D<(!>;6(3 :/N,5 M"N& B,:G'C,83#K%\^\3^@_>=_)EQPQ>*?$K+VRU#.8!%%BR5MAWZO C]OY, M'%ZNA/%O.'1[,[*8M\:JNE>F>",+++[6CXC30"P]$=ND3P+>8C."<1Q"&J?)$WCC MP=&QQQO_C:,A; 63]FM_X;?USEA-5^3W)TQE@ZG,F\K^\YG^ QP\X5S"M^5A MGUC\"Q:P.](E^4-IR)G%O=+D=JXHDXP%58*M$$HE*"&YW ,S)+L$.G"+]0ZU M/_77F/>3)(0;EE?$31_A.:N;5_VD]F MF7_>.@.5$@7PNM'J,[I5 ]G8_:X+@67J,Q\/R[ M>9JDKR!)+N 799F :3C-)O3.LH1,T1:6YVW="CK<@FH E<.,7;HS3\8L>L'DDA!+=F2;A))WX,4OF%(HS?+RC% 70I^"">+HN\L;^(Z7V@*\ :XG3'J!1G5&^$.#E% MDO0D"*D&ULK55M;]LV$/XK!VT8$D"P M*.K%W!FS?ML(\+%'I_2Q*H^/$:[G9.C^1S*<[ ML<$[=/>[6T->(^7J)0'(AI_'#"C4TH?^-@^HO\0:J=:5L+BI59O9..VLZB* MH,&UZ)5[K?<_XJ&>PN/56MGPA?VPM\@BJ'OK='L()@:M[(91?#CH\"B@8D\$ M\$, #[R'1('EE7!B/C5Z#\;O)C1OA%)#-)&3G3^4.V=H55*-D3>"^T;O92*1!= Y\5#%?2UDK;WB#\MEA99^A/^?V9 MM/DI;1[2YO]%VG\-(0+$!?SDMFA ?KH00XR,;OK:@?&_ MI@WE*UE31R$Y5.[0B?)/; @%UEI1BU(*TM]ANZ(TQT. %T9;"Y?"F >/O:CK MONV50 M,L*XOGG[Z]OEIQ*E19P7!06PCR9?:,7ET MZ[5H-N%NM]0"?>>&"_ T>WH^%L.M^??VX>UY) MA3MTI1W=R,'&PO=V]R:W-H965T,#D)T$#9"@ANVT#8I^X.Y2$ALNN2&YEM5?WS?D[DI"K*#' M%VF/F3#GV^E*7P UM)@S=SZTH1<.L6 M0U\Y*8JH5.KA9#1Z.2R%,KVKB_CLUEU=V#IH9>2M(U^7I7#K:ZGMZK(W[K4/ M[M1B&?C!\.JB$@MY+\.GZM;A;MBA%*J4QBMKR,GY96\V?GU]PO)1X!#O4=Y(K1D(;GQM,'N=25; L,LP;H.L$--D#=$8?K0E+3V]-(8M= M_2&"^K 1V/^C093<;?P3ON(CV.>,?[(O4>-1[C]2I6Q.^S MS >'NOCC._ G'?Q)A#_Y_T3^)Z#7]+.A6;U 2=!Q(J5/AV$IZ<3T?G; M^5S&$B<4@HP/Q^=0%*B;ENA62O4PA)&471 ;.4R6^\$.G>V)+C" M_N72!4PGJN"_"1Z,.%%@M&'L]3%7%K7FV$%.!<8?A?:1)@LXUW /*1V#1Q1O M/WS^[?,U?#DYG9S38<[SQ3ZIC,"/)F]US?Z\V(GH-F6R"X#Q%6!!<"E=KH16 M?XD8!MQDO4^&,\-E/K]&Y'Q334%365W!A$SK> MZRHNFJ62CPV'F_+;JC2(2TQVT^3V:RT3EI;:4^[V9ZGMO:<$.WS=WMFIE$^N[^AT]'T:#PZFDZ/IEG+ M(@]#5<"]1:T*3G?$_P8%V?W4K816M$\*V:HSKA.N7)0V?KX9V@K9PRCF:!$B M4MC PXX';W&@8AUIT=CUL;W-%FF:&-%8/6A'!7W6 )+7J7$=K8KIT#PBC.EM8X_5W!% G%M KG" :.I"/'_ 0'E.^R-4 M],-F8Y!\PNG?@[23Z90>HL\1.0K'9_!P:P#N':GM[$:T8$7R.,2AHHAG@[:$ M/4N)R!08Q4-7X[U6 EV#A*9.290T1Q.> F"^8!]3#JQ&!<;MABG!11N/QH/G M#GC#K5,SUO B?AOPCH0KZ0#=/>T^/V;IU+T13]\N'X5;*.Q7+>=0'0U>37N) MU?8FV"J>P3,;<**/ETM\0DG' G@_MQCRS0T;Z#[*KOX&4$L#!!0 ( #J" M8U/D+.4#,@4 "\+ 9 >&PO=V]R:W-H965TI*1 _?*Z7=>:_TOCX=#EU>8B7Q=GX6QA+\Y,XY74N+#@FJH2=C='9;;G MO;2W/[B3Z]+SP?#BK!9KO$?_I5Y8V@T[E$)6J)TT&BRNSGNS]'0^9OD@\)O$ MK3M8 WNR-.8K;ZZ+\U["A%!A[AE!T,\&+U$I!B(:WUK,7F>2%0_7>_1?@N_D MRU(XO#3J=UGX\KPW[4&!*]$H?V>V'['U9\)XN5$N_(=ME,U.>I WSINJ528& ME=3Q5WQOXW"@,$V>4#3U!\H=AWJK/HWKVC/H[N#7:EPX^Z *+I_I#HM+Q MR?9\YMF+@/=8#V"4]"%+LO0%O%'GWRC@C9[!N\*EAROIZC68%8D3:@6*N='VZ#@9)%3(2G%/ M!A(__S3-LN3] XNQ"V&?OB=SP0,6$#$HY_" M6DFY$G"2O0UVHJN!=1=,H]6.T\DI<0S+]AY#PA'EDY6T)#PZ;@E'>UU("%,I M:GO/)2Q;:DDVH4 4L$1A'8>DLVG)/7;Y9#!Y!;5J7#!Q@%K)2A+P25O>ID#G!>QS6N5AANUW@J0KQ_;L#C3O52?%;F!=2AZ ;6QXBGL43J&!_*=D7>!#/9.%8= MR6I*HG7T.N^Y,\]&(:" M;^>E4$0?H22$)2*I4A&MC95_$U+;S3>X0059%U$A+6R$:DA+HA4V+W<141]> MGT_Q8UD^EL/^E0%14X5]E]1>I"JI2P_@^<4ON%^(^D90XU-(G_29:W&9UMY2 M'*?XDHFD5D;1\,.J/M#JRH5,-:&G0VO+D)<6ZZDC9JGD6L0YYADW3J,S?'NF MV7O>9##N'Z<37HX@G?;'QQFOQY3P_?D$TJP_2J;P8+Q0AS2.X#CI)TD"7[2H MN)XY&P4]I*:AK/.]$\HW-XZ\>)WVL^GD38OR+/4CF$S[)V3YO][>X<$04Z%= MAU'-0; 7YYGNM)L&9W$(>A2/H^2ML&M)MX7"%:DF@Y-)#VP&ULI551;]HP$/XKIZS; M4T02)T"@@ 2L4RNU")6U>YCV8)(#HB9Q9IM2_OW.#J14&[SL(2K98,%52U18DF4E9,$UJ7+MJ4HB3VU0D7O, M]SM>P;/2&0WLWER.!F*K\ZS$N02U+0HN]Q/,Q6[H!,YQXS%;;[39\$:#BJ]Q M@?JIFDO2O 8ES0HL529*D+@:.N.@/XF,OW5XSG"G3F0PF2R%>#'*73IT?$,( M#T>L4IYKD!(AJ_#YA.\TD3>"H?T;_9W"F7)5,BG;? 2D2N[PJ[V93T'DJW2HC@$$X,B*^LW?SO4X20@]L\$L$, ML[SK#UF67[GFHX$4.Y#&F]",8%.UT40N*TU3%EJ2-:,X/9I1WQ<\1P7+/)'GB:D(W=2PXHDQJ%G4'IP8,H]4;!39EB^C'>(T8-+7:D-6$7 1=8M2#T M76 ^"R[@A4V:H<4+S^*MZ21I>,1*2)V5:_@Y7BHMZ5#\N@ ?-?"1A8_^LXH7 M4(&(1N MU XA8&Z[PR (7#_JG$,++! ]5K#+Y&DV?A[?W8.M/[N&=C=JY, -67P.[.A$ M0/1\U&9_>5]!1-0H4:I"[';CMLF=,3?LV7H0_1[Q_M<9]DZF0H%R;6!TCB0?26$/BKF \U/9_0'4$L#!!0 ( #J"8U-H$(ZUHPD &<: 9 M >&PO=V]R:W-H965TK]_3 $E1ENR)9W=K'VQ14*/1 M??IR&M+I5JIKO1;"L-NF;O6;D[4QFU>SF5ZL1<.U+S>BQ2=+J1IN\%:M9GJC M!"_MIJ:>14$PGS6\:D_.3NW:)W5V*CM35ZWXI)CNFH:KNW-1R^V;D_!D6/A< MK=:&%F9GIQN^$I?"?-U\4G@W&[6452-:7D+P5^*T26SUY M9N3)E937].9OY9N3@ P2M5@8TL#Q^XX6>G2FZ9(FEHHP?KJMT-XZJ6 M@G)I%#ZML,^<71JYN%[+NA1*_\PNOG>5N3N=&6BFSV>+7LNYTQ(]H*5@[V5K MUII=M*4H]_?/8-%H5C28=1X]JO!2;'P6!QZ+@BA\1%\\NAE;??$3W&0?I!'L M'V^OM%%(CG\^J:J@6+)(;C-KR]^UDSO>9*:%J?FN"S+Y R%3)SQ7A;,M[(KC4D MAFW#IN$HF-1:M=13D,7J&EUGBQ/9E4 I&:&@!U)74]F=">*&UQTWO7G]]H5L MRXK6M.>.8QM5+80U1F*_8DMN$7"F]MK8IN:M)J<[4]5 A8G;2AOR8L'UFLY> MDP8(++O60>:T3X#;*+E2O/'9NT[13A)JX0!K7#$(*@:&5#8N1$,^>XRCM)NN MYM21<(;A-7D4>_C4FQ=!CYL';,P:PEO;6Z"+WPB%5MF[B"W/8C^+/(;F##&" MQZV&H5\,H?2V8L_LTD*#M)"*S..:?4$WUYVZZ[.J2"0WZI9&-WV(,9H;O;=,P8 ME]*#%;9L;H0V3*'O7\$I= +* K-60KRD,]A&J$J61[4><< JDPC5FM=+5C6- M*"L'%V^'ID$T3V&U(GV!\K8%/DJ#TTFA/<05FXW$& +!%^L^H(QOZ?@*^8"B M:VQB]=IV:+!.#QET7G-DV>4"31$X[-I (TM10X(;"!-"&L-%[RS5A+C=P#DH MOY%4;#5:J+=;+*N;"BE>ZLD:A6GR5I$=L!W*EJ(RG1([,"I]_7()K%$PV-5' M C&\.#BT(M.P=>QK%6):W9>P";%&%T*;7J 0=C9/^">@W-FGZ3M9;A+ -CY2&]B22WM2=IOYC&=HNNID6?I[]Q#X?3U(6^"F$ M0C^$S+?[[#*ZB^A:Q%S#FO>O[_JRZ7&U$TKTNF\R;LPF0Y[JVY93_>Y<_-#9 MSX':@8%OQU[_L3/:H!#L^&'8WWG;41L*>YV9%\P#KYC/V3.6^&F*E\C+XY#] M9''IYDGE1&$-O%" >0BTJRH'G M89H2A[]@H)B _3HV#LV>IW'AY4'T GNRZ+[M1R IO#3-O"(KK/E)@)?<2_/B MJ>1JG7+3X3#_[+-*.3HL1D?V&;/WRDJ'7I@6 "9CV@X,?59[X =-F8-V4=_U MS-R"A*%G(41I67Q"D4=H&6DY3J!TTK/(SW"8Z/./1O!WOT4"(,2@(M!,(FLA\0W]+=O1>'' MTT&]:VF:6[5VN-\;PA92&PVS:M[3?BO;E]1@\<[.F,_:"F<\[TGA\^57W?/ BZ'-64^TZ*T9YGWJ,G:\Q, BN]6: ML$E\]OFX_O_2B!UEN1?/"T9F'HQ]D]SLKUWZR/SG@>WH+!M=+=I*TK39HB\U M @PRC >' ]8XSO_0@+K+JV.SU"0*#A]+U.,%RG'U]TZ20'^290I];)08;6[' MEMM?W';$)RTO^P2<@\Q--,2>+H> >&TA=NR_$BUZ=0U7[%AI9QMNI\N# /\O M&>-W^*%( B]+J;V"-4=6>) -4)5>.C_@@CA%5\]H-6&_N>)ZGN14R,4+MSIE M@8$O1][\71K(X@00Q\#&X#N'AAO*#4UX^UO ?*T0O2T OB>+2Y+Y*A M>P]9B\]6!)#-([!"G-LO+&(?$>FO)7O=U,[&.V!="8VXV,*WM50^>,EX3U<+ MK\_F/>OW*_%>W28[!AL:N#VME;OC!XCM!>4/LI3//BFQ%$K1I[:,'L8^2>)) M^"\QVN+I_$#!T,('@;&-4Z'?!W/B%Q*#KG^6(:;ZG^S1!5CBN#MKZ$$SJO<@Q5&$F3#,6!E0( MF#?#C&$IR5,O+@IZC+/,RY+@GGZ&%U M9SO;A;O\($XE+5$^:S"H)HC@DK2R,O M2D.L%3D&ZGG.4B])<^A+'5*DY>!+MX<-#H/(2Y!M.3P/@]3+\MAJ#8/82S*< M,B=/$MP\YEY2Q$,T'HNE"Z6+9$ W#!H]TV-?4<\F7_XW0JWL3QQT:>Y:XWX' M&%?'7U'>NA\/=N+N)YCW7*'+:E:+);8&?I:>X*9M?]9P;XS&ULU5U;<]O&DOXK*&_5*;L* MIB7*NOCD4B7)=N*L+RK+3AZV]F$(#$G$(,#@0EGGU^_7W7,%0%G.27*R#XDE M$ICIZ>O7/3VC;V_JYE.[UKI+/F_*JOWNP;KKMO]\\J3-UGJCVEF]U16^6=;- M1G7XM5D]:;>-5CF_M"F?S \.3IYL5%$]^/Y;_NRJ^?[;NN_*HM)73=+VFXUJ M;B]T6=]\]^#P@?W@?;%:=_3!D^^_W:J5OM;=Q^U5@]^>N%'R8J.KMJBKI-'+ M[QZ<'_[SXBD]SP_\7.B;-O@YH94LZOH3_?(J_^[! 1&D2YUU-(+"/SM]JK+[GU]\Z,V MZSFF\;*Z;/G_R8T\>SQ_D&1]V]4;\S(HV!25_*L^&SX$+YP=['EA;EZ8,]TR M$5/Y7'7J^V^;^B9IZ&F,1C_P4OEM$%=4))3KKL&W!=[KOK^L-YNB Y>[-E%5 MGES655=4*UUEA6Z_?=)A"GKP26:&NY#AYGN&>Y:\P0#K-GE1Y3J/WW\"TAQ] M,=X1VZ]1SS>T>]9;_*\:+.R;OM&)_]SOFB[ M!DKSOW?,^M3-^I1G??I'QSJ+ M2H%^O+:MVT(F:FA:6&I+<\*E-4PJ5O/B+--7G?Y[!%KU_EO MO6[)=Y)B-6K+C[3!VS#Y^AJ>Z_WG1ZQ[R[H$_X@GN;>G!NQIF%$!_?_XK[/Y MX>DW$$JUJIF)$-=*1 -EZ-9[)D^QB&PV24*:T*#S@V_R&+?XJ]>7 M7V! 1O3N1O/ONF&8]/J-#DZDC*DN(/-)&T-PUJH[-,*IH49%?\'>\E9-!6O M7Q2>M ZJ&+/IM[YHM-@V5(4>OGYQ.4O.\YQ5&8+,=0>S:P M.Z&!)-%5\./BX]OSG\]?O4[>5B MU8V(-'4"2@>Z]Q"1CD/Y3I>W8IM&,"2[$J;1%Q/',E@8][#Q V#/E:D"O;A!IO M:EX!9 L*-P6%+HSTDZIZH,]D/K>C>1TK(.="?&W%MMU (@W)G"P""-,*\-75 M>R<_3/%Q=CT+5WB:'I\^2P\.GPFI#^,EXO/1$DDF5Q_.+^ FUKK,22%$*LX) M#%E8P>+Y1$KV@-EJ162!LN%4S5P"S$&C81 ]B+HNE M0-V4L3UK631\J1!'R:UEZ58AG>.(="T=J.AI>O;L-#TX.YA24?HXEA^S?*CD)\?S M].CT;&H$^GA* QS8J';*@IE[S$_<)C/#)P@=';T_H<#ZLW(,](AC_\2D@G"0 M>@<+&^CBB']F1IA%-/0Y :"IKYSL1PQ)[6*<\C+L@G^&\RZZOA,)QL.)KK+] M$!#LFMXP;I)L/UE2J09(O@0HNE[#54.Y\1SQ Q#' 7. M3O>,2<8&B-B20C.(0S2O/?S&.V(CXHUZ0.\3MK@3RZJ^LE$T ]*F#\7M.N@2 M!T8%R-J$FA)+QL:]FE86T_XKB2?=J(0UB:&7NOM2+AIW]H4D@TU" 1#QE M-NQ_[G)FUN%E$&-%U@#%V+,\HZQMKY.^92T/8_E>RHE="4<8?@(+=G.)-Z>D MH*A#27A]#-S"UMC0C79$@Z(BXZP#66"/1 +-/$0_-\37"99H@.>#(/&/ P: M,;BX#Q![:%4@M4HWCR+4=J\@\#7!*$)OD,=/E';>?AFDW0FJ M0@ %H!0!+%HY\L%^"?;T-*#X-1AU*UGP5R$M0]L0D)REIR?'Z>')Z50THH_O MBD9!!D\I3\NRQ"(AFZV&3V8GU%&>RI8QU@!!8%Q,F108DGHXWU88_\,&G5+K7(EMTI3Q)(%@\-4#HG;&/TZ(>P&BPE MB*&"SJ*$YVP_G5"!KMB6)I@Q)RGMQ:09'#JFF/9W7EPBIH_75Q_>^?!(=H1@ M;U]:DH>+)AB#S2!2TMJ1)A1<4BDI"E$J">=6PU^7Y+7+0M([%W%MH&9_^D8U MB%04S6(=O#[J$DHV=?TB'$;^N>1(- [A)+D$FKMLA--\']85 ;9G!A29\5&YGIB02%[R($F[E?$=UZS[>0! O+2@+U!EY# MJ$J3091#8PS!84ND@=-_/FJ)4V2@W M6[O0N2>'%LH'T?[H8$H"UG"LHY&860%-)@M59>#]6BL.<(9RP99F_GV%08,3 MC64M>R0EPX4-.1"E^51K O([2.T0]^:7<8,7SZ]?^-MA5ZSJ1KQ2KI?:F"I2DY9=P)XBYXO7%Q\OS\<: M=W@:N@B?05 QOZC^$$S*>)0ADB'"0\$]< %)!L)A+SL7[8UNK-4YNB9Q2BW M9 B%W%J42?/9U954!%6TZG0:@)E83"F&CX'S8\LT^BY8I'!"Y9NB8@AI:E"V M&J2#N&PW8L(4#XDX>Q>1OS+Y/(2RM?B;E-W2N-"9ZEM]%],IN^?:"I=@D911 M41^QO>?"*L QDT)/,1AQ8S<>A>Q)NR-S,IC@]#\@#TO"X8F%)13-+6/'L%A1 MI;7N[BXIW*].^V7BWB*\AF7* 7@ST=<6%?=RB"QKRADP6E)%23LQE,;S;IHR MJ=R2-Q%A0,LP2)^$L9!G_:J:=#H1A#V=UL/!DR+T%YD4:RFN+NACQPV/B;S/ M@:/]4Z,MSH_7Y\$>Z'G6J5W1/HI2@3-; MFPS5I$$:7NS"\E*(:#"/:A2L8+M.7OTL$7V)"27&4_J]CY@TB7:E#4%N!Y9> MAAN6)D'> MOX8@_B,4G+]]?FZT&!"3E^:V1U_25V2NR0JY:T,[J$'IA]!A-*3>V[X>&)#XRP]/3A*#T^GBT:GXZ*1 M3]$FM28H5',6"9B&%8! NVSKD6C-Z;Z5A?531[=/K4;D&=6W=>=&%2V5::O' MD1G91I'6>-;!Y(/1_<2MW:[8KRX! 3*YVC]]A/;#53A7,V)F85MAK(]G_\-3 MVBGV<";1!9<%X,L(Y\,(H*E]E1LOF]<9(GC%E21J2H!YT8+C.IP)PR<"9J54 M(Z6"H08^2X_G\_3P;')#C#Z.M,DJE15LX4J;!*T(>;&',*9MPEIH]*KE$KH+ M.L.B<%SPF!O,+GQKV;'>Y0%4[I"F7Y=I(B!_0%M?B=I(;\BE#^?*E,/3<(01 M#RSJ\C3I;_'QP-\.]S0N7KPY M1Y*3K:NZK%>W?Z(9O$0J4])&0AU __F4W%15 1)E%N(4U*67.PY#OTG-6MUU MI8$F*[AY_HGC(4N8W^0&P-T>A.PIE(5Z(XAUQ69[-I$FYM\C?[8)"BR4] M4VO-@*,4+/3GK.Q;@JHE7JEX#V(/<[>4&4.=Y1,"1PU8MB!8#^&4)?,,WUM M0GV5 S 2\;2V&;H ^S,*$EHU@/8V6+C="JH3;6!BT!$R& XNE*B[LJXGFE+$ MK*Z6W&1:4(7QPY0O$T\6=KKM=V-MX,?J(%-T6,1G2P?V(Q*/CV5S^_%>;(G$ MXWYPA$\?#DZM5 M)1V[N)6]8'H[ZD0.^D9HOV^AH0TZB%)BK,*_T.70;HPRH*2:ZCP;$]/VS8[L MJ :RX0KX$*2";YT,"'K&P;BO(?<45%TJVZY-?W1_<$& M33 !-NX4WJ!QQ^(0V[HK4.3TGE D>5A48( T"O+&W6>%J 3>\1F6A\4CR7'/($*F?%9:0.A,!2ON7XTU=Y86%&];W MVDDVJOFDX>#74/)'DQCN_ X,=U[N:I ?[Q:?WM5E\>62_!1LL/-<+9+WR LY MU_P'9/H-'MWILM[RFZ]?7Z;NT3>J[%3RSAW\X?,M_NLK*G1<-.1-P]?X4$)- MG0VJLP'2OO(#TMAM_,#PD((]B2)O!#4-J>K:.KL=,:ZS#XWC#N#)3?HB0:J[ M&V4?E&#:L I("W'A*Q5?KS]OB\8X18;\D+AH%;3 M^>6CN=T5"^1,AX-:<3.^8^S2Y_K2%&/V=\2((LQLB+@F)$0KQM=/C^%( M;A'/>4O%2L(8>/1>Q.34,:N00T*:(PVS7DZD6'_/[.U!D'3X6B>-&8ZP?CDA MROQV,- 0+9M^)#:M8-2Q)[:'\'Q=TW?$.N?C[,4LN=1RTJIL:W\:P)[5$J:[ MDXNV_ JPR/Z[,I/J>G:"OL;W:J+T.V"853XW\[[4 "LN-9W@:JG=$Q,B M[S1G=L+N^Y K9J4PY]3]3,9,>F9^AWE:YLV2]XJ\N:=)Y3N)CW55NM9_PLC- MJM\XOR*5MS$U>WM$!=LQE%B PW0XE$_'<9;A3FZZ%4WD2*V3>"K@,D-22Q 8 M\.;>#!WW4#+O;/.,/TY'CEI%+I=Q5%Y7VFHE':U+:55RWH_#^'B_K>CD0"!' M@%[.@B+>(,C;N.5V\\S*F>/<"_@BD*MIDC,ZGZD&$5[QH=!^L[6YO7W5@DPZ MU\=R!,\I%\CX%.(ME@_CLX>$=W2L%XJM2?G=63"!NW366+O",)39=9J0%H2RJ!O! M;>CZO 4,<333IR'5?\RUMW;CTJ_#9@04P-6T)=8^%DD53Z"4,[FKP M$4TN5!&<):IJD[^>6$I"&XT.I?A."7?4BM*<3\@-BID&,I)3*Q[TQH.]XR9-K/MZ7=\DEPQ9;M:W MP'GD\Q2) M_TI11;X'Q^I(YR<.=2CJX+L/^YJ&WIPZU!1N94-N!45$H1.J(- MY@%;(7L[*D=H:M>1#NM_C8X2ZL^=14U'!X\9A7"Q(]CS_%%UV?KQ+^KSAC!B MUDV9JQ7;0RY,+5F4?&' (WOZQU O(G5G]/:*M: @1AQL.$*I.T4: B56.OI% M^!2+E>,BQZH0!.]8$$;):RL!3FJ_MA/1966!*RR"YB1;<2*A+BC&@N/V]!BA MT!6B>TTM ,,B@>4.3=JJD@,B[1B"+SMIX*'BC4J>4"+,^YRV\QS1=4?[!6$2 M]))=#=V-LE 5TO0W.B\>7X-%R<-?ZI)OG?COLK_1S2,ZE)Z;9/Z'NF1>0,4; M.<)_G34 R5=-S;4?>Q:HB 4@@'KDA\R"1"%2!TVVZI:F7R +K_BT55$)$]N^ MX9/<7-53*^WX/W1+BX9($&.Y3-' '*C$>T^H=9VJ M3P7U+C72G4&XRR7F!;M=N@QDP<3OH=*EH:9VU6B D%QMU"KVK)'#E-*1JQ9- MJ7/NSSH$ZDQA/F_4C6N!$,TPA9S65R0,"L0\?*;*OE<-7G22,@.0[3F%]H[T MV51XI;,%8(HOB5CE"-$/37<_].,[N^1VEU[O1YTF\#9T Q$6S7GS>?-)52U\ MU#NY 2#H7_9].L=A;>9:[@Y9NE=%B+YN1.Y*FQMG"GN"DN7!KZ:CHW[V?HE1 MH[Z;X!(^C:_0H("!\3U6=J>C_.$X&$LJ)\F*1=_5]%O#5V'P%WP*A3 AOB6S M\IFL"4O^P>BS3_K)VQ: M9*J!(C:V7I(ZA(>)@5*DQ$#7XU#:M*12P[NWU^]>O[J6@U/G+($FB0:QVTV-05FD["0;>C8ZNV MC$"V9\[/%J4[07[BCNM89%*/#_>6/7F= M@X?]/0U#3_EW*GGZ]^Y=[E1W%3SCQJYGJ10]WXKFO98"%JM9+% 67ESLY%TU MJ[Q1?=,6/2F:* $:]ZBKIE]7%Z5M']<6=H\::5 2_0LJHC%#[ZJ%_KTKG1-: MX.!=O,8_H^HY1 ]?]%CA08/(TJ/#3(%O0"Z'0&8QVSZ')W"U,L,:S^>CG#L* MX Y1!G-[H,)G T8G%AL@^IGS(A% 'MUY\G;[]!?3M-5 )#J07]HBG_>1O3'WH%>?SW[G#Q;93 MM#X4G;<6EHWWE&*L\R=M+CT'=-OQ$=!!%4 :>^_JS[@VXDD.GYXG5TW]^58R M-&9L6*KE[URGFT.>5CB MA%0XJHH8\4;KCF\; PG;NJ6C9(<\S]SM:#/=K3EUT-79)[I;2@YR3T? "-2 M7S4>$6DI0O%P/M+,J3HKMS@9\.?W8!A@@/NNA6)?4U9-)5 J5T*%J;;JA,NW M,8R&$=\.3$OFPB]*I XD_'SXSCDQ?Z,'!]"XHTIT122SJZ7,:^NR=BE]97:! M\9R[[QO+D6)HW;2NXY+7(C >R3[=DTJ!Q UH'MNH7_F.%KDUBRH@&6_-NWHP MP31.Q4D?3:R\)8,?,#%:]0M+V7"U4E]!4&*9.?;>EUE1]NV^;*-M$UN,G[)U M=P?0A%6EU)A@&@7YXFC>:'$6U#)[H1=\D73-)DYW,RMO MY%.*J/)=T7+5+RX,2\')%MEB.CBT<[^TRNMMYYN(^9[=MNA8J=@.HV611.2N M::-ZP9"+6UNL5D-;=D^YN\GNLG5_BZ[.J) IE_6Z,FQ4DW6I23TX>7XVV.0+ MKL>YJ>VU/%A$M+R!EKHK0_I.P@1KW%T7MO$QK[X)+,S=)6QJO)=KVASP]P^/ M5I+"J+B= 5,_;^ O:,]M-TLNBAJ/@ J\>YT5FEM4J!;5R.65M(DN5P7#!%6) M?R]G@.54H*%U/SXXG9\]/O_A(GF(80CDSAY%9NB.XXUO.S/Y:EBS''2,U M3;+W4:5NGP4,TD"?[LHN7>"3G?1_H#H,=:P':O1:W<"6&EM&6!9YGQ5\S5\O M=SW*I5[C^PV'"Y<(F9HK:> :51I<\QI=O!JPA(^*$$]<_Y"]G%CYHS/1:OS+ M8>F.;ZJP_@):\?B6.E=<[RF=2_#:EA-R85=/\P0Y 2J5O'>I<:MT&>#<&ZZ&EX9."+Z3?4I8RUM&Q \NY7UF"P*CE8N#Y.OQ7(, _/)*]VE MU!.U6DW02%D47XUMKT-L^RUA(RNUB;')=]0D0-L22^@K'U4;)E;/108D;=KM M7MHKB.5V)N"RME>"$Y4_,Q&PO=V]R:W-H965T:;@\.9+HU] M< 6BAZ^ETNZ\5WA?G0Z'+BFP%&Y@*M0DR8PMA:>ES8>NLBC2H%2J830:_3(L MA=2]V33LW=G9U-1>28UW%EQ=EL(^7Z RR_/>N+?>N)=YX7EC.)M6(L<%^B_5 MG:75L$5)98G:2:/!8G;>FX]/+R9\/ASX7>+2=;Z!/8F->>#%I_2\-V)"J##Q MC"#H[PDO42D&(AJ/*\Q>:Y(5N]]K]/?!=_(E%@XOC?I#IKXX[YWT(,5,U,K? MF^5'7/ESS'B)42[\PK(Y&[WK05([;\J5,C$HI6[^Q==5'#H*)Z,]"M%*(0J\ M&T.!Y97P8C:U9@F63Q,:?P17@S:1DYJ3LO"6I)+T_&Q1QPX?:]0>KI_HUTV' MGF!9.$Q6$!<-1+0'XAW<&.T+!]!/39S1N0M8'7R!<&&%35KV2EJZ L8X7 M++DT927T,PBM"2W!E':%WQ(5(@71,"#QKZ;0\,&H.I;H'B0(USW\\P\GT?CM MF=O+L0^891BN'ZL2BY;Q<<-X #=VT+6PE$J!0]MH['6>EPH^FRCL>@,[7\,& MT?CLS0#N:NMJ03+BP$J[3O=WYB"F' N9,G.J]9HBR0T#"755 MI<(#03%?JZ&2N8P5 CU['?4*;7@'Z=(<,A1')B'S[&26/DQJ:]FI#L>7I=4J-':87 AFZZTUAU;PE263]+SQVP>% M=."\L!Y2$C7IZB1Y9Z&PSE95[ HOM15DSP_D&_:7BKC.:RM4'XS&PW#U[;1^O_BR;7H OY&401\X_G0Y0UI8I#^@E6&5\BQ"'C#=;CQJ*3Q0@+F!?T-4">I2X[(UMLK>RD4GKJ"8WZQL>88>4ZOAO9DV%L*>V"91:7;H99RDTL*G,*,5*FDCWM@FT&Q67A3A>$L-IY&O?!9T&R-E@^0/#/& MKQ=LH)W69_\ 4$L#!!0 ( #J"8U/BWON>)!P A8 9 >&PO=V]R M:W-H965T-$ MB&Q?7 SFH=A=)"MN=C%5W9*87S]GJZ7))FUG,@\#S$-BD:RNY:S?6:I?WCG_ M.2R,Z=3]LFG#JX-%UZU>G)R$:F&6.AR[E6GAEYGS2]W!1S\_"2MO=$T/+9N3 M\]/3)R=+;=N#UR_INVO_^J7KN\:VYMJKT"^7VJ^O3./N7AV<'<0O?K7S18=? MG+Q^N=)S>.:?]JZ6[PZ>':@:C/3?=/]ZN[^;N1 CW&^RC6!_J_N9.SI@:KZT+FE M/ P[6-J6_]7W0HBO>>!<'CBG??-"M,OO=:=?O_3N3GD<#;/A'W14>AHV9UOD MRDWGX5<+SW6O?_%SW=H_-))H@N>S0;F9 @X'TW::*=?6D6OX6[#SULYLI=M. MK5QC*VN">G M?QV^/.E@7SC[225[N.(]G._8PW/UWK7=(JBW;6WJX?,G<)YT MJ/-XJ*OSO1/>F-6Q>G@Z4>>GYV=[YGN8B/20YGNX8[[+JG)]V]EVKN(QU7]> M3D/G0:C^:\\"C]("CVB!1[NX<&O\+0C<&.V^[DEU9=WWI@$)!R;=P [;"C;Y MKNV,;XF+NIG Q^IXHCHW-]W">)"T;J%L%X"YTV!KJSUQ$D2*=.;6-&L8O3#J M/_[MV?GYZ<4;MUSI=DV?SBX.%8B*5EZO;-VLU1R.C 0**U-9W71KM5IH4)O* M]!W(2J,J?AI4IH;/G:EA(VH%>P,Y"PIVCD_3EH+QUO6!Y Z?:LR]JA;>M;:" MSVUM\3SA6'V KU$('->UMT\&65LYW,^"38TEV=5_!"MU"=\JV5=/7<$K8 M5&/_P"61 *V#P])Z,'P%9.A0UH&D;^%I.VV,>M]7[K)>F !D40\.KMZ^OSPX M5+7OYT=U)'MGJD7K&C=?X]%J W.Z53S%TGBDB_W#J!;8I5>K!LF )Y%MWIH6 MJ8T$A0UJL'VU@BWKN@9E#+35)1X-]:YOEV"QET3*!B8T]08]!BL&.F2BA*5U MU,?CFV/5AT@#=]>JH!L8#+:^,NIN8>'<:%-I1 N\\EUK?%C8%?.I6UA?T]>X M83CR\)B#-<$A@(B9O#!N5E6&MJXC'8??XK "-K$I>9;76+DZL MALDL26Z$H4HWP+_Z-S"8_/T#?-0&TED@;XL6G#GL3=5[C]\7XP^!AJ P =D. MQPH!0I.!'Z-75V>O0/ M.C,NMC;:*X-F>'N/Q^J- >F#R6;.=:WKC*IMJ!H7>B"3D!@L0;GLZ+Z JB T M/ !%P-=$'9*I'R\OKX$8H&1$C4Q0V*!;V@X/N^I]Z%$+0.1PTS?(44M"B Q^ M>U\M=#LGRBUM8/S0-_*K-_.^T6)!WG5HQ$ B4'#IU&0EF,W?(H93HQ 3X8E@ M\&]]RYA#U,1\Q0RX-Z1I(!M@X&@E'4<%X7_(SCU^ZW'R6X_W>I]KT*/*KI"V MH!WYD'#V,5?VIR?;IUQ[S4(G5J;'+UF!(QTGZM);\#+7 S<5V$L2._CW#W=. MOKL$&U."'XO>]2CZ-5%RYB0@@S;HBLU[%F?P%(#A<-O[J/\D4?_)7H)]!"&% M,QFP<@!/3=BE<&.L^&MF)KZP.I6[0F2]U"4(!?HI8O]6=3 M[ 8IK - TA43F)16SV: 6FAY5@ETG\O$>1AO1,T:JZ?@_9/!R%9,! ^]!JZ\ MZQE>!8\1#_PM9R3YV+%+#Z"A[65?YGZ%%>Q8W8SN>*E!WZ?K4L6C&7@1Z4I[ M@(;Q( P["?P 2=P=*W+HJP6,4G. 9KXE600\,_=Z"?-,<=&)A&A M]%L'H^%?\&M&Y')2 "(2*PP7X%MYF)$A6)\Y?*X^APO9 1C_WK?X+P#A6Y.^ MG[JV#_2Q<]7G(XQ%&1\#9TC[+EB:#<@ >U?X$4R@O@?V[S$W3Y.Y>;K7*+S1 M8<%[QC]046]A7SOLRY^<2NW^10 =RHP#+= DG#ARZ5JS!O;[SPBNQ-@?\TSE M! Y8%:02L;5E8/) .0BCU? UWN1(P)^\ Q(2PW_)?D+"]#6([#X2P46'(S% M)N!N$>!Z5JJ%G2^:]5%C87WD!+!1I)I$38.E]'8.ZM/ QCM$+Q1:/S\%J[(. M"': XX2IIV:+%,.%,?6"J"QLCLL>B=;,R@IC.]OUA>TLK.T4?!0H"Y,+MH0G M417(D^W4[V!R8*>#]1,"\ MD? .T!&91$_!;4V6 \QV8/?$RIJX7SZS7A'8A&VSF_'E.BKWQ4Q;^LL(VL<1W]%-@SL$ODV5!]/)C; M#M$J!&D:0UN6=9(1' 'NQJ"4PVHU 4FC@;)@L>#_/;@!1I8SZT-W9-N)_ 7Q M'82CX'3 -^6-B@:DQ8-^\7(T=-9-TZ6PFD, M-CA2+5P,SG:L?D'_"YH*T,(W:_:_DX%7!&5OUC$KD$_78,)BZ*H+9XAKY;%D M-3AF)2?CIH *0&PF8V,T2QXC 2 U:GY()P M=HS]RA%3?^/?H@B0*RU%E'<>*K0IR>6BZMR852<1DV02:3/;H3MHEU'?/3Q^ MI):V:6+"]+OSXX?Q"W3YF!?CG-H^L_$\F8WG>W7_UVT\,V9 OGD2=5W2:>-3 M5#QO&M0 $&G^'GAP]?:GJX]O+NGD-^LE4-M"P#1\/ :E+6P#G39F?#DVW2+U M*4A>*"+@O,['GR\_7;[[:6SN^%L)E[N%-U]>C#C(IZIC4@$^&LUAT-P[]L4L MH2PBFX":2/@'P3>F*HM?L<>[!23&N$LG\J*HB..NI4\&QHF2Z"'W>C4@8.19"';(X\5DV0'8AX1'1@< H*P M&2"U"7R_YC 0?-+VKW)LW@ONH;2'_10\(>HU[X?2VAS&K6.*(9/+4K9RBK;G M6/US0:DX]H.4F%YPSIS6BY@?UW-3!%\<&96<)1(.[6X!$>'3K$7C4VRYXX>D MWTAC-J*N33&)"#4?[OKRW<__^-=/X/<>/3N_2.MF>+#I&!M;8?RH-'AFQIF$ M-SY\^!=FV'*52^^O7MY5^QWGM3:W5Y-1'MK6]M37R+WDTC+<"IP@-AGEBO0GDD6=P9%EERE2> MRAL#(HD-A!T!Q,0)(V%!7,$6KF(N +Q:W= '!%LV.90H^DG<9WT#\+PATU". MQ@"8;2RYQ+ MC28LY()M0@2\(M )8X6!H]P>JVHGL2\%WK (UP?$R#)U!PX+3T#]$Q(I@UU8 M"_N19AB1H!7A4(L+&-'Z;+G75.#*2D*AP44XR8X5$0GQ8SEN\)1SA<$4S1T3*>E0 M^R9*U0KB(Z:CQ1&C-*80;)(-,&<()V5FLD@D3C:F2,E*_,#*!BNB%M[BMS'- M&3.8DN,J>GNC!F4L#BJ&\@FH6\" MH&[4:$7G41:5A^J6R;X5MT9F%J0HR!7K_B5I,_YI>]@?=B-P\DM3P@&?^!U+ MD/$+S"OH3H2(<4P(J9 M0(/H[92R>GBZMC5-GF(!OX)3J*ADL(,$\>A%TT2>H 8(5'6$KOM6&A=V;A@) M4]D5;=DBGL')I#Q$"6N@&^5M4G> 5W.$N[;:,0LJ*767=&A^YVO%\4O83/C# M.4XP44'Y8E[(#7>FFW71XU1Y2[EZ+.9H!59\803J47/#$2*K]I MR?W!+KBL$?>'F4G,QG&2AW.=90V:LS_E'*6P8FZ7CKTPS0S@WLR4W,$TAA3V M\51F(]S 8L'8UGL/FPNQQ4 /3CHX7-G%,K"'A31E.129 Q/1-$<0=[M^OAAJ M*/?XM31P EFKXN:)] BAR:W0 "X2EAWM\,PTTT^&@\6.DV*CZ< MA<;F":!3/E%,5V!JJZVY^69#V;?RCB/*/Q0&@F6%7ZMWSCTVUX::I74Q:*"J MV(:0308 BL%9BGA+O9:4'3:/@2F9FK63B ^<$J(4?%1RF*\VTV?"^!GI[ MIX"+II$ M*+%R'6(=!JNN#&0342?$"JJ_$R6B,V3J380>>X2#3#%*!_?1EJ(H@37L#P 2 MR@FW4A. C#U>%+*!$<%,-'"&\-!<^UK2F-;'#"P"0@80KCU:#)/C&1SLB?J" M,-.TB$/#8*=H5>]-U7?4P-%SH(.^ %NHJ':!-9*:#=;7PNT9YE!*2S#TDU1+ M<@C7]D#[E)ABI<(:8M$L4>:O7^1LB\CVT1NN0:4<$(2H(&%^'8.8#@+! /AE99#A"!,1@B,Z>'9%I%R7EF8I"#+=MATLQ,6B^/>A+@I:"D*)@.F"!BP/P1X AIA('RF'EM6>0EM4!\@0*><4AP@"LA^9))# M#;'YV)J]/E:_<,0B&RNB^!AF)3/'/0.K1E,B11"I\S^.062G&M]3QW'%@PF_X5LH';>[]'?%=%6UGE)\RI7(SGA=PD8G4P)O;#X@(H%B02R[D@35L(^< MK:J[,U0J$%J#^">V%U65N$/0)-^I[V-FZ$]I)E7N.UY= LPOJNL#>RBUM#CH M:,0RR54*=! P83%VUE/!-^>S'EB8L 1@J7A'*&;HSO$$\,#>)YS4!,M[$ /D MELT%-U#LREX5A:O(!D'T(=.T[*89Q.-5H^TR!PY1]B1P8AR1#)A$8?(,\24Z M6FJAG#D_$I1(,T=L9!ZM64P4@&)QG'LC*5OV*S&F,VA$9AQ7<&,L 4[I=GV3 MB[IO4F+QZ,M2.+B34N8D_]\E_)]Q"==L\]1E0.&GGSX-,]5'I29-)*K"& $# M0/AWDD"]W%_!4I,3NR?D.(KM'SDS3O%0A)[1\FZ7>#;3YMR+,M(/@R4]$,QA MPE)VAI?6P!\=N=D19;KY1MY:8@H('(E&?2[Y;,N][<* RME^;.UPFO-AV5H4 M_HE+:64H$'N:8S@08!!2E$,C?37D2\O[ISN:3)A&0FI0P1.(I<+ M-QG(I])2RRD=L!=/:(%5'+:JKT,C-?,F'"T-2SW0N&>5ECI[+I& M2EUT5333DXS%F<&F\!D* [W1@>'V09,A(N:;*/G8\6KOX414UDD MC2,#.KSJD_)^B#H%R7I6B=T]RL@;)U]2JCCC92\MSYSJR#QLV(1:)-N"I=+$5 M4&E?H^;9:;Y@?[K_KH/C2PN4&QN]'/\-SZOAIT&S/QS5&F99 3FZTIC2*)3[*'0+0/[Z(ES8.URW8N--90M@G^G7"S@.)*8$BMYQAMV"D>DY!2X#3;[@;!$=8B\$ 5KKR:-_2 M$3C>%N_Z[DAZU0#?@57[+/5!-+P5(A-MB[OOAQ.YJK EYGBU9HLZ%4R8;JH5 MC67?()O4D<*=&.I'@S9LUR67[>=A^X"YFF$J/>*7F2TPYE:32:%.58=)&HW) S1T2>8^+04]M.[C/8%(FA7,?FOH3EMY0) M;&M@>2G"WKVVLG@9R=E>6_<>'!Y0-+I5N8HCZ@%?#.\P^7[G]=;_C74&_AI+ M*/D.T7 "\#A+[2WU2K&8%P@MWD 8P%[N$@L<_A)F-)[<9;[L+5D!<76IW)?> MZ=!1X9T:(C"PZOGRID[7F>C&I[REH/RJZ$K> #DQ2X[2355/J5:SG6)T0\D" MZ3O+YFMD_T535%J?M=;YC869&I$W.V?D6>X@"%D =\-&5%-,5[1\<"UM]-HJ MF4*]L3?I7M2W$(%Q8_B ;:@XF7RYS90[U=NZ>%L)*^\47[>!>TU]+/)J!H-8 M6 *BRR1.>!&.)*T@7JJ^ED09GAT, 5_*P0.3P<^\3Q#*M=0:PZ_^:.>..O!X MW<3H*+YRS4H$AO(8@[7CQ?YFZX"!D;U(L2.X* MN-6PH^?FMA76* $-N*;/"%7$$$;/K*3KMJY*@EU;KAJWCKK":(I?^D158HR1J)(*?",1V[XVM%D.EKCYN\=/CY^D M*T/(*\^8/TV92H=5"C;C;T5/"Z9QY]QB(8(^>GEIHIX_^?>-XO#?PMCZ2X+NH")$?\@75&#?=T;5,J9U%#)&:[SA8=?VTF_5-<0NTK3<,9HRR MOO;*U9"KV )!9GLV?AI4[$&GCT2]9/#6A)SZ-LH#/I$W&'*LF1O9FW6.C9U< M/"VY1H -X>FTBUXTY>LY]9)_Q<28Q4@<.C\]>\[R_L/ES17=V8<1ESCLW.Z.H'&Z0->2UI"-[.3]+0Y+IS1#E(;XZ. ^ M/ )Z .0^X(J; Q.KY1@D5YSG=PT*/'5Y/ N+1G3N,NJ<)#S=VXU+RW_#X; MO+VUI/SB^\A6*O9N77OIT]W*L /V"6ZA-E MJ?<%\+EW5GS/XHL IS&O#E82T1Y\S5)#5\8(ED%;D4VCUN#\R*XW M++'B@",C.YB?GPS;J"$(!/&F*](HC[PHZ5/QA+RJ1*,6E"^$@E"F'V3ZEAEU MX_TVW,?V#N(-DW1%D?,W7*>BMYR4=QGI,F+++VJA%@DL! ^O^>2*V@-,T]U; MKN&8PUQ$)>7&GBHX(H9&NL:N,W 8V+HI+Y:(B#LME>?E[A[,0J(NE3>#HF.3 M.2A6PJ7D/2E4&2I"$91G(4PL Y>\R#1:6#!+OEJD@DQZ;PX>D9M5Z;4Y]P A M_^!+'3U?9G53E#C-[32 HR19:]NMD7V[/9:=Z8@8['H9!L%W[3WW!::[(:3$ M.U\8P7=-XBLY1M[(L?4NCH1UL_ G"<,*^90T!>\"ERWT="1Y 09E%'N)YX0I MQB:&2XF==R89[N.E'W([]*J) ;1)P\Y_F. M.>G"A?0![7@5T?:RY.CRP>@M'IF-O.##M.#FT '/'U"L<:^QD8*9-,.NMZ7# M-QQ0;9$>3K%'D5D^)''(C7V=I"+P):+4 AZ3(]M1MM">;NJ4AFWTM4([('?F M5J1P//B55!?'+_CO?OO,=^KL]'3R].P4_A*DDO[-OXUYG9/BY:Q+X^?T"MK M(12_IS5]J^)K;B_YY:YY.+\C][WVU"S8F!D\>GK\]/$!=R7&#YU;T:M>IZ[K MW)+^Q!R1\3@ ?L<7]\4/N$!Z^>_K_P902P,$% @ .H)C4X7!&M>D @ MIP4 !D !X;"]W;W)K&ULC51M;],P$/XKIX 0 M2-7RTHZ-TD9J!P@D)JIMC ^(#VYR2:PY=F8[[=BOY^R\;(BMXDM\MN^>>YZ[ MG!=[I6],A6CAKA;2+(/*VF8>AB:KL&;F2#4HZ:90NF:6MKH,3:.1Y3ZH%F$2 M16_#FG$9I M_MM'I0K56<(D;#::M:Z9_KU&H_3*(@^'@@I>5=0=ANFA8B9=H MOS<;3;MP1,EYC=)P)4%CL0Q6\7P]<_[>X9KCWCRRP2G9*G7C-E_R91 Y0B@P MLPZ!T;+#,Q3" 1&-VQXS&%.ZP,?V@/[):R"M<)> MJ/UG[/4<.[Q,">._L.]]HP"RUEA5]\'$H.:R6]E=7X?_"4CZ@,3S[A)YEA^8 M9>E"JSUHYTUHSO!2?321X](UY=)JNN449]-ONF22WS-7HHG3QPVH JC!!J5E M7>5D/C3-W1E>2E[PC$D+C1(\XVC@]17;"C1O%J$E5@X[S'H&ZXY!\@R#=W"N MI*T,?)0YYG_'AZ1FE)0,DM;)0!!+,QPJ#$+A6.^<\P=4493.E#M_B3F?R9JB,5ZBWKLRAR^ MX@X%Q/V:].N4) K*B0[\WS X8Z;ROV/F#+QM.27WK%Y"'$63DS@BZ]6+TR1. MWH_KP]U3S0H?#4^-NO1/A '?\VZ.QM/Q%5IUP_?@WCUAYTR75"H06%!H='1R M'(#NGH5N8U7C1W&K+ VV-RMZ25$[![HOE++#QB48W^;T#U!+ P04 " Z M@F-3@,+S-IP" !C!0 &0 'AL+W=O:S#KMF7Z?8Y";69!$NP.'OBJ ML>X@*J<=6^$CVN_=O28K&E!JWJ(T7$G0N)P%E\EDGCM_[_"#X\;L[<%5LE#J MQ1FW]2R('2$46%F'P&AYQ2L4P@$1C=];S&!(Z0+W]SOT&U\[U;)@!J^4>.:U M;6;!10 U+ME:V >U^8K;>@J'5REA_!=Y_(L[QFEI53K3:@G3>AN8TOU4<3.2[=3WFTFFXYQ=GR5KZB MM$J_AR!I!(Z?V$*@.9E&EL"=2U1M@>8]4/H)T!CNE+2-@2^RQOK?^(A(#A#P$;LSR.(0TCA-#N!E0Z69Q\O^5RE<?EPEA-H_'K0(9\ MR)#[#/EGC/O!!K6$73*.YJ-6'L1Q.IR8CE4X"TAH!O4K!N53@[!4@D3$Y0JL M^TTD"G\OK0%+UY5J.R6]213X4"]S]@2HH1;;!6K?U6NLMD82P@/;T%!9U)P) M T>0ATF>T9J%V<48GDE7IUR>=EI5: R%431,%09F$\ M*FB3C,*%T>$$N>^'\=>^?GSNF5UP:$+BD MT/AL5 2@>TGWAE6=E]%"61*EWS;T"J)V#G2_5,KN#)=@>%?+/U!+ P04 M" Z@F-3=SZ47?T" "=!@ &0 'AL+W=OQNR1 V]WA#MB 8.VVAV$/LLTDPF3+)\E+ M^^]'R8[C 6NQEU@4R>_[2$G,^J3T-W-$M/#8R-9L@J.UW744F>J(#3=7JL.6 M/'NE&V[)U(?(=!IY[9,:&;$X7D8-%VVP7?N]G=ZN56^E:'&GP?1-P_73+4IU MV@1)<-[X( Y'ZS:B[;KC![Q'^[';:;*B":46#;9&J!8T[C?!37)]F[EX'_!) MX,G,UN J*97ZYHS_ZDT0.T$HL;(.@=/G.]ZAE Z(9/P_8@83I4N]M!_4Z5\R#R*M]RR[=KK4Z@732AN84OU6>3.-&Z0[FW MFKR"\NSVIJI4WUH#._[$2XG VQIH4_=8PSO!2R&%%6C@SP?G-G^M(TNT+CFJ M1HK;@8(]0U' >]7:HX&_VQKKG_,CDCMI9F?-M^Q%P'OLKB"-0V Q2U[ 2Z<> MI!XO?09O+-U<:N?2P)>;TEA-M^;K"Q391)%YBNPYR<.=![6'.]5TJD77<[)^ MM_^_:ON+E.XU7YN.5[@)Z+D:U-\QV#X<$?9*TE,4[0&L9]3H_4Z$)7?UDSY^ MUM?-]/%1GYS=#^["KX'.QF)3HO8']!:KT4C"2ZEGJ%>P"N,TI6\6LB2=RM98 MOTT5#@PZ,F-26VN!>$NPSSE,$BS/)\AF5[W1K(PS@N MR)>PF4\]<>G%)V&2YK"*,WC@CWA1N,A3\L5L.>5(/'!)>WE":,EBQG/H);>* MSA@?G3Y"844&:;&"G59U7UG0;D)

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end XML 60 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 61 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 62 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 188 301 1 false 41 0 false 4 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.bdsi.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.bdsi.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.bdsi.com/role/CondensedConsolidatedStatementsofOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity Sheet http://www.bdsi.com/role/CondensedConsolidatedStatementsofStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 1005006 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 2101101 - Disclosure - Organization, basis of presentation and summary of significant policies Sheet http://www.bdsi.com/role/Organizationbasisofpresentationandsummaryofsignificantpolicies Organization, basis of presentation and summary of significant policies Notes 7 false false R8.htm 2106102 - Disclosure - Inventory, net Sheet http://www.bdsi.com/role/Inventorynet Inventory, net Notes 8 false false R9.htm 2109103 - Disclosure - Accounts Payable and Accrued Liabilities Sheet http://www.bdsi.com/role/AccountsPayableandAccruedLiabilities Accounts Payable and Accrued Liabilities Notes 9 false false R10.htm 2112104 - Disclosure - Property and Equipment Sheet http://www.bdsi.com/role/PropertyandEquipment Property and Equipment Notes 10 false false R11.htm 2116105 - Disclosure - Intangible Assets Sheet http://www.bdsi.com/role/IntangibleAssets Intangible Assets Notes 11 false false R12.htm 2119106 - Disclosure - Acquired product rights Sheet http://www.bdsi.com/role/Acquiredproductrights Acquired product rights Notes 12 false false R13.htm 2123107 - Disclosure - Notes Payable Notes http://www.bdsi.com/role/NotesPayable Notes Payable Notes 13 false false R14.htm 2127108 - Disclosure - Net Sales by Product Sheet http://www.bdsi.com/role/NetSalesbyProduct Net Sales by Product Notes 14 false false R15.htm 2130109 - Disclosure - Stockholders' Equity Sheet http://www.bdsi.com/role/StockholdersEquity Stockholders' Equity Notes 15 false false R16.htm 2137110 - Disclosure - Commitments and Contingencies Sheet http://www.bdsi.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 16 false false R17.htm 2138111 - Disclosure - Subsequent Events Sheet http://www.bdsi.com/role/SubsequentEvents Subsequent Events Notes 17 false false R18.htm 2202201 - Disclosure - Organization, basis of presentation and summary of significant policies (Policies) Sheet http://www.bdsi.com/role/OrganizationbasisofpresentationandsummaryofsignificantpoliciesPolicies Organization, basis of presentation and summary of significant policies (Policies) Policies 18 false false R19.htm 2303301 - Disclosure - Organization, basis of presentation and summary of significant policies (Tables) Sheet http://www.bdsi.com/role/OrganizationbasisofpresentationandsummaryofsignificantpoliciesTables Organization, basis of presentation and summary of significant policies (Tables) Tables http://www.bdsi.com/role/Organizationbasisofpresentationandsummaryofsignificantpolicies 19 false false R20.htm 2307302 - Disclosure - Inventory, net (Tables) Sheet http://www.bdsi.com/role/InventorynetTables Inventory, net (Tables) Tables http://www.bdsi.com/role/Inventorynet 20 false false R21.htm 2310303 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) Sheet http://www.bdsi.com/role/AccountsPayableandAccruedLiabilitiesTables Accounts Payable and Accrued Liabilities (Tables) Tables http://www.bdsi.com/role/AccountsPayableandAccruedLiabilities 21 false false R22.htm 2313304 - Disclosure - Property and Equipment (Tables) Sheet http://www.bdsi.com/role/PropertyandEquipmentTables Property and Equipment (Tables) Tables http://www.bdsi.com/role/PropertyandEquipment 22 false false R23.htm 2317305 - Disclosure - Intangible Assets (Tables) Sheet http://www.bdsi.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://www.bdsi.com/role/IntangibleAssets 23 false false R24.htm 2320306 - Disclosure - Acquired product rights (Tables) Sheet http://www.bdsi.com/role/AcquiredproductrightsTables Acquired product rights (Tables) Tables http://www.bdsi.com/role/Acquiredproductrights 24 false false R25.htm 2324307 - Disclosure - Notes Payable (Tables) Notes http://www.bdsi.com/role/NotesPayableTables Notes Payable (Tables) Tables http://www.bdsi.com/role/NotesPayable 25 false false R26.htm 2328308 - Disclosure - Net Sales by Product (Tables) Sheet http://www.bdsi.com/role/NetSalesbyProductTables Net Sales by Product (Tables) Tables http://www.bdsi.com/role/NetSalesbyProduct 26 false false R27.htm 2331309 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.bdsi.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.bdsi.com/role/StockholdersEquity 27 false false R28.htm 2404401 - Disclosure - Organization, basis of presentation and summary of significant policies - Additional Information (Detail) Sheet http://www.bdsi.com/role/OrganizationbasisofpresentationandsummaryofsignificantpoliciesAdditionalInformationDetail Organization, basis of presentation and summary of significant policies - Additional Information (Detail) Details 28 false false R29.htm 2405402 - Disclosure - Organization, basis of presentation and summary of significant policies - Cash and Cash Equivalents a Recurring Basis (Detail) Sheet http://www.bdsi.com/role/OrganizationbasisofpresentationandsummaryofsignificantpoliciesCashandCashEquivalentsaRecurringBasisDetail Organization, basis of presentation and summary of significant policies - Cash and Cash Equivalents a Recurring Basis (Detail) Details 29 false false R30.htm 2408403 - Disclosure - Inventory, net (Detail) Sheet http://www.bdsi.com/role/InventorynetDetail Inventory, net (Detail) Details http://www.bdsi.com/role/InventorynetTables 30 false false R31.htm 2411404 - Disclosure - Accounts Payable and Accrued Liabilities (Detail) Sheet http://www.bdsi.com/role/AccountsPayableandAccruedLiabilitiesDetail Accounts Payable and Accrued Liabilities (Detail) Details http://www.bdsi.com/role/AccountsPayableandAccruedLiabilitiesTables 31 false false R32.htm 2414405 - Disclosure - Property and Equipment - Summarized Category of Fixed Assets (Detail) Sheet http://www.bdsi.com/role/PropertyandEquipmentSummarizedCategoryofFixedAssetsDetail Property and Equipment - Summarized Category of Fixed Assets (Detail) Details 32 false false R33.htm 2415406 - Disclosure - Property and Equipment - Additional Information (Detail) Sheet http://www.bdsi.com/role/PropertyandEquipmentAdditionalInformationDetail Property and Equipment - Additional Information (Detail) Details 33 false false R34.htm 2418407 - Disclosure - Intangible Assets (Detail) Sheet http://www.bdsi.com/role/IntangibleAssetsDetail Intangible Assets (Detail) Details http://www.bdsi.com/role/IntangibleAssetsTables 34 false false R35.htm 2421408 - Disclosure - Acquired product rights - Additional Information (Details) Sheet http://www.bdsi.com/role/AcquiredproductrightsAdditionalInformationDetails Acquired product rights - Additional Information (Details) Details 35 false false R36.htm 2422409 - Disclosure - Acquired product rights - Consideration (Details) Sheet http://www.bdsi.com/role/AcquiredproductrightsConsiderationDetails Acquired product rights - Consideration (Details) Details 36 false false R37.htm 2425410 - Disclosure - Notes Payable - Additional Information (Detail) Notes http://www.bdsi.com/role/NotesPayableAdditionalInformationDetail Notes Payable - Additional Information (Detail) Details 37 false false R38.htm 2426411 - Disclosure - Notes Payable - Future Maturities of the CRG Obligation (Detail) Notes http://www.bdsi.com/role/NotesPayableFutureMaturitiesoftheCRGObligationDetail Notes Payable - Future Maturities of the CRG Obligation (Detail) Details 38 false false R39.htm 2429412 - Disclosure - Net Sales by Product (Detail) Sheet http://www.bdsi.com/role/NetSalesbyProductDetail Net Sales by Product (Detail) Details http://www.bdsi.com/role/NetSalesbyProductTables 39 false false R40.htm 2432413 - Disclosure - Stockholders' Equity - Additional information (Detail) Sheet http://www.bdsi.com/role/StockholdersEquityAdditionalinformationDetail Stockholders' Equity - Additional information (Detail) Details 40 false false R41.htm 2433414 - Disclosure - Stockholders' Equity - Key Assumptions Used in Determining Fair Value of Options Granted (Detail) Sheet http://www.bdsi.com/role/StockholdersEquityKeyAssumptionsUsedinDeterminingFairValueofOptionsGrantedDetail Stockholders' Equity - Key Assumptions Used in Determining Fair Value of Options Granted (Detail) Details 41 false false R42.htm 2434415 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Detail) Sheet http://www.bdsi.com/role/StockholdersEquitySummaryofStockOptionActivityDetail Stockholders' Equity - Summary of Stock Option Activity (Detail) Details 42 false false R43.htm 2435416 - Disclosure - Stockholders' Equity - Summary of Restricted Stock Activity (Detail) Sheet http://www.bdsi.com/role/StockholdersEquitySummaryofRestrictedStockActivityDetail Stockholders' Equity - Summary of Restricted Stock Activity (Detail) Details 43 false false R44.htm 2436417 - Disclosure - Stockholder's Equity - Schedule of Earnings per Share (Details) Sheet http://www.bdsi.com/role/StockholdersEquityScheduleofEarningsperShareDetails Stockholder's Equity - Schedule of Earnings per Share (Details) Details 44 false false R45.htm 2439418 - Disclosure - Subsequent Events (Details) Sheet http://www.bdsi.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.bdsi.com/role/SubsequentEvents 45 false false All Reports Book All Reports bdsi-20210930.htm bdsi-20210930.xsd bdsi-20210930_cal.xml bdsi-20210930_def.xml bdsi-20210930_lab.xml bdsi-20210930_pre.xml bdsi-20210930x10qex311.htm bdsi-20210930x10qex312.htm bdsi-20210930x10qex321.htm bdsi-20210930x10qex322.htm bdsi-cfoemploymentagreemen.htm http://fasb.org/srt/2020-01-31 http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 true true JSON 65 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bdsi-20210930.htm": { "axisCustom": 1, "axisStandard": 18, "contextCount": 188, "dts": { "calculationLink": { "local": [ "bdsi-20210930_cal.xml" ] }, "definitionLink": { "local": [ "bdsi-20210930_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "bdsi-20210930.htm" ] }, "labelLink": { "local": [ "bdsi-20210930_lab.xml" ] }, "presentationLink": { "local": [ "bdsi-20210930_pre.xml" ] }, "schema": { "local": [ "bdsi-20210930.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 362, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 1, "http://xbrl.sec.gov/dei/2020-01-31": 5, "total": 6 }, "keyCustom": 31, "keyStandard": 270, "memberCustom": 11, "memberStandard": 28, "nsprefix": "bdsi", "nsuri": "http://www.bdsi.com/20210930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.bdsi.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112104 - Disclosure - Property and Equipment", "role": "http://www.bdsi.com/role/PropertyandEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116105 - Disclosure - Intangible Assets", "role": "http://www.bdsi.com/role/IntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "bdsi:LicenseAgreementsAndAcquiredProductRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2119106 - Disclosure - Acquired product rights", "role": "http://www.bdsi.com/role/Acquiredproductrights", "shortName": "Acquired product rights", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "bdsi:LicenseAgreementsAndAcquiredProductRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2123107 - Disclosure - Notes Payable", "role": "http://www.bdsi.com/role/NotesPayable", "shortName": "Notes Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2127108 - Disclosure - Net Sales by Product", "role": "http://www.bdsi.com/role/NetSalesbyProduct", "shortName": "Net Sales by Product", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2130109 - Disclosure - Stockholders' Equity", "role": "http://www.bdsi.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2137110 - Disclosure - Commitments and Contingencies", "role": "http://www.bdsi.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2138111 - Disclosure - Subsequent Events", "role": "http://www.bdsi.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "bdsi:EntityOverviewPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - Organization, basis of presentation and summary of significant policies (Policies)", "role": "http://www.bdsi.com/role/OrganizationbasisofpresentationandsummaryofsignificantpoliciesPolicies", "shortName": "Organization, basis of presentation and summary of significant policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "bdsi:EntityOverviewPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - Organization, basis of presentation and summary of significant policies (Tables)", "role": "http://www.bdsi.com/role/OrganizationbasisofpresentationandsummaryofsignificantpoliciesTables", "shortName": "Organization, basis of presentation and summary of significant policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i658e803410aa42949cfd2a13e31aa680_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i658e803410aa42949cfd2a13e31aa680_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307302 - Disclosure - Inventory, net (Tables)", "role": "http://www.bdsi.com/role/InventorynetTables", "shortName": "Inventory, net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310303 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)", "role": "http://www.bdsi.com/role/AccountsPayableandAccruedLiabilitiesTables", "shortName": "Accounts Payable and Accrued Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313304 - Disclosure - Property and Equipment (Tables)", "role": "http://www.bdsi.com/role/PropertyandEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "bdsi:ScheduleOfFiniteLivedIntangibleAssetsByMajorClassTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2317305 - Disclosure - Intangible Assets (Tables)", "role": "http://www.bdsi.com/role/IntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "bdsi:ScheduleOfFiniteLivedIntangibleAssetsByMajorClassTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "bdsi:AssetAcquisitionTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2320306 - Disclosure - Acquired product rights (Tables)", "role": "http://www.bdsi.com/role/AcquiredproductrightsTables", "shortName": "Acquired product rights (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "bdsi:AssetAcquisitionTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "bdsi:ScheduleOfFutureMaturitiesOfDebtObligationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2324307 - Disclosure - Notes Payable (Tables)", "role": "http://www.bdsi.com/role/NotesPayableTables", "shortName": "Notes Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "bdsi:ScheduleOfFutureMaturitiesOfDebtObligationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2328308 - Disclosure - Net Sales by Product (Tables)", "role": "http://www.bdsi.com/role/NetSalesbyProductTables", "shortName": "Net Sales by Product (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2331309 - Disclosure - Stockholders' Equity (Tables)", "role": "http://www.bdsi.com/role/StockholdersEquityTables", "shortName": "Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i658e803410aa42949cfd2a13e31aa680_I20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404401 - Disclosure - Organization, basis of presentation and summary of significant policies - Additional Information (Detail)", "role": "http://www.bdsi.com/role/OrganizationbasisofpresentationandsummaryofsignificantpoliciesAdditionalInformationDetail", "shortName": "Organization, basis of presentation and summary of significant policies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "lang": "en-US", "name": "bdsi:ThresholdLimitForLiquidInvestments", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "div", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i658e803410aa42949cfd2a13e31aa680_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Organization, basis of presentation and summary of significant policies - Cash and Cash Equivalents a Recurring Basis (Detail)", "role": "http://www.bdsi.com/role/OrganizationbasisofpresentationandsummaryofsignificantpoliciesCashandCashEquivalentsaRecurringBasisDetail", "shortName": "Organization, basis of presentation and summary of significant policies - Cash and Cash Equivalents a Recurring Basis (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "div", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i658e803410aa42949cfd2a13e31aa680_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i658e803410aa42949cfd2a13e31aa680_I20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i658e803410aa42949cfd2a13e31aa680_I20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i658e803410aa42949cfd2a13e31aa680_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsAndSupplies", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - Inventory, net (Detail)", "role": "http://www.bdsi.com/role/InventorynetDetail", "shortName": "Inventory, net (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i658e803410aa42949cfd2a13e31aa680_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsAndSupplies", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i658e803410aa42949cfd2a13e31aa680_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411404 - Disclosure - Accounts Payable and Accrued Liabilities (Detail)", "role": "http://www.bdsi.com/role/AccountsPayableandAccruedLiabilitiesDetail", "shortName": "Accounts Payable and Accrued Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i658e803410aa42949cfd2a13e31aa680_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i658e803410aa42949cfd2a13e31aa680_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414405 - Disclosure - Property and Equipment - Summarized Category of Fixed Assets (Detail)", "role": "http://www.bdsi.com/role/PropertyandEquipmentSummarizedCategoryofFixedAssetsDetail", "shortName": "Property and Equipment - Summarized Category of Fixed Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i658e803410aa42949cfd2a13e31aa680_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i63c46d1405f24d4aa4de2eeaf4a0a236_D20210701-20210930", "decimals": "-4", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415406 - Disclosure - Property and Equipment - Additional Information (Detail)", "role": "http://www.bdsi.com/role/PropertyandEquipmentAdditionalInformationDetail", "shortName": "Property and Equipment - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i63c46d1405f24d4aa4de2eeaf4a0a236_D20210701-20210930", "decimals": "-4", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "bdsi:ScheduleOfFiniteLivedIntangibleAssetsByMajorClassTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i658e803410aa42949cfd2a13e31aa680_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418407 - Disclosure - Intangible Assets (Detail)", "role": "http://www.bdsi.com/role/IntangibleAssetsDetail", "shortName": "Intangible Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "bdsi:ScheduleOfFiniteLivedIntangibleAssetsByMajorClassTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i658e803410aa42949cfd2a13e31aa680_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "ie54457ffd59c4cf786109207d16c9aa2_D20210803-20210803", "decimals": "-6", "first": true, "lang": "en-US", "name": "bdsi:AssetAcquisitionPriceOfAcquisitionExpected", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421408 - Disclosure - Acquired product rights - Additional Information (Details)", "role": "http://www.bdsi.com/role/AcquiredproductrightsAdditionalInformationDetails", "shortName": "Acquired product rights - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "ie54457ffd59c4cf786109207d16c9aa2_D20210803-20210803", "decimals": "-6", "first": true, "lang": "en-US", "name": "bdsi:AssetAcquisitionPriceOfAcquisitionExpected", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "bdsi:AssetAcquisitionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "ic9bd38a3f96946c29244b4f2d81e70a0_D20210803-20210803", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquireProductiveAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422409 - Disclosure - Acquired product rights - Consideration (Details)", "role": "http://www.bdsi.com/role/AcquiredproductrightsConsiderationDetails", "shortName": "Acquired product rights - Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "bdsi:AssetAcquisitionTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "ic9bd38a3f96946c29244b4f2d81e70a0_D20210803-20210803", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquireProductiveAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RepaymentsOfNotesPayable", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425410 - Disclosure - Notes Payable - Additional Information (Detail)", "role": "http://www.bdsi.com/role/NotesPayableAdditionalInformationDetail", "shortName": "Notes Payable - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "ia6bdeac1415f49ddbe2fedaf2d0beb5f_I20190523", "decimals": "INF", "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "bdsi:ScheduleOfFutureMaturitiesOfDebtObligationTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "if955f713980c43d8ad2eb3ea65e3dd8a_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426411 - Disclosure - Notes Payable - Future Maturities of the CRG Obligation (Detail)", "role": "http://www.bdsi.com/role/NotesPayableFutureMaturitiesoftheCRGObligationDetail", "shortName": "Notes Payable - Future Maturities of the CRG Obligation (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "bdsi:ScheduleOfFutureMaturitiesOfDebtObligationTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "if955f713980c43d8ad2eb3ea65e3dd8a_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i63c46d1405f24d4aa4de2eeaf4a0a236_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429412 - Disclosure - Net Sales by Product (Detail)", "role": "http://www.bdsi.com/role/NetSalesbyProductDetail", "shortName": "Net Sales by Product (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfProductInformationTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "icdaa288725d3415b95496c33528853bb_D20210701-20210930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i63c46d1405f24d4aa4de2eeaf4a0a236_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations", "role": "http://www.bdsi.com/role/CondensedConsolidatedStatementsofOperations", "shortName": "Condensed Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i63c46d1405f24d4aa4de2eeaf4a0a236_D20210701-20210930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "id7fb9aa421674ae5adeb914a7526eb1a_I20201104", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432413 - Disclosure - Stockholders' Equity - Additional information (Detail)", "role": "http://www.bdsi.com/role/StockholdersEquityAdditionalinformationDetail", "shortName": "Stockholders' Equity - Additional information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "id7fb9aa421674ae5adeb914a7526eb1a_I20201104", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433414 - Disclosure - Stockholders' Equity - Key Assumptions Used in Determining Fair Value of Options Granted (Detail)", "role": "http://www.bdsi.com/role/StockholdersEquityKeyAssumptionsUsedinDeterminingFairValueofOptionsGrantedDetail", "shortName": "Stockholders' Equity - Key Assumptions Used in Determining Fair Value of Options Granted (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i53bdd654730c45f0a0d902a4692a15bb_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434415 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Detail)", "role": "http://www.bdsi.com/role/StockholdersEquitySummaryofStockOptionActivityDetail", "shortName": "Stockholders' Equity - Summary of Stock Option Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i5103d9c54ed146ca8df27369245f2af4_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435416 - Disclosure - Stockholders' Equity - Summary of Restricted Stock Activity (Detail)", "role": "http://www.bdsi.com/role/StockholdersEquitySummaryofRestrictedStockActivityDetail", "shortName": "Stockholders' Equity - Summary of Restricted Stock Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i5103d9c54ed146ca8df27369245f2af4_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i63c46d1405f24d4aa4de2eeaf4a0a236_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436417 - Disclosure - Stockholder's Equity - Schedule of Earnings per Share (Details)", "role": "http://www.bdsi.com/role/StockholdersEquityScheduleofEarningsperShareDetails", "shortName": "Stockholder's Equity - Schedule of Earnings per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i63c46d1405f24d4aa4de2eeaf4a0a236_D20210701-20210930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i78c20a78d59142acb23d0c692bbb5500_D20211025-20211025", "decimals": "-5", "first": true, "lang": "en-US", "name": "bdsi:AnnualBaseSalaryOfficer", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439418 - Disclosure - Subsequent Events (Details)", "role": "http://www.bdsi.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i78c20a78d59142acb23d0c692bbb5500_D20211025-20211025", "decimals": "-5", "first": true, "lang": "en-US", "name": "bdsi:AnnualBaseSalaryOfficer", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "ic283e06391994daca08de9c560ddc345_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity", "role": "http://www.bdsi.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i01c7f7b0bc1f4957a4117a9ccfbfdd92_D20200101-20200331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Organization, basis of presentation and summary of significant policies", "role": "http://www.bdsi.com/role/Organizationbasisofpresentationandsummaryofsignificantpolicies", "shortName": "Organization, basis of presentation and summary of significant policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106102 - Disclosure - Inventory, net", "role": "http://www.bdsi.com/role/Inventorynet", "shortName": "Inventory, net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109103 - Disclosure - Accounts Payable and Accrued Liabilities", "role": "http://www.bdsi.com/role/AccountsPayableandAccruedLiabilities", "shortName": "Accounts Payable and Accrued Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdsi-20210930.htm", "contextRef": "i28e0f747c1984ba78f1ac16d83f65959_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 41, "tag": { "bdsi_AccountsReceivableAllowanceForCreditLossPercentageOfAccountsReceivableOutstandingLessThanThirtyDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounts Receivable, Allowance for Credit Loss, Percentage Of Accounts Receivable Outstanding Less Than Thirty Days", "label": "Accounts Receivable, Allowance for Credit Loss, Percentage Of Accounts Receivable Outstanding Less Than Thirty Days", "terseLabel": "Percent of accounts receivable outstanding for 30 days" } } }, "localname": "AccountsReceivableAllowanceForCreditLossPercentageOfAccountsReceivableOutstandingLessThanThirtyDays", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/OrganizationbasisofpresentationandsummaryofsignificantpoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "bdsi_AccruedLegalCurrent": { "auth_ref": [], "calculation": { "http://www.bdsi.com/role/AccountsPayableandAccruedLiabilitiesDetail": { "order": 5.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued legal current.", "label": "Accrued Legal, Current", "terseLabel": "Accrued legal" } } }, "localname": "AccruedLegalCurrent", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/AccountsPayableandAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bdsi_AccruedRegulatoryCostsCurrent": { "auth_ref": [], "calculation": { "http://www.bdsi.com/role/AccountsPayableandAccruedLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Regulatory Costs, Current", "label": "Accrued Regulatory Costs, Current", "terseLabel": "Accrued regulatory expenses" } } }, "localname": "AccruedRegulatoryCostsCurrent", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/AccountsPayableandAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bdsi_AccruedReturnsCurrent": { "auth_ref": [], "calculation": { "http://www.bdsi.com/role/AccountsPayableandAccruedLiabilitiesDetail": { "order": 7.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued returns.", "label": "Accrued Returns, Current", "terseLabel": "Accrued returns" } } }, "localname": "AccruedReturnsCurrent", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/AccountsPayableandAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bdsi_AnnualBaseSalaryOfficer": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Annual Base Salary, Officer", "label": "Annual Base Salary, Officer", "terseLabel": "Annual base salary" } } }, "localname": "AnnualBaseSalaryOfficer", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "bdsi_AnnualPerformanceBasedIncentiveCashBonusPercentOfBaseSalaryOfficer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Annual Performance-Based Incentive Cash Bonus, Percent Of Base Salary, Officer", "label": "Annual Performance-Based Incentive Cash Bonus, Percent Of Base Salary, Officer", "terseLabel": "Annual performance-based incentive cash bonus, percent of base salary" } } }, "localname": "AnnualPerformanceBasedIncentiveCashBonusPercentOfBaseSalaryOfficer", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/SubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "bdsi_AssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition", "label": "Asset Acquisition [Abstract]" } } }, "localname": "AssetAcquisitionAbstract", "nsuri": "http://www.bdsi.com/20210930", "xbrltype": "stringItemType" }, "bdsi_AssetAcquisitionConsiderationTransferred": { "auth_ref": [], "calculation": { "http://www.bdsi.com/role/AcquiredproductrightsConsiderationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Consideration Transferred", "label": "Asset Acquisition, Consideration Transferred", "totalLabel": "Total value" } } }, "localname": "AssetAcquisitionConsiderationTransferred", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/AcquiredproductrightsConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "bdsi_AssetAcquisitionConsiderationTransferredTransactionCost": { "auth_ref": [], "calculation": { "http://www.bdsi.com/role/AcquiredproductrightsConsiderationDetails": { "order": 2.0, "parentTag": "bdsi_AssetAcquisitionConsiderationTransferred", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Consideration Transferred, Transaction Cost", "label": "Asset Acquisition, Consideration Transferred, Transaction Cost", "terseLabel": "Transaction expenses" } } }, "localname": "AssetAcquisitionConsiderationTransferredTransactionCost", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/AcquiredproductrightsConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "bdsi_AssetAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition", "label": "Asset Acquisition [Line Items]", "terseLabel": "Asset Acquisition [Line Items]" } } }, "localname": "AssetAcquisitionLineItems", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/AcquiredproductrightsAdditionalInformationDetails", "http://www.bdsi.com/role/AcquiredproductrightsConsiderationDetails" ], "xbrltype": "stringItemType" }, "bdsi_AssetAcquisitionMilestonePaymentNetSales": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Milestone Payment, Net Sales", "label": "Asset Acquisition, Milestone Payment, Net Sales", "terseLabel": "Milestone payment, net sales" } } }, "localname": "AssetAcquisitionMilestonePaymentNetSales", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/AcquiredproductrightsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bdsi_AssetAcquisitionMilestonePaymentRequirementNetSales": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Milestone Payment Requirement, Net Sales", "label": "Asset Acquisition, Milestone Payment Requirement, Net Sales", "terseLabel": "Milestone payment requirement, net sales" } } }, "localname": "AssetAcquisitionMilestonePaymentRequirementNetSales", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/AcquiredproductrightsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bdsi_AssetAcquisitionMilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Milestone Payments", "label": "Asset Acquisition, Milestone Payments", "terseLabel": "Milestone payments, total" } } }, "localname": "AssetAcquisitionMilestonePayments", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/AcquiredproductrightsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bdsi_AssetAcquisitionPriceOfAcquisitionExpected": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Price Of Acquisition Expected", "label": "Asset Acquisition, Price Of Acquisition Expected", "terseLabel": "Price of acquisition" } } }, "localname": "AssetAcquisitionPriceOfAcquisitionExpected", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/AcquiredproductrightsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bdsi_AssetAcquisitionPriceOfAcquisitionExpectedAdditionalPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Price Of Acquisition Expected, Additional Payment", "label": "Asset Acquisition, Price Of Acquisition Expected, Additional Payment", "terseLabel": "Additional payment" } } }, "localname": "AssetAcquisitionPriceOfAcquisitionExpectedAdditionalPayment", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/AcquiredproductrightsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bdsi_AssetAcquisitionTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition", "label": "Asset Acquisition [Table]", "terseLabel": "Asset Acquisition [Table]" } } }, "localname": "AssetAcquisitionTable", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/AcquiredproductrightsAdditionalInformationDetails", "http://www.bdsi.com/role/AcquiredproductrightsConsiderationDetails" ], "xbrltype": "stringItemType" }, "bdsi_AssetAcquisitionTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition", "label": "Asset Acquisition [Table Text Block]", "terseLabel": "Asset Acquisition" } } }, "localname": "AssetAcquisitionTableTextBlock", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/AcquiredproductrightsTables" ], "xbrltype": "textBlockItemType" }, "bdsi_AssetAcquisitionUpFrontPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Up-front Payment", "label": "Asset Acquisition, Up-front Payment", "terseLabel": "Up-front payment" } } }, "localname": "AssetAcquisitionUpFrontPayment", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/AcquiredproductrightsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bdsi_AssetAquisitionAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset Aquisition", "label": "Asset Aquisition [Axis]", "terseLabel": "Asset Aquisition [Axis]" } } }, "localname": "AssetAquisitionAxis", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/AcquiredproductrightsAdditionalInformationDetails", "http://www.bdsi.com/role/AcquiredproductrightsConsiderationDetails" ], "xbrltype": "stringItemType" }, "bdsi_AssetAquisitionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset Aquisition [Domain]", "label": "Asset Aquisition [Domain]", "terseLabel": "Asset Aquisition [Domain]" } } }, "localname": "AssetAquisitionDomain", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/AcquiredproductrightsAdditionalInformationDetails", "http://www.bdsi.com/role/AcquiredproductrightsConsiderationDetails" ], "xbrltype": "domainItemType" }, "bdsi_BelbucaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BELBUCA (buprenorphine) buccal film for Chronic Pain. BELBUCA is a partial mu-opioid agonist and a treatment indicated for the management of pain severe enough to require daily, around the clock, long-term opioid treatment for which alternative treatment options are inadequate.", "label": "Belbuca [Member]", "verboseLabel": "BELBUCA" } } }, "localname": "BelbucaMember", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/IntangibleAssetsDetail", "http://www.bdsi.com/role/NetSalesbyProductDetail" ], "xbrltype": "domainItemType" }, "bdsi_BioPharmaCreditPlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "XXX_Bio Pharma Credit Plc [Member]", "label": "Bio Pharma Credit Plc [Member]", "terseLabel": "Bio Pharma Credit Plc" } } }, "localname": "BioPharmaCreditPlcMember", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/NotesPayableAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bdsi_BunavailMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BUNAVAIL [Member]", "label": "Bunavail [Member]", "terseLabel": "BUNAVAIL" } } }, "localname": "BunavailMember", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/NetSalesbyProductDetail", "http://www.bdsi.com/role/PropertyandEquipmentAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "bdsi_CRGServicingLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CRG servicing LLC.", "label": "CRG Servicing LLC [Member]", "terseLabel": "CRG" } } }, "localname": "CRGServicingLLCMember", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/NotesPayableFutureMaturitiesoftheCRGObligationDetail" ], "xbrltype": "domainItemType" }, "bdsi_ChiefAccountingOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Chief Accounting Officer", "label": "Chief Accounting Officer [Member]", "terseLabel": "Chief Accounting Officer" } } }, "localname": "ChiefAccountingOfficerMember", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "bdsi_DebtInstrumentAdditionalFacilityThatCanBeObtained": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Additional Amount Of Debt Facility that Can be availed", "label": "Debt Instrument Additional Facility That Can Be Obtained", "verboseLabel": "Additional facility funds that can be obtained" } } }, "localname": "DebtInstrumentAdditionalFacilityThatCanBeObtained", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/NotesPayableAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "bdsi_DebtInstrumentInterestOnlyPaymentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Interest Only Payment Term", "label": "Debt Instrument, Interest Only Payment Term", "terseLabel": "Interest only, payment term" } } }, "localname": "DebtInstrumentInterestOnlyPaymentTerm", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/NotesPayableAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "bdsi_ELYXYBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ELYXYB", "label": "ELYXYB [Member]", "terseLabel": "ELYXYB" } } }, "localname": "ELYXYBMember", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/AcquiredproductrightsAdditionalInformationDetails", "http://www.bdsi.com/role/AcquiredproductrightsConsiderationDetails", "http://www.bdsi.com/role/IntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "bdsi_EmployeesAndDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employees and directors.", "label": "Employees And Directors [Member]", "terseLabel": "Employees And Directors" } } }, "localname": "EmployeesAndDirectorsMember", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/StockholdersEquityAdditionalinformationDetail" ], "xbrltype": "domainItemType" }, "bdsi_EntityOverviewPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Entity Overview Policy [Text Block]", "label": "Entity Overview [Policy Text Block]", "terseLabel": "Overview" } } }, "localname": "EntityOverviewPolicyTextBlock", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/OrganizationbasisofpresentationandsummaryofsignificantpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "bdsi_IdleEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Idle equipment.", "label": "Idle Equipment [Member]", "terseLabel": "Idle equipment" } } }, "localname": "IdleEquipmentMember", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/PropertyandEquipmentSummarizedCategoryofFixedAssetsDetail" ], "xbrltype": "domainItemType" }, "bdsi_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities": { "auth_ref": [], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Operating Lease Assets And Liabilities", "label": "Increase (Decrease) In Operating Lease Assets And Liabilities", "negatedTerseLabel": "Net change in operating lease assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "bdsi_LicenseAgreementsAndAcquiredProductRightsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Agreements And Acquired Product Rights", "label": "License Agreements And Acquired Product Rights [Text Block]", "terseLabel": "Acquired product rights" } } }, "localname": "LicenseAgreementsAndAcquiredProductRightsTextBlock", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/Acquiredproductrights" ], "xbrltype": "textBlockItemType" }, "bdsi_LicenseAndDistributionRights": { "auth_ref": [], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "license and distribution rights.", "label": "License And Distribution Rights", "terseLabel": "License and distribution rights, net" } } }, "localname": "LicenseAndDistributionRights", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "bdsi_LicenseAndDistributionRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License and distribution rights.", "label": "License And Distribution Rights [Member]", "verboseLabel": "License and Distribution Rights" } } }, "localname": "LicenseAndDistributionRightsMember", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/IntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "bdsi_PaymentsToAcquireProducts": { "auth_ref": [], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments To Acquire Products", "label": "Payments To Acquire Products", "negatedLabel": "Product acquisitions" } } }, "localname": "PaymentsToAcquireProducts", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "bdsi_ProductRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ProductRightsMember", "label": "Product Rights [Member]", "terseLabel": "Product Rights" } } }, "localname": "ProductRightsMember", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/IntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "bdsi_ProductRightsPayableCurrent": { "auth_ref": [], "calculation": { "http://www.bdsi.com/role/AccountsPayableandAccruedLiabilitiesDetail": { "order": 10.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Product Rights Payable, Current", "label": "Product Rights Payable, Current", "terseLabel": "Product rights payable" } } }, "localname": "ProductRightsPayableCurrent", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/AccountsPayableandAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "bdsi_RepaymentsOfLinesOfCreditAccruedInterestPortion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repayments Of Lines Of Credit, Accrued Interest Portion", "label": "Repayments Of Lines Of Credit, Accrued Interest Portion", "terseLabel": "Repayment of loan, accrued interest portion" } } }, "localname": "RepaymentsOfLinesOfCreditAccruedInterestPortion", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/NotesPayableAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "bdsi_SalesInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales Information [Line Items]", "label": "Sales Information [Line Items]", "terseLabel": "Sales Information [Line Items]" } } }, "localname": "SalesInformationLineItems", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/NetSalesbyProductDetail" ], "xbrltype": "stringItemType" }, "bdsi_ScheduleOfFiniteLivedIntangibleAssetsByMajorClassTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Finite Lived Intangible Assets By Major Class [Table Text Block]", "label": "Schedule Of Finite Lived Intangible Assets By Major Class [Table Text Block]", "verboseLabel": "Summary of Other Intangible Assets Net Consisting of Product Rights and Licenses" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsByMajorClassTableTextBlock", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "bdsi_ScheduleOfFutureMaturitiesOfDebtObligationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of future maturities of debt obligation table.", "label": "Schedule Of Future Maturities Of Debt Obligation [Table Text Block]", "terseLabel": "Future Maturities of the Notes Payable Obligation" } } }, "localname": "ScheduleOfFutureMaturitiesOfDebtObligationTableTextBlock", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/NotesPayableTables" ], "xbrltype": "textBlockItemType" }, "bdsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options grants in period fair value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Fair Value", "terseLabel": "Fair market value of RSUs granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/StockholdersEquityAdditionalinformationDetail" ], "xbrltype": "monetaryItemType" }, "bdsi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options granted in period fair value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Fair Value", "terseLabel": "Fair market value of shares granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/StockholdersEquityAdditionalinformationDetail" ], "xbrltype": "monetaryItemType" }, "bdsi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardTermOfOptionsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangements by share based payment award term of options granted.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Term Of Options Granted", "terseLabel": "Term of options granted period" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardTermOfOptionsGranted", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/StockholdersEquityAdditionalinformationDetail" ], "xbrltype": "durationItemType" }, "bdsi_SymproicMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SymproicMember", "label": "Symproic [Member]", "terseLabel": "Symproic" } } }, "localname": "SymproicMember", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/IntangibleAssetsDetail", "http://www.bdsi.com/role/NetSalesbyProductDetail" ], "xbrltype": "domainItemType" }, "bdsi_ThresholdLimitForLiquidInvestments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold Limit For Investments Of A Liquid Nature", "label": "Threshold Limit For Liquid Investments", "verboseLabel": "Threshold limit for liquid investments" } } }, "localname": "ThresholdLimitForLiquidInvestments", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/OrganizationbasisofpresentationandsummaryofsignificantpoliciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "bdsi_VariableRateFloor": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Rate, Floor", "label": "Variable Rate, Floor", "terseLabel": "Variable rate floor" } } }, "localname": "VariableRateFloor", "nsuri": "http://www.bdsi.com/20210930", "presentation": [ "http://www.bdsi.com/role/NotesPayableAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity common stock, shares outstanding (in shares)" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r289", "r290", "r292", "r293", "r373" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]", "terseLabel": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bdsi.com/role/PropertyandEquipmentAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r289", "r290", "r292", "r293" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bdsi.com/role/PropertyandEquipmentAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r245", "r246", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r361", "r363" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bdsi.com/role/AcquiredproductrightsAdditionalInformationDetails", "http://www.bdsi.com/role/StockholdersEquityAdditionalinformationDetail", "http://www.bdsi.com/role/StockholdersEquityKeyAssumptionsUsedinDeterminingFairValueofOptionsGrantedDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r245", "r246", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r361", "r363" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bdsi.com/role/AcquiredproductrightsAdditionalInformationDetails", "http://www.bdsi.com/role/StockholdersEquityAdditionalinformationDetail", "http://www.bdsi.com/role/StockholdersEquityKeyAssumptionsUsedinDeterminingFairValueofOptionsGrantedDetail" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r160", "r233", "r234", "r332", "r360", "r362" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofOperations", "http://www.bdsi.com/role/IntangibleAssetsDetail", "http://www.bdsi.com/role/NetSalesbyProductDetail" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r160", "r233", "r234", "r332", "r360", "r362" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofOperations", "http://www.bdsi.com/role/IntangibleAssetsDetail", "http://www.bdsi.com/role/NetSalesbyProductDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r236", "r245", "r246", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r361", "r363" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bdsi.com/role/AcquiredproductrightsAdditionalInformationDetails", "http://www.bdsi.com/role/StockholdersEquityAdditionalinformationDetail", "http://www.bdsi.com/role/StockholdersEquityKeyAssumptionsUsedinDeterminingFairValueofOptionsGrantedDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r236", "r245", "r246", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r361", "r363" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bdsi.com/role/AcquiredproductrightsAdditionalInformationDetails", "http://www.bdsi.com/role/StockholdersEquityAdditionalinformationDetail", "http://www.bdsi.com/role/StockholdersEquityKeyAssumptionsUsedinDeterminingFairValueofOptionsGrantedDetail" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r165", "r318" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bdsi.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Relationship to Entity [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.bdsi.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://www.bdsi.com/role/AccountsPayableandAccruedLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued liabilities", "totalLabel": "Total accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/AccountsPayableandAccruedLiabilitiesDetail", "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accounts Payable and Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/AccountsPayableandAccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r31" ], "calculation": { "http://www.bdsi.com/role/AccountsPayableandAccruedLiabilitiesDetail": { "order": 4.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/AccountsPayableandAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNet": { "auth_ref": [ "r17", "r349" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "Accounts Receivable, after Allowance for Credit Loss", "terseLabel": "Accounts receivable, after allowance for credit loss" } } }, "localname": "AccountsReceivableNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/OrganizationbasisofpresentationandsummaryofsignificantpoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r3", "r17", "r166", "r167" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionExpense": { "auth_ref": [ "r211", "r212" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.", "label": "Accretion Expense", "terseLabel": "Accretion of debt discount and loan costs" } } }, "localname": "AccretionExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r6", "r7", "r36" ], "calculation": { "http://www.bdsi.com/role/AccountsPayableandAccruedLiabilitiesDetail": { "order": 8.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Employee Benefits, Current", "terseLabel": "Accrued compensation and benefits" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/AccountsPayableandAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r12", "r338", "r351" ], "calculation": { "http://www.bdsi.com/role/AccountsPayableandAccruedLiabilitiesDetail": { "order": 9.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/AccountsPayableandAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedMarketingCostsCurrent": { "auth_ref": [], "calculation": { "http://www.bdsi.com/role/AccountsPayableandAccruedLiabilitiesDetail": { "order": 6.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Marketing Costs, Current", "terseLabel": "Accrued rebates" } } }, "localname": "AccruedMarketingCostsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/AccountsPayableandAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r6", "r7", "r36" ], "calculation": { "http://www.bdsi.com/role/AccountsPayableandAccruedLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Royalties, Current", "terseLabel": "Accrued royalties" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/AccountsPayableandAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r18", "r281" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r89", "r90", "r91", "r278", "r279", "r280" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash flows from operating activities" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease": { "auth_ref": [ "r177" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)", "terseLabel": "Change in allowance for doubtful accounts and credit losses" } } }, "localname": "AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/OrganizationbasisofpresentationandsummaryofsignificantpoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r72", "r198", "r203" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r83", "r144", "r149", "r156", "r170", "r289", "r292", "r301", "r337", "r350" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r5", "r49", "r83", "r170", "r289", "r292", "r301" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r252", "r276" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquityAdditionalinformationDetail", "http://www.bdsi.com/role/StockholdersEquitySummaryofRestrictedStockActivityDetail", "http://www.bdsi.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r1", "r28", "r74" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/OrganizationbasisofpresentationandsummaryofsignificantpoliciesCashandCashEquivalentsaRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r10", "r75", "r78" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/OrganizationbasisofpresentationandsummaryofsignificantpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r67", "r74", "r77" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r67", "r302" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r81", "r83", "r106", "r110", "r111", "r114", "r116", "r122", "r123", "r124", "r170", "r301" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bdsi.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://www.bdsi.com/role/StockholdersEquityAdditionalinformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrant exercise price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquityAdditionalinformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Warrants outstanding (in shares)" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquityAdditionalinformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r40", "r216", "r341", "r355" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 10)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r213", "r214", "r215", "r217" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r89", "r90" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common\u00a0Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common Stock, par value (in usd per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bdsi.com/role/OrganizationbasisofpresentationandsummaryofsignificantpoliciesAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common Stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common Stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r16", "r223" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common Stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r16" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common Stock, $0.001 par value; 235,000,000 shares authorized at September\u00a030, 2021 and December\u00a031, 2020, respectively; 102,057,290 and 101,417,441 shares issued; 98,791,606 and 101,354,447 shares outstanding at September\u00a030, 2021 and December\u00a031, 2020, respectively." } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment\u00a0& software" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/PropertyandEquipmentSummarizedCategoryofFixedAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r130", "r131", "r163", "r299", "r300" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/NetSalesbyProductDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r130", "r131", "r163", "r299", "r300", "r369" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/NetSalesbyProductDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r130", "r131", "r163", "r299", "r300", "r369" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/NetSalesbyProductDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r130", "r131", "r163", "r299", "r300" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "verboseLabel": "Percent of net product sales" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/NetSalesbyProductDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r130", "r131", "r163", "r299", "r300" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/NetSalesbyProductDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r78", "r291" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/OrganizationbasisofpresentationandsummaryofsignificantpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/PropertyandEquipmentSummarizedCategoryofFixedAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r57", "r332" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesPolicyTextBlock": { "auth_ref": [ "r235" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.", "label": "Cost of Goods and Service [Policy Text Block]", "terseLabel": "Cost of sales" } } }, "localname": "CostOfSalesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/OrganizationbasisofpresentationandsummaryofsignificantpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/NotesPayableFutureMaturitiesoftheCRGObligationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/NotesPayableFutureMaturitiesoftheCRGObligationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CreditLossFinancialInstrumentPolicyTextBlock": { "auth_ref": [ "r172", "r173", "r174", "r175", "r176", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status.", "label": "Credit Loss, Financial Instrument [Policy Text Block]", "terseLabel": "Measurement of credit losses of financial instruments" } } }, "localname": "CreditLossFinancialInstrumentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/OrganizationbasisofpresentationandsummaryofsignificantpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r222" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Notes Payable" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/NotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "verboseLabel": "Basis spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/NotesPayableAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r13", "r220", "r339", "r348" ], "calculation": { "http://www.bdsi.com/role/NotesPayableFutureMaturitiesoftheCRGObligationDetail": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "totalLabel": "Total maturities" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/NotesPayableFutureMaturitiesoftheCRGObligationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/NotesPayableAdditionalInformationDetail", "http://www.bdsi.com/role/NotesPayableFutureMaturitiesoftheCRGObligationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r38", "r85", "r224", "r225", "r226", "r227", "r311", "r312", "r314", "r347" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/NotesPayableAdditionalInformationDetail", "http://www.bdsi.com/role/NotesPayableFutureMaturitiesoftheCRGObligationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt instrument, term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/NotesPayableAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r72", "r206" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/PropertyandEquipmentAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r72", "r142" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r56", "r94", "r95", "r96", "r97", "r98", "r103", "r106", "r114", "r115", "r116", "r118", "r119", "r344", "r357" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic earnings per share (in usd per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofOperations", "http://www.bdsi.com/role/StockholdersEquityScheduleofEarningsperShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "Basic and diluted:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r56", "r94", "r95", "r96", "r97", "r98", "r106", "r114", "r115", "r116", "r118", "r119", "r344", "r357" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted earnings per share (in usd per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofOperations", "http://www.bdsi.com/role/StockholdersEquityScheduleofEarningsperShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r275" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost related to non-vested share-based compensation awards granted" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquityAdditionalinformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r89", "r90", "r91", "r93", "r99", "r101", "r121", "r171", "r223", "r228", "r278", "r279", "r280", "r285", "r286", "r303", "r304", "r305", "r306", "r307", "r308", "r364", "r365", "r366" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r295", "r296" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/OrganizationbasisofpresentationandsummaryofsignificantpoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r296", "r322", "r323", "r324" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/OrganizationbasisofpresentationandsummaryofsignificantpoliciesCashandCashEquivalentsaRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r237", "r238", "r243", "r244", "r296", "r322" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/OrganizationbasisofpresentationandsummaryofsignificantpoliciesCashandCashEquivalentsaRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r237", "r238", "r243", "r244", "r296", "r323" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/OrganizationbasisofpresentationandsummaryofsignificantpoliciesCashandCashEquivalentsaRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r296", "r324" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/OrganizationbasisofpresentationandsummaryofsignificantpoliciesCashandCashEquivalentsaRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r322", "r323", "r324" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/OrganizationbasisofpresentationandsummaryofsignificantpoliciesCashandCashEquivalentsaRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r78", "r297", "r298" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "verboseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/OrganizationbasisofpresentationandsummaryofsignificantpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": { "auth_ref": [ "r315" ], "calculation": { "http://www.bdsi.com/role/PropertyandEquipmentSummarizedCategoryofFixedAssetsDetail": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization", "terseLabel": "Right of use, building lease" } } }, "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/PropertyandEquipmentSummarizedCategoryofFixedAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Weighted Average Useful Life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/IntangibleAssetsDetail" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r202" ], "calculation": { "http://www.bdsi.com/role/IntangibleAssetsDetail": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/IntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r199", "r200", "r202", "r204", "r333", "r334" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/IntangibleAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r202", "r334" ], "calculation": { "http://www.bdsi.com/role/IntangibleAssetsDetail": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "verboseLabel": "Gross Carrying Value" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/IntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/IntangibleAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r199", "r201" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/IntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r202", "r333" ], "calculation": { "http://www.bdsi.com/role/IntangibleAssetsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Intangible Assets, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/IntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r58" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r195", "r196", "r336" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_GranteeStatusAxis": { "auth_ref": [ "r248", "r249", "r274" ], "lang": { "en-us": { "role": { "documentation": "Information by status of recipient to whom award is granted.", "label": "Grantee Status [Axis]", "terseLabel": "Grantee Status [Axis]" } } }, "localname": "GranteeStatusAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquityAdditionalinformationDetail", "http://www.bdsi.com/role/StockholdersEquitySummaryofRestrictedStockActivityDetail", "http://www.bdsi.com/role/StockholdersEquitySummaryofStockOptionActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_GranteeStatusDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Status of recipient to whom award is granted.", "label": "Grantee Status [Domain]", "terseLabel": "Grantee Status [Domain]" } } }, "localname": "GranteeStatusDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquityAdditionalinformationDetail", "http://www.bdsi.com/role/StockholdersEquitySummaryofRestrictedStockActivityDetail", "http://www.bdsi.com/role/StockholdersEquitySummaryofStockOptionActivityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r54", "r144", "r148", "r152", "r155", "r158", "r335", "r342", "r346", "r358" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r84", "r100", "r101", "r143", "r284", "r287", "r288", "r359" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax provision" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r69", "r76" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Cash paid for taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r71" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r71" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r71" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r71" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r71" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": { "auth_ref": [ "r107", "r108", "r109", "r116" ], "calculation": { "http://www.bdsi.com/role/StockholdersEquityScheduleofEarningsperShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants", "terseLabel": "Effect of dilutive options and warrants (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquityScheduleofEarningsperShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r205" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r53", "r141", "r310", "r313", "r345" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense, net" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r66", "r68", "r76" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r194" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventory, net" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/Inventorynet" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r44" ], "calculation": { "http://www.bdsi.com/role/InventorynetDetail": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/InventorynetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r2", "r47" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.bdsi.com/role/InventorynetDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory, net", "totalLabel": "Total inventories, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets", "http://www.bdsi.com/role/InventorynetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r9", "r48", "r78", "r120", "r190", "r192", "r194" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/OrganizationbasisofpresentationandsummaryofsignificantpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsAndSupplies": { "auth_ref": [ "r46" ], "calculation": { "http://www.bdsi.com/role/InventorynetDetail": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.", "label": "Inventory, Raw Materials and Supplies, Gross", "terseLabel": "Raw\u00a0materials" } } }, "localname": "InventoryRawMaterialsAndSupplies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/InventorynetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r47", "r87", "r193" ], "calculation": { "http://www.bdsi.com/role/InventorynetDetail": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "negatedLabel": "Obsolescence reserve", "terseLabel": "Inventory obsolescence reserved" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/InventorynetDetail", "http://www.bdsi.com/role/OrganizationbasisofpresentationandsummaryofsignificantpoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r45" ], "calculation": { "http://www.bdsi.com/role/InventorynetDetail": { "order": 4.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/InventorynetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r191" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Inventory Write-down", "terseLabel": "Provision for/(release of) inventory obsolescence" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/PropertyandEquipmentSummarizedCategoryofFixedAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r35", "r83", "r150", "r170", "r290", "r292", "r293", "r301" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r22", "r83", "r170", "r301", "r340", "r354" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r37", "r83", "r170", "r290", "r292", "r293", "r301" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r33", "r85" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]", "terseLabel": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/NotesPayableFutureMaturitiesoftheCRGObligationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]", "terseLabel": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/NotesPayableFutureMaturitiesoftheCRGObligationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r33" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "verboseLabel": "Secured credit term loan" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/NotesPayableAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/NotesPayableFutureMaturitiesoftheCRGObligationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "London Interbank Offered Rate (LIBOR)" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/NotesPayableAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r13", "r221", "r339", "r352" ], "calculation": { "http://www.bdsi.com/role/NotesPayableFutureMaturitiesoftheCRGObligationDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Total notes payable obligation" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/NotesPayableFutureMaturitiesoftheCRGObligationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r86", "r218" ], "calculation": { "http://www.bdsi.com/role/NotesPayableFutureMaturitiesoftheCRGObligationDetail": { "order": 4.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/NotesPayableFutureMaturitiesoftheCRGObligationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r86", "r218" ], "calculation": { "http://www.bdsi.com/role/NotesPayableFutureMaturitiesoftheCRGObligationDetail": { "order": 5.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/NotesPayableFutureMaturitiesoftheCRGObligationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r86", "r218" ], "calculation": { "http://www.bdsi.com/role/NotesPayableFutureMaturitiesoftheCRGObligationDetail": { "order": 3.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/NotesPayableFutureMaturitiesoftheCRGObligationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r86", "r218" ], "calculation": { "http://www.bdsi.com/role/NotesPayableFutureMaturitiesoftheCRGObligationDetail": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/NotesPayableFutureMaturitiesoftheCRGObligationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r86" ], "calculation": { "http://www.bdsi.com/role/NotesPayableFutureMaturitiesoftheCRGObligationDetail": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "2021" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/NotesPayableFutureMaturitiesoftheCRGObligationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r38" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Notes Payable, Noncurrent", "terseLabel": "Notes payable, less current maturities" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/NotesPayableAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r38", "r219" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/NotesPayableAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]", "terseLabel": "Machinery\u00a0& equipment" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/PropertyandEquipmentSummarizedCategoryofFixedAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r67" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash flows (used in)/provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r67" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash flows used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r67", "r70", "r73" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash flows provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating\u00a0activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r51", "r52", "r55", "r73", "r83", "r92", "r94", "r95", "r96", "r97", "r100", "r101", "r112", "r144", "r148", "r152", "r155", "r158", "r170", "r301", "r343", "r356" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.bdsi.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r94", "r95", "r96", "r97", "r103", "r104", "r113", "r116", "r144", "r148", "r152", "r155", "r158" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net income (loss) attributable to common stockholders, basic", "totalLabel": "Net income attributable to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofOperations", "http://www.bdsi.com/role/StockholdersEquityScheduleofEarningsperShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r105", "r113", "r116" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "terseLabel": "Net income (loss) attributable to common stockholders, diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquityScheduleofEarningsperShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements, adopted" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/OrganizationbasisofpresentationandsummaryofsignificantpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes Payable, Current", "terseLabel": "Notes payable, current" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]", "terseLabel": "Office furniture\u00a0& equipment" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/PropertyandEquipmentSummarizedCategoryofFixedAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total expenses:" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r144", "r148", "r152", "r155", "r158" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r88", "r102", "r135", "r294" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "terseLabel": "Organization, basis of presentation and summary of significant policies" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/Organizationbasisofpresentationandsummaryofsignificantpolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r6", "r7", "r8", "r36" ], "calculation": { "http://www.bdsi.com/role/AccountsPayableandAccruedLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Accrued other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/AccountsPayableandAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r59" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other (expense)/income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]", "terseLabel": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r63" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Payment on share repurchase" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r65" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments of Financing Costs", "negatedTerseLabel": "Payment on deferred financing fees" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r60" ], "calculation": { "http://www.bdsi.com/role/AcquiredproductrightsConsiderationDetails": { "order": 1.0, "parentTag": "bdsi_AssetAcquisitionConsiderationTransferred", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Payments to Acquire Productive Assets", "terseLabel": "ELYXYB acquired product rights" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/AcquiredproductrightsConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r60" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Acquisitions of property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred Stock, par value (in usd per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bdsi.com/role/OrganizationbasisofpresentationandsummaryofsignificantpoliciesAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred Stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred Stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bdsi.com/role/StockholdersEquityAdditionalinformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r15" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred Stock, 5,000,000 shares authorized; Series B Non-Voting Convertible Preferred Stock, $0.001 par value, 443 shares outstanding at September\u00a030, 2021 and December\u00a031, 2020, respectively." } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r4", "r26", "r27" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSecuredNotesPayable": { "auth_ref": [ "r62" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from borrowings supported by a written promise to pay an obligation that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).", "label": "Proceeds from Secured Notes Payable", "terseLabel": "Proceeds from notes payable" } } }, "localname": "ProceedsFromSecuredNotesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r61", "r277" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.bdsi.com/role/StockholdersEquityAdditionalinformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductConcentrationRiskMember": { "auth_ref": [ "r129" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.", "label": "Product Concentration Risk [Member]", "terseLabel": "Product Concentration Risk" } } }, "localname": "ProductConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/NetSalesbyProductDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product sales, net" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofOperations", "http://www.bdsi.com/role/NetSalesbyProductDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r208", "r316", "r317" ], "calculation": { "http://www.bdsi.com/role/PropertyandEquipmentSummarizedCategoryofFixedAssetsDetail": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization", "negatedTerseLabel": "Less accumulated depreciation and amortization" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/PropertyandEquipmentSummarizedCategoryofFixedAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r50", "r209", "r317" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.bdsi.com/role/PropertyandEquipmentSummarizedCategoryofFixedAssetsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "terseLabel": "Property and equipment, net", "totalLabel": "Total property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets", "http://www.bdsi.com/role/PropertyandEquipmentSummarizedCategoryofFixedAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r11", "r207", "r315" ], "calculation": { "http://www.bdsi.com/role/PropertyandEquipmentSummarizedCategoryofFixedAssetsDetail": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization", "totalLabel": "Total" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/PropertyandEquipmentSummarizedCategoryofFixedAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r30", "r209" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/PropertyandEquipmentSummarizedCategoryofFixedAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r210", "r370", "r371", "r372" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/PropertyandEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r29", "r207" ], "calculation": { "http://www.bdsi.com/role/PropertyandEquipmentSummarizedCategoryofFixedAssetsDetail": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, plant, and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/PropertyandEquipmentSummarizedCategoryofFixedAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/PropertyandEquipmentAdditionalInformationDetail", "http://www.bdsi.com/role/PropertyandEquipmentSummarizedCategoryofFixedAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r11", "r209" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Summarized Category of Fixed Assets" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/PropertyandEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r11", "r207" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/PropertyandEquipmentSummarizedCategoryofFixedAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r64" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "Repayments of Notes Payable", "negatedTerseLabel": "Payment on notes payable", "terseLabel": "Repayment on notes payable" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.bdsi.com/role/NotesPayableAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquityAdditionalinformationDetail", "http://www.bdsi.com/role/StockholdersEquitySummaryofRestrictedStockActivityDetail", "http://www.bdsi.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r19", "r228", "r281", "r353", "r367", "r368" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r89", "r90", "r91", "r93", "r99", "r101", "r171", "r278", "r279", "r280", "r285", "r286", "r364", "r366" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r139", "r140", "r147", "r153", "r154", "r160", "r161", "r163", "r232", "r233", "r332" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net product sales", "verboseLabel": "Total revenues:" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofOperations", "http://www.bdsi.com/role/NetSalesbyProductDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r79", "r80" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/OrganizationbasisofpresentationandsummaryofsignificantpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RoyaltyMember": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "Money for usage-based right to asset.", "label": "Royalty [Member]", "terseLabel": "Product royalty revenues" } } }, "localname": "RoyaltyMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r130", "r163" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue Benchmark" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/NetSalesbyProductDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Summary of Components of Accounts Payable and Accrued Liabilities" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/AccountsPayableandAccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r199", "r201", "r333" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/IntangibleAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r9", "r23", "r24", "r25" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Summary of Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/InventorynetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of product information that are included in the discussion of the nature of an entity's operations.", "label": "Schedule of Product Information [Table Text Block]", "terseLabel": "Summary of Net Sales by Product" } } }, "localname": "ScheduleOfProductInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/NetSalesbyProductTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r30", "r209" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/PropertyandEquipmentAdditionalInformationDetail", "http://www.bdsi.com/role/PropertyandEquipmentSummarizedCategoryofFixedAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r144", "r145", "r151", "r197" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/NetSalesbyProductDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r252", "r276" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquityAdditionalinformationDetail", "http://www.bdsi.com/role/StockholdersEquityKeyAssumptionsUsedinDeterminingFairValueofOptionsGrantedDetail", "http://www.bdsi.com/role/StockholdersEquitySummaryofRestrictedStockActivityDetail", "http://www.bdsi.com/role/StockholdersEquitySummaryofStockOptionActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Summary of Restricted Stock Activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r255", "r265", "r268" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Key Assumptions Used in Determining Fair Value of Options Granted" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r136", "r137", "r138", "r144", "r146", "r152", "r156", "r157", "r158", "r159", "r160", "r162", "r163", "r164" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Net Sales by Product" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/NetSalesbyProduct" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]", "terseLabel": "Preferred\u00a0Stock Series\u00a0A" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series B Preferred Stock [Member]", "terseLabel": "Preferred\u00a0Stock Series\u00a0B" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bdsi.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://www.bdsi.com/role/StockholdersEquityAdditionalinformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r71" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period of shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquityAdditionalinformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeitures (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquitySummaryofRestrictedStockActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted average fair market value per RSU, Forfeitures (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquitySummaryofRestrictedStockActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquityAdditionalinformationDetail", "http://www.bdsi.com/role/StockholdersEquitySummaryofRestrictedStockActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average fair market value per RSU, Granted (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquitySummaryofRestrictedStockActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Outstanding at end of period (in shares)", "periodStartLabel": "Outstanding at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquitySummaryofRestrictedStockActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number\u00a0of restricted shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquitySummaryofRestrictedStockActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted average fair market value per RSU, Outstanding at end of period (in usd per share)", "periodStartLabel": "Weighted average fair market value per RSU, Outstanding at beginning of period (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquitySummaryofRestrictedStockActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted average\u00a0fair market\u00a0value per\u00a0RSU" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquitySummaryofRestrictedStockActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquitySummaryofRestrictedStockActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average fair market value per RSU, Vested (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquitySummaryofRestrictedStockActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquityKeyAssumptionsUsedinDeterminingFairValueofOptionsGrantedDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected\u00a0price\u00a0volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquityKeyAssumptionsUsedinDeterminingFairValueofOptionsGrantedDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquityKeyAssumptionsUsedinDeterminingFairValueofOptionsGrantedDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquityAdditionalinformationDetail", "http://www.bdsi.com/role/StockholdersEquityKeyAssumptionsUsedinDeterminingFairValueofOptionsGrantedDetail", "http://www.bdsi.com/role/StockholdersEquitySummaryofRestrictedStockActivityDetail", "http://www.bdsi.com/role/StockholdersEquitySummaryofStockOptionActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquitySummaryofStockOptionActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Stock option exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquityAdditionalinformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r267" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Intrinsic value of options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquityAdditionalinformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeitures (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquitySummaryofStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquitySummaryofStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r276" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value, Outstanding, balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquitySummaryofStockOptionActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r257", "r276" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at end of period (in shares)", "periodStartLabel": "Outstanding at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquitySummaryofStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquitySummaryofStockOptionActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r256" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise price per share, Outstanding at end of period (in usd per share)", "periodStartLabel": "Weighted average exercise price per share, Outstanding at beginning of period (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquitySummaryofStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted average exercise price per share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquitySummaryofStockOptionActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r250", "r254" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquityAdditionalinformationDetail", "http://www.bdsi.com/role/StockholdersEquitySummaryofRestrictedStockActivityDetail", "http://www.bdsi.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price per share, Exercised (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquitySummaryofStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price per share, Forfeitures (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquitySummaryofStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price per share, Granted (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquitySummaryofStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedPaymentArrangementEmployeeMember": { "auth_ref": [ "r249", "r274" ], "lang": { "en-us": { "role": { "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.", "label": "Share-based Payment Arrangement, Employee [Member]", "terseLabel": "Employees" } } }, "localname": "ShareBasedPaymentArrangementEmployeeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquitySummaryofRestrictedStockActivityDetail", "http://www.bdsi.com/role/StockholdersEquitySummaryofStockOptionActivityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": { "auth_ref": [ "r248", "r274" ], "lang": { "en-us": { "role": { "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.", "label": "Share-based Payment Arrangement, Nonemployee [Member]", "terseLabel": "Officers and Directors" } } }, "localname": "ShareBasedPaymentArrangementNonemployeeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquitySummaryofRestrictedStockActivityDetail", "http://www.bdsi.com/role/StockholdersEquitySummaryofStockOptionActivityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r270", "r282" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Weighted average expected life in years" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquityKeyAssumptionsUsedinDeterminingFairValueofOptionsGrantedDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r14", "r15", "r16", "r81", "r83", "r106", "r110", "r111", "r114", "r116", "r122", "r123", "r124", "r170", "r223", "r301" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bdsi.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://www.bdsi.com/role/StockholdersEquityAdditionalinformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r43", "r89", "r90", "r91", "r93", "r99", "r101", "r121", "r171", "r223", "r228", "r278", "r279", "r280", "r285", "r286", "r303", "r304", "r305", "r306", "r307", "r308", "r364", "r365", "r366" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bdsi.com/role/CondensedConsolidatedStatementsofOperations", "http://www.bdsi.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://www.bdsi.com/role/OrganizationbasisofpresentationandsummaryofsignificantpoliciesCashandCashEquivalentsaRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r89", "r90", "r91", "r121", "r332" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bdsi.com/role/CondensedConsolidatedStatementsofOperations", "http://www.bdsi.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://www.bdsi.com/role/OrganizationbasisofpresentationandsummaryofsignificantpoliciesCashandCashEquivalentsaRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StockCompensationPlanMember": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.", "label": "Share-based Payment Arrangement [Member]", "terseLabel": "Option" } } }, "localname": "StockCompensationPlanMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": { "auth_ref": [ "r247", "r283" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Grant value of options to purchase common stock" } } }, "localname": "StockGrantedDuringPeriodValueSharebasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r42", "r223", "r224", "r228" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "verboseLabel": "Preferred stock conversion to common stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r15", "r16", "r223", "r228" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Restricted stock awards (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r15", "r16", "r223", "r228", "r259" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)", "terseLabel": "Stock option exercises (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://www.bdsi.com/role/StockholdersEquityAdditionalinformationDetail", "http://www.bdsi.com/role/StockholdersEquitySummaryofStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r43", "r223", "r228" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Preferred stock conversion to common stock" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r223", "r228" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Restricted stock awards" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r15", "r16", "r228", "r251", "r266" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Stock-based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r43", "r223", "r228" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Stock option exercises" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Authorized stock repurchase amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquityAdditionalinformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r16", "r20", "r21", "r83", "r168", "r170", "r301" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets", "http://www.bdsi.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r82", "r228", "r231" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r309", "r320" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r309", "r320" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r309", "r320" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r309", "r320" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r319", "r321" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.", "label": "Treasury Stock Acquired, Average Cost Per Share", "terseLabel": "Treasury stock, weighted average price (in dollars per share)" } } }, "localname": "TreasuryStockAcquiredAverageCostPerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquityAdditionalinformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r41", "r229" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r41", "r229" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury stock, shares (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r16", "r223", "r228" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Treasury stock, shares acquired (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquityAdditionalinformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r41", "r229", "r230" ], "calculation": { "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock, at cost, 3,265,684 and 62,994 shares, as of September\u00a030, 2021 and December 31, 2020, respectively." } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r223", "r228", "r229" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "terseLabel": "Treasury stock, amount repurchased" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquityAdditionalinformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredParValueMethod": { "auth_ref": [ "r223", "r228", "r229" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the par value method.", "label": "Treasury Stock, Value, Acquired, Par Value Method", "negatedTerseLabel": "Share repurchase" } } }, "localname": "TreasuryStockValueAcquiredParValueMethod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnamortizedLoanCommitmentAndOriginationFeesAndUnamortizedDiscountsOrPremiums": { "auth_ref": [ "r169" ], "calculation": { "http://www.bdsi.com/role/NotesPayableFutureMaturitiesoftheCRGObligationDetail": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred fees paid by borrowers and unamortized costs incurred to originate loans and leases, unamortized loan commitments and loan syndication fees, and premiums over or discounts from face amounts of loans that are being amortized into income as an adjustment to yield. Excludes amounts for loans and leases covered under loss sharing agreements.", "label": "Unamortized Loan Commitment and Origination Fees and Unamortized Discounts or Premiums", "negatedLabel": "Unamortized discount and loan costs" } } }, "localname": "UnamortizedLoanCommitmentAndOriginationFeesAndUnamortizedDiscountsOrPremiums", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/NotesPayableFutureMaturitiesoftheCRGObligationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r125", "r126", "r127", "r128", "r132", "r133", "r134" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of estimates in financial statements" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/OrganizationbasisofpresentationandsummaryofsignificantpoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/NotesPayableAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/NotesPayableAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants and Rights Outstanding", "terseLabel": "Warrants fair value" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/StockholdersEquityAdditionalinformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r105", "r116" ], "calculation": { "http://www.bdsi.com/role/StockholdersEquityScheduleofEarningsperShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average common stock shares outstanding, diluted (in shares)", "totalLabel": "Weighted average common stock shares outstanding, diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofOperations", "http://www.bdsi.com/role/StockholdersEquityScheduleofEarningsperShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r103", "r116" ], "calculation": { "http://www.bdsi.com/role/StockholdersEquityScheduleofEarningsperShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common stock shares outstanding, basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.bdsi.com/role/CondensedConsolidatedStatementsofOperations", "http://www.bdsi.com/role/StockholdersEquityScheduleofEarningsperShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r102": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1828-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r135": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r164": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=6378536&loc=d3e10092-111533" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "30", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121647444&loc=SL120269210-210444" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "30", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121647444&loc=SL120254536-210444" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "8A", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121648281&loc=SL120267834-210445" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL120267845-210446" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919260-210447" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919272-210447" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "3C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL120267966-210447" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "3D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL120267969-210447" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121614247&loc=SL120267897-210452" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "13A", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121565518&loc=SL120267917-210453" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121565518&loc=SL120269220-210453" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL120267853-210455" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "3C", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL120267859-210455" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3D", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL120267862-210455" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r194": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r205": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6392676&loc=d3e7480-110848" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394232&loc=d3e17558-110866" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r215": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r217": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r222": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r231": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r235": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "705", "URI": "http://asc.fasb.org/topic&trid=2122478" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121321822&loc=d3e3913-113898" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=SL116886442-113899" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4549-113899" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121323062&loc=d3e15009-113911" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r294": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r321": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r374": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r375": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r376": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r377": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r378": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r379": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4),(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04.(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r88": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" } }, "version": "2.1" } ZIP 66 0001103021-21-000106-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001103021-21-000106-xbrl.zip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�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�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

.FBBH1:CX%KY+=)=390-\3RYD>=-(BN'P?SN#K_><9 M 6VH*31\D4P3 "-S2O%0(ZR/AS/W!9T/2IEM5-'B>+@>;2X#';_AY>:)0H?@ MT8.)R=0K+CBX1'\(;C&YQ)ENTUEH)9H#!*5[5=K-8]_.$M]'W.CYEZ_]$-'F MS#3/->^BUC6' *$6A156;T,FAU3P-HEIZS$]82-E)[7LP\"]TF]Q$VA[-4T. MW7"V-SW>QX^.2MB'+7(%(BM,!L803"9G7/E@(#"M@46CA2#'+[ FF>U[Y\?V M%DAS>FPC^P:T6#KKMQ!>GH(&[H1,'ORBYJ\F\OM$$&.2EAMC&2%O>"BR!M81 M6"*[:G#U64D?XF^?,?=N/DE_G$Y&]/#9R_\^KYFA7Z]I&_9QE^=V+^B87==A M-#=R[LC_D"8G,D71J)1S$-HYEH0*Y)1DQP;;O:JC(W$:IO@\S#"_F)Q]I(4O M7,R,:1A_6.03D%GT]2/+"[:>_1FF^?6W9 IODC$E OE:9%7;FNJK@H-HN;4H MF="E22_+[M [>V%5461+GD_3*;V$9N>':3A[=CX_G4QKY?M%/P8^X#)'$Z0! M+72BS8#S_%,#N??EG M7C#%/, HE#(I@G2BMGU1DA9]+\&F*!4OPFC79-+=@>G)T:@O_32P MTZY!NP3U[!-.PP=\,9G-W^!T 7@@K.)"<0G(:Y(]_0<.;0'%,&;+E;.ZB<6V M*<"G3:J^--<@T'$-YS_"Z!POP5:4OR*MI7E@D!E5A(.@HP654$&4,H.)$J6. M///2I+7*)N">-K/ZT%B#XZF=171A)W\K0YV=S$]Q^OXTC$\^UD?,_DZ/F,]> MC6G^#&FP(M+D>,*"RQN.@@'3<2-[N%NA7" M)\/GX]%SCZT!-QO4;-VH:D^QDW)]; /I+MKSUAQ;+Z3M0]Z;1!6\"=);GXXQ\XJR'%BRG'![F8+"6CJ>;T(B?.@:^Q &=# M3EQD9/RXCL56#.+)D/G@#&C0 7%AY[^:S,EKN,4<1=9.DUNVA/CUFMM7F;?ZY'F*%"3'/ M:B'V.H#.) M'*6/CC$KCOD[AXAZ&F3->/OM_.)6O.*,U 5!VU /DVN.)+/UDCPIK(E."77, M<^#;2+X3?J]<6,'NSE&LEVQJLBR\JZ*&Z<4_1] M]+LK]"?#^0? C!43H7NN^BC,9B?EGZ&.<7XR?3O\<#H_.9_/YF%<&W@-4O!) M9(D0&*.9&H4%;Y,$I%GJ98Z69G&31.1[@#T98C;1U HJ=;ZF:B7 2PO_S90V MD*^_G"U_.^,#SVS)M8TEEU*"PGI7=&1D#FGF0PDZHVK2X7,GM-])U[M.5S"Q M\^U8EXB>C?,%I*O3)*#*WCH-P:,!E6T@=S)&\-DH+WA(DC6IV;H+U)/C56\: M6D&?SB&J-Z1UG$XQ7TDZO(K/,:6TK=UGT#E0)M.>+34",I>522Z+T*@MQ9VX MGAR)^M33"AYU#PY]*XG4"'1DT&@(ZWH MG%9T3O-1"R%1A]PFYKD&T1%42>^3(+?BG'THJD5%[!4\RU*^31 U+9B^!>DP M==(]Z6RU?=]5X/NA@C:+)CPA M&+"-G%OT7<'I$&?/KUMWEW=32:5,I)$Z5=-]9)$5FEZH M?.ZHLIN[04_R;E"==['?7=;[2U0\*?(&=4HT2"8X1$.PBN1DS4LM=&R2RG(- MQ=.V''972(/RJ-T%\6T8X_QF%,:_A;/+U@&;C*FEO=%B4(>Q6#IP9=NH^[X4 MW6*W:S$V80J-(!O(3M*R+7P![[@ ZY+*LF0C99-+N!\.>>^QM8ZB M.L+#T>:*OW5G4U]:Z]'2JSV/WU:)+"9:X 9S5I'LR\79FS U+22!*[HFOSHK M\B8I0QO==O#UK4_3HMM=\#V6)'\%L23A)C#ZOO#DROOW?\7)CAJXJ<,.XNOY M)I.K<&RPAM6K&G(Q",KY3$BL QO-^.^SO+?M*'X'K> M2G\-GZ\ B5G+*!S9" 4#J'HYN ]. $:G2L@YJ,![T^#5-S] #>XLN ;V]46I M+M8#W_/91:M+KQT+)H)!54"%&,DZLT2I(+621F;5YG[*6TB>IK'4CV)Z[%2Q M$M!E=]L-(+4\P5J!Z3 '4!VU=9?N.XBZ]7IQ"8WE:%T.8!/20IB<^,%@FB M3^3):]J\G$UF4:&,T7KG;C9%6%-L<,=+]G^-ZQM:G%Z1J\:?_A:6C"YT?BCSQ[ '3'TWB:X3YG<["2"V7N3L$^:8G+8A M'B9ZT+[9\*X(ONKTBN)??OZ(];3U'Y,1/69$Q'@;YCB(*7/:<0QM0[4]%'DG M$)G3@)A5=3K(@SFNXM_-QW:$A^S]LKVW'(O%9(=)ZG;-4IL,Z6G2__#L.$2FU2[[ MW,_#3\-,IO;%+A>9%]$8\"9X4(RVNJBB XN66_283)L#SN8C>YJSX&BXTJ)_ M=F]'T1F9C-Y'",(J4)'K"S&K>G-5T(@I-KD8X"F6=76B]$$T?NBRKNNA;>X] M=RPI\%A[TREKP?DH(#%ABI E<+?)H8%2!@2'O&:*)1H.YPA2!:ESM*J(WB;@D:3F[*S!G06W=@XV#,^].S\["],O MDW*EQ>^S-"?_9?ZESQ#$TC9XX\'#98KEQ%5)H TOY%DX R'0]F(0!?$Q>X%-&@H]X'#9,NYYI5G+ MV\EH],MD6G\YR(S6858B(&>F9M%*B+&FTH8@54$KK6S3[:3)$,-[ MI%@[UN_ CT,4IFYR/];7CJ=_GTYFL\7-AS(E6DP$D@G(?(!87(24,T/G/;(V MS1X;C.4[Z8^ (RU"7=O? 6-0&6U4!$L3%E1* IQB-%&SKK=VV!S-]QM]CHBT M;35\3#>V+@="4BLXG)]/OUVT,8B:'&Z>.9A8_6BA:HV,=! E251%E1&/*\EO M_5B^L_H(.-*@N*5_DXH+$B]3Q$NI!2@3:L(XS6-C,R:=D(72)N#:UN0^J&C_ MB;6![]?[TZ\UAZ[D+DMR6^N#45C N4#[>@JY'@1J*%PP6RS]NF&"TUZ'^H#6 MHZ/S^%NPZ0B=HPU'/.!,1Q4LZ8(9VA&\C>!-\F!T(KLC6JMCF\:I^QG? YHI M>Z+J86;65CP[JB98*QW).X(AMBF,W.,8 MOT^KKM/J0'P[JB:)Z^YHO'.T)4ONBB?V,ZS9RBI ,+7(5J$+QO%@&G7ZWNLP MOT^PUA.L'>L.<3YSWVA7.-]WCE=G'31+";RN%^QXVJE])+.=!<-E\CJ4V*3% MWKX'^GV>M9YG+9EWW$="=P[38U#2!PM2TPB55#1@SR)$EJQG2;-X]+'9S>?5 M_M7P+.?%/ ZCGX>SFLM>^?28"N)NS],;MYT[*95#C432186K,N!9%L#18%;) MJ%(.L[7O.J('1/S^F=?N.*<#;5H\'T?BA:^+6=Q<3T=#,$Q&,3R1+Z10$FI$@N#;:)55OX6G! MVT?8H7$K0MS;H7$;Q>RI-]\FD)YHA\:MM+5!D[Y=1+TG%ACKL]5& G,ET.J; M8FTWBU"$USSDP@1NTIWW>+6_=8?&OI6_C82;1K4NU[AO2^!ODS$NFQ N"YNT M\"A-U!"U]:!$T;3@20\^:)$Q"OI)XZJ'#5 >1]_'K?2ZU@3O6RE-BPYN@WUY M':E*W MI,YG]B8&R48'G,M-4BBP&3V!3V3=]7CXA[G10QT'+%&_<"M.T5/'N M=[4K5]QBC#=*%IU7W(>,3!6K@F$QFI@L8SI%P0MG=Y4LWOW6@Y*%@E^-2:_G"S_F9'Z*T_>G8;P\GZ$- MY!-I'?/5K%[C,M>!;!EN%.TA,6MP:#+0,L25M63E'.@RMEZ'^8".^7:; [V= MY;5GT3&5/VX^VF6.MD;4-"0RM%)F]3+C#,%Y!R(JA407SO0*_GI@UL-6H]!K#()*B0%#C."X@4E63:.V&.JSW!E@/\ M/IT.,ITZL.R8XK'WCO,?"WU\':?S*9'O9DD%U6*PY.%%*SVP7&_)5)ZA"P]K M-ET?X/?9=)#9U(%EQU1O>N\XE^EF5X8:LS+"*P'I&W-JV=1#A M@1GI.\GA :V4#^80J1D/'Y13O+DX:K./P ):R+EH4$E&<+8P$([[I.G+Y!^8 M1;+YX!_0!#R&&7"$LWDK^CZH*7QGS>4*06CI%7+#0!=;LTF*!.=+@!*$RMZY M&.1Q-9SH6P+?)_-Q3N:61'[ 9VOW"X(Q(Y4K H2(!I0P"J)V9&X55V1,MI30 M.,?EP!+X/J./U+L9D!8SG[6N%ZMD^\!" M8KOZRX>LFU.&Q\ ,@O2:F(B,07260^1&)*\95Z'-8OH$Z^8ZG?@=1./'4C=W M 9\^?'$GDPA)>%8@!T]FD*JW^=** ='3;U!*(6V3FKEK*!Y^O=Q61)CTI9"C M:@/W;1CC_&84QK^%,UPF_&\RII;%=BT&=9AJO0Y4VQXY-S=1K\-.'NC5.5W4LCL[;O? ME[5,Z+VREO87'Y# 9>?(R5$.F"/31QL9,#4AWYVHCM!];J[X22NM-2@8N%W= MJS29)LISR,4OS)3:")//MD-"W M\K>1\,$[)!AM6(@Q@N"^W@RE)'C'.20RV2*S/L:R]Q+W(^V0L)5>.W5(V$8I MA^V08$MP#C&!E!Y!T2X),8BPN/Q%163H[-X;;!QCAX16W.F@CCUT2#B/,_SO M\PKS4[6_+JKT9SLU0%CSJ*[]#39!>*-] >>B7I>=O=1<>6V"RPF3ML4*03K5 M@W4/[3@IKS_UV\%Y2<;1@A"!A5)K+A.2MQ,X%*.%4";ZD%23*;@&T*ZK3]7, MX-EX?!Y&E>SOPBA,OYR4,DQ$;$E4-M%QH-E"\R<:":[V<_8NBLB*9CG?RZ&[ M7G S[+=>P5?3&>#S_ABS [?3X9G\_H M$_5')^4V_,1BY#IJT"[8&A@*$%32P',4QB;)A.9;J+X+EL?#DKUII(6!6P]F M+C;9:Y=-+H+'B\TRWCP%&!BEC#->02FU2DEZ 8%E4\^%+$T+Y[1L<]:[/=8' M3K)]::E%4N9U.5P<"VEKDDG.0MWF07$RVD(P#+RWV;/H4\$V%NX*,'L+YS9 +@,@V::@D99%IE4$E:4#A]9#+-67*P4-:]-B?S6>@YW(=M;S M/<391=XMMJ';L);.WB; FD;'UR$[S'%K+_J[GQ,=A+]7=KC(C,Y)T/Y6;WL) M!#"0%0Z."5&,+\[%??AKK5EQSS'L?DFQCZJK;LYL(.H>W2!9]/YX/UP7J.3K\9Y^&F8R?6Z MH+E2,666P ORQ)4GKD=.SI0G3YU\J2BXV"2SE%YP1>_TW4V=KT7PX*V#?F3; MHQ>Q$M _A_/3MSA:N#>ST^'']Y.7Y&;/OUQN5AM W<)2V(T.=V/P"V:H4N- 2$M=FZ39CI.63)?+3I$!7-BG*?3CL66-;')X\VVBB M1](L#O9>G ZQ/$MI9!*1BPJN!2: M5.-?WM%/Y0T?LVL,X$Q MD(S79!G#:066"71)4MMD93:'N5;V:,B[91K_D7%W&_VVBC9>'4Z%=YENXYF. MR4O0EI%)P:*!F-%#8D4&LCF=S>VBBJLQ/9(4_JV4OBKRV(/&&IAK=U<7&ULY+UKD]PVEC;X?7X%MON-'G=$P09(D 3:,_-&Z6*/8F1)KR1WSZQC M(P/7$K>S,JO)+-DUOWX!DGG/9 ),DD7/=LQ84A7)<\X#\L$!<"[_\K]_NY^# MK[HH\^7B7_^ OT5_ 'HAERI?W/WK'W[^_ .D?_C?__9/__0O_Q>$__GBXUOP M:BD?[_5B!5X6FJ^T K_FJR_@;TJ7?P>F6-Z#ORV+O^=?.83_5MWT2Q)A!%E+(4HXAD\TG^47?@S/]25C]\NY1\56%^42]P]@KW+[B^#+H?01S! M&'_[6ZG^\&__!$ -1[&G'SHMB[ZE.2^:TQ*G3\H_GA'UW MA?H]Z;LZUK4'Y2ISW_6E8QNF[WI3][/E!SV\PCMBKE:Y?J%>+]18[^Y&U-6J M#Z]Q7Z_%*%VSY=ZC M0:[^]0_V;[/'$MYQ_C![NUS901ZE6 MU&0H(6RVVB@^TPOX\Z>UZ.KYYQ_^AP"+5F>&H-#E\K&0VSGM?GYJHK)SE)O5 MZ'<+?J_+!][<8#5TTW^M]+]5^(/%"DJ79O;K-T1 M^D[/5^7Z)]#]!"+0'FYHKOY-(Z-P\KN(>XU]NBL*.H MG0O[XFE[R0?^Y'YT^RLOU.M_/.:KIS?6:2LJ5[=\O_JBB\]?^.+]@WM$^:-] MQ*I\LZB)?Y92DG"5&(@$M;XIS5)(8X(AQXFT;FD<T:\!P7U6EGUU5?),O0.E,+/\<1C"CC;H?>4UQ) Z%8D"NP:#7:L M!N()[%[76 XJTV] ;3S8L1Y4YH.5M1\T -R &@)@7Y4:A/Y(>.QAZY/@1]-] MU,EC[!$YG)A&EQ\VZ0E5YK.WN;2*Z=N%>I5;<;EX= (^NMV7\B=]+W0QRT04 MIX0AJ*FT?BM&B9VKC():IH1JZ7ZM_>8J3XG3FV(:G0%?*+"K-:C5]IMN?/%N MGR4&P'!HK[."76N/_IU\45;/I6'US8Z*Y)WB<5U+MHEKMG);?7C^Q M!6)3ST?N)C?+8,1B5,TQOH\996H(M&G-Z*&WA1&QTOELO4?^V=XZ,ZF*(LPM MV2*-("$TA@(S81<+(I(XQCC2T6RUV?DZ^W8?/CAHE^#,_EV?[_#F8, IY_?Y M'V'5SI;7(# P+?H9[_VUGK-TZR:6:S^QU/+;N^77[^PMM8MH_W+H&1X];I3/ M\YP1Z^_P[.]'7NXW;MC[QY4[I7$'7V\6EA$692[_RN>/>I903*.$,<@3HNP7 MK%.[M*<"4H,2%8F4IHGT^8('UW1JE'![=U=46[AVB=;H";XZ16_ C@TW0/"Y M.QX;::%_<;P'7MGW.8K37\IO%NM[([ZQ&%0F3V#A[CLJDUBI7U3V][$T]\6\ MM[6XM\!N4U"ULG^W7"P?=&%5GHYYQ0BE),PX)HQJ2A"#("%50 M:9+@2"$2JSAD'FD7-[7)H-[ ^T;7VOWYN[Q2]@8L]/G#DRXH^[%W?]@-3,$U M;+N:@EI5\$VC[/D-\F#V]$.E3PJ\('%4'O.S_I",/._JQBB6W^[S5;5M:)>J M+Y<+)T O9*Y+NVZ5\V7Y6.C/^K?5"VO(WV<9-H@;'$&6X=0RC')K395 %,=: M2J)B$7FM-;N)GQKC[&A?[:SLZ1_&.8'CX,=!PZ$[,">U @NVNH-?G/:@4O_\ MCF P2W7#K4_6"M1@5!;KALXAJW5\RO,LW?=/4'XLEF4Y4T(*9)"!.&76XZ(I MAX+H&"8H24G$,BIH-N:B_82.4^/+YSM[;QG'<1;C5X[.[V@9?GAF[GYBK9W. M"KQE**:T]CZEYN]JU=V"<]_K[391'6<,^R1=WGZP+X0N"JT^K>PLM#XLI(I3 MDW!(F5*0()5!D8D8UM08?*/CG_Z(4_1]I2FH]:]_Q)S/^ -3;"5EN 6;/0$-787C[/#Z?$R(+W27(NX<>GJLMU'M.-Q2S?Z ML$OT0ENR>J7K/]\L;J5-3J;=H6@, 6\]AB*8SJY#LD^FZZC)J"1X'5J' M_'CET[I1YVT,[+/0X'+/6$.2 QXT7BAQNXUY(8:)A'-=)QRE4H6XLJUR)HJ M;A=-5EGPRUI=SY0&'Y#]G+V>H!N8O3NC%NS]>>#1IQ?8)FY4;]##[D.OT.>6 MK@$I5N?%JN!UND3Y]Q=/+_1"?KGGQ=]O?\O+F5WJZ<10#5F,8TBP4G8MF!!+ M(!*I-$(\U4&[[Y<$3HU%]O0%3F&PT==^%E;C0"*YB+@?F_2)X\"4<@V$'8)) M_'#I-WSD@LR1 T;\$#@.$?&\KRO3E*OWYL?E4CD:^Z2+K]8=*C\MYVHF->6I M4A0JF;G"86X?GC$#)1&,XRR1,0\,J'GXE'R]8F_ MS)21DL$TX\+R >>0&>MSX#1-8J4(L[P0D-2^]_"0=WN<_/47K]^^^/FEYTG^ M";0\]I$Z(S#PU]WHU27+_."-\=_MZ8S%2!LZS>L OA&/#X5>+(N'+_E"_QE8 MI26? Y//[X%9%N#EEV*YR"7XP//%MV!]5VY)$CSP8I7;:^\?X?(A7^8*\#M[ MK672ZB@7K%RISRJ:+%^H7%9E/]TC5U\TN.<+WD2@6=I]X"YV4-L/00.KR^/= M%[!:@D+_XS&W/U$\GS_= %XL'^USW=W218_>@/FFEE8C?RO1R?GU2RZ_ #ZW M5RPLFE_USN^7=8B1?:C+,N3*BK+Z]94Q?W+P6W>F]N\8;_/II*9[^TNGK^@8 M?V7?ZFK0Z^HF+BQLN:B"A=V*1*E8\MA.9#%)E5T#\A0*PR.8<,ICD3'+RR0H M JM-VM18!N8U8,1"P^Z\D&BU["K5H'C!E[YV'X4 M>N5UT]3J\OU5EW9J6L>9_DV[:AY:W=K9R$Y151#J*VO6#SPOFL3^+-6$9!2F M--*0Z%A +B2'B&9II)6,D#"CY CT;=G4.'&M,."UQL!838';*-"KNB( >- % M^/CIYQM0FUHE(3R6JOIYE8PPF3J H6^9)UE/1=\)30SC51)L7KJ=K(C-*]L M52=. <5<%A-IG#!4.,_B62+WHW[?:1H##6FXQ4U[*I@F$M1%JO93_DBOW^\ M;Q;V.C($4\J@ZP@!"4)VZ2%1!)G*1$1-G&GN=?QT].2I3:F-O487GC6VA8*M/?LT)_]UR'U'3]T%.HY:\OZTS]_03=O?O,)OUD\ M/*[*M_JKGL?KN& NE%WQ:ZBS-(,$,PXI<4XV2S)N&,$!KX$][Z3ZX2E%/T!C2 #1 U[(%)G[Y.F[A1O0\/NP_] 9]; MNF9:"H#B+H!&$0A+9^9JZ%AH8TQ@KPQ*,=%@V MU:&(J9'"AV+Y-7>-MMRN]G??%'I>Y? LC4O>:90'2U%:?4JI@ROBG<#8CS6N M0VY@LM@H!RKMH++J]9F_=,[T?G.3CJ2,G'=TSLKCG**S5X:[YB_M0F YSY4[ M,'J]6%7I1Z^6]SQ?N"/;3)"$0YXF4=T_AT940)Q1K!.98(&]C@C:Q4R- '8U M!6M5P2^ULIXG!!> O>S8]P/7P%]]1Z2"?/[+0%R[ &B1,-IJX+*5NTL#CZL[ M!IT7KD#:ZNF#'>;5[:+:07BH]A,6ZH=\X>J_OG6S856"^[WYN=1U/+RQW^6M ME(_WCW.GTRO]4&B9U_L4"W5[ORQ6^7_7Q_@QC1C&B8:$6*^"&*TAS4@*.6&" M,6TDD4$E?X97>6K\M+:X.O?7:W,[U&@<8;15''/&HPC&$A/K/B8I%!%VT<:Q ME)AE*)8TI /;Q$9[M+YN#[^C,?=S9ZN V:36C,34:((<^EQ5:)<)@SD5$6NF+,B:4I( M@N/945_;B]QU3IX7X_@U[>TY^ZN.PEOL]P<-FSG.@IP:$FM*4YB0U,[Q68R@ M$'$,E4A18A"G)@O:0+X*W1']L(V>0P'K-Y'V =? T]]611=^6BFY+G[3WRQU M"8<^YY:SLD:=$2Y9?,CC%Z_O$N/_N.!?>3YO#D"(7=YA02DTF:N>3UV!/VD0 M9%P2$F?8+OX2[WH3^\^>VN?_XN=WMW^]??,V)+Q]'ZSV[_M*" ;^I->*=8KR MWX\^\C1-I5/V+&[BWSJU]W67SN% MZUSZH*MR]64YM_>7=0C:IJ8&(PF/,7=E.5D&B40)%(G0T*1:_OW[YZ_?'3G_YH7:CL>_#Z M__S\YO-_A2TEO ?";VDQ!+P#,\2.RIM-MM73(*5.0M'I1!K75ZO>1OW2$8F^)1\=/ MGEH2\@_+PNA\]6@_L\NYH4:FJ7$1D$)E#!(><\A21*$A493Q+*,13_PJUTS+ ML!"*&J=J3D@*\HZE$\Y##GK1!IZ;GNWEF?K\YIV!O /0_Z3DXR[C/HDIMU_+ M?A_3]B"C.5[.<2?M.KH/\HM6CW.[QCRM:[7!M$Z%MO)J&\OR\;[^V6=W.+[M M%YR@-#:I2B'6TC@W@%DND:Z!"MPH"WXNZ](- MK[0K(98O7(_T+4NZ?9?&5-!T. V]9 M9E+K#.+4HIH02)@R4*38@BPCFF4D0R)5G;MN>2@P-1+9J S6$=/%5NDJB2FD M5GKG86EGF3' 'IA]3K2-VD*_]MT^[D)OC0"?1H#^BL9=/0_!\W7PNGHHKFOF M%8!C4%J=VX_GW5G7"F5&3B3 D848XAX4D"*9(& M:I%R19"A*@VJX32N^E.CIZ,S2MUH"QZJ%IV;,\@;L+9CA$+)_;XQ/1U$/MM[ M,($#Q_+"B>-FUW0#0FMAX_55=1_8$0\5!QG#40\/^[5@6H>$@XQ.\&'@,%IT MK07P52\>];:/JV2Q*S.,H4IY DF*7/0.-I#&VA!B,A;CP/3T?0%3FY_6^OTE M- O] #>_.> :- 9FZ;5J@R1_G+.[WRSS QDC9Y>?MO XJ_S,=>$G,)^T?"SR MU=/KW^07QRWO[.C.=)2R),4,&H4S2!B)H*"E_T'+21 O'[!<"\W0+E<8*D'G*6VF7W&.V[2>EVW M*?B=7KWDY9>JD*[2ZL63B_UXLWAO%S_6ZT!VOUW6KMFR9&Z<]@8P386C&(&]$=Q#X=C0Y:C.J*=$?IT%FYXDE= M>S >)K&ZRCNO\E+.EZY\P3;D+$HCCDU&H<34]6%((L@E22 W,L%2*R22L/!" M7\E38[Y=Q?^YBS&T:V\CE.ZN'S)/'AQU($;;01D]DKD;M$-'+P=J]>P1R]U0](E2[OCDCBV\SA?:?:'-LM [E7;W MRG'31#(:$P,3';G];^=2(L(@2TA,(D0BE0;US^VJR-0XN-+=,?!CJ6^ >,SG MRBWXJFX_@1W!N@Z-'^N. ?C 7+M7W/SF9'5S49FR5]Y\F&KFU\+9:QNRKKJ, MVZ/L2L2.&IA=^[QN#+I9Y+]9R.6]?KLLRQG#Q- H4S!Q_4<)S23DPJ0PY33A M2:0)(B2D/\4)&4&\-T)#B5HSX(89+&MU[9P5QGBGH/0CLRL!&IBGMOM^#4K? M. 7/Q^H$DT^+^7WRRBDQHU)&BYV';-!V:8=\C5=:K+;IQU4^B"Y7[Q?SI\;) M_ZR+^UF*<$999+T@G=KOGFD&*5'VGTS$$NE$4NKE%/F+G)K[LU83+*V>-YO$ M#)><&Y +X(=V.S4,@^' 3.'TW2D7<0,V>#J=-PO*ST/ &9!,T3NL(Z5/] %O M6+I$$%*M"1)^3QHO)2+(LKTDB+ [KZX=O,X&S5 <)5Q32!)A(%%20J$2#E&D M8\DUD29+0YRR8Q%3\\GJ)E^R5@[,M_IV+O_KEUG;#T(#4^V.-GV@ M>KVC9M)>MK*E!F\?V;-2%H]:?=2KQV*Q>2ECQ+3DBD*3N!Z01&%(%4M=!WI, MA-::L<@_/_:4B*EY6XV2H*BU#,FV/(F@AT=U-2X#?]9K2!H%+W_:OMB$Y)I> MB]%8V:3[K\^W?:6(MIG?G@1Z\LX1TSS;--]/Y&R]LFN5D(_Z+G?Q(8M5%5XI M!<\2$S.(F$O3U)Q [HI$Q5HP)4F"N/2*W3@G8&ITUI2YV"H9&*-Z$L1V3NL# MFH$9+1"5#C4_3IM^=:V/@\>.7./CM%''M3W.7-Y!_R>:C\_F+-W2-W^2K*A[DO6EI MIT-233,F%$2&$$AP3*'0DL($:).O-NOAA*&,)3B&:1Q12(3;3N55#1FS1K3<%:U0$V8OU Z9-K+D@D>N"Y>OV;^V[T[4)5I;RK,)W-^VX(,YR8V"Z1&(9$9AP*Y#+XLHRQ*(F- M\=OX") Y-8)I5 :ZUKEN.[BLF@>L#W1XI7]P(:N+Z/NQ3<^8#DPY:S@;=2LT MZU8,M<8#,$\ 0#V7P;HH=NRJ6+XXG"B2Y7WKU'H!O5LNONIRI0^KDIQHT))B M&F.E$HAUFEB2HP8*J1'4-(X4CB2F+)X]5"5.K.-7K#Q7>Q,P+80!#@T)109>*0)?2QB*FMF-<: J=BQP/&$T#Z34_7P3/P M9!&(3#!/GS>^3]8\(654#CMOY2&CM%QY_?=]^UM>S@S&A"@40=RUL^YKWKNOV+5LGXSY?5?["[<*Z' N7I*87,M?VL]91''-,84:%783C M3$&*5&;G\)0D"">Q,%X1S!ZRIO:%[ZA:;<[*767!-U6)(8P"U[=M6/M]_STA M.# 5'(*WIV=_G. !1I_TT"9N5*;PL/N0-'QNN:+TVYNR?-3JU6-AGUK7OJZ6 M$1_M:J/(Y:KI*E&M4M[IU7NSTQYWQEV.JL $(B92NQ[0">094U!@+F)$A619 M6"3BE0I-C8FV.H.RJJ+$G=:!YVQ7CY+GKMB(V ^]HU5A7=L":F,V?0LJ>V[ MSLC45S<[6:[LYM+LME'ON>I<#PCW7HSN&IW&KU'7 X(G2]?U\=R.<0SU3I#K M//Y1/]BOX LO]7OCB+^IVS2+#,-:X 1F<1Q!@B(-A4PC*%+!3(8D)1&9+?2= MJTCR.2":X:)DK\^:U9_UD?P!#^&;#>CEHCZM ,5&_< HALO8>P8Q] /E2#$, MC;+ + NP5==17ZWPAJX\0O>*!R%+_C?V3%$LXJ$V(0J M4Z898US Q,C$\0V!3"$*-4\0QUARA8)VA?8?/S4_[?;3I]>?/P7&6>X#YD<2 MW6$8F!!JQ0:)U#YM!;%#&7&4)BEL66T%!,HC#!0QU(@KN.(14&9 M(GTJ-S76:[1;!WA9U[Y:*87N/O4Y?)YD^$R#,O2NU/5Q5M4?8#VPM8D3B)%J MP7T2L4ZG]/M]Q"RU(-M;[%&;C,[I?LO'ZICBPW*>R]W.35)JK",40T+2%)*, MI) :B:%AV-",&RJS()?TO*BIT?%64[!6M7.Z<0O GNO07F ;>DW:#;$N>7T7 MP.@YI^^C\OYW"P+=^,,Q4D6$8,A M3X6").(19%1Q& MN(J6)$#$9Q9'L;,+4^,V[Z_Q(_F?W=V-@+W64$9^^+[O) M"M@!XF);^6%*23S;2$[".^YNQ>_#A[YZE'KSM*_7I/\XG]/&S%*!5,P1A4GB M>CUJ$D,FL8(HS2*&(R4C$10^&*["U.:WRH*&RG9+=?07S'-F**X/W[D>X#&F MD[*)V-G$Z%SL?\:-'?B=6)UQ0G7:T1PK..>,%I,)QVE'*20 Y\*3NA9(O57* MOG-E5?[H?5'UV[5&SU*&F&'NGUH5C[]6^9MO%C6US81FBF$90<-4#$DD":32;8>FC"OK<.%,F75$ MW\![$(&J=P@)'.&H2]-!'9$ZP:_'Z$,#^K A.,,@,X"X$RX 8T13S? :0LJ=7OLM'85 M7+UV8^NFR;@=VZY"ZZBKVW5/Z\7QN5VHIE[Q3H^Y5WDIY\ORL="?]6^K%W.7 M$:9-DE(64:A%E$$B$(,<"5<6*>,R59)+R:_PC'SUF!K[';H'54SXND+WVZX] M([L.4B>?:PCH1W;*SJ$.MF: 7YPAH+*D_T"JKE@.Z-QYJ_*B>^:%8JD>Y^NA.L8^6CY$TG.H8QH8B2*1@4&BJ89P@NW;,I#12>/?0;!$T M-19L5 5%I6O8,O(BJ.VDUB=4 [/6&J5:3?\%91A< 9TV>X)MI'Z;7>$+:[_I M@4EK$\ZV^\=KQ>EAQ5Y#3I_KNW<:?JOO^'S]?DID-*%4P1CQQ.4S<2B,RB B M]M\L-8DV-+3/\*Z J7'CVBV9.QW#^^CN8>=!A5 M6[@K.B-W%JY>F77#DI[["Y^"P*>[\-Y]H_<6/J7UJ<[")Z_KMF#^J%<\7VCU MFA>N/\[=$>\K;7*9N];IF&DN"4P)B>W:6"50,$VA8;&2$4FS) MJ MN'-9Y 1);JTA4+6*82M>#Y3]%K?]8C[2#8*GS_9#UZN^J/3 MY\K40^JHBU!_% [7FP%W]A^W_-(51"]*._6X*CCN[ZO<^FF?M&RV#F<49P:A M1$%!&8=$V_\PRTU0*\)HR@7A2/<5PGQ1FZEQU ?[1FL[(ZP+$\J- 6"U=/'- MK@94V5H#:H A\V.UT09B8,+S*%.X-:=(.!&<^!4#XV<;L>]G2,'0'-@%NP# MR X1U5[P7!U8W2YEY/AJ+Y./PZS];KON /:CECK_ZC;:WNG5>BM#R\10I@CD M:689)HXT9#*.H"+* 1 9;CJ=LIX2-C5ZV1SJ%1ME;\!"!RXD6^$-.Q^]%K2Q M#D$_[N!5YX?=SN?+7[G]1JIBIR^MSYNOP-ME.5"+Z(MH#7',>5+>LYQEMEE^ M[L"R]9YNQ/+&.D0+.U9//^2+O/RBU8_+I2IG @G*28RA3%VL&DXTY'$:PY@) MDB@J4TV""M:?%C,U,EDK!^Z<=F$4<@9(/_*X'IZ!:6.CX W8@%3I> -^+"Q% M],<,[5#TR0EG)(W*!NW6'O+ A:N[G+6Y>JNW_WC,R[R*N'==FCC)L$Y3^^TS M2P D4QJ*.%909E1%448C'7E]^^<$3.VKKU0$6QV#>EV=1='GU.TZ;(;V% :! M)>38[3IXQCIV.X"IKP.W\\:W'[B=N&_$ [?S6N\?N+5?2],/2@-SW!J@:AZMXD$_Z>)K53^I5AH,$O]Y&9M^>WJ=E39R2Z]+ M5A]W]+IX1\=&,G7DTDNG^&)5[]A\S,N__Z3OA2YF/!&&8DL6*R2AU-,(7?=I6BL>(2P82D-JKY[\/RIT<5+7GX! M#U:QZ@1BY=0,W83=Q\]W][4S*H-ONSK-0*4:<+KUN<]ZTNA^-UCW18R\LWK2 MON,MU=.7/7N![G>/E9>,K+\@*<>09A1#PNW?F$DCB)04*9N0'PCJYB6\OG^8+Y^T;O::3ZOW MSH6JNMIEE2;EY^6*SW=_[_9&WRU7_Z57'[580*(U M@IRG&BK$E.%91"3V2I,<7-.IK3Q^7A0;W?:JEMM_E"M0Z#JW9K4$B^4"UN;6 MT\J)2N> 5T" ._N"K5K6Z"._''[3SR2&?,1IZ&3!](U]ZUFG.BBR%H$GO0); MFV[ [;V+S.IOXAD<_CXGH.&4'74B&ASSPPEI>(%7%GO_8)_-Y_]W_E!%TK,, M)XAFVDXH*H/$B-1^.RB""68\4A$C,O+J1=#^)1%_EW?+:T^^FK.\0#NF)QY9?E7+W- M[_/5#\OB;?Z/QUR]J:BHJB\W,P+K"+,42LPI)(G,H-"1@90D<9Q(BC*)9U]U M(99> 8*7)8:\Z+MR!SR56>L,YD[I:K=Z7JD-\JW> 9%R'K"W4\4 4 Y]LK7! ML-+6=:I)"R. V.Z@Y68FH.WHQ[0OSF_VO>X\:JA\"#R$0 > MF-V;J.BM"56*_M8(L&/%#=@="6?("*,0'(<^Z&B,&ZO>]ZATB6SO#*=']'OX ML\>.D.]L_8DH^N[/ZAH[VU1$J<)?JA(+LXPJ:12A,"-$0!)%&E)N%UDIBUA* M"-9Q$A2G5A5^XG47X MUV75JWVW2LG1T_X7^A8A#!YX ;[6)4X(B==/7NX?>'ZR+UT5Q/BG/^(4?1^C M&^ ^C2J>_966N[_"U:_L!?8Q#]J^$E_U_.E\D3CO%\!O;_G*81UXSCH:@Z:V M3%U7I,_@W;,H]!NQ>RQFY##=LW8>Q^:>O[0;2[F,CE_S^7P6Q8BEKE2HCM*J MNC*&#,<"ZBSC6F2Y>?:H7^*A18>?W]'OK\\D?K6\Y_EBIA(<4T9<+RS$($G3% JM#!2*Q$G" M$R)CK]R[\R*F]AT>I\W6>EZ1.-M@Z;UPO *A<9:% X#3/:\X'*1GRBR^#-95 M*<;[.(0D&3=W/EN:\;[F;8G&!U=VH+E/3_1!8=P@&9JZU8I>3^2["$$!5 MW>$8B:/V%>R)F$Y;W,1T6G==WCH#.7=%O7O'^H]G<6=Z^;'>M9IC01 MUI6"%I#(]=B*H6!$P#BBR @1IU'$9BL7/>*WP#F2$$1$&SD#[ML[&9L=^[^$ M+7B.\?-;^5R%RL#>"2L%AAG&2(4F-]"N_U"9D:K[% M6D^P5134FOJ'69T%M/T#[PNF@;_Q#@@%15==@N"*V*JSCQXMLNJ2<;MQ51>O M?9[,P->_Z4+F957[L27#\V!_T;;YTL1.QY4/V?D68=JZ(56CREB.W9.+T7L["!,*47L6,G? M58K868S[3A$[+ZAK.3O76*1BK ^\>%]4Y<3K?@8?=%&I,L-1EF2N/*]AFM@) M@*9V B!V'4B0S+#FB'$55M?NHLRI47JM\OJ\=G-87C'Z8ZE<#G#-[('$[@._ M'U7W#.K Y+N/IU78=1:H5:Y/PUW?E9IZ^ZR&YPU1OV7Q+HL=N3Z>-P['A?+\ M;PTCI-(NH#[GJ[E^;]XL5/XU5X]\7E5RC7EBC!0&&DZ9I1^<0I[:_V"..34X MY5A'/O1S5L+4R*92TE46V*H95!/W/)3M5-(+0 ,31P=LO'GBHOTMK&#OW6$$ M^Z]#-CC_\%&^_8NVK;_TRQ=VC.:K?9GRO?DA7_"%S!=W+D:PG%%#5!(G=GF9 M: .)(!FD+$Z@P%BEA*:<$C);Z#M'-)\#(OO.R/-ZEUG]+A])'>Z]7J\L[*2H MUM%A9JTX,#JT0-59N/V\B:O0&RF*KE'1D<%&R2I^N,==Z4LX]!I'=T[6N,%T M%RP^BJB[='W'XZ?5%UV\S;G(YU7OM'=6^Z9-3FQT1(5U!2+K $"29@@R)&.( M498@2:ROD ;% )\7-37'H-(4S)>+.VC%W8/Y5NG PZGSZ'J>4O6"V=#'515< M.UI6]19DWRV&+F/1ZQ'6>6GCGF5=M/KH4.OR'1WW,.:\M/SS-^YV45;OBX_Y MW9?53BV=6425X3(14$5I8ET,AB!-F66,C&51&F592KWJ"O@*G!IO-(KNQ_-W MWHR^"+?GAD6/( Z]6^%4=7Y&HZS;K*C4W2L.UN-&A2Y27)(Y[A:%)P)' M^Q.^]W4NF^M*\NI7NO[SS>)6RN)1J[WJGD]N=W9&J$9(,0,E36)(L%W7L(1R MNZZA*+8^2B9DT+%9@.RI\4]=5O:A5BZXT*XWXGZ\,Q". U/06FOPS5KO/P-+ MX =U>]L![E*Z-Q2JGLOZ>HL?N^1O*"XGR@$'/Z)C0(#\HM6CV\]I&A.\69AE M<5_G;KKG;QON)$GF8OL(U#06D"ADV4HC[:K#"J$RP=(LZ*#'7_34&.O3X_T] M+Y[^X^ Y['\(+@.?=[>*.TP7?CT;]Y<^[J%W,"I'I]GA3^A&8C_PO*A.F=XL'JPW]U9_U?.H"7-/D"4F MC8BEJ32UK&7LWSB3,$5))&,:46&":I&VR)H:356Z@2B,CMJP]..?GA :F'"< MEIO4ZDK1&] -D"G) ],^N24-G&CDHB'W8>LX7-+AXRINE#=^Z^NUJ7^];"9 MH$@HPR3"D*=V$498AB 5:00IB3@2&:=2>.T:7Q8U-9)8JQF02-0.93M)] O0 MP!S1%)1<*QK4C3$4MH!TK-[@&RD[ZQ#&!L5?>G7F_)%IS>!J?\)X"5U>ENSE M=_G=T3U#Y/\\\L(2TOQIG2""70%.0V&4"5?++>:0$YI!&C-+EA$W)CQ!Y$#& MU+ARD_VPT;-S>L@AFNVLV1-& ]-E.#R=WFG[92<1U8K$D,G4':%3#3E-,R@1QU1I:90R87O3VX=/[9/> MZ'8#%CIPYV8/-,/2-.&&0V10!HDP$HK(_BW"7."(Q1G/3$C^:V?01DM]S1L- MJZ/SZ\#SW9OO!LG@F^^;5^A="PH=]M>/S>UW WWG^2/OD!];=KP%?N*:;N3V MT2XA%X_Z!ZO'RZ7KN2M7?\M77UX^EJOEO2Y>_R;GC^[XSU7IL/^G/O/?9HQ3 MA&.D($I2# D1,:144LN!&8\R1*64R*^\^!5:A+SD(Y4.+H":_W!K]8 L+; I?(U-H"U$>YTM3_.OP+"/J>&+FJ,.H-< M@=/A1'/-HYXG"?N'96%T[NKFEV\6'ZK^DC.A*1<\PA"+U*[&B\O!WMWH.TX MU[9.)PN[92"FE(=]2LW?529V"\Y]YV*WB>HV;[S-%_J]>5EHE:]^X-(%2C]5 MB7L4,<28R6!L4FW)7T>0XBB#R*@XIHRF=ND2XB2?$S0U3_BM7ECTP#M[25 * MY$5 _=BW#Y@&IM A((Y[Y+Y?1+765FCLL\EBP\IY.+U/;3>^2FW*\#5;29C$U$I.>0Z8I H2B##RD",8Y%1H=.8>@6^!$F=&D-L]'3QQ753 MU84.6C:'@>YQ^#T$E .SR(F&+5M@/ZR!W81"#@'L%8UR^@#X^3KC= +ZNE8X MEP +ZGUS]F'/U^SFDGVMW6TNWMRUTHZUP^T^5*7>\O+OUF-T/^!W&L]B'HDD MHW:-0V.7!*^97=<3!6DB69)D"4$J#=N,;A,WO5WG1CD7&[RX;O.S%68_KZ\O MZ ;F[#TU@=/S!FPU[;-LSF4X^JV7TR)OY$(YERT_KI#C<4_'7<5'4>I_/-J' MO78G9\[W?+/2]^4,940HRA7,9$*M(Y@BRR,XAJF(TY@I8[CV"M2Y)&AJOM]6 M3U I"GYQJH)*U\"%XEEL/;?I>D!LZ+VV3F"%[Y-=0*+7S:YSLL;=L;I@\=&V MTZ7K!SIS*"]L9_U8Y8BO=[+^IEWJK%:WU@&PW-74'=0?BEQJZS?%!'/-(3-* M0\(S2S@ZQ5"F,L-I1DBJ@TIPC*C[U#ALK2O@M;+K@K%V/>O4W586O &5D?;* M:XL.COFF]'3*\3SC/X'3C]+W^*-&8'OR<0,V;U8#P[I*K6L":8$8\6BD_]$; M]*>USNY'^:;MDM1%#$121B1-()V MSK-+OS/__S/V<=L0O;[;R$2>ONYMF;Q]O-O*3_WN[E MQ8L[KB9<8=_[O94P2R*<8*(@0JY09R03*)"45112%FN2Q"S,Z3\2,34BW&AX MS<;",9">/O%5\ SMNH8A$^Y2GC6^5\_O6,JX#MI9*X_\J/-7=CR-V#NR;GJ; M:F-42BU4$>,Z?\A[\RJ?/]J? M5LNP.8VH$)E0:B)CK-!NG":0Z45#*2$C%K2^0!)6#"I0_-:8XVJF3=1.+ MLFKW5,<5[U;8O &JMJQ[W''PB*%(&QES**)80D)3 06/-=3$#I5 F4)1&I*B M..2(C9#%^#L8,;\Y8L!Q&'CZ.-J$K'5W!_VUVKL55&] 8U%_DTM'Y/J<=T)5 M&'5*ZHC/X6S5]3'=)K+7O%C8IY3KEC,O>)G+&5,QYH8E,)&N3V&6*D@QSF"& M&18R92;.<,AT=5+*U":E2BF@&U6W1T)7'Q*=QMB/KJY&;F!26NNW;3)U RH= M^^.=5@CZ9)?3@D;ED%9;#YFB_>*K"L!7;:F:M1?A&#%B?=;52F" M1B@=*Z)DE'@UC3HO8FI,L"E27KE:L/V$]0.4 M:-^5\AQ%V4]8>:8,^ZDK>YSQ;Q>J<3!N15FE]1*$:8H23Q#APX*6)JG&.5##C[/HU:.Y_T@\70OL;' M'\%&06 U[!(9. M_MNO[-P/_,$R8_'Z'X_Y@WL!FG>/4Y5%*"50:I- DC %>8PB*"/,XQ3S%*.@ M(NMGY$R.U!HU@5[K^:<_XA1]_R=^__ ]*)=F]6M;B^H@B#T76M<#-S0#KC'; MJ#A N?4+,/3Z)/=^OEW2L//_&6*Z]((!*7R^&(PU#M M33^'V[)\O*_CME__]J!EW3O['L]8Q%2D%8&892DD<8(ADU%B20,SFBE#XRBH M%]YPJDZ-;4ZD!]7:@GENM$OW>-*\",R1'G"D_7AL&N,W,!_V4-QLV\(&[!CL MBE0V+T&_%#O\L/2>MS.,MN.GZ0R*^LFLG&$EAG>A>%UUM_@AGS?1 S.>D9@D M4D(=)\*ZECB"0A(,LQ3I%"O),?.*1CWU\*G1?*T?< HV$3+^#2>.@&OGX&OA M&'KKW1^)H-X2YTR^HJG$T2-'ZR9QSIC=-A)GK[FVC>BME,O'Q6K=GO1VH9K6 MI3N]W0_:6J;")#05&52Q<;76(PFMVRU&6F'8?P#%O03 M&M/?S0J_MG]GV[0$%0)@92$X*FYN[Y]2:?/N@S>)DN<=U)]6_8[^QZ6W$NE7 MJ-#];.I57LKYLK3DN@T(Q DRC G(>:3M]&409)DKK$EB+ 5-$9=!2>NGQ4QM M35$=Q6S5](E4"P'5_[#J.JC&.+ *0ZG3J=5Y$/H^N3HA:?33J_/6GCK!:KGZ MRL(5E<<]2Y3.F(@15-CUL'79[#1C&J:N@8Y("4]T4![ _N.G]MWOE&6H].M: MJZ+&SM/UZXS(T-Z9-QC=RU/LV3Q(:8I:PO.4I=BS[FQ)BOVKPK[:LEC-/CI? MHFK*P246/(NMJQQ%,22QG;&I0A(F)HYY1F-!>>KSL>X]=6K?:*584#.3?9#: MO\K.IH_P,>;E*I=\#G[2W!%^_6GVU++DI-TM'Z2]?N=CM/\Z_!#W'SC*]W?2 MAO5G=_J7?11_J=XJHZ4R*"(01(,$VR5$LD M0BJ&^(L.XH,1BH6XGBO2J@[,?/EK";YY+*O=MC]_]]#8XG;RS-H.P#>&A%%& MP-CX4:0*+??QZP?(](8*4SL(H(' M[?>=%S4U?V:C*5B*T@HMI;;C#HI:W?/'!:$(1U%B,*,6X51@2%RY0!$E"$9) M9)=O$8D02\,.!*_$>-3SN_5')C@MV_C1DNP5K,_)K\,19_, MW2)M5*:^;/4A,WO<<57EE;]Q=R*T>E]\=-'J>V79-[\LF]^6>&;]S4A(2])* MNF1"CB)(C8FAUI))+%.[U@PJ+-A)BZGQ=Z/@8?\/%R2@EO,Y+\K.M9RZC9+G M2G9H[(=>[*YKPZSQ7Q:@TO+FH%_&SC7EYJ(>N>PJ( <$ M3(WM:OWJ@DPWX'^A;Q'"X($7X*O3]GL0Q$X+7(O"P?M?H>,'J3,7R3HG1S99P0>V5VHHIH']J=+X/@]SIY ML\?W98R=-G[2PA/YXJ>OZT9O/RZ7 MZM=\/K]=V/6__2SN32)%Y+JC//G]JGW10-J'0$:R5#*RCL(WCYB[X2EX&_YC!( M.I12.&GXU=44]I\Z!%N9SGJCJ4^V#_)I^VZ?:"L]1P MIB%/20H)Q0;2)$[LNH&:%-.4(1FX*7Q>V-0^Z0]%OI#YPUQ7AS-R5_/0O=$6 MA'WW2?O!;? ]TQTU;T"M*/BE^7.0D@0^R/2[F]HB;^2=UMS3-21* M%IJ7^I6N_WQ3;^9^6<[M,\HZ&_/CTS7!='+QZ*PZZR/^F%9 MK/+%GR:PA"A MZZD>\!EZ+_2P-,0@JZ<+. Q7'>*9UDP7[&VO#]'72FE3PW8G#;G<_/#?1\+E4+ +U6ISHE9]P:52V6'E6J:KOVVFKX%SK, M'A10EW$J)=84*H$0)(3'4,29@JGA,4(BPAD.*K/348_),<=.J76OWLM=:]Z' MC98GZPP_!D,34RC\(Y6Y[X3G,!7NPU1YIN+VG? Z7]>^V^-Z:2U93?J:$IP2 MG,"4)]+Z4%)"QG#J6M!F0N(TXR1X6_9 QI2)\.UR<0==50OM8I,<_9DK+-TVJ[M!LOO,T7EHGV*Z2]M6LW731; M@HG"1F8J@LK!1V3"()#4&,/I6_4.VB_:=P-JI3MN MRUZ$W8\X^@1S8!:Y&L=@_O %IT\RN2AS5&;Q1>"09KSOZSV3[R?^_RZ+JF#$ M._LNK2E($L,S[(H5)P22R"@H,HT@QRK-4G=\;%!/27VGY$^-D=J3T6Y 90.H MZZXX*[J>' 6.DN?9T7#8#WUZU#OL?68$MH$W4G+@216FDB?8AD] RF#K8\+8 M4*@R'[#_RX]5/9UU\Y?-J=C,-6;0-(ZAT,8N^J*4NU;A!$;2X,1D28:,5\.& MYU%_?%WO:HKZS@7Y^.GGTMPYPSPW4A[IG>AG;*G/\)#+WR=8>!% M>_NQ%TW[L>:ZO?9CY[N/?=[I/@9J).Q53>>QG;;DDWY]5)-J60GZ';]&>W8, M_3K57>KD[NO$][O9E3O7/32O$Z]>)UV_3OG.Z[3<-K-;-J_37?TZY0M7S]"] M3L:]3A4[G2][Y>V+/.]PUJZ,T\$Y*!BQ&%7NR3-I-8IW\[R(KYVC9]9B:HU< M]_7]FW95"[6Z_:H+?J>K7[[B*[WE2IP2B;(L@M;'XI!H9B!E.(9*ZQAS3B.* MP@XFIV+9U#RRM<* UQK7[+?GHKDRK]9'NZDG7GNIJP'[6*K.]5\G,QC/WDUV MP)=G#&=OE%ZS/V[FYQJE&[!Y9QN@ZDN @\K'%YQ00]J.X__[:%<;:MS_D&:V M'<=TO%:W716\LCG&B6*.*N(84Q-!+0F!)$X3*!(C(,9)QF1F.)=!AV4MLJ8V M[VX;$O100K,-8[\IKB?D!IYTNH+6O9'#.'4OV\0]3RL'_YJ6/K=T8XY;*0OM M&.OU;X[_](Q0@@V*#412.KK(,*1<)#"2@LHL9E3%.(0N#@5,C2,V^KE=4N4" M2)3%>/GH-C@6"LR7UDV2R[*EZK\?KGX4<0U: _/"%JA&M_Z8X)S5?7[^1S)& M_>;/67CXH9^][MJ]AK7SLG5MWBT7^OYAOGS2^J>J-OV,L23A$4MAS)2$Q$0) M9)(JF)@H8I0HG.&@3S](^M1XX;TQN;1RFA#80DO[#@>20!C\H>ODGD$=<2V[ M6:-N5;\!.\J#7VKU^PPP[@+;,$M 'P6>:9D6@,WYI53(0ZY,YVX.P.M42_5^ M\5'+QZ+(%W 8\C1%4&6]M@%43=L:*ZHL@$#2"QX'];-I@5F)A8)I3#-(@$)RS(H2&0@CS-$ M(L$3H8/:IH:K,#5:W*BZT^GY+[VT>FX;!S_^&Q;=@1GP0NOG+>Y;*P;9QY3IBN8Y1%D%! M,Y2:5'*>!(5KGY$S-4+;[ZBVU^"N.F"N?Q+:6?0,QGX\U@-R Y/5/FBUDH/V MH3N%PT#MZ/9$/5=7NE/VMC2G.WEY1WJP9'2[4.X/=X+WE<_=V=VM):FB>+)\ M5 1GGW5A5AZTX6/W)!/8%?Z@%^" MF[+=_I=T?]%;S0,)PPMU3_KH&\FAR60-8?67'95O7,O0M=9]!U,$H=0KU7@) M'I=X0K XHJ&@F[N14A4ZX#;^+;^]S;EPJ6W6(VJJH<[2+"'4: PSXZJV(VX@ M)2*"46JHQB)6*0UJG-XN;FH>3*-H'5,<1CL7G/[-8JJ2-!,2IMP=N64,09&A! K7 M=Y)RE4GC59+T6D6FQD5;!=>)5 'Y=-<,2#LWC0GSP*1560%VE+X!E2'@O=G] M*5C;<@-VQN3#J&,2D*TXTMB,E'\?=,'WSQQF4A"38A)#A3F!))$C@!Y\MB(UPX'E*^A0..EM0\3S@;'M"Y]YFEAH+/G^S4/JW_]!/,\M9:0JIB274<9HP'E-D$AG8U&Q?PM0\Y]=->ZY:2U"I":R>P6W,#H!L MYYQ>X!F86H*1Z=*Q[+3UU[<1DHQF!!,70Q^!BE)"!3<_CMCD8Q56 S^&4%3^[@;/7>:[G7-TSL+K9]O MT0=@ W_NG; *CYB_ $2OP?'G9(T;!W_!XJ.0]TO7=T[)<^EGY4%9 M+V,F)681%0+R)+;3/<,('0&V%K]#X>H7>[AUY3__9M&WI= MDOK.H]-S9M\)06.G]YVW]42.7\O%/6S3'W2T$-PD595:3ET!@)0GD&OK7 A, M%",L0PGR*JGO(6MR_'&XS7C%OFY0GY">L1I[QSPD!R48N2LVO;LC^%S[V@-M M4K>U0?'G[FY3[X=\P1TAB;",-,&F27 M]Z[\CL2IG7L))P;))$E%@^?KA>?&8A]HKH4-AZ65T">0GH[Z5= ,[9_O*/?/ MZ\+]MZM5D8O'574%;IR)\O;A:J.,>R\^*%8JD>Y^N@JP^]4PU.)$EF2V#5 M!QNL&P- ;0'XI=LQ<)>7W_]H>-@!&.FX.&P@>CI+[HY.=^;:] M<^@K'M-[6^H73]O&K[>_Y>4,LT0J0B-("!)VN:,E% )%=OJPBYV86 MU(>RIS9KM/=%=HDWNYV1?W$F]->)^FA@_'S3@> >>"KI%>D^FT^?PVRDQM-' MXJ?2=/H<+@$-I\\^HDNS:?E%J\>Y?F\\!1X$DQD=4<(3#:5Q^]8ICV%5+ DS M@S*J#%4Z]:O5UHW_/BR6U;UQ6"CK_1*C%QN2CSN@2KO?+ M_W/ERYJ9+\3QOG9H/;SP$8=KZ,5_8XE+@*]M >X'Y/:6QE?*&+%!<3]H[+<;[NF97>L;6ZM=(J)[LS_FY=\_ MV^>\6M[S?#&+4*)I:AU^D[J]9(T99)GBT(B(Q_4 W]-%K5]0Z%#N^B$>_!8_/BQNYZ/%%NX\+'U^^ MI1MW[%0=O%VH$V7HZ MWVI=>;Y]G:9>A-^/6OH$=?!MYGTD7[>C%LPJOE#T22T798[*+[X(')*,]WU= MBY7<*F7?I/*E_>O[XO/RU\5,&;M0CS6%0AD!"=;(M2%.($)242:D4)G7N5:+ MC*EY)4U9CD;/&^ TM3@"IVMHT9)C0-OIHB>8!F:(3@AU*%YR%H.KRY<N_;$.^=X5*8$Q4EJ70=J/W:>NIKEUJ?( MB*(ZX[%)I5?QSXN2IO;);Q4%M::!@2UG$?5S#GK!:>B=KD.(_,Z7PR-;+F'1 M:X#+66'CQKEZL _Z\O16?[4HN),Q+C@V0FB8 MJ$A!ZQY@N^)(.)3"2!W'B*HT*(O%3^S42&/;'Q)LE*TW?^UV..F'ON>Y M9.^8#GTD>06J$S2!O-=LG/TSS3"XVS+3/][N[&3!]UN2IR5WBV6O;\ MO,A7Y<=//Z];H),H05BF4"+#($FC& HJ&<2")6DJC.*95ZT4+VE3XZ&MLDUB M6*4N^,8J'-HCKAUE/^+I#;N!^:85M@&2Z[QPZ9-IV@6.2C!>MA_RBM]-UQ5K M:[HM5/%@YSH.$4U4*K5;"[E-UAAK*(B,[:J(1!2KB,=9D+<3('MJ5+,I>M&T M8:GF9]XT+]K9@>U6S,UG,!(<(2V9XW>,("$B@316%)HDYC3"]M\L#MGL'FHP M1MOWYL\^)'[3PD! #SQ);%[X#SOHCM.MJP-@0Y3G\Q'_+$7[ G Y5\HOY!'= MYID?]<(ZPG,G0=WGB[RL3@B_:M=%85'J&4D82D@<0Z0IAD1P";E)"8PC3#&E M&;+33U.:33WINGWQW ^YJO6ORVM,\C+W'53VB.# __;B#V[ZN MH%&V/T+R1*5/$KHD"M^W<=U60E[_#:+*): MX-0NDQ%+B'5G8^O.M84?@^8KLO5GL=%>IC%B'9=XN M]IROH>$/B)8=>AA&"I$=9CC"8F*O@;(U$+;3@\>+?KW&[KV0UZL>U+6:AZ5I M]WZ^-ZZ_S@^N*]6FD8,TD:$&&[=6CYROBZ"PX$",(J6,5()&/.ATN478Y!S= MM:XN3Z-J)U6IV[U;1AO0GH?./<$W]+ES=^0Z5%6X#$F_]15:Y(U<:>&RY<<.L:*6,JR?BB37[G2'NR+.$J)(:**X22*) MM@;Y\^-:98 M)W&5?.ZVE1;:LZGI:>C\J* S( -_^VLL^C^,.6EQSRVJ=P2,W9#ZV+83[:=/ M7-1A#?KR2ZY-LZ%F/8OWQN12%\WKER2*4VPG>COW*SOE9P9R00W,B$0H2VF6 MQ5X-["]*FMI77.D*MLJ"1MN I4HKL!XKPK[@&O@;/X?4Y8\^$+* 55Q?T(VT M6@M^V<(68CYHM"ZX6A\PWL+*QXZ]!937#1V3>I:+N\^ZN'<5J'_BJ\>B6GU] MU$UO^?*]^5#D"YD_N,J+_Z5Y\8-]6V9*J(1D L$$628EVBZ>F) QC)6(F!"1 M(%DHHD>BJAW5>TSWH8O7TP;YOJ]N%7 M*UF%MLI(:N6:(QL73DSL/R%-,84L(YQGRA L@PC.0^;4Z&RM\@VHE-YDX%5J MWS29OAV"BWW@]UXM]@GJ&(16UW?XO%?=H?>8X@!<>EYI7A0[]OK3%X<3JU+O M6SNL5?_*B]P%?'SD*_W#?+DL9K%FB63([4F[X@N$2,@TCF"4,&(=JM0=07HO M4(\>/S5N62L("JLA,$[%@-75,7H>J]"K,!F8&C9P..5NP ]7XQ&PQ+P*EY'6 ME4'XA*TISYK?NI \OFN\U>-9C?>6C.>OZKN0Y,^E-H_SM[G1,\J$1E@S&$F! M(4FMZR0422$E'%$3<4G"FL_[")T:M?U-NZ)G=I*__:H+?J=!K2IPNO95(G(' MN+<;$]45)EXN M[Q^6"SOU-'65C$)I1A"W"&-'/=@NV#)+/3I)"14T9B3UVN!OE3(UKFEJ_&^T M[%BOZC2B?LQR-4X#4TDX1,',T0I!GU1Q6M"HW-!JZR$9M%_<,8Z]L LRK=V1 M_V/9O*DXEM0DJ88Q0S$DPG[[/(D53$S,4\TC(VE0/,\)&5/[\AL50:UCQ^_^ M%)9^7_V5" W\S8>"$QZ ?M[\7H/.3X@9-]#\O)U'P>4MEW8M F69XWZYJ'(N M/WWA]@UY_[@JK5/A&O_,$,^0$"F"2>;ZG!!D(-4:0QD;C352&3*!]:#:Q$WM M^V\*'\E*Y;K$W TH*ZW!K&NX>]X*56SC_1B[+:PKHM M"I=P46_T;B_Y4)]&W?[*"_7^P5U8UGQG%SD?JGYGFWH3,^/^EZ0*$A=N1!!# MD"O"(!6,Q9JJS&#_C=RAM)P:G54E5^YY\7>] E^KRBM+LZ:SN]J&D*+D0XVM MQS;S%$9L8+*L] >5 6#72+!CI2M8OGM=8RFH3 6-K: QUF5TU.:";>V=*8QW M2'7Z"8S[6&7KJW$5U;C*W?'G.^,OGNKOM[FN.<\'O!K_93/^S:?M\MOJMI' MN/&O&.#;OBK:#SPP[:7NAQ(^8@W\@?';+XX_M+!NFPZ?BZJC]U/EAJS[=37[ M^R^7Y[TR M^75]*,*;0Y&'(I>Z6IVHY7S.B](10,T8@96BO,?&;V=C",0'GH\W8-?5H]9* MWVQ.H)S>;H*M9^3^MD%"L>IS;\1;]J@;)J&('.ZB!-_?C<_>Z95+E/I0++_F M2JL73S^7CC2;'NN+NUNYRK_6U;W7J7P(,<)U9*#)"*Z; S(N4D@9IU1B'2DA M0Y@M7(6I<=Q&5< WNOXEC+LZC(,?BPV+[L!\5O43<_F5:_6=,_F-L\ ZBG\& M6]RW5@R2A-D=Q#Z)KH,6HU)>=Y0.R>^*)W5NAF2?\RB=ZVA=QF)YY\J;-UDZ M629X9JB"48H()-@(R%/.(349$@FAL29!A-7C\> MZPNT@1GK$*^UH@/DB_H@TG,KI//RQNZ%=-'R$\V0+M_3N7"G*]3V4[5I:=G) MN6>;2H0<2YPA)ES=W\QZ2TA"D<091%EF8H%8)N.@5FIMPJ9&'NNBA(46?-6A MW.-Y5/TXHR^L!N:,-4P;/:MEVD#U&R\"TG/!QO/RQJ[0>-'R$R49+]_3]43[ M,__MC;(/RDTNJZVM=X_5;)BZ[HI1FL!(I\;R!2909':QA1*3\41$R%"OP-F+ MDJ9&%LW!J]46[*L+:GU##ZW/ >Q[7MT#;.,<58+5.3S#[HPR^+>+N[K\YPW5>/2_*MVNP OEHO' MTEXAJ[).[O>?^)P73TWM@QF) -1#M&,-K&,E-O;4NZ OZB%J;'*]XMUEH#;KID,]GQ[&*B P8MPQ M&RD$8J2Q"XMTZ _IUIB&'L2,%[W0'R9[<0H]/K;C[M/]LECE_UV]YN_-0:I5 M.5.)73GB3$*5V?^02'#(J$E@*A*54CMS(K]R9W[B)C?Y[6CKIK1\FT%8E\T. MW)-JQ]IS5ZHW!(>>E@[ .TR_[*&J,8A(3R%(F8$Q@Q'PG")L%^FUE@*3XW9/FS]]$V[ MI6)CRE[FAYV90(R LE:$^(8CO 0^COZTAG;XHX!Z*+>JWX"-P=5(UB8#9_/& MG72A7>\WY19W[][-60'.=.!L![7QX-7T7HF0]<2T7HVQ%AP3>D4"5R7CC5?[ MLF4$/49:^=&K,LCC.9)!*FRJ[1_[_NWK7';1Q; M%_Y^?H6 #[:O_XE M)=F6;5DF94JE/L!,IU*1M-9Z*#Y:)-<%TD0 ED8)0&$6QC'6/V9.!_$G3Y^; M=V "Y_)*.^]%SF_>OJRYAI8D\ZVX+YAB6[# (=F0Q#K0C,TE7 MZZF\W7JJ47V4\TIWQ'PRCH/T2>G('95SKAKPA,%UU86).=3SG]'U;Q^5DMHY M,M7X/KQ_]?%S$P4;0A)%"4> 8?T?*#$%),0Q2,,8D,#OT[:A?M8/[01OBN9^PN9'10=%B+?U958;;E$FSZU%8=B M@'45LO-=Y#?[@3J.G;'N4-K*C-O>0,_;0O>A['V?:* ZTV\OS$+F MW$C5G 1],;V+3?F(ILNL8V]S"Z#MV-$S?".S8*-M<%!W_%6> T!>DW0LQ$Z; MJ6./PT6ZCL.M ^MET/*[IC'SA\D'^J$GEV:S0Y&UH\ EU&M!*4,!.$I3 "F- M !,, A+%/.0,B3!VJH-F+7EN)%1E 1A?H,JVD4?='4MI6"-OQT>CX#DR*QV@ MK'YHJ;UH50UM,97'FANN:'DMP&$M?-IJ'*Z87)3F<'[ '5FU[\MR)\6;7:%Y ML2X-67MKGV6IW36^E:*NN&9*26J_X:-ZMRF4S+=:?+F$.(VR-,,@91'4OA0C M@":Q)C,.(\8EY#!TJ@1TMT9S([FCSG6]Q[K*ZQW+U?O'S-(MFW(DQG;:*N1K M8X+:FJ:H\KZ2_2)H#513*](8M0B,JZP7L"W#/&=>^\#8>W+V74I-G[_M \/. M%&\O#QZ0<-*LR3Z;TK#[LF XS@1G*@;"U$R"*-..(Q0(1!D,18AB@9G5NO6: M@+E19Z-B4.OH$)7?!5X_Z?F 9&0..T7C=HR"'2P.R05WPC-1,D"'EIZ"]7OL M[PVN[[IONF#X'JU/@M?[KAN8AENG@":9(EG(,R 2' *8< IP1#"(8R6(#),P M#-5RN]G2E9V'.""M]O#P\5Z[KT;&L Q:ITS9V67$^DY['2^]]2726/O35>]) M2VT%1'W3'^/'-Y)M]]W7ESQ-L. H!3 BL9YSF00X2040%"H8.GDA M9&[>@M$1&"4#H^4B,'H&_S::.G;^ZT34;GK>B]/(DW4(1$-"':]BX#FR\5+. MU(&,5RWMB%N\?NT]W]=]_<]0,E(W%>Y26G MJW])6KQ=BS=T*Y<9QY&I8*J]8:D E%P AA@$:9SAF) 0,6F5@MDG9&X?ZD;/ MH%8T,)H&6M7 Z&I?TO0JI/USV1=08Y_G#,'(J8CI+1#NJ%]Z]=&3E2Z]95R[ M:NG-:X=]G0^I4V__,+VZ6EU*!.),*1*".$$8P! CP#*(@/\>,R^M(VGVVO> S\GP_)D[NE1PE<_(F%#X_[M>%3?JAOVGS^4?_ M]@T#&:'X1M=-=2K3>V&SRD7UEU>TS,N/ZI-^H?;[HZ]V9;Z69?E&EKS(JR"Y MA[5HBD68HPA],\]E>8RU8E!A3N((Q#3- ,0H MCT92$I$TE*8*;_Y\0J8VH[ M-V9J&[LP55[STISY/;5LK*(KRMWC(RV>JP:\^;=U5>):?Z6?&OL<>6W4]\&2 M&^N14C M4F"KIAG=!DQ^R]=K\Q?SH:L;3 ^/29KLU5"1Q F-4L"4*=ZKUTL 9R@&5"1) M)%,:IS)N7@V]COO3OQA[&R9[+:3^OOVI7@@[/V>60SRRSU,9U'0V:%L=/)RV MHF]?UYB^CWUK.H^TS \J^X.MJ8?8(+ (#A@LO/79>;&!\QI)-YGRTT;<33TF M%Y%YDRO@ON7_1?)=H85%,?N:;U=RF44BA7&2@DS&&$ HN/Z&)02(%$,H*>(* M6V_UGS]\;NOI2BGS'8GBG]A?@[VZ]KO[%^C=WM6_!Y.1F=@5#J>-_&MVW[&! M?_'(R3;NKQG3WK"_>LVP9WS)SUD6[V ,ASQ5#'&6M3ME>4'4PVM MBHS[J'XMZW+RKZ3:%%*OMG:/NQ75C/%&/A62YW2_#FO5HE^2*(HR3 B0/%4 MXD@"0C3L2019JI *,^P4 S>!SK,\\G=S0J<863OWMA72VN1;^6'_(?IK'3:Y^07N5V&2:*DT!\$/BI+1F9_TY(UG>-:2UD7G( ]<,5^:&F'[.5WH%O%G+9N%< M+E6:)HE>NP*9AC& "F& *9$@DE"[LS%E^EMMWYCHEKBYK64/"@9/C8:+8&OO MC%IBW,\G_I$;F4\J78.6LHO@B.->7Z\ NG3)\0GD5#UN[@+4L2N-+3[]/65N M/F7"CC"V%IWV<[&^:V /^?%KNJ,N7F47^D?\A"/3A%$),8"0)E([;ZED7;? M! &1, >C&682$:<6E=LA DY)B%88$ MA"337AA*&" AE2#D,(UCCD2&K)JZWY S-T8XJAE4>@[/Z[L&K.4)\OUPC7W> M.P0I]P/9?AR\'I]>$37M86>_O1='DS8AQCX%$<(QDD, M%(R,JZ#TX@S2%(@$(@QEE,'8*9O@NJC9,4-+T[_\!XZC[.]5$;GMLV."00^Z MEMS@!;.QZ:&EY/_<1W9T]W\;)??@-DC>BQAU2YN^.E&OU9UEA_KOF#A^LXF- M:$6*?=ZL5N\VA?G')<4Q#:F* 6.FG&684D 2$0)FTAWPRG\;._V[?/5EVN!&SRA9;IN\V"7B*<]"(4&J9S> &4T M0R0%<19A1E@LM?^W7,MO)A+"SO<[DV#U!I/Z#6[+&36RH%(PD+6&@QKAG:)H MYW0-06:JMC -)(UJ/ANZ=-KLMTG+J8B)&Z]TVG?93*7[LF&3N!V2I']>R:ZH MQHQ3E84H BR*]9H.I69U1R&0,4$I"W&FW)I]I;/;#+>"V&[:^P9N M[.]\2]U%<%!XQ&!-%X!\$H>5W$G9Q 6) IQ:;( MK 2$4^V9**801S%7#.Y=D:_VO#6JT@.\FZ\3\-X'4_* ML*NQ7G8-;69R2_P M$MA1ZLN/Z9\H"O_/$W[_IPN\_W\HY/Y%@NU'#;,OB^V^(OK'XHLL?N2\#A9( M>(I%AC) TQ@!"&/3T5E$@(0HEC3#INN-C6=\3<#KJLR>AF%N6[5GAYG4#RZ3GE.6K M?)O+[31])RN4O#HJZ%@* MO86:G7<Z?U%ZA&WV*UZ@]F"K);=2[T54/8F7^WT@FG)M0\4\ECIQ4N8F+IZ&! 3OH4HR5(8(Y(0IV!R9PWF M1KJFRV->9U7\M-(V_#6@9Z&1O#*E;N+9V++0$Z6RQLVKH>#,3KW(8<_:.+P MUT/;Y8>RW#W6857F+-8T__S/S4H_1GO"SY]-[PD<9S(+)0(1U ,+H5Y9DCC) M0!1&@DG"XQA-$PMKK_/P^\(K>UZZF1!M3TF MM<-I^RX;YHJV7-RF#7<&A5"2Z*5X'#, F4@!)5* ,$YQ%D&*%'%JV'HA86Z3 MMU:P]NPJ-=V?*VU[BWV[L[NS173??I@%P*F=1=N&KC^A4/GN"NVLQ^1=HXO"S/-0*M*R3T'OO MC";,19$UFT((#BC=4:-N"%HO59INI#)TW>4B+*O/35O]P4K_WEISGFH^7(VM M_)"OY?NM?"R71-_(>8J )!@"F&@O! L"@0@S*FA,(A@['07>%CDWG^,L4OHL M4/K?1N^@4MRQX)0%^'9^B%](1R91#VCZBQF_ &B2P.^CU'E$;U^@8!V"?7GG MX#CJ4C^WB>:;Y>1E*DF4(F[( E)FLG!E01"3*1,KW\(2*T*RS<*V6& M;',9/ERK:LDO_:#V4XHWJ,9G$7>4AH197T?!4ZQUAX"I ZZOV]@1==USL63A@8>F60 ,I.X("VQ\_!!+G&P=D(Z;AUZ[J)M M6.MU51UY6?[V2J[Y]T=:_-;, IDQA<)(@BC&$8"1<4@BI%T3[9LDF&"AL!,- MW1(X-PXZT32STW,;0]N_"$Y^CG./2 ..->Q0\;O,<\-F1.?^M@A M<'D(9'G?\%/>?%OMPVHVT\),4W8M(==^55[RU:;<%?*P-QB%*E5)G($$87,, MK C 4#$0LQBG$C.!8J?002?I\^.A@_*5'W2B?G#4WWE_=MC8V)\MCX+X!.?. MOL >="KM#)KO$VM[!28_S7;&INNDV_TA8^>AO*)ESI>)2$.1A!+H_YI57R(! MPQ(#Q1D+N>0$":@$ MO)=)"JI5F&E*T D^PQ."3A\S(([A[8=__9]_O6HB!T4$481C[72'H=#_D1$@ M61@"E4&$4Y@(%&76B>;M)\^-Q&K=' (93F#J)YJ[C!^90FJU;H=4WGI/[*,W MA@(Q4<3&C1?!+4RCR];>T(R3&Z8+Q^C2\R0$H_."@=V9]RD@[]=/NVWY0?Z0 MJZAYC;@0)):9TBM[T^ /$TTWBB5 \CC"C/)0$*M#3PM9J8[+8(:D4700/8"-'@%IAX;<#<(V[:[LNW[;YHO6QQR]""ZKPP ME>W>R/K/]^OW:],U;%.8@DN"8H;U_P!-L5Z""6%J-# (( P%2ZO.R[%K>?4> M>5938>)BZP?E7$NL]^%J1QKW8S55^?5:O^"GO:9_U2O5P :[ 079+3#Q6YZ] M3^#$Q=HM;+\LW6YSD^^P"OG']I56_; M131TRBJ[+7)N'L>7W>,C+?+_-CGH3>Z>Z;GU+O]#_Z:*!7"D%@O4[?C%+Y8C MD\R-F,ZOU6Z,43RH-)\DKN(;Z20":)=& !PF&<-ZM1.GD?7&2J^HN='. MOD]W<=!VWS#&I1!=/[H6^S'>,!N97O9P'14-*DUOMS9W!%.EX0P& MT3$MQP:7_MR0A@0"3D7">")2 N$DI:H&J3\W MPJ_;N=;E#+1_:=HU%7E5HFC2]J[#7@4[AW6^ SSRU\E#(:NFVW8+@Z "(=AJ M%([-8@] Z!\/_8&KQY;S:QY[U[#.HNC5, O^'/6O[AH=;Z6P[M/"0X)ZM3)= M*B%AB@4&F<)Z7E/&GN-I?+Y?6?:-Z;U']ZY( ,&-2Q\G#(5.J?P]LN9&> =5 M@[REJV,EH1YH[7QD3X"-S']'K-IJCG#(; &'U]H_/>*F+?%SV^Z+2CX6MPR, M1BSH.LCS[^46S*.#?HCM>,$;<&-ORIQAEA\P&X$HK$#Q21C] BN!C\I*==?6+Y5T?7Y;Y!M/1Q)AN8L8\4*[!K2X+:E*"V9=&<]RV"HSWF M%+!E47 TR:/KY 5:KS[6?1I-ZXQY0>_":_/SU#M8N7W<9R((&\\CB41(,!4@ M4I !&$MH^D@B(#.2Q52%C-BUYK60-3?7KCZW',"-5Z!T(+[[ 1J;U;H"(%HQ M$B,L^&[CXIV2KHB;GF_Z[>XDDQNW#&.*KR:U85<\5Q+JQE?FR*LPT0*E7FMN MOV_$,M9T4?6:%4R8%":6 )(PJ$%&<8PC&,;$*LG:1>CB*5ZD]=)@&1"D61 MB!A'R&U'R[^2;&'!"_^X0CZ#GQ]N)X2%_N2HXHZXXLCK)>M"^%C"(6Z85QF"35T0<% M-.8A4! BG!$1<2B73_6B?DN+K>5JN27"A13.!8W'#Z_DMWR]-M/Z%=7_P.4= M^XIM/'F&HA3' B0BDJ9&J@ XPAG(TBP-F0A1%(L&S[=KRYH(]Z&Y%S,>EEJ" M?R M=QT&0C/%-D.Y:+9//6="G)GK/4]A__SILPC.+.N,\3^_9H0#G>H?/^Z[ M8LN"YYJ1EU$8(<[2", 09@#"2#O7/*0 )6D,TS0)8^X6+>*LPMQ/!^;9'3+IWAXFC!ZC&H2)SLIZ49[L?*Q;B_F$%QE%KRT4IK5@VAX,+S(Z M%TT<7D:+ 0G87_AW*78K^5&]VVUWA3QV)?^H3)?RCVR5?Z.'9,ACU30DHA"9 M6&&!0]/_)H6 1GH92! /,T2PE,*^"O=0+>:V"*RU#X[JFU"P[7<9_++9ZK]H M[[>JO'8TQR&#>?!(]7^<)L-_[-5(8T+P4067PZ!_:>QH(>]2!<_C8#ADG$\Q M*!,EI1\&1T\'50_.X\D<$69P-L?!J=IT_,U3ZOJ]0/9FMP]^^'0)\/?:?Y(C M?_?#ABWQ?J;\>[Z6Q7.[)N(^=R61$8FH7HH1*0%D&0,T8QADH5*<0P4I=6K% MUB-K;A^<@ZIU*:N_T,>GOU>KIDIGMS53'\1V"QQ/P(W\I3AH>5X6U7NXHP4> M/OWZ/G&3.N$6=I][S#:WW-G;03-6OJ9KGM-5J\+1I\TJY\]+'(DXQ3P!*#99 M;SPF@ @4@33C/!9,X11!QZ1Z&[DNTV*:Y)-C6X.Z\'*C>;L6VL!^$+WXVQ&, M=TQ'IAH+,!=!K77P[^;/4B+9IH%7O MF7_<;?\/5";KF[ZPG(L?=B3S#46&_>=0B8 M&W$8%5V715?!L]A/NQ.2D2F@0L-AW6,'B\/.UIWP3+1I=?K2^-J,ZK&]=Y^I MZ[[IMI!ZM#[9'>J[;F!NR&JU^=V$4K[;%&\V.[95N]4#YR83J_PLNBD[YW7<,X)VOM=4XS(R,>]5#HXZ+X*'D]%Y78^# M"97O.P[WF(GA 5JO&1?WZ#-M9H4'Y"XR*'P\\]Y^%_N*X</3ZO-LY2- M*\#26%'"$ M?LB"?I-U?XZ/ZF)I7?6F7TH2(:&B$" L0\U8,@8DCA#@H2(D5"J1F5.Y R?I MVV")@Q8_CNF]M8V3'>:",P,ND=P&\4O^PL\[&-?*6^ M/]H;A)I/YG-38%+R&X3-.?\->\@P"C3A&,>S"?/$\LN3=@7%Q_5_TB(WGJ() M(HR668Q%'%$.6,92 *5>(;,LP_K3BWC(8R@$)6Z'G[:BYW?^6>D:E)6R@2:] M'XVZ0:'U=:,U:_SM&&T,3$KHB<\Y;S_<,HZU@(X)TVX?5FOCCZGNI!^!"7 __VY, M(7+B_KV'$*"'LMP]UIFLG_/RMW>%E'O=S+=P*1!121HIH#)3*<%T5J>$<1!) MJ5*>A#"B3A7(1M=X;AL11D>@M)+ZDU-K.< +'W^<7;=@9S!Z$^[<#BP-T J= M;-F]"(SE@3']\%WRO':8;)QFT5/76ND_1QM=US'PUCG76?# C]:.E?*_=F:S M_(>)-W6LOR9IV2MVP^&(FW+I^)*^KO#;# MFIHA[S:%DKG)/"O?K^N#[K,]U7U5D4]%SN62($F4BA*@?3 ,H% I($I @!"7 M(0JYRJ+(JQ/FV8"Y^607AT/[6E?!DU$WT'Y]?0BD/^%'2ZNSH5TICO\\I!S> ME.^-)Z?N!=^&&?AXI6W]I_:K;G,B( ,9P((I$( L?XT$B%CD(@0 MI8G@*HF/ZA1Y:N-2Q TL1,AF'0FB80NWH0CVE,8$41(A0)).(9JG3 MO.Z0,;>9?=Z@I0E-&AR'U 6KW42_$ZR1I_IY^Y5:P9$:K9Q:/UI?E4;,R[51 M.;6SMVO*V:5>MG[VH=8)B7!,,OTA3Q( N?Z:TRR6 "P,Z#9@AW8<&Q74"H^_?^;I1<(9D;',.* DTJO+)!+Z4Q0G $&FTC1#1+]1 M@UI^S/$U&K^;R/"72*[%G_#U&?DH?;P78@:;K;9[K2?Y _/98?4[9K,X7'=4 M?5[[J7['P]M!^T#QP]ROSYMGNMH^-TN$F(5)1J7VC^)8+[B$J2: 0PHX93A, M]5<.2Z>UULG3Y[;&^E1LQ(YO@Z)6,BBD=FIWK@&_IP#:L?M@6$;FX$:O$994 MG1;[9+!3 9/R3*=MYVS0?9&GZFD/N^WW39'_MVE(QY,41RS5ZQKMDT(2*Z = MT@2(1(8LB2,H6')7\;2CK+G-Y\[::?2@KL?2:2V\[2:\)Q1'GOY=A=."HZ8C MEDV[A&/4JFDM<2];-.W2[ILUTSIN&;CQVI'+LW5-)_7>?;LO)/F@ZE MSV=UWR&,!%:) *%>'P.88@:8_A$DDL6Q2'F(0ZN*:R/I-S>V^K)[?*3%LUG! MMAK"U#WV]A8XKF ]#ZCE2O7EAFG"%6EG<8Z+<3/&+0ZCY])_P7VQ.0[L7A>5 MGE6<=O$X#KX7B\21Q QU+#4VZVV=MF1BNU\]?]5/JL)!6))PG&8A4-J--/OG M%& <(H 4HAG*H-1.IYMC>576W*CZ1-4Z/<.H.BC.I@]B6U_2"W"C^Y*#,!O@ M2MY$PZ\K>5WC+Z+JMCDH>CJ(OAF ME'8CD1MXV_&(/Q1'II(C@)6JISU-%L$_>O%S)A0[6'QRR@V)D]**G?7GS&)Y MUV!RX5***KNZNQ,U$1%EB#(0,6)H=Y?G*++N^T^UKNGXE/[(MS==Z,B J M4\03!!A,)8!0<< B2D!&,6(BI&93WJ["V# %7&;1-'7&CDH'JM$Z4+NUGEU; MK7S Z3I@FJ0:_1UJ\[L/3C]3C0_XR+1U5H0L:"&_5S\P^@?:@."5Z8. MW1)&Q7ZB7@HMS!\>3;7J0T?6PQ!L]T.@7WOZ@^8K']^2^P#L;KVC M*[.O_X6N:/'\4:FX!F9!!IDC(I!K:.>Z;66'B!R\,0\0#65OS4 M,C>GZ@86O:[3M7NGY!&[6=L#4@7H-8;PJ=-K#5%H.+8%?K&XEFUY1/=>-U%:R+ .^ M*PJS"?1(M[NB?WU@#ZX=B]P+V 8B(3( &3&-/D@&8H;#4*^WHBQU M"E.Z(F=N1-#:?33[*R!?![S6U+&3Y158[>:_![#&7F@=<3(JFDILKV_@Y-Y/ MLA\%KZTBKXB:M@MDO[T7#1YO7#XP=)&6WQ_6POQAH@]^T)4I5';N#-,4)S%/ M*4AX% /M+&2 2AR:\F!,H)AS)(1;&R KN?,[FZMV8JNNM^8'>=3<,9K1"G4[ M\O".Y,A4-I@2!F&NSI=LJ M:>#UBI;E1U7%*U0QOU+ ,"3$-)(E*8 $,8 13T&6H2SC*=/_[E:\]YJDN7DL ME7Y5S[\JRF9(+/5U5.T8QPM68[.,$TSN:22W(/":$')5V+2I';=LODC2N'G# MT--@4T5I4SQ?N"E8)11'!+ XP7H1(Q+ M&<"$JI7-I&*,Y8Z'@MW"YH;)QST M=#T2OH*C'0WX0&=D%CBH.(UO<0L1O^?!5V1-?##<;_'E"?&-Z^]I#OB5_O'V M#Y,")E_)M53Y=AERI3@S!R6,F.;-H0*,QA1D J-0QMI+2-!R+;]IGK*L.'5% MDM4[3^IWOBUOS%=_WXHO>"HV/_+2^8SD&JBV[# B7J"3W%5[N[O 7;]\0.C(\#KL9J_UHVKBH>O*S&))8TQ( MF$" PXCJE48H]9H#?*94J^X@3O[K-S0\Q.AJ?N\F;"+[5:C:EYAPB M,CP/83]CO?# C,QRE=)5N$=?,XY738&XYL*3 G%!-:P?U2&CHS'RY<;3(3#G MY<9UHGB>>MCJ:@N\/;[TK-E*V;KPJ1E?6HWOMGO:_LU3/- X0] ;1N19Y'31 M1^-@=1*T-)*(>QSWPT;!H6E=IIC &<. PH0#R'D"*$()(!CA**49%HGC2KY3 MSMP^H(U+>M#3IL.=$ZXNOOM=:$WCNSL!-=!UOPJ#?]?]4M0+N.Y7[>UVW:]? M/OQ \NQ,X5C,I3ES./U%Z\IE%I(P4C@"$88)@&F8 H;B& B6,"*YBJ(X=*]6 M?I=.+K-FNAKD5P\RKY09=S_?'#Z(,8SCA. 09%(JT[E" 9SHOT8R(Q&3$:51 MXEHI?.(A'+_^=^\ GI3XGG+H[(^L)QF,"8ZR%QWGV*T"9X=A.O_=6XO8@4&' MVW<#Z_O0>[A"DQ^&WXU=UR'Y_0]U^Y*6Q7;Y-=^:XFCOUR+_D8L=7?TSWW[_ M+%>5KU]^SY^^;MZNM_GV^;KI?XRHB0D*1!400 )IH"Q$ ,LI4CUOPB: M*1M_>X#LN?G@;4V#[2:H=0W^76MKZ8P>QXQ>"O =$:3;V3]Y_OUIT*:H-PW M4LFBD*(Y(=",^7'[718/92FUQ\$9AA2C%(1QA@#4* &,0@98S 4B>AF@G4CG M([X!BLSO!+#1.I"UNF7EAFR,Q@&M5';>4A@R/M8[#F-A/MF&1*5X\-/>A+]6 M[:J;,=@?,)HAJ P('OJ'8,AFQ1T(>M[+&*+)U%L==Z#5L1-RS].&\>5;6I@E M>OE)%M5V[9M\M3.'(U)E"1$9 0E%9NLTC@%3A ,1*YJ2A$>2."6'7I$S-[>M M42N0C;K'AE9WM[BZAK0=M7G ;V3NVFL8:!7K8\!%T&CICY]NP."3@*Z)FI1A M;MA[3B&W+G?C""'SY0<])*M/WS=K^ MZK6?QC*V2O3L>OC.$:>W Y(6,_I/I./$[G< MS^12\K]]V_SX__1M]236/YS/W:X94MS$.P /_KUU>5CE= MOSZ]*S;K;7/8ND0)3I52&APN,( )PH!)&H,00CE5Q MK*#I+X[3_X@):^18V7):*L?NEH%)[9P7.RGJ7G&Y+%_7Y0F6F>!8R$B"6#$" M8$P1H H*0(6D$8$93'#LE-3>+6=N'-JHV31H="YD<0U-N^6.!XS&)L\&GH.* MB^"U[WH6-U#PFLM^1=2TN>S]]E[DLM^X_.[.;/*;H97/\FE3F**/[]=J4SQ6 MWY)7S\T_5AV E@F*D, L! E,3!YI%@.2"@32-$T23%G(8S2P^YJM#G.CC[T) M5?9DK6=PL")HF;&H^DHW5]1-NUPS40>,F!T-C3P.(U/4.$-P3[,T5Q!':HAF MK<9+-3USQ:FGL9GSHSPL1%]OUF4N9-WKZ&M!UV6]@;VD<<83+#@0C$( TTP" MEK ,Q$F40"QCG-)PN=ULZ6K DO2:5"=F/,@>\13;R A^T-5.WK&\NHKQ@!6J M#^2F7ZN>:!VTU!X#U3N6KS[0?;F%K#O*]ZUH;Z'EM+:]^K"76^7>LJ]WO7OS MYH$N[ZUDCFNY'&=-7\KWZT]5L&A%<>_7VR+7^O+_-%2WQ!PR&D4A@%AH'SE# M'! 412"-H92)TDOJF#GYR!,H/3>G^J!=_?EHIUO)FPV27F[H+9WMF0WHV-YY MJ\'QM93*RB_O:H1LS%[L4RD7A^Y8914M4AF_"(XORW_V^AKN#OV$ ^5U!3"% MWM,N&286RXCPB%)& !(1 9 *H:=52 %$ MBF8]&98@/A M>$@S2JIO+P9>3VLZ!4U[5M-GZ\5)3>_% W8<&W^B_+JI5L>%_%1LQ(YORR6" M(DT%1@ SE@"8J A0%!,0$2R4"!,A$F87R=\OR.K5GCA2O](LH,?] LN/^PU( M+784[X-IHO;"C8[!UTW0:!GLU?2"D\,>H1>\)MH4'(2;VR;@33AZ=_VNWSW= M-M]-"T[V]6Y?/9RY#F[+TPFKG'OD":V2.-+U"0%7)R2B\"/Y1;$J/Z44V M*/CTDWKE3>HNV5A^[C59W3.4*)X*R?/Z2Q6G''&>$: (S_1"*2$ AYP $

M=C=\ +7R 0P M 5(N!7-](#95[=MAR#F6K[T%2'\EVJMW3UA4]I8%I_5A;UX]U#EZ^RB+;WH= MI)>FOV^_F[-GNGY>J@SR,&$8X!@J !.]FJ$B8R"6<8@95UD$K3I/WI S-WYL M/OM[78-:V:#1UM4]ZH;6UD&Z&[!I7"17K 8X2+U(W.TB=3]]8B>IU\1+-ZG_ M\J%MW3;\M_=EN9/BS:[0#Z_#2*K D>K?S@)-Q#*6*6=,:9(@,@$P2E) &$^ MX#35"RJ8RMBJ/MU@#>9&'W5;LSJ$\!!!Z+@YZCX,=ILGHX([MC-6X5HK']3: M'\+R*@,634>Y?3.$MS>C-P?/UDAS%L6MBM>WKSVWL3D M=_DZW\H/^0\IWNOE\?I;SE:RCK&ILULI5D1@%0&2F=50!$WM\TR"2)"8"Q$1 MIMP<'6O1<^.'=@YLK3NHE ^.VC=%%._-/;XY*)9NSRA0C^WO^$/YCO1B6\#& MR2J^*?V%DHEM4;F>0VS]A(FSS][1O*@\+*W+[G'O8#U)4P3]C2DV+-?BLR;A M)4-()5S3843T"$+M)0$V&L^-1?>Z!<^Y7$V5868] MO);$.J=!&YN/[\\M,U;7:]6@9?'-X)8_L,DLM_6DJ>E"3=T#AG.L>[A]&5B>8U[39-(.G/ MA]CGS[*IBEI^5)^*?,WS)Y-W^XO\8_OU=[GZ(7_>K+??RZ521)JB#" F6 $H MF/848$2 3"*(XCA*$KM*SUZTF1NYZ1P] ; M6YX7P;^DYCHO\6Q>,?-)=OL'NG!K]/'0@8^9K^5&]UKR<;]]1GJ_T M2_TUU6^M_OTR#07$.",@CK%),*8Q(+&ARDRI#*,X M2\-X^4,6;&--D0[B7:9K6XD15YV2[XQ7PBO]ZX;@JPUUC+-W&@)+6AP)UK%9 MT$2A;510*Q[L-3=T6.D>')0/]MI[I,4!F'EE01?YTY+> &0N.&[(,P861ZB: MKNM[JP/-!&8A%$0"B$P8L20Q8"R*0 PC!L,PY,CNC+CSZ7-STBKE J.=TXEP M-W)V5#,8CY&YQ!X*]ZH'729[K79P(F#:*@==MEU4-^B\:.+#$-/Q=?M\3!H7Y3YE_^Z[_?-!> ?TF_Z$?O7VCEYZ'/;3/F]7J MW:8P3UV&!!-HRO1%<4B J:T * H%"#%G3##&,<\F.3H9Q[ZY,=9>]X#6RO_E M/R(4_EV9O?A'6OPFM_4OZEVT)UG4?_W\Y=>)SF1&>LM&/L%Y^7=G_N<]-49! M"Z2FQ>16PW2L-'A :A$-N9?:G'QY-(?G_;G+ "&.*B@QD4:97$PA%@(I8 M 4+CF$ F0[VDV!=;^FKO)+AK8L7%I]68ODZQ #EJ&[35=?M:#Q@8NP_J2#A/ M\\WKCS-;!,[8.W^%AL/G\T,Q0(M)N7PX2N=T>\>3!A[W=Y1ITD[W]OF3?A.W M#^N*QY^J]G:$Q0*3D(.$XAC D"A $QF"B#"2Z!644@BY-9"W%SZ _$;GO6,) M.K.#^=2HO@B>C/)5 W.Y5]_QZ-]^3"R/__WB/'$MN^U)3;8&Y$KS187RVYLH MNX&Z[*J^KTBA:NI=R0VGSQNLDSF+B/:JK]>R9/G-ND:Y>R3\$YQZI]N=UD_\GS;G\[^N];,4XI= MI[7WYM6=/G2R9+I.6]H9=-T7^(C9K?9CRH?=]ONFR/_;-/921)(T,Y\_R ', M: Q8(C,0TX30+,9A$M\1JWLN;FZ3]"*4M(K&+0-ZT+B*U:U_>U>0[@7PEMZY M-SC']LC/D:QU#8[*CA6(>PV4\0)P+R2^8.#M->O[ VZOWN7N4;]IJE35&?]O MU\)LSRXQ,P7;,@P$EA& "<\ #04#%),4\A!#G%BEG%V5,#Z^]PR;N?.YEOWFM6VTGOOW"8R_!^_4,_ M<5,\?Z:__ZP?5^1T5>H%^)?=T],JE^52,)IR)&,@!*0 IE0 [4,H(+*8$8[3 MB""G?M^W!,YMLFLUZ\B#Q[VR]5_='(2;,-NY"#[!&YD*#JHN JUL<-"VVJK; MZ^N]ZKHM0#X=AILR)W49;!$X=QJL[QO&,U\+2((!)"($E# %F(QBB7 8L2@;<,YJ*W^FIZN5$Q<4\DD_ M\#LM+5T-9_#M6,@KEM.PT5[E_8JEJ4RVU[O.*ZR#>&K=_5&2*UH^JNV 9@#*2 ""TQ1DD:EU MFLJ($RN2Z1-,JY,34. E. )J$ .,PD MD E2:8HY)':-@JPESHTFS^(@3\,@;=*1!@)OZWUYA'-T_^M.) E#= MC< =1L..GL?!>&3R-? :K8.]VJ;.P4^_UBC_-3@H'SS_IRK#M:E/N3%CI?D6HDL@$ET- HB0!D*C8 M;%-BD-$PDMKYS21V6HJ/JNWMY_&VR-=ESNOJT1.5NK$:83MB MG6]0:B%Z^K:D]GAT-B-UN/W>=H0WZ;2\QJ=U8[R(94DB0PFDZ3$ M)<;:89&=NTV>S:^5MGK;-W;\/#>8;>DT)<8S+%) M=MIQO*.EHB?,Q^FX>*]R+]20T1.FU_LU^A(P[+OP3VH$;I&U8U-? M>(U,D >HS$E9K>@X09\V>/@DKUYYD_*1C>7G%&-UST@;L5MII'7F$1N;%=A>'6T/C?QOT#NPFW?T\-CWO0-IYK_,> M67=L<5:5K*5XLROTQZ,NWE!E*5:ZL'-]ER@C$@H(092$VG%$J78<990"A:A( M612K##+G[4XW'>;&U'6Y_;H5A%Y(;NJ]:5,1]+!YQS>/CWHI6>V,#M@'=1PC MASW1\9"?XHBK#!K]#SG3G8OSXQQ;!%3I5R)XMRF4S+<[GUU9[\#3^T:JHQK3 M;ZH.PZES@W7@HP;D0;5;'W[(U[+<=PY[X+S85<6PI7XIMY],X)=)1D$4T22C M(*,Q!U"E C A8A!%" H9AE%FU^-KB/"YD>1!?4.1)E163\5:<1-64&D>/-6J M.Z0%N8Y(/S..C?/(E'C4//BH@DIW\T.M?56'OX)[;T#P:72X'7*S1H1]HHPM MW_"[Y74-Q*\WV\OUF=/E@ VT]B0S;.@SW"L3?BVHV9GY\OS(-JME)#7[(R1 MEL3,]&IA@"F!@0P9CS'!.+8[9;MX\MPHOU$NJ+6SKS]X"E<_9=\%PLA\;&F_ M4Y7!3EOOJ"YX^KS)J@IVFM&N)MA]P;T'Y(,C+9Z-I[97W#DH MWAITU]-G?U!.>+C?_ Q)[-5I:?Z+-Y9O/\)0^UO4APS4J< BBY9J6$Z?4D-N2D4L*ITXY;AXRY M$5"E8O!4Z[@(>*VE8U9.!Y1V7',G0"/32HW-ISTVKV]@XYY*<]UZKSDS'6*F M38ZY;N=%%DS/I9ZK1QSCF(]?R$B_"#B3$B@R%SXT9]KI;]M2Z'WP[RA@+TI&YI+^NQ%%W[:R,X:8,06V2>A-=\N=1>J(' M&>LJ%'W/&$9G'S;K;WKV/[Z1;&L.*IM0 9((%D:* 8Y2 2"*!<""4D XD]IQ MB1G$3B4(N\7,C:*,EL"H&1@]%Y91 BZXVG'2_6B-S#[#@')FF7X_M><<<>-JGR%D2XT9QBD10'&DW1C-"8"2F($8RRPD@@H.W1*E.L7,C0VJ M(\KF0)JWP\KE'^9G+TFT=\5DS8@0;A[>_Z+G@"DQ\/8&=IY"KJ8+FII#V)-; MX-*]"Z".'JMB9ZH)-(VDETE"!2$9!'$<"M/(.0.84X 5CP%7*$%AS$.FG%(C M[U5H;F1E@@?>3K#Z.J^>_W=ML:W!;K1DQ M8V<#K3&;9(U!9QU27KCQU37*Z;ER&(E\5"KG\K!!W71?$D*EF&<8X(@3 %,6 MF^8U^B<GO@1QVWM6-KMVT MOQNSD6=^ U>K&+KWSE:]$/@D@&Y!DW) KZWG--!_L7N8[.O-#UE85O2[N'Y& M[V2EE]<">5>MO2/R\_1YDT5^=IK1COSLOF#@LC^G+%]5#G$3MW%XO5+(,Q81 M##(8Q0 RO:IG)&4@)3C$A/(DQ4ZQGM=%S>T+LP] 7!TU_E^.2_?KL%HNRKV M-?9R^ZAD*VISA+*7M]'PNFJ^+FW:]?!-JR]6NK?OM^N-.==3%@H JTUZ80;.;PGM5 M@P>S8;17UB&QLP_5_OGL$ZNQ9W8W3+>7C&YX.22]>L)MH@37(WYF7U+L];V^ M ^F6P6H!1F^V:M_]TV6F6EAQDH5J<_VPQ<][_4*LO^5LU1RA=D4W,QIE$9(4 M9#@* :1$ 4:1!"AB!"4*JS1R*@-H(7-NY'E4^59(P&"4[19%GK$;F4PO8!L_ M7-P!()\+)ANQDZZ<'' X7T*YW#JT-=7O#[QJ=V6JL12;M?Z1U_6M/FU6.7^N M_]M*NL4X2S4/ 9%R!B!D$!!FYJC W/A(ZQ\<#0A.+5@$ M5&R>ME*X=JAR'!0[QAH3ZI'IZP;*M>+!OYL_1Z&SH>CY[5SEJ,/$_:N&(739 MQ6K@42*0.=+, *&:]A*2 MQB%->224T^&FC="Y4=U!YSILJ=$ZV*L]N$6TU0#849QO6$>F-0^(#JA[9P^1 MWT)W%G(GKFQGC\1E*3N'>Z_Q4GM0/^B?_O?_V/]&_\?D5?SO__'_ U!+ P04 M " Z@F-3I_^\-J=C O@ 0 %0 &)D M+3&L,?_TQW3]X:>_95S]_:>R7%S\]+?%\N_33P'@WS:_]&SQ\4_FR"UMUA .15!,9,A2%3 A'/><":4E?_W^W_F.2F+SD .48,*2H)' M9<%[KDQAOL@D-@^=3>=__^?Z5PPK_(F8FZ\VG_[KGSZLUQ__^>>?__CCCS]_ MCLO9GQ?+]S\+QN3/US_]I^V/?[[W\W_(S4]S[_W/F^]^_='5=-!)C.5^LP3_4%J^D_KS9??+E(8;V1^7?I^FGO3]3/X/K'H'X)N #) M__QYE?_T;__TTT]7XE@N9O@&RT_UW[^^>7'KE3&OIG].BXN?ZS=_?K8@*+P. M[RNIFU]=?_F(__JGU?3BX^SKUSXLL?SKG^HO0M4I\Y+5%_Z/;[_\\[=W?USB MBN"RX?4E?6'[C/JVX^G SVN<9[SB[?H-LT6Z]4.S*MG%\OHW9R'B;//52<;I M9//D)W&U7H:TGB03'9-*0?0^$*P\0L@Y@@Q"!Q---LS=9KN2O"*:-XI88?KS M^\6GG^G!I!#!Z@=5)@P8WZKA?]Q[Z95T3J/^>O6]HY^=&.$T-UF!UMS2T@D. M?- *LG:>66\M4W8 XF^^\S;M-W7[9)E^6BPS+LF(7+\T+-,]/=\&\/8G?OX8 MEO0@2!^FLWS]V]6:#*&W]6( ^5TIA\C]TT_$=<'E$O/+*]WL96[#V9I,*VY^ M<@B]_[^784E/G'UY@Q\7R_6D6,6CS!JRL R43V0623" #(-!FZRQ?D (W'G] M06@0_:/A'*EV HS7N)PN\J_S_ MMRA/-9?%6"-!,$+(-]T#;IH-BK @I68U) M# B+6R\_"!2R?U"<+M%.(/%N&>:K:17\%M91"IZ8UZ"M]Z"$)-GP[ C6.C+% M1$0[Q&:W[_T' 4/U#XRSY#HR-GZ=KZ?K+\^G,_S]\B+B]!6-#]8N$L.7:!@3?X?EJ%,%__'BYP4K3.0J(! M%DD:ROL"41&043D9E+,J%S48#FZ_^R LF-ZQ<(8\N\##"PKZEV3.-H)_2_+' M9XO+^7KYY=DBXX03/RI*!H&$ 2K9!%&0JYP0R5?2*'T<8NLX@)2#T&)[1\MP MTNX"/._"YQ>9Q#) M. @PKG? #"'A+J#R)&=2P6K[S\OI'/G$"HK"A;7 L7@*E+DY;0V8)A):#DJ M8=)@,-E!P$$0\;U#Y%S)]@2/9_3AJ^6[Q1_S"2/F=4$+4FF*O*I%)+,8 05Z MQX4R,0V1XMCS^L,27NP'P<:)8NT)&9O-\M7R]7+Q:3I/M%?&;+P6AG9(BL!4 M41I\%8Y&SJO(@A3#.:Z[:3@,(QUG10<3<$] >;U8KI"PV:F>=-,/%N;LH. PD'2=+!Q+NR!"I%O#)$L,5W5JX$FP! MIQ0%[9HA>%$$B$CNMC$RJ4&RYS??>1@,.DZ/GBS D15?SUMGKS\LYM<9&^-M M*-PYL"DP"K*D(,\9'4@GE'(BVHA#Q"9WWWL8 #I.@YXER)%!\!;3Y9( S$5\ M-UW/<)*"EL)1O)2LI/")EPA!Z0C M+L).#,"OG].','^/FUQM\)E9BPS,9A=C7I"'&RQ$JYGBK!B1AX# KG/DLK/']8OEEXBRW(3,"MC8< M%$5&X(UA(*253(F"RIO!\''KU8>5:'6?OSQ=G%V@X>U%F,V>7JZFCH/D5Y MOGB[0,G;#SB;75.?;+%2%8*W-'7_RPYBB!EDP4PAML>$0^0I[K_Y,$QTG*\\ M4YA=0($(OZAE(HOT][J.DQN 3'XT,09,D-*_IMQ+!1?*A)8$] MRH3!Z^&@\1 EAT&EX\SFP,(>&3I/+G">:[WJ\UEX/['<),OK":9D5-DF 3) M(ED^$1-$[0Q81M$4R4*$03)=>UY_&!XZ3GL.(=:ND'%UQ^&*":FE]#%%*-%% M$HKCX!5MC=Z+&GGG9-P0.8R]!!R&CHY3H<.(M@^'@]A8AMF+><;/_P]^F6@3 M2@@F 5:$I0.Y#%901Z30Q89H=\,6*!WY^6'X:+_#.@9(AV[9N(J"??-ZEU? MBE+%. JR(S"6.'G3M!GZC RB$(DV2L=#&B*MM>_]AR&CXY3G(((=#!S_\O,] M.;ZD+YQVC9Q@/E]AI@]6B]DTUTX!3\.L7H*G4 S7J]O4'WJ__+M/'>#B^7&4 MGWDC_7(%[T/X.-D4W=7-XU5Y/IW3RZ:T@RRN;IE]A9EF7,7,):2"%+PZBCMB M/6#+H11D4FNE=^S0UZNMA%7<(&#[SJLEA[/UZOHK=]?>,<2=:E^NW_%DM2+9 M?F6U*(U%%$7[)#/U2IT$'YT K2,G*:!W84DV]5L3^I4)D[3@(D:PFI$\8JU(*YC!HHO.6)N\V'%D.Q1P[E S+G[.4>]. MI)PCZPX \RRL/CR9Y_K/K_]U.?T49L3,ZLGZ65@NOTSG[_\]S"[KUJM-C%9" MX2S6!27 R^"!.X&Y!&F9WN'JG@^@@ZCK 5!GH6#16B4GXXS\N;@8RC2E5&_S MK=Y@0F(JSO!W7%\?92-74G$NP&5)SJ(5'(+3'KQP7"EGG0IM+-0#1(W3R*,= MK@930 =FZ\7\$U&]6'XA%B8EVI!I!0!+2$:T3'R&IT&Q40] M TD,0DHQ.,L\[BI=&=B]'J=Y2,/=ZF01GXZ/Q3K,!K) BX^X7']Y/0LDCGFN M?MS'&K72QU=A*[[$L,(WM0?DJ_)76A:5W2>%($K;].7%Y:RF6'Y!8H BW(T6 MY_G)1:T3_>_-IY-DR"(+H4&&@*!4"21;5T@V& U+1NSL$ 6O-6@]^UR ! M8F3M/6%?BEM@>:QLM-X["Z#%:3'!4C:Z]!^T*!K1*.($TA MKBLN)%3)ZKM-E^XGQ;_[EAY\K+/T/ZP<.S -5S*9*,5<5C$ 8[4636@+/I/S MP)*(.9?@H]UQ>C:4+]6#$S5@;O(H:7;@-KV.Z,,W/2)KHJ0,; M=(.ONZ&,8E$+&SD$K*%,5@R\E18L11Y%&.6";'+VMI^D<=/>;2"P'V?GZ*,# M9%WG7E^'+S7Q6MWXE):71,<]%B?&:0J2/=E]G1(H2VN4(EQ)8BN,%ZD3+SOJ M$8?+A1] 8S?8.PL6>_+C0^NH _C]OECC-5_7+/!@8K*H(89:G\,"B8JE K5O M34E1>N=+"YCMH&7<[;(1G,Z5>0>PV0%\:1,+6!RDR#D!WR*$Q#1@R#([U,[M M:HG;8A\<-X1O!)HS)=Z##[^8OW^'RXN;\)\([Z4UM:5>3 P4408NRMH<1Z+U M(631R%_?04PWQJ:AWW2N#CJP/9M#HAO2^GTQ3]=6U'#%;,Y0>+6BR#W$Y"PD MM)GE9"19TA9HVD]2-[:H':8&TD<'R+K!Q"1HD611$F*LK6!+)!FSA!-V@8-Q7YV''<41+O8#NK%Q^GZXM-!=:\UC_71BTX3Y45;T+V.2A MRW/MZ%/'KY%+9WV=OF8P2;VC4^( 57'[:1HW@?DH8!I*(QU8H@XJ/"JV!]-$!LEY?OW?#TE7%*).8 M,J( *U(]*U8.?,QD?DT(Y!D&96*3T&T'+6/?(1A&S??KG,Z2>0>PN7'-_XK^ M@M%;@Q:R*P;(B))KYX2!PJ(5F@N>8\0R65V#$79X $]FYZQ@W. M&F%G"-EW *%W2PRKR^67&XL L],V&P:^Q%BGUF&T0U+S!=9C.,?\:EG-R_E>WBN7*-$W7$\4- M,DZ1 "^\]C^K>VYF"2RQ*-!K&VR3P/[[I(T;HC5"U< :Z< RW1?4)*4@(X8( MQM0B9%]'6HHD 7UF7H>,4C=QH.^3,FXLU@A#9TJ\@V31]X+4"?/!15\XY(BI M]K=0$+1 8-EHU);KK'4+!'V/L''F!XZ5@SQ?-X-A[5';2[S>:.,#KJ>)O.); MK S5:^+V*QZA\<0#/#UF%PIK?%1UNH\SBI"9O2:39P7DK)U$(9QU3>+DQ^A" M\?4=[S;GB(ZX2;1]@_,VU)I2VL=9G<-I;0P"T91>^TY;Z9[.P6KTJ&VO[Y/-T-0D42S@;-'#IR#\0RH"W*8.4,C GZ)L)FX+G M+D6=X.@$->]#S%DR[P \-^G_97%!8<5$!(O*^@+9JGJL8^I0-5W ^&*-E,F9 MT.2NVWU2.H'+>3J^FX8\3^ =0.8M+LFM>WH[ ?\;;@9QZ<0LL[5A6" &5,@: M0K$9;! >*;XP+C=)1CY T[@@.E?==^W.0++O 4;7RXL<5'Q!'ZXF46>6H[?@ MC2WS2W7 MJ3KH %(W2ACVKA(=@O962,@Z$$L^J:M++YF^7'C.),HF[7$.H&WL$]Y!H36T M+OJ"U_U-WC+'N-,@2[W/X&O5NLB39)@?TTC7VTVPI.9\F^1QB] M6*TNB0T*2)U"BF PJWH'GACRP2?01=+.'E12[0JX=] S]JEN6_B<(/,>H7-S MLU;D_"D=(H1$X%>1)7"T>X/F*5ITTHI',D''>DO-CG);@^A4Z7> I%N%5U?< M3!3CJ%3)$&,M^ S1TW8<#1A3C.68$-LTK]]!RT&X&7R@2"/Y MK1;EU4=<;MXPW!R)/8]OF_F!,I^/6%WQI6,H%<8Z$M21/F"D]D M7-!#"EX%9Q(9FB8W2_?0,_#)/>VOLO@8H"A;9[51;!F5B^"8?I@DW9XG)>TS!UFL'IHX#=10C M&E5GBV/BS!JMC3@ )O3\&Q"AS^["8Q\!G62J3U#F8D#)]H&,3:W<%0>K[6&A MBEK:;!RP4N>,,\YIS1C:416GW21&+@YJ/'L,/.Y3,0Y&AE'L?92<*>4.G-LM M(]MS7VZ3* MN -\O%E\";/UERWQD@<,%B/8K,BH*A00?;U_$DS,.B!)ITG7%&T$9,QY"QXG=O,7KA+2"=.ZXF*O7>;ZPPI M]X.2YR2GVA^DLO"WZ?K#L\O5FH*_Y:^?T^RRIA!KEV3ZD]^%SY.8+'&4/6 = M+J&451 C&4QDVBJRR]RS)H??)] Z+M;. \=NI#735!>3SYXM5NM7I7;JO[GE MOUW,\L2C%9BU@.(Q4^" 6*@CWQ,17!GA>1-JE/WDS3N9CP<&;9L. MG;_?#E&ZT22>1Q&2T^ ,^01*FPC1! 1KR?@7^H_61 L [:6H$V=IF(UP&+EW M *"_X)PXF=6>QOEB.J_3(HBO3[CE:Q)BS%EQ!QIS >4#@U#JJ2SS3M)"*SDV MBX.]U VK\[L65 572 K'M"FF@F2C&;QB.FMH/T'B+* EHFCMFCTFT. M4>Y1,JXI:H.>\\3=P1WYKPQM$67< EQ=S,E6X6E];1Y5B,M84*)S72[65?%[;J',> M8M:V%-$DM7R'CNX*1\^!R3DR[J(?T*8W\>^+^>(VWJ_YR2BL28&LK"(N%$\" M@J60PK%"CC^SPKLFY]X/D]5=L>A9EF8X#73@TWPSE]>)B>G\DICZ5I7R%,MB MB5<_]RY\QM6OGVEO)Z5-YV'Y92//VB"[IC06L]E&'E=K;.)$,+%8!2ZS6CI; MI>!BK?(OKMC:!;DTN0'?D*?NZE;/,X9]Z+Z+O7?+XG89/Z7(I=1.7HDABXE6 M2Z-]N"=]'17\7H^_,Z3>1=[\N^X_K:4GGP*TUD] MOGJWN%'2N^V_]#2LIFFBC/+,A52+,D,=8EKJN$H%4O-03/'"I"9M98ZDL[LR MV7/ UE)''=BOZV:$U[>?-DQLAJ7.+@GF7^/Q+"3)J@A I\@LDR6F518XI*"4 M*%['9)L,7#N0OH,@YW\0R+7020<>X]^P#MTE^C^1E_ >?[^L11BORKU+"U?K MR'FEDR=N2(YU0E2Q$(7-0&SY((-1,C1I3GH4E>/F7IO@9/%82NL D3L%2!XH M!?9960B2(UGPVADA% E612$]TTFU&=^VDYIQ\[./@;#SE= !DO8LDZV<[M_+ MHB#')R8<6!X3*!<5/%8UBY4Q3Q0]ZXV]%(^18[ M ]V\V]>ON>D-O._Q-GQWW0<:/\?,Y&8&JG?>@?)&$)*< )-3B<8D9]DA5Y). MKP5^B+J!;^GYDK00KH#COE!T):L5YA*842S[;%A132I:>[JE-SPJOG-G[QBA M=[#U[6\$RJ)S(1L#*%AM?>8XN!@%E&P2RBR3,DV:S_T8#7:/4O/!#7:/D7D' MX-G1 %2A09Y2 !V=(L_/)HI(0N4E&9MR%%DT<9E^G :[1^GX^PUVCQ%X!Y"Y M:O+Z9&>3UY)+MEYEJ%T7006'X"U6IP\I8A")Z=(D>_H 3=TUV#U*W3L;[)XO M^VY@M+M7L,U.29T9:.2EMOM(X+W.4+S@CHO(DFHS7.?,/LW-\E--8'2^['N MT;65OO('GRTN/B[F-6K96&KOK*33"[F)NFG!ZGJ MI"I^0"_H;-EW *0[/&Q76JH!3&C-$:@TTJ='92TXD_ M=+ZV[^:,SA9]!_C9:4R%U%'(G"D,M;69OE:U'IM!9%PGYB1MT$UR%?TY0@/H M^,'NN2<(O /0W"BN^,I \2'Z!-84!ZHH6D<9)7!G@DO.9M%F7NX]2D8^D!L< M+N>)N@.L[)GRNV4F6&]0&()[[7"O8@P0A0I@LS5*9VVX;.(R/TC5R,=J@V-H M.!5T@*=;?1&W+#A3N+ F+N#?;=<)&[IO^3 4* (*M7)!T48^BCF7$\2D379LG:3,^Y5BN%Q,X#0 M.X#.CLK!7%1VDD<0O)"KIFO?FI)K%;Q$9QP7F-N>3KP\JJ=/^WM^ P;DITFY M YR\F*=J)_$7O/KWQ?S^F=^;Q6SV?+'\(RSS1.@8G? ,LJTM(9C)Y,.1+37) ML>B\RJJ-NWPDG9U$[B?"XOZUA&8ZZ@""MSK4%ZFLC(;VY5B'CA?ZR-7[U3DF MQ9-3,F&; ;?'C@)HV22WG;;OVJ]317\R;#[B_D(X3$:*GQ$)S@4MHV*<03)[LW"^D?%4CGJ:$O.%VMAU\NE^3^O=Z\ M8#/'Y[J$KY9M7=3[81M-UDD(,JA4K^349H\Z>5I + /7D9Q0+0WZ1N51QY(Z MKMOUZ'!LI\8>-LW='%X9],TW7WW<7)C]]3,NTY2XG:A8EYY R"4B**D5V7=! M1AZ1UJ,*2J1&M6W'DCIN*J(#H ZEQGZ!>K44=S)HA+"IBM(930PR&R!J?#VIXOP=UZ\*B;;@ M='U9)]RP8HLIT4.D#^K^(Q"_0;&05';$+_KJPUOPBFL(RDC& N.QS6VR7%4$^?V&@]%K'HGHZDN3_.(= I^MA4#0]9F.,9V'UX?EL\4>;2=3? MGMZ^#<8>3H;O?O'U15_;&V!2:+SCP'P]#HRY@"O&0@G,.LV,"+)UTXM[1 W@ M#]5GOEXN/DU)?$^__)5D_V+^M5']D[2>?MH$']^F)20G6?(29)6%DHE!T)&# M#6ACDIEDTN3,\'A2.ZGX.A=+.[RHECKKP-6Z[2=*Y4),9)RQ> M*T7X?T&5 M%73BR9+GV&2G/,%+;X6EUBI_T$\_1OX=@.=)_M^7J_5FNWBW>(-I,4_3&=YB MZ=WB6&G&9)1$'L%P"EA45/5698E03,K.JE+'2K>YVC,\,^.6H#TRE$='0PD-Z?I1L7T\0PWNI[G)Q>+Y7KZWU?%3CF(0F*N457QM0FF!*^] O*%>:;_ M:C4)B#GGS1P0 M*4%QU.3K% 2M2\I,L% (I=1VP](7\)*\A2Q+R+E.7V9-1K*=<2NA615M=Z@;0&'AIIKH,]^SYG%(4M+LDVD&7 Z:=-SP*N(K-.D>/!-'F] MQ14(?G//0A=:;0I=F\L&AQ#7V^WI88#Q7?R=J:4NQ@;>Y^K:!ZXV/F6OO4$+ M:3.9&)T'GVEO,[W$CV&:?]E2M$TW MD8^Q&6V\#?6=949$$IY@7%&HSS(X56\_^F1T*N@Q-PJ43R&WM\O6CP3,P379 M*6*OS?WK\*7:^IJ03VEYB;>\8HE6Z>(YF7WF0 D;(:BD@-E8.Y'9I+-YW&WZ M(7)[NW7]R!OW8)KLU8FL/-T8G+WE=\*#"]S)!(F5VMA,9_!2:PB;$R7)A$B/ MYTONIK&WB]:/A\P!=-8!' \/#B?)^NAR/5***H/RO("WPH(1Q:B V>@VD"1BB&'TMG8>7.R[MLD\/8:%C&:+Q,YS"8ZP9!IL"Z8FC^HY^[< M@0\>L9YQDL=\4')\[RNZ+'D<3+&+P:7<15BRBQ6RS.LOKV=AOB9/MEY[^%A_ M9.+09\%(7%SQ.JZO2'"U8[_)!;7.:))O4LA].(E=5BH.C<#&FNL"E8>+6 5*20U>< F%:XKOL3+9)-6]CZ NO!/,MKKCF09AJOTDP5YW)@R_D!!N#.@DN0FA2V? = MNKIT!UM!;D@==6#7;K&SNXDICXG)%*#$NI0RNH!>%O#_7RQ)"M^N4P?P@IK@Z6OH\@F0=9^SL6#DR+24C+D&F=N M07&>C".AY=RD^/7[I'696&X&O6$UU=%V^]5W^"JZ9XM5S2[5464JV]JZI/9M MSC6Q%!VMK!2=M[Z>Y[0$WEV"QCU4&PEN9VFE'Y =+KV)C4%Y:2A6CHVTVNUAU.XKC%UX\,Q$::ZR#%4MFJ_Z^9RT]AAIM:R.L&M/4; M3^;Y]A=N_.159\3[1^!I=IE)*K]^IOUA_A[?T#+ZM10D)4@A3.;D$I.,2#JV M#E3*!$,6'85CD6FG2PM7GCRQ$(6CB2 MTC-RSWR;JD4O,=HLI/&C2_F:R3EK>NL:?+3)I87%7RF!<<*K;^B M-R-?/12K51WY*EB;R5YWZ!AWF$$S>)TC[0Y23;>J,J=Y$I-2NB0!6=;+/H(< M=57(3EET593=_/IV6:PGS]<3&;IAHQW^+LL,:>9[[Q[&:?0W(\4 /0 M;>5_;5J5\:J\OJ&,IY>KZ1Q7JU]PE9;3C]<=I^[1]HX4\716<[6E6(Z:6UJ/ MCN25@ZKMO4OM'9@*9PE%&[^M*5>UX2,T:#<2:"4E% L,( "S8&ZQTJUB0;.+R]WM0H_TJ/7']Y]0F7GZ;X MQ^;17[XMLJ!US5@IX%IYEUO'M?8* TR@-$C=Q;<5@\ M#:Z%#A#UUWH _^MJ/;V@(&XU*4D9-(%!CI+$4N]%1*XXH''*&Z^X\TW.JV^3 M,7(WQ#:H.4/2'>!DF_J[>RIS!_Q,Z%H@[B RIX@I7<#7 2N82;*X)O Y MB+J1.QTVLD6#ZZ6+$8E?VS#>Y:34(7@Q&BC!YRJKFFN.'E)V%&DD4;QNVSCS M%%"U:V38!E2#2+\#H_4&B8\Z$CJ24GJ=RD;N3EA&UP-JX\. %;+R5Z5MV1T[YE,>*37SQ0?10 ]8HE=.U[7OY[8N+,Q>S$E"E_5HY9XA M+M(SK3/83-9866? >]1 .SO6/I\4R#:YIW8,D>.>2K7"6RLM=8# W_&/&U); M+N;T8;H:RW;%V5W^LF!:6)W(6@M:83):<+H.+RZ9FUQRTFUVSV,)'7?Z=",D M-M56!VA\'J97XXB_EF_?7&I;'B?*>*RT@Q*FMMLT"EPA]E"9S*)#$VV3'/!! MU(T\5;H1\(97S( A9S?'0N_J';X1#H6V[QWY2&@7]^T/A*12(D55@ M>CTB3 MI\ A1]"!HR@Q"!F:) ?:'>!_76M7331_VXQNQ_QJ_J9>&%W2&S&0J&-/D$.!80KL]:#H&0WLM8PMM_>.=G#_)>9,$ MJ-M'62POMN/.UF$Z>WR[^1 Q(QO3@^74WL+JX)1&@Q2[B=UAM5)!]',Z^OW/LP59B5L3@J$8R0UH8D_ MGSV4%*4*@G'AFTRG.XR\;D_SSP%; \V,W5/R'4%C]6$QRR^G%]/U\\7RY?2_ M+J?YJJ77)DB;9.XB%I7 RT*>!Z]M#U,=%Q1T5IJ$:67YWH9[X+NZ/-#%UF8A2C6Y7+B?I&Z/ M\L\Q1 -IH(/-[OY8G'K7QT4MLXT>=.0"5%$9@K>9@AU,0F@G8VQR668G-=V> MVY^#H//E/O;.=9^#)[/9XH\P3TAF]MOA"VW+J2KL/;XJ]W_GU>5ZM::@:C.] M;K5Z]R',WWV8+M=??@E?5A.%UEI)$;Z0,=>@.T%DS)!X4/-:J^X+/VCK>P1B MNRT#.'GO[$W#/9C+&P+X97$9U^5R=I_EW1T0)J7H6"?K@%"Y^J5,@#>DEY!C M%MIFQVR;*>IG$-UM)<)9QO>QM/B/EPBLU8OA7A%CN)TU'2LQ> QQ(R<*3Y9C M^\1ATDD&3;".3C):65G5N34*HK!)R,*TRDU*!=HE#K]>>WZWG?LH"B8R&,+6 MIHE1"G"J%A]E1]P&VH1TD[%?M\GH-AUXC/[O3<<^7=(=[.Y?#X6>?OGZX?^: MXI*(^O#E)7["V9//T]5$A%B"1$%[#2;RTFV :*T'E)*'S%&7-H7-AY$W+J[. M <"^([KAM-$3QK9'CE==-N_Q]\OB(DSG$XKWC' \ Z8ZB3%J!V'3SX[+E+RP M/"?;%&J'4#DNXEK 9!\2!]=93X!\,?](H=I&8OPWO(BXG 0,QM:52_N! ^5H MY09=NWJ4G+500G/1MF3K/DV=@&UX).S#W)EJZ11A8LL*ZA XDP&*]37YG@V$ MI#R4&+*R0@K,34ZI'Z!IW*.S<1%VBEHZ19C9WOYY-SW%] M2@KVUN^?G27=3\U BU1H6+FX)*Q1&:D?=NX8DVC4?'[B1K7B@R% MCKT%(.>JH7<+EO+S]^G-4).YBYTBP9 M2-(F4('63] 43R;"N1"(R36VM7L(Z]?.'(.2O3[-$.KH(!3_RL_?%LN_OYAO MABFNB MG22X4VC&LD[$M^6FQEEPJ5Z(73!>MVY9(WR)GW-1- /1\ M.I^N:!/^RV*15Q,5HT!C9=UA([GW7(,WW@":Z)QG2?K0%D"WR!DWE]P<0*>+ MOB< W;\F0,Z@1!426%[K7C$5\"(+\$%[2<$B9ZQ)]J_7BQK-@72>"LX=+3DL MG.I5 2:"-B$K$-&ZVA8D0%0NU3$;*2N>BA1MK)]8_6$O[:= M,,;8@!J2%740DJJS;0)"]))K*X0RL=6$ZGTT#74+;/N*)[ODO"O3&2-WM"02 MN7$FU$SGIA;>0J#=6#'E0E1-1'$BO>/&;4-A:M]5LI;*ZS%==(AQ.#U]?<33 M'\7,-4QW/P1,+1BW)5I@49*3%'*]Z*(,>&N8D!A#E$U2, V-W;=\ZB$KYTZ. ME7%6R"&0D+&.JL68(&A'*T?SHJ4N%)H[<]1ZK% M\<$K29Y'M!&4S)96@E8@9CV M,%GCIMT;PVH(5730GJ2R\@;7E\OY5PYX8<(5Z%/C0H!A)C/Q;FS>)+F%5_\IJ-8HW&8!C$+"C\, (A^@9-YW>V*:<)?Q^,'1CT/DU(\D;%%8[<$XS4"XR<*@"9.\4,C1" MVB8G,7LI&K<346,ZQ+ MMNAC-J6;#Q^W?T_++>ED$78"@3?X_G(6-M6<-YUWX6LY.M-@R7L'I2@>=($S M,%)*RW.).APV//C!UXP[\*>MIW*V6,<&R.OE(E^F]9OI^P_WT@6))6GKV';F M6*E 9P1YET *Z2,F'\D]/P@>#[QDW!D\3< QE$@[<$1>K3_@\GZ.]"O0L\S< MJD+>0DG5->IY5/,J N.D#6(>> [&A83<"O*[FEQ^/H+&PS#WH^>1!]-2C]5+9+8_XG+])A;FZR)F5)8>U4= MZWW1@"'Q$H1PR;4YIO\>9>B !%=5$4[ M%EF3\X=CB!SY<&M0)-V?S]!(63T>P>]:_:>7&SWPM"9VJF4YT7?]A+-,QJ#G8,IVFF!_%'KW=="">_C?F9V&-[Q>U&?'SZ6?,5U/O3J\0 M.OUE3:S9"7P^FK$C)SLS'S,P9PVH;!)X3.3Z<^.C,2:YT&261G-C]ZT ;__J MVG2$,D)&C2*!4Q0+*Z0J M]G+S],L[>L2FY:N,/E@;$92(I6X8'J(6#K)6#.F1UK6YJ'D ;2/WUFH"BD.W MW!,UU#/H*D/;?HDEDK>@,@=DG!:K51P7D5P7-+.$-$DE4L4J4EQ M\@,T=8JO4_6_:*.,#G#U;''Q\9(>=Y>-PDDL0B'08@NT!D6&8*($QK0UT3/: M )K$Y7OH&;ETMS&>AE!"!UAZ50 M>9.:J)W4C%RKVQA'YRN@ Q2]K*.UZIC6%Q8"FD0M]&R-J*&6,74?S(L_NK0OA96WWP4!F:6IW MZ@ N2PLRT'>D,86^>5#]S(Z'CUR_VP@5@XBR Q/S;#%?K9>7J>ICTY+J/2GH M&M:!>$#+))" :F,A:\B!JZWNDU#)2L53:.3Y["=JY#+>YN[/0.KH %I[9?7R M:^]RBTDKR6B)D,T$DIF&R+R#%#"E8%U4.K< V/=)&WEXP*BIJ-/TTS/B_K)< MK%:3E*TI&#E$59'&MOED; Q6)GM MHR^7 X7!HRN>._+8ZTT*VNDLN&)JO_O@/.>(O,V4^Z9<=9KP&76)-,##N6U6 MWXV]I3PIZ\V%D$,$$XW666N$I#E9#5TGTD:&4$MLDW8EYS;3B=JSUFDB;-S5 MT@@9/\JUC2UM8Q"-X&A[RXS)H,;.ZGV-"ABV@M!^'K^#Z>?3V*SZ"M52SIVNNT<8/& M'[O8\!@$G5QL>(R21HPO5\OU)D^]F$USM=F_SM>;ZW6;6B4F?<[>(D09:@M) M1BZ-P0"8I)G>WPBY4/&J9V,H#&K H=3[W?PABG!,9?:JY9+0=Z@$. $$YC? M0A9GLJ^EA%!;(U/(DA1X65M5:(;,!6&P317,/\P!XBF;4"/]=("XF^'G)$F! M+DD&*>5:U*,M1& M$YO;=:>$[_>>,<"(SH>H&B@ KU/(_IC.9H20N^_;,80H*<90Z2HXV8I%(+>UP$J0UCW,4@ M5),6O@?0-J[9:8>G^T.MAE73CV"8SIE=OO-)@QNIAET8CH,6HA)91@?D'7-0 MFZLL*7J046H,-D55FG@ CV*J-@'"-S^QCI1[%\-@NK MNQ-#%.W**O$(V=11)273]A])8)('#(6+6*+X'JR&(.1',EC'H.I6-/>8RCK9 MDGW"95P\EBT[9Q[ZSB<-;LL:GGLNKV\ AU!Z$LEZLY4UNBAY.XH]DTXY! MU_[SD4&5UD$ZX4 SO41-/9R MKC(L3.Y7AS;16=]P_,;8[^'B^B(+DR9S:PV@CK2H*1 "Q[!>K;RQCW9>3A/.5[5I*VTMZ^4T7FY&DF_:4F^/+HRUNFB% M4%RT)#KBQ'N303O/O0PQR;L-G/<$&M]_5[=X.E_/BW9"'S!@&*)!_/6)ETL8 M-4= (6DG\%I"2"2L')51P5I9S F-X7MHQ/!H.#E7K"-7&FS)?[5\B\M/!/F- M(4XQ*UL]55<,&>)8'5<3$['#?##<*6X/R4$?5&.PBX!>#@>;>%*#2+T/U-0V MY5L.KL_BHY0$>F1@6$TWU\Z;/E*DDY$'6DL.K3FD4^DQT+E/Q7A5"NVG_^O(__^,_GVX)=XD0FFT$BS+07HBBELHHX$C;HHC!B@-# MD)M/'>>682--GRRNOI,C+[]5N_#H/-L4T*E:+54/<4BWP'-DQ?MB57KL)-W+ MHPK.FMU7'3\[=YJ6^D;>59>$@"63Q I@8)ZB+;OIJ*C 8U"E<"V,;7)4\3W" MNDV4G B%P[%VO%Y&]5P.X&A?SP/RX+.M?1<%L[07,%JVP0?R[Y5W*)V2+#7I MF7(\J=VF8YJC<0C=]7/'^ %&?\?U1!1-[E1)$+43Y)SH#-'1\K,Y6&:RMR$W M.<=^F*QQ-]\QP7>L3CKH]+"?F[^NL%S.7DX+3EA,41?)H" Y*,K01RX+!2X9 M4:+2@ILF-R8/(6[!6&+3?I]5,JF78_Z.Q" MI@/H.[..Z6H^\57/#'K7:G-I_,:-6^-*4(;"1V-K14F!X+0#;7/*VB>.Q7]/ M- ^^89 3R_=+O&H$NQDX>26Q6P>6S82_0]C*TZOXW[H<6WL1H.*[H?196M3$),1@HH2 ME'*60C,6"%T1?6::ON+&LQYW'WJG3C>D8.M9+01=YR9P2RZ[-AZ,LIPGIUAV M\B3B>ZB9'DYOM^?<#R?2'\8"/-!H93B[\.!+VEB+P_EJ:D,*A205)UOYU M003P%4):H(FT=>4H#[MA_G@V9"(SUVB, %X;4"ODY!7+P$%PB89Q7YQ@IYN. M'BW&,5KZOL4X2H!CGTY=_6PSM2_PG*NJ_[TR77F>:O&\\3WX4%0UNF0U#D2$.4CAQ>SY)GUD5TX13= MCUES,HRZ'M#]";(;6_NWCEFSBHPK[R$ZE/7ZJX=@&8(U0G)D)5&XT^94^E%T M?8IZ]AY)'R.KD0O0WH3Y^ZOB*N6\3Z@8>%\WN)@U1&41M+/."V=U48><_AU4 M,#508V##U?_ MV 5G)VKLKLY/$-_(6O]M.I]>7%YM?%N> 8F@H\A!F;M(8-Q M#M/^S3>/5WDXB/9/%N+8/MW=7>_EUY,T#-DSE,<7K>+Z\Z58F]8^.O'Y\O%?/TZ?*GG'1-AN,P9'8@1.'(IU8FH)P'B]GM&CP'.5N-#R#A#IKW!X_5RFO!5N?&57S]_Q+3&/.'& M%*UU@,!JR_0L(T1.ZXJ>& 072%([#2K[W]E1Y- -@/)^L>!T+=<_/520:6* MDMR!2K2U*D?,TJ::@,)QJ4+)Q;O#$@YG$-'1CO6H(#M/&[VA[K?I#%?KQ1RW MS/R.Z[>!OC31 GTQ68!4.9+;KLC],TF"-[IX'6OY$#\)8OO>.$Y!U6/A:1 Y M]PZ>-[@Y2;S%G^>2!1XLV*S)C]2;OJ2:F-1&B^RT%'=[JIR(HQTO'V?:RUB0 M.E?ZO:-K-1'1<,^RI>BQ6EM&J\8I'\'5+K<,<^V3, B6#D/.X!..QT+.<9+] M86HS:C?W*6FJ24W&SH>WJ<7X/A]-:S!D-K+H[$!JB]6I=N"$5N #LXG3G\A. M*X5J6(.A$RV&8"-H5_L[9D\Q0 D!6"D47"HIQ8$G9E5!IBX*7VW]1"'1-U]UV#<92ROE>#<8SD.M/\ M]J#:>E3"?\(-1A'J>O[-1C'R&YL[=^J M*Z!0J20E))2*?!5JA4%1#HROAT^"T>[8J#/ 8]9@'*6>O348Q\AJ;"7O=X<5 M2K)RR8,,ND[2H8]BUL0%>EH*L7AY8F1YW*',8U9@G&GHSY5B!Q?UKR.6=XNM MJ[R];C+]M+W^-HE6\U2$AI2])!DI#RYD21%P,'8/$61(Y M8 GEM$3I@01T9*3.@]6C:>%'0=K$)^LT8Q&,XI;VZ2(AR-JZMF9[O&$FN6,< MV>^_L98.DK./4ZU_GVQQA59XTUNXH0$UZW?/SN'M9^:@88N_()QO:/_ MO8S<9%$7?FV#L-%B=*Q $E$6ABEP?TA7R!-FQ>TBY_PQ>#>?^NT6G=5)YH@* M&*M)8$W\.H6&=M@B#?F T15LSV4G0U\&0,+]@7CGR[W'#/G-57GZM>4=3QG4 M7C0<.[4'*SD)JRU/D*W(]>Z:)]N?&7#/%>E%AR":M),;UFIL]KL;_=\NU_30 MWP+]O9EA^ZK4U[V*L^G[\#6:O('M'#ERFT&D.E[-UP(&02(1,MADN?59'CU! MZB@*NK0BQR!CWXRH=GKHW<8\<('X7,/ST*,'M48'\]#61#%>*(8."(R0!RHJ M!&\+A=+"Y10-TUXUR6BTS.E9E]\F(">ET0G+H>1ZH2P7"X1U!2*D*%DN M4<9&8W[OT=*E*3H& ;L=E%9>4>_<]7P7+M@Z\Q1EG6Y MXB'4'L8Y>.:RY,SX)JMB%S'C@^8L#2\&%G>'D-F>GY (.&97N^1%6D@R$A>% M,RBTKC27(MJ[_23:@*:'J4GGJ_D[N#E!YF.GYIY.%Z\_!-KIG]&+I^O7L^N. MZ;D49:-.( 522%E*!,^($\:=+)G)B/&PIA[[WM 7%DY1W6)H.79@1OX]+*?5 MGKX)ZZOUD:.VB@0!J!*YZ**ZZ+XPJ*T.%')T4C9I?7J7D'$[[0Z]XYPEYLY@ MLETZRGHF)%G.8 UQ$*4D;TTH8%84K12WUC89W'>?E'$MRWFJ?0 G)\BY Z20 MH PH$O67F7 M1':AE6_[?>KZP=,I$+COLPRLCPY =ML\?SM)BRP4GVFM6:%2O:T4(#(=R<-S MY-]9%KR6+6"UAYYQ&W8/O8<-(?0.L%,)?U6NW+;G(4UGT_67[97^IXOED)G M?8G:)/K\;H^6/8'9T:_NR04_#UB/(/HN9J_<,?D4[TY(* J#%2 D>0R*&P-> MV$U!+7(AO.<'M78Z-_-,I/2T&PYCI\X4]]BYH-OD;UQ$7*U?S6=?MH6/&XZ$ MB\;*VMFH2/K+UU'BGB=(Y$8(D;G+]K [B0>];MRI$XUMSA B[L"#NLW4T[": MKMX2+2&_FM\,7OBD%$__*0':H]K.YQ &(60O?.;*,7P$=WP_@>-^^E87>KXA9E_0&? MO?G+M[JX8>K$#G[/H$5CIW'7N#0^!1ZYSA""DK4@6@"YU 5R5BYK5$KH)H=1 MCU=!ALD[X\C&"E2T/G((X+-/M(E[DZ0.*=P=#/Y_5@79,0@XI(+L&'EWX"7M M2IEN3B-1^L1=0>!Z(Q>G(48?(?&B. N<.^=;X&8?0>.#YRQ-'Y"I/EKLG<+G M9;77R^T1I'!24W1@:7M6=;95;7*MR ]0O-0+V\99T:0LY'N$C5Q5-(CZ#\#4 MR;H8V_LFO^ M+C]-TW3^_N7+9]=-L[DIQ@L'/# 23PF*'$J9H21E99#:V;OE MT'M\[)V/[P\3IZMO,:@L.[ T.Q:+U\&;$C2DVL])9)!Q<=>.V<-0:Y;>/1[")F M7%-SKH(?Q,L)TNX ,3>M[]9 QJ)-0I8 $>L0;T_V-ED)3HMH9.(F.]':=>EA M8SI?O0\X*B?(N@.T[,MZI<*\CR00P16MHA#)?6/20$Z,94'[<^%-(//#U)&= MLRT-(?0.L%-O%+S;WBCXE@R[F?9\O9S.T_1CF+W!NM9(2Z_*\^DJA=E_8EA. M'"M1ENR@B*1!28/@@RSDQZ7@M80"O )N)-$:\04T8P3 ITR1.I31HYG49NGR5YCPO- MH]7V(X+S^>)R.>%9B:Q+35I+8I); ]Y(!,Y2*3K'*/,ADX#;8[-2VVI(2YS*0X;=:$$,>-;CB$AB'F?[EUNE' M..B^352?-8'GX&PP%0S6+O)T./UU'BYJ%=%_TYL78?YL<7$Q76_N>,SSJ^7T M_72^4=5SQ!5]Y<9/US*"RO#JU?+U$B^FER146C).9:V@7I4#99@G#\1%"*KD M++)'$PX9B7PT_(9DHL]*Q'/@.IJ*CX>WOX+W'-^']?9GA]S))R9&Q$@NLC2Y MCH ,$5PR#I*T&%+Q/-RM3QQ^@^ZS5G&H??*#*V1+@N=[R[B,YKM[GG4\(:F8=O=O4!B.J0<&(-HLJ%=)'$(V7(0 MWG)?M+=:-DD_-C,W7[N^;H5ZHV?HG3ZOQ9N44B102XI"E6>T@2KGP)22O6,F MQ]RDHN=P$CLU/L=@YI[Q::.?'\(&G7&?8L^CAK=!#6]%[,43QK)"]J4_>HDA3*ND?9_H>W07??< /L3[]LOWE5JV!"5"7&!*EH5J>7TYJJ M-U^]1(*[#LA9&QD<3VNG5ND8%.VW2FTT-F(Z<[5<3[9K^]7RJC+WJ@-<"=PR MJQ)@<20OD1"1\F9 M4A[[*L53G,7+%+:5ELPFJTQM$L+)'"MMR&'G MZF@QB,#&[WCQ]LO%Q^5B>MU5N/" F#AQ;G@$%9B *&0"%H3S40>N[O8ZV#? MY-9SQZF*:J3N,T0V^M*^G(=/%!Q\)5T[VO$4;7^UI5VDC3#6N_!6*[)UTFVCO.*%(Y+)\%S(\$%PW*N+3O; M9(IN43%.F<_PZ#A?Q!W@X]EBGDAJ5Y,+L/S[QA421K@4 M8ZEC4FHC5Y),K)V<:D\.%XWW,C4IT_D>8>/6V3Y6Z-%$35W"[IJ;[8(,7COK M,@+:4&^L\LW=U0 8F5.*AWK7['%@=YNPD6]6#0J#[V+L#)UT@+%-4O0-?L+Y M)?Z.U_89A0[!HP<3DZFM5CFX1'\);C&YQ)EN,TU@)S6]H>D8*WN4R^GZ9Q:_L[V!-/4DZ/ M.+LQ.8@5)@-C""93U*%\,!"8UL"BT4*0EQI8DX8H#]#4F]DZ4>_?P].)2N@ M3]N0Y!Y'UQFJP)V0R8/?E)W5?C$^$4LQ2$0 MJA@[>;39TF_8\I=?"R(5.A&5JYW0^&;6G0#G,NWM(7F;"UGQ>.?DK]>("E[]^3K/+7(]_5RND M/_E=^#PI)J C-B'SVL_*5!95(N>32252+-:X)E7Q)] ZCKT:$B+WNO"VU5<' MD+QGAE_CLGXAO$<^B28DZXP R6P&E82%H)D$(9V.+CF+['%R#C>(&B?-U1!D M@VE@P*.S 0O&WJX7Z>\?%C/2R^K7_[JL4Y-.J!7;\92SR\2^1]E0%6+W7E-; M^GZM\/'!!^8IXL](KHY2M"&&>G6"!2>\%]ISV>12R<-DG9UJVOGT7479LF1B M4EK0LD[8DRAIZ20&R .M'J6T:C.?_6 *1R[I&0X]]Q)237348]'J?4Y/KYS? M^ZP&]JAE[?S#N$K"^8)>@HW<4Q1&OGH,H=0HSTON?>*R21NNQE;I6]3R@5;? MTT ^VW8:T),_PC)OWO[J8U7;ZM_#[/)JE:]6EQ=77[M3RZVR"%E:!Q3%T.)S MQ=23;PU"B2"3-C:%-IGS0=GHVKX=@\,'ZE\?6]L=./:[N'^VN/B(\]6&T9O< M/TGKZ:=K>_.-8ZO0\SJ5EK/::LZJ2,(W$DH1NABI4X_):$M/T9)Y_FT.Q@?AXG0G/1>N'('34F6U "/=2QDL +%!2U&8"&8Q,*#7S MMT^AN,@Z[C MLF/0=^P.WT;'/>SMI+X-6\]F8;4B]JN,-U4:4@2O:RMO6;<=I6.@?2!&X%YJ M+81$'7*;Q;R'HF[N,3XF0N[E1X=05P>XNTG_MH!#&\Y*\0@Z< W*&$LN#OD< M62>M,&7N;!/K>)^4LZ1WGL [@,Q;7$YQ]?3U]>LWK%R//9)*&7*( M:^FKK2-H965%4X!E(A)/TK?IT_< 32-72IVI[GNMC(:1?0HB$VBN0F.:F%CDT*-V]1T;MW^]OEJ9#0],>,B2"5#6;/>%1)X+SUH;SYNT57R0JI$=NM%!N:["&U08@N1@$Y7PFBJT#%RV3$8O2!\T:/1PU8_=5.5%C M=W5^@OA&UOIOT_GTXO)B2[A+/,K")8@03)US&, KKL G&;WA-MJ#)OH=I/=; M;QY9\Z?H;3&$$,?6?OA\@_"8M8S"T899L#;T]@DH1!6 T:D2<@XJ\,&T?_/- MXS78&43[)PNQ Z?U+[07KA%K;NUR=74+T6O'@HE@4)7:'[YV/;6JCNK32AJ9 M59N+!/;6U(C1_WGJZ0U?6Q<=68[6Y0 V(2VTY/[_]JZVMZUC1W_?_T)@ MWE^^+)#;I(M@NTV1IBWVDS OG$2XCM0KR<'MOU^.)">.$]LZTAEICKHH4-BU M:PW)AQR2,_-0D:-1E%0F:Z5R#%8UZ2U]9RV7+8!.M.Y36#E"U9=^H?GJXY\W MR[]VLTE>SE>8Z'?7=\15WC.C18+H$]5>FJ*JL\D [:8:H_7.\?#WFPW)5IS7MYH_Q M&9[ UL@T[@.:[ M%8;U[>JOK7A;_:U?I'_=TA:39QB%4B9%D$[4\8I*@C?U9F:*4O$BC'9-PNP3 M:[KP >)E(3B6K7J#W9T0+S[A*KS''Y;KS=V]W9FPB@O%)2!'7]]84L:$EC)I MAC%;KIS535X,'+K "W?&.P+D6%;L#9WU=1K>"5>E^A^DF)]G!IE113@(.EK* MY5%!E))2H"@I!8H\\]+D%M;1*=]>'OXR-7+_9?,#5 MNP]AL7^HMBU3UZ\7Y*MSTHLW6:22,H0BR#^Q4%DIZZPVR;)349M&"% M"[ +Y[ ]HJB#H0/'JN6^\)COI/\QS%?;L#.+3F)A+@+6\:Q*.081A24?*#I( MQXW$9Y_>-%WA90=\7\@;^K'YI1NT)W2!-<@;V??*>=,VW_]CNO*J+AS;S[+Q60I&;FU MT]N1# Y\)75U-N147UVQA^<5%\Z+OB/$9<>73S7W.14-/7A"K81>K]>WF%_> MKC[+L6LAW6>M>/5O7*4Y*6 6T4K-K=Z>(H$JA8$SQD-&RSWF**)N,\5W\%(/ M0K6_5E2WM6P'V/UEM4R(>5UY0!\3R+DD68"<(P>EI0&7M02I3;".9$]!_)2 M0>5#K)6S,L"RSYRLD 6VB;MG$.XP?[C: \3>X',]+E6O)/Q\N[T,(XHS4A<$ M;4,]7ZA#8AAM=E%+84UT2JB>_>>+)(=5X6&!UXQMV%K_UDP._KX^?E MXA,5)KBK4=;;@'#_Y_6\X^?EYG]Q\Q;3\OVBWE.8<:ER,-(!ZMUPP5+?0V20 M%"CJ#;1"O]#"0YI)=)BG7.L9;!] Z;Z3.=+)QI<^+WK'==0%;."4O%K)MSP M@+3ILJRLB^*P"ZQG7_IA_G)MI\,3@$D'V\Z>3>./4%6R>;-Z.W__8?/F=K/> MA$4=MC%+P2>1)4)@C()"%!:\31*0 H*7.5H*&"UVC^<6=ABHK_5@=U2S]0K# MNP+HEQ7ME*XQAT1M6$-_VHU1X& MV&L[>SV?@3M \9T +Q9Y)\%]CPRHLK=.0_!H0&4;J%*/$7PVR@L>DF1-.&.? M6M1AF+RVH]+1S=4!]+[FK]H=!]P7QS&EM#7U;H)S]?D1I252(R!S69GDL@A- MVB3/K.LP %[K$>681IL&3?%_XU_W9C[\1EJ=5U9?7'V<5_KFSVGT\L%5A#&9 MC$]<0P.RXS&U> M.Y84>*Q'L,I:<#X*2$R8(F0)W!U"O=> 36H"_,:#+/Y=-JDAZN\!,_L7Y\H4 MA2;5*0F%-EDQIDMT?9I(8H\=+6_XH(26$,4@8$ MA[R6-HG$Y[3K2A6DSM&J(D;S^@[9I(ZV_M%*[*"/,$)%C#)IS!B ,4K,%*]7 M4NHNZ1/FF)RV(5Z&W7<\?[JWW]BI9_]?7E# M?^:&*I>W88.SF#(G?S=@L#X2T )QO=DJ)&4? NW-$!)E5;1'BSJX+=.^RHH5,4G& MV[#FM)9L\F0GW;C2R;CIQ9'B\PJ)0V)+?>?'9\Z88J2A?#2$0*EM9N"D\>!8 M+"8[3%*W>_3?1*3)T[*<[#J71THO/C/V?OQR_FF><9%WNW%D7D1CP)O@03': MDJ.*5-RCY18])M.&7+>Y9).GD.EF\SD9-],XR_WU]N/'L/IK6>X]]KH;"SWF M>>T!G]/@3':H=.%K3SMNK,]6 M&PG,%8IUF 5"$5[SD L3V.1ZS@3X^0=9]P!^_B&J[@ MW[K1%R_[>;G M_>.R_>&5%AZI^*N/)JVOW,::?$IZ\$&+7!EH11O*RT&K[ AAQV#BT4ID; -U MCKY77TNF$O="V@R>)0;*1LHZ>.7K])'%X$FX5,X-O5?#<=>L6WM.W)U@FJY M=_PE;Y835R6!-IPV#4X)!N6\%@RBB%9ERH>;O-WX_R/M,5*\,P-@RI#?WR^_ M]PCA[?+FYL?EJOYPEIFD?TH$Y,S4!^(28JSC%4.0JJ"55C9.!\849_('UX- M.3+?Q@@(N2X_V;..>(DQN)RAV$A[8V"!0E1VM 5+JBTR!B[Z.IM^3)*)>L>( M\&SG,4=@Y6AG^7/'#[@)JTT7+O,U;\)_K9;K]9:;7Z9$X4N@!,5\@%A8'OPV;_NY?>!$C/!>>;V]477$8N/5HCN'^0,KPC$V6^T5H=\X0=[FJZ:$U@?AFO'(2YZ?3= M'CU ^VXCY4D%"2F=C+;>I/:,C%CJM!LM04LA+),Q1-5DP,8999SH]M>I8UX( M>U/8)Y]3S3=3'I[43LF2N^+)%TI:SWE%3Y2@<*"X3)Y'4IL\P+AS()>38]S M$C[:$H53\-*1,G^/04D?+$A-&E%2D8(\BQ!9LIXES6+WMS-.]LDIM%&[\,D+ M8.Y*&J\OW/9Z4:J(I:Q_MU/'P)8%<#2853*JE,ND MEL=*-.WNZ(BH;;C]\I:B@$^( F3G0.OE0/FE$_:R("I"6J?7%7GI59ST"Q;6; #.'Y+3BM]M0/40O >JETTQ%GHJVR06.XQB&)O#\_)1]_33S](:OO?,5J8SD M*@./J$D$\A-7B4=(&[6SD6+*H3G">MA93[3N 0Q#0U3= 5J^=:.G"&R,-BS$ M&$%P7Y_R*0G><0Z)\I#(K(^QG)WF90(,0X,P<1+#T! #=8Z^!S0VM@3G$!-( MZ1$4!7&(083MBP@5D:&S9R>WZIUAJ!7N3C!-5Z [^OC-(>G/,@V:Y[*[L!$8 M$X A!QN-0O@%'"C/*B8-3@T&;+5G$HUZ93LZW'P46)V7J2/ M#.*Q?*@]HOX>_K9_**H1-:E @T^9T=X;,P3G'8BH%"8KO.MLP,%0"2?J96> M^?D]\@C,3>=%UM'J^?JYS,Q6ZDZ/ 2PR*L%"4D 56*&D.RK)M'?"],4^.5# MB;[%NB:'/ %Q1_OC)US%9??;X^];"W[6C/,I84R6C%8S'&LS1$L%,,N99ZT\ ME:9-^I[G$G"B]UBOR1=/0-RT>6Z>U, M%\7[(J5J4C_V]\KJFASR%,Q-_8W5X6;A?4,G'QT3OM39 MTI1F!)D@9!,HX>"JK3@F^[A(^KSC&C%2N"! B M&E#"*(C:47)87)$QV5)"XXN6%]; U7>VKR :M 3U54>#>_Q0SVLMHH\H,@// M>0:5ZR3'.M6; JORJ+3A.+$288CX5]]/OX(XT S.5WY8/:"XLIUP.4H3.25T,DI?20DIJ&L?P+*DL_,\.-?D5=2@55ZXS=@.BNULU0$0 M[S:>7_8;STX(;K)FQ3O(BG/RIJHN9CT8)9(2Z%EL,__INZNY<,>J';!.UWT' M #H\4+^(4A;A?,6HK$!O+4A>!YUD$UZ "=LK\-50@9?;4O1<+,W M\_9C7FPVJWF\W>P!$&YN[FA=%_F/L-H>2\V\3(9[Q\%HTHW*.E-1&1@4TI D M,%BFFMQE/&'-!_FNF:#OGLN._7KQ/B9]XR8SF974AAL(6%DP,VV?0:4(M'M* M'S3CC)W3CQ];YT'0M!.$9DM['0_')7E*DU3Y;F\,4;GB:#-46OM*P$9B"$O? MFF08:JM4&WK&1]9S$+S=.[F$>O-:1>I7W/N_%@\_[PC;_&5V6B6R")G2E5&EY**#$^HC:A*"DTAB= M:5)9#%KEJ6'HH ][1_K_!_U?_YRYDAD:7P"IG@3E#V&ME]OXQK_=4M_YM6G*O-19S4/_\;I!S%/KFJL4Y8' M'_(9/LZRE)F)@"I4^$1'23BGKQP7JH@2.6MS'_61!9U\C/_@[WY!K]!","<# M!"?JR"<1P F)H$H65'PHIQI-Z7QL11<^+1D#$=^Q_Y4Z-' MDJ;'MH_!QR)6GD '-@H"C::8JF$KJ6@86U&\WQ_/5VAYPA#/X.<8[3>)WCV7*\N,J-SJ@<# M=89L($$"*QH<$Z)0;NY<;'(3Y-$5]06@H^S]/(:.4'Y_*-K3^";AK4T4D[,O MF83P D)!!&TB6IL-!FQ#!?&]U72'GF,L_31^CE#[!;&S7FUF[^:;RMW[>I'G MG^;Y-MSL7$JI2(5!HAV\5@.>_"KR8,%S$VNC7'!QR$T\^H![F*'O'N+ET15< M^$K/6%O5.!KN#2)_S#0^CPI)(1BPHNA29-SN'3%-M='!R[TCI> MPQW X_BQ!$^,/M/,.A,8 \EX'[T$<5_\*L[=3!?/=$Q>@K:,-@L6#<2,'A(K,E FXFQN,\SS\35U MSA?4'# /$3R2]3H XM/S'3F++C.JC0M6)7FIP"6FH.A8IQE)QGB3^W*G3^B\ M'%O-N<$XG@4[@..#E.BGSVQ])1D78XE ^7(=?$"Y4>"!0S%:"&6B#^D[7NR@B*YKE_.P!\5,?T%7#]$C3+4?68Q]8^ 579;GZ&!9I%XY?TQ=42'_" M'\+ZPS^6B]MZ5;3^IS?E6W$3BY'KJ$&[8"M!:*B7CS7P'(6Q23*A^0#8G+*6 MKMJLHR'L;-;I86.K>_-N4&1^>;N:+][OJ)NVQ S;?"$^S"EF1BGCC*?-NE3N M]&W7B&53AW=;-E-, >BZ+M;]1M?]!_5==ZG_^Q_\!4$L# M!!0 ( #J"8U,&=3(YM < # @ : 8F1S:2TR,#(Q,#DS,'@Q,'%E M>#,Q,2YH=&WM66MO&[D5_=Y?P971K WH_8ALV3&0V%[4Q3:;35T$_510PSL2 M8ZYE\.S'RY_N;CYYZ'GZPM6:[1:7WH7K=;ES27[R\W??F;]9KO#;@S/K712YURU6E\J'Y+:6VI*9RHG9_Y)_@D+L[_=/9#H\$N=5)F ME#N6&.*.!"NMS"?LBR![RQJ-:M:%+A9&3J:.==O=#ONBS:V<\3CNI%-TOI1S MUHJ_SUIAD[.Q%HOS,R%G3(IW-=EN4\*3I)L*$OV^2'ER+))TT.X-!\.3]GCX MKPZ4;&%Z7&/=0M&[6B;SQI3\_J-^MSD<%.YT+H6;CCKM]I]K8>KY6:ISA_T, MUL>O4B@'?Z=^I%&RC.I M%J,?;V1&EGVD.?NL,Y[_6+>(2L.2D6F<:.6_"2IBD_!S'BT80HZ2.2TMZG2] M#5=W4SF6CO4ZSUSV![\F\D/(79)Q,9<(]))E.V2G/0>=L^[?1XH],_Y$?[!N=_ MKGU_I_;7=?972E-#"_:!2T6+.DM"=!;,3;E[2\@3J77N0Y3S2:!T_DR;<<_+:W--M(M(63H'YV8+=YGJN2$RH M'KUDHF^$QHZY!L]#()/!XT2I=< K7]L'6P-3(K0C=3^C5)B *&N$(FQG@SX)MU.6*CVW2P@8FDCK MC.=:[A]&O:%E?2.2=JG,EK:O,9C])KNY9_F;@^-N9WAJJW!57.W!K6.]##ZY M9MQ0\#Z\*<>*O)<8(>1C)>W43_?3,B2V3V[_6TB;*&U+K/,I;[2*82B,3DC@ ML66'\+H@A#&Z]NHNF?)\0NP]LLE7/KM1^@:'=!1_0DCU?"#B\_4 Q 1.5-,>$.%0[11K6I8$ I-],VI#4F$5YD.-[B#4=;%**(<5# M8"L>7@>B7M&-'Y2@!NABM9(B'#=L.;922&ZD-T#&:A%(+O>22NL9/.2F? M* #G&2B$@T985* -D$FIN&4F0 MC!^"9._TV\+*_HF[-V0 LYD4'@G.J#'GF78=S 8HWNN <#=MV$5Z5HCUX(_[< M79<#&+ 0.6]C]1_KTCVNP3[,QE>SR;-DT!WQ0] 7U"+/T&KRV> M MD>7;7M,=N<.H.J9FV#L_]F1VR; )!O\63 M&3M\9$D*A"#['LRN%$>?2.$@XL\H>;G2ZRAJ->5V58!\W@9$D0B$%OQ1D[Z+M0]((-Z.!;&]!P !=+_-77Z>6S?1,#ZTSS47Q&1=IJ M'%:J<30/3AN[*@+A 41F.)DZHB>X;*Q19ORXD- O"#D$4D =UE,3_OH69@EO M^JV44#] NJW]XWNP^%_>8I[5C2KEBN>6G9D)!=8:&F5D(]&OFH*L 3A0^VNQ[)@41-LF<'Y M<$HPIB+"G>?=5TOY:/#>@]E3 \#7X5,*.8JHA!8*JTI*Y1>$$;G4QUSF=\#!X+Y7RD=S3_X^]%+."TD-/L($[(QF7A^[-7C MU<92?1?ZU4JY,8!'I@$=%2\LC99?3L&'A>*+DH>X^2D>3SH^:L,9_!?+#>N;CF:X9:CY<3V6+_;/.[V'AUN M-SN/CCTE=M!OG@R'>XEM!96CVG",+7C^KM:K+1<47/@V?]0M[ECG_IV%HG3+ M-]$MOS\XPD72FX,^P!X^'[Q%7Z&Z\L83AK:]F7LZIP)6R(D"YOIC,5O:^4S/ M0<@+N>UW<=5KPM'%5%*Z??45ZM1EU8?\WTWGAT]<$QY]EW]:@8F_6N=KC]X: M;RQY#,Q,BYH=&WE6FUO&S<2_GZ_@I5QJ0WH;2793F3'0&*[J($V=5/W@OMT MX.YRM82YRRW)E:S[]?<,N7J))<=R_/P3&W7[$;LQO+3225URU>M= M?FBQ5NY<->[U9K-9=S;L:C/IW7SLD:A13VEM13=U:>OLE)[@4_#T[&^GWW4Z M[$(G=2%*QQ(CN!,IJZTL)^Q3*NPMZW2:6>>ZFALYR1T;] <1^Z3-K9SR,.ZD M4^)L(>>T%WZ?]OPFI[%.YV>GJ9PRF;YMR>PHSJ*(#XZC038:'(K7@WXT.HI& MV5'4%Z,X_5<$)7N8'M98-U?B;:N092<7M/]X-.@>'U;N9"93EX^C?O_O+3_U M[#33I<-^!NO#UR!F4Q@W$\ASNAH?09 3=Z[#E9R48W_"5I"TF)UHIR$)9]$#/V41>\_+YMX96.%49F8:*5_Q90$9OXG[-P@F/( M4;(4BQ-% SK#Y5TN8^G8,.H./C_ =M6CP>>Z)["],,^D_+DP3F8RX01)IC-V MGDN1L1]DR.7,Y=Z_V#E^?['*.96S( M,H5+QH/C9SM7U&57+.=3P8R82C$#2[E<6O9KS0VPHN;LHZBT<0S@^T&;HO%: MO_-K^ 9 OI?Z0B@Y%3#/;XD490+UK@AI)0\\VL;/I OSO'EIYAETV7MN810< MOYBSVU+/E$@GHAVL9()M4HT=2PVBAT N2\;+.:M+9VH!A4']/@O 5)P5^&4H M;#.>X)%ANI ^)/R\C0FE@#$M 0]3"GXKL.^:3(MG*93!ELJG$.Q!$Q)ID#(P MS?NBAAD-F^4RR9FMZ6.U?@8X-T+H (6T"KF%TM1,NAP'M)5(O((DMX)J.L4Q MX6P8)9ZOF^$E^G?X!?\*EBU)=F6Q-IR+Z1@V:^.RS! <@:-EF:@ZA4QX9T;*]YTBZ4V=#V)3ISU"5Z7COYJ[W7@^CXQ#;N:KB: MP*U#TO0VN6+<"&]]6%/&2I"5F(#+8R5M3M-I6H' IN"FWZFTB=*VQCH*>:-5 M<$-E=")2/+9L'U9/!=P83'MYE^2\G CV#M%$Z<^NY;_#?7$0?D)(\_PP#<]7 M Q#C.54M]F04AFM("9XC_9ZV>?; YMEB<[+'?4Q!'TH;7YWSCH;/AA-4&^Q" M6%1$,(\GQ,?]V2:N3GAM=U]"I!D+^*'9*="PK@T$(/RFTOJ@QBQ1>CE40ZSH M8)U2C%#<.[;AX94CV@W=T* $-4 7JY5,?;]AZ]C*5'(CZ0 R9 M/4P :&BB$3L,OJE &R*16G)@+Q_)*K#(!5H2\LIX.\2T6-!'D@O4B M_6HR>4Z0Q/=!LG/X;6!E]\#=&3* V52FA 1N46(1:W$+%%'&)WAPDRYJ]YARU9C6_X+Y'C7'*BJ307 6)_,DD2;U"O@:X>)*)&C M%'"#$5$1(&D*ZJ* #0!75IZ+7B ZD@-V.>6J]G%&IA-9AN2-*KA$P;:9A)>I M: ?>"#^WYV4/!BQ$S-N0_6-=NX[S48_&B:/+X%L$2T,?[ MDC9X:?Y,$>W!5)LFIVJ^2:!^9*M?GQ#C1/,Z26I#AEWCU"U2"VT=GE/C#EDV M@: _0F?&]A]8D@$AB+Y[LQO%42<*WXA0CU+62[T.@E8YM\L$1''K$2523VC> M'@W9S-%NW K5="7WYK>_V43?A*)G+$ /O[8 ]0UXNL!?>Q5>%.WK&%A%&GGQ M"1EIHW!8JL91/#AM[#()^ <06: S=4)\@"EUH_OT+E1DO:OYJ "5=O^W8=L"'Q9Q\T$OR5& M#DG2<[)/[[[Y7W1Q3_)F4W*%KF5+1/(4"ZU8!N2#GF^* BR!^Y"[VR$M6.0$ M6Q

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end